Company Stories I-J

Stories that earlier appeared in Nelson's News 
Note 1: Carl Nelson Consulting, Inc is not an investment adviser and may hold a financial interest or client relationship in companies discussed.
(Note 2: Carl Nelson Consulting does not endorse these companies or organizations or their activities.) 
Looking for other older stories? Visit the archives


IAP Research ... IBC Advanced Technologies ... iBiquity Digital ..... Ibis Technology ... iBLogix ... IBT Laboratories ... Icagen ... iCardiac Technologies ... Ichor Medical Systems .... Iconic Therapeutics ... Icos .... Icosavax .... ICx Technologies ... Idaho Technology ... Ideal Power Converters ... IdeaPaint... Ideaya Biosciences ..... Idera Pharmaceuticals ..... iDevices ... ID Genomics .... IDx LLC ..... iFirst Medical Technologies .... IFM Therapeutics .... Igenica Biotherapeutics ... IGM Biosciences .... Ignyta ... II-VI ..... Ikaria... Ikonisys ...Illinois Superconductor ... Illumigen Biosciences ... Illumina ... Illuminating Diagnostics ... IlluminOss Medical ... Illumitex ..... Imagen Energy ..... ImageVision ... Imaging Biometrics ... ImagineOptix ... Imago Scientific Instruments ... Imanis Life Sciences .... Imbed Biosciences .... iMetalx Group ... Imiplex ... Immco Diagnostics .... Immersion ... Immtech ... Immucell ... Immucor ... Immune Control ... Immune Design ... Immunetics ... Immune Pharma .... ImmuneWorks ... ImmuneXcite .... Immunexpress ..... Immunic .... Immunicon ... ImmunoCellular Thera .... ImmunoChemistry Technologies ..... Immunocore .... ImmunoGen ... Immunome ..... Immunomedics ...Immunomic Therapeutics .....Immunitas Therapeutics .... Immunophotonics .... ImmuRx .... ImmusanT ... Immusoft .... Impact Biomedicines ..... Impact Proteomics .... Impact Science & Technology ... .... Impel Neuropharma .... Imperium Renewables ... Impinj ... Implant Sciences ... Impossible Foods ..... Imprimis Pharmaceuticals ..... Imprint Energy .... Impulse Monitoring ... Imricor Medical Systems .... Imris .... ImThera Medical ... i-Nalysis .. . Inari Agriculture ..... InCarda Therapeutics ..... INCELL ..... INC Research ... Incelldx ... Incitor (now XF Technologies) ..... Incodema3D ..... InControl Medical ... InCube Labs ..... Incyte ... InCytu ... Indalo Therapeutics ..... Indiana Nanotech ... InDi Molecular .... Industrial Heat ..... Industrial Perception .... InEnTec ... InfaCare Pharmaceutical .... Infarct Reduction Technologies .... Infinera ... Infinia ... Infinite Electronics ..... Infinity Pharmaceuticals ... Infinium .... Inform Genomics ... Infoscitex ... Inframat ... InfraReDx ... INF Robotics .... InfraScan ... Infusion Medical .... Ingeneus .... Ingeneron ..... Inhibitex ... Inhibkase Therapeutics .... Inhibrx .... INI Power ... Inland Labs .... Inmobly ..... InnAVasc Medical...... InnerOptic Technology ... InnerPulse ... Innocrin Pharmaceuticals .... Innography ... InnoPad ... Innotec ..... Innovalight ... Innovari Energy ... Innovate Biopharmaceuticals .... Innovative Design Labs .... Innovative Microplate ... Innovative Pulmonary Solutions .... Innovative Scientific Solutions .... Innov-X ...Innovative Silicon ... Innovative Spinal Technologies .... Innovative Technologies ... Innovative Trauma Care or iTraumaCare .... Innovolt ... InnovaWave ... Innoviva .... Innov-X ... Inocucor ..... Inorganic Specialists ... Inotek Pharmaceuticals ... Ino Therapeutics .... Inova Labs ... Inovio Biomedical ... Inovio Pharmaceuticals ... Inovise Medical ..... Inozyme Pharmaceuticals ..... InPhase ... Inphi ... Inpria .... Inscripta ..... Insert MRI ... Insight...InSite Vision ... Insitu ... InSitu Biologics ..... Insmed ... Inspired Solar Technologies ... Inspire Medical Systems ... Inspire Pharmaceuticals ... Insulet ... IntAct Labs ... Intact Vascular .... Intaglio ... Intalio ... Intarcia Therapeutics ... Integra Group ... IntegenX ... Integral Molecular .... Integrated BioTherapeutics .... Integrated Diagnostics ... Integrated Diagnostics InDi .... Integrated DNA Technologies ..... Integrated Fuel Cell Technologies ... Integrated Photonics ..... Integration Associates ... Intelleflex ... Intellia Therapeutics ..... IntelliCyt ... Intelligent Automation .. Intelect Medical ... Intelligent Bio-Systems ... Intelligent Epitaxy Technology .... Intelligent Medical Devices ... Intellimedix ..... Intelliphage ...IntelliRad Control ... Intellisense... Intelomed .... Inter-4 .... Interactive Supercomputing ... Interdigital ... Interlace Medical ... Intermagnetics General ... Intermolecular ... InterMune ... Interrad Medical .... &IntersectENT .... Intersense ... Intersystems ... International Stem Cell ... InterValve .... Intevac ....InterVene ... Intra-Cellular Therapies .... IntraLase ... Intralytix .... Intrepida Bio ... Intrexon ..... Intrinsic Therapeutics .... Intrinsity ... Introgen Therapeutics ... Intuitive Biosciences .... Intuitive Genomics .... Intuitive Surgical ... Invenra ... Invensense ... Inventev ..... Inverness Medical Innovations ... Invirsa ..... Invertix ... Invictus Medical ... InView Technology ... Inviragen ... InVisage Technologies ... InvisionHeart .... Invision Medical ..... Invitae .... Invitrogen ... Invivosciences ... InVivo Therapeutics Holdings .... Invuity .... Inx Medical ... IoGyn .... Iomai ... Iomed .. IOmet Pharma ..... Ion America ... Ionic Materials ..... Ionis Pharma ..... Ion Optics ..... IonQ ... Ion Torrent ... Iovance Biotherapeutics ... Iovation ... Iowa Thin Film Technologies ... iPierian ... IPG Photonics ... IQuum ... iRhythm Technologies ... iRobot ... Iroko Pharmaceuticals ... Ironbridge Technologies ... Ironwood Pharmaceuticals ... Irvine Sensors... Ischemia Care .... iSee ..... iSIGHT Partners ..... Isis Biopolymer ... Isis Pharmaceuticals ... Island Data ... Isogenis ... Isomark ... IsoPlexis ... IsoRay ... Isothermal Systems ... Isthmus Biosciences.... Isto Technologies ... Itaconix ... I-Therapeutix ... Itherx Pharmaceuticals ... Itseez ..... Itzbig .... Iveric bio .... iWalk ... Jade Therapeutics ..... J&International ... Janssen Biotech .... Janus Biotherapuetics ... Javelin Pharmaceuticals ... JDP Therapeutics ..... Jennerex ... Jnana Therapeutics .... Joule Biotechnologies ... Jounce Therapeutics .... Joyent .... Joylux .... Joyn Bio .... Juno Therapeutics ..... Just Biotherapeutics

IAP Research (Dayton, OH)

Just a Report.  Toward the end of the 1980’s, the Soviet Union went away. As a result, the defense budget began a free fall. We concluded that we would have to do two things with our company. The first was to find some other technology to motivate us like electromagnetic guns had. Electromagnetic guns really have only weapons applications and weapons are only of interest to the Department of Defense. The second thing we had to do was move our company to more of a product development orientation. Perhaps, even production. We had existed entirely as sort of a research institution; solving problems and writing reports for our customers. The Department of Defense was willing and able to provide lots of funds to do that, but industry is not. Industry needs something more tangible than a report.  Says  IAP Research (Dayton OH).  With 20-some employees for 15 years, it has had 15 Phase 2 SBIRs (all DOD by 2004) which is only enough to support a minor fraction of the workforce. Somehow it has attracted other business, although not necessarily as a direct exploitation of the SBIR-funded work.  But because it is a private firm, neither it nor the government need publish any economic results  - a political convenience for the protection of SBIR as a political program. Founder John Barber observes that government will usually settle for a tech report. Sure, since it acquires all the IP rights it needs to use any technology that results.  Which is part of SBIR's problem with low (although mostly unmeasured) economic results. If the government funds mostly companies that are happy to produce nothing but government reports, then nothing much good will continue to happen. 


IBC Advanced Technologies (American Fork, UT)

IBC Advanced Technologies (American Fork, UT; $0.5M SBIR) a company that develops and sells molecular-recognition technology, received an honorable mention in the chemicals-materials science category at the sixth annual Utah Innovation Awards Program. IBC was lauded for a process that removes bismuth impurity from copper. [Salt Lake Tribune, Jun 28, 08]

iBiquity  Digital (Columbia, MD)

computer hardware developer Tessera Technologies (Columbia, MD; $200K SBIR) is spending around $850M to buy California audio technology firm DTS  (Calabasas, CA; no SBIR) up 23% [Sep 20, 16]. ....  it means Tessera has bought another Columbia company, iBiquity  Digital  (Columbia, MD; no SBIR, 120 employees), bought by DTS less than a year ago for $172M. According to the company, the plan is to meld the various technologies for use in the Internet of Things and with virtual reality.  [Eric Schwartz, DCInnoBeat, Sep 20, 16]

Ibis Technology (Danvers, MA)

After stockholders voted earlier this month to shut the company down, Ibis Technology reports that it is officially no longer an operating company in the eyes of the state as of today.  [Mass High Tech, Feb 17]

Ibis Technology said that its stockholders have approved a proposal to complete the liquidation and dissolution of the company. [Boston Globe, Feb 2, 09]

Too Cheap, says NASDAQ about Ibis Technology whose common stock has fallen below the minimum pricing requirements, and risks delisting.

Ibis Technology down another 11% [Nov 6, 07] (already under a buck) on news of the sudden death of its CEO.

Ibis up 12% [May 17, 07]

Ibis jumped 18%.[Nov 17, 06]

Ibis up 11% [Nov 14, 06]

Ibis fell 19% [Oct 26. 06] even though it made $2M profit in the quarter. When you sell an occasional big machine, the profits are lumpy.

Ibis had a big stock day last Friday (Jun 30,06) up 22%.

Ibis rose 12% [Jun 28, 06].

In a whack-em day on Wall Street, the biggest percentage loser was Ibis -20%. [jun06]

Ibis had a cold day [Mar 22] with 11% drop, second sharpest on NASDAQ. When your business sells a huge item infrequently, it's hard for anyone to project earnings and value the company.

Ibis Technology got another juicy $7M order for an Ibis i2000 oxygen implanter from a Japanese manufacturer of silicon wafers. [Mass High Tech, Oct 27]

Ibis got a 17% boost after it reported a $6M order for its  i2000 oxygen implanter in silicon-wafer production.

Someone Knows Something Good. Ibis rocketed 51% yesterday way up to 3% of its Y2K high in the gold old crazy days. No news published - yet. 

Ibis plummeted 45% after reporting soggy financials including a big charge for dropping wafer making.  And II-VI lost 12%. High PEs demand high profit growth rates. 

Ibis took an 18% dive Thursday when it reported that it would throw in the towel on making wafers to focus on SIMOX implanters. CEO Reid made the requisite happy noises about the bad news. 

Ibis reported a $15M loss for the quarter of which $11 was an "impairment charge" on its 200 mm and smaller SIMOX wafer production line. In a world of 300mm wafers, a 200mm line has value only a as scrap (which might actually salvage some real dollars on present booming world scrap markets). Even so, prospects don't seem bleak to stock traders as the price is nearly triple what it was a year ago although down nearly 90% from its info-tech bubble high. 

 Selling an occasional implanter and otherwise making big losses is not the formula for stock market price growth, discovers Ibis as it reports another multi-million dollar loss. Cash to cover the loss and to keep the operations running came from a $13M secondary offering in October. But even with yesterday's 18% hit, the stock is still more than double its price in spring 2003. [Oct 03]

Ibis Up 3/4. Ibis rose 75 cents a share (15% of a depressed price) on news of a deal with IBM wherein Ibis will takes both will develop a better, cheaper wafer-making process. IBM already takes 10% of Ibis's products. 

IBIS Takes a Hit. The stock price of Ibis got whacked 20% Friday (Dec 13) and 30% for th week when a broker advised "hold" the Wall Street equivalent of "sell".  The same broker by contrast has a "strong Buy" on Varian Semi - same industry, different prospects. Ibis stock is at about a third of its 12-mointh high. 

Nearly Breathless Press Release. Ibis Technology shouted a loud headline on its press release: Total revenue up 316% from preceding quarter, includes system sale to Chinese customer; wafer sales up 25% over preceding quarter, marking fifth consecutive quarter of revenue growth. Thereafter followed the ugly facts that losses are still mounting as costs rise faster than revenue. Net quarterly loss $2.2M, and $10M for nine months. Fortunately, cash still exceeds current liabilities although not by enough to withstand many more multi-million losing quarters.

Ibis got an $8M order for its Ibis i2000 oxygen implanter from a "major" semiconductor maker. Which is more than last year's total revenue. CEO Martin Reid claimed it was because of the i2000's ability to produce high quality, 300mm, thin SOI wafers, reliably and cost-effectively. Ibis's stock price jumped 25% which is only 1% of its Y2K high. What claim can you make about the cost-effectiveness of your innovative product?

Ibis to the Birds. Alexander Soule [Mass High Tech, Apr 26] relates Ibis to the bird of that name. He notes that artist and naturalist Roger Tory Peterson once wrote that birds are an ecological litmus paper. And semiconductor equipment manufacturers are the canaries in the coal mines of the technology industry. Last month, Ibis raised nearly $12M for a second generation of SIMOX implanters The North Shore is now home to several companies researching various SOI technologies, including Ibis, and a breeding site for the glossy ibis, a large long curved bill wading bird. Unfortunately, Ibis has not been breeding profits as fast as the birds breed. Its most recent quarter took a net loss of $3.4M following a loss of $2.4M million the year before. This month, the Audubon Society reported spotting about 20 ibises in Ipswich. - just about the number of Ibis machines that exist today. The market last week voted Ibis down 25% in a roller coaster week for semiconductor stocks like ATMI which has been up and down 20% in April.

Ibis sold a $11.7M secondary of 900,000 shares at $13 per share.

Ibis Tech has steadily climbed to more than ten times its mid-September low. On Jan 3 it said that it did the first implants using its next-generation oxygen implanter, the Ibis 2000 for big wafers, both 200- and 300mm.

Ibis Tech jumped 16% as it announced it had shipped an Ibis 1000 oxygen implanter to the Shanghai Institute of Metallurgy (SIM), Chinese Academy of Sciences. Now if all that shipping could actually turn a profit having had only one profitable year in the last five.

Ibis Starts Shipping. Ibis Technology, the leading provider of SIMOX-SOI implantation equipment and SIMOX-SOI wafers to the worldwide semiconductor industry, today announced initial shipments of Advantox MLD-UT wafers, which feature an ultra-thin silicon layer as thin as 300-angstroms and all the advantages of the IBM-developed, production proven MLD process. Ultra-thin SOI wafers have been demonstrated to provide superior results especially in terms of increased power efficiency and heat reduction in the manufacture of fully depleted substrate transistors for next generation semiconductor devices. [company press release] The news shot Ibis up another 17% which makes it doubling in three months although stilll down 90% from its winter 2000 high before the info-tech bubble burst.

Intel Loves Ibis?. Intel calls [it] the TeraHertz transistor because it cycles 1 trillion times per second, could ultimately lead to new applications, such as real-time voice and face recognition, computing without keyboards and ever-smaller electronic gizmos with higher performance and improved battery life. ... "... they've basically invented a new transistor technology that's fundamentally different and manufacturable," said analyst Dan Hutchinson of VLSI Research. "They've completely re-engineering the transistor as we know it." [Reuters, Nov 26] Although Intel has not said anything specific about the substrate, some speculation centers on silicon-on-insulator which could explain a one-day 45% jump in Ibis stock. Notice that Intel wants different and manufacturable, not just better. Government, on the other hand, in SBIR wants only a little different and cares little about manufacturability,mainly because military uses are not cost-sensitive.

Also blown by the swoosh was Ibis Technology which says Total revenues for the quarter were $1,256,000 compared to $5,920,000 reported in the second quarter of 2000. SIMOX-SOI wafer sales decreased to $771,000 from $1,442,000 in the same quarter last year. Equipment revenue, generated from implanter, parts and service sales, was $340,000 for the second quarter of 2001 as compared to $4,224,000 in the second quarter of 2000, which included an implanter sale.

NASADAQ traders dumped (-20%) Ibis Technology when it announced that due to a substantial decrease in wafer forecasts from one of its largest customers, the Company has revised its outlook for the second quarter and full year 2001, lowering its revenue projections. Ibis' customer, one which manufactures optical components utilizing Ibis' wafers, has informed Ibis that it expects to order a very small quantity of wafers in the second quarter and substantially reduced quantities for the remainder of 2001. While the impact on the first quarter is expected to be minimal, the Company is now projecting second quarter total revenue to be reduced by approximately 50 to 60 percent compared to the fourth quarter of 2000. Full year total revenue is still anticipated to be up, although only slightly, compared to fiscal 2000. [company press release, Apr 12]

Ibis shot up a third on news that it has licensed from IBM the right to manufacture and sell SIMOX-SOI (Separation by IMplantation of OXygen / Silicon-On-Insulator) wafers, using IBM's proprietary SIMOX process, to IBM and to all Ibis customers.

Ibis Technology suffered the usual penalty for reporting a loss - a big dip in price. Down 72% from its high of a few months ago when it was making at least a little profit. Ibis blamed lower equipment revenues offsetting a nice business in wafers.

Hedge fund Jeffrey Puglisi is hot - a 451% gain in 1999. This year, the fund is up 80%. Puglisi's forte is technology. His top bet for 2000: Ibis Technology , which makes what Puglisi and others say is a ''revolutionary'' semiconductor chip that runs at higher speed, lower voltage, and with less power. Ibis is the leading supplier of Ibis 1000 equipment that makes silicon-on-insulator (SOI) wafers. Early Ibis customers include IBM, Motorola, and Mitsubishi. IBM is ''on a very aggressive plan to convert its microprocessor products to Ibis' SOI wafer,'' says analyst Michael O'Brien of SoundView Technology Group. He sees Ibis selling 10 machines in 2001. IBM has bought five Ibis machines, while Motorola and Mitsubishi have each purchased one. ''They are also buyers of Ibis' SOI wafers,'' adds Puglisi. Other chipmakers that are buyers of Ibis wafers include Advanced Micro Devices, National Semiconductor, and Fujitsu. Giant chipmaker Intel is said to be testing the Ibis product. No wonder Ibis' stock was also a huge winner in 1999, zooming 402%. Ibis is up more than 60% so far this year, and closed at 108 3/4 a share on Mar. 22. Puglisi sees Ibis doubling in a year. Soundview's O'Brien figures Ibis will earn 13 cents a share in 2000, on revenues of $26.5 million, and 81 cents in 2001, on sales of $58.2 million. [GENE G. MARCIAL, Business Week, Apr 1,00] Ibis had some SBIR help along the way, and is what Inknowvation calls "involved" in SBIR. In 1989 when it had just five employees through 1998 when it had 60 employees, it got about $5M mostly from the nuclear hardness people at DNA (now DTRA) and BMDO (awards managed by DNA). The awards were relatively modest improvements in Ibis's established SOI process. By contrast, DOD put SBIR into the SOI of Spire whose market cap has gone nowhere in 15 years despite tons of SBIR money in many different technologies. A parallel to Ibis might be Emcore which got some SBIR to advance its deposition processes and later zoomed up in market cap. Since its 1994 IPO it has lost $11M and shot from $100M market cap in Jan 1999 to $1B. If the DOD had taken a proportional equity for its early SBIR investment, it might today have a few percent of that $1B, say $30M in equity value at a high-flying PE ratio over 1000 waiting for the prick of the high tech bubble.

IBIS TECHNOLOGY got to a five-fold rise for the year at 50 on the strenght of its SIMOX-SOI technology is emerging as a key enabling material to drive the technology roadmaps of several leading integrated circuit manufacturers, particularly for high performance computers and low power communications devices,'' said CEO Martin Reid

Ibis Makes a Hit Ibis Technology (Danvers, MA) was up big (34%) to $11+ in a sloppy stock market on news that its technology would be part of IBM's new SOI-based 35% faster chips. In the last four years IBIS has lost a total of about $50M. Someone had confidence. The stock price actually rose from $2 in 1995 to $14 when the Asian contagion hit semiconductor stocks. Inevitably, some voices sing negative notes, Despite the obvious advantages of SOI, industry analysts aren't sure how readily the technology will become mainstream because of the costs involved, since each chip company will have to work out manufacturing kinks or license the technology from companies such as IBM. "In theory you could begin production of SOI devices in a standard production line," said William O'Mara of O'Mara & Associates. "In practice, it is going to be quite difficult. The next two years will tell the tale whether SOI can ever get beyond a niche and into high-volume." Indeed, Intel, which dominates the PC market for chips, has only a "low-level" SOI research effort under way and doesn't plan on implementing SOI "in the forseeable" future, said a company spokesman, adding that the chip maker has yet to see significant advantages in using the process. [Dow Jones, Aug 3] Did SBIR make it possible in a way that the private market would not have done? Ibis has had only five Phase 2 SBIR from DOD (four from Defense Nuclear Agency) for improvements in its SIMOX business. A titbit also came from NASA and NSF. DNA loved the radiation-hard electronics and if you think like Professor Higgins about Eliza's twenty pound offer, you realize that DNA has invested a noticeable percentage of its tiny SBIR in Ibis. The company has grown from 7 to 60 employees since its two 1990 SDIO Phase 1s (note: BMDO has never advanced an Ibis Phase 1 to Phase 2 - too incremental and performance-based for BMDO's taste). The Wall Street Journal's description says, Ibis is the only US manufacturer of SIMOX wafers for the semiconductor industry. After planting its roots in military applications, the company has blossomed into the commercial market, where big US customers such as Honeywell, IBM, Motorola, and Texas Instruments account for about 70% of sales. Ibis also has strategic alliances with Motorola and Mitsubishi Materials. DNA (now DSWA) should take as much SBIR credit as it can for whatever Ibis claims even if commercial payoff was only a required pretense at the time. Nobody's unlucky all the time. 

iBLogix (Waltham, MA)

Two area clean technology startups have won grants under a new local program, U-Launch, that aims to turn university research into commercial cleantech solutions.N12 Technologies (Cambridge, MA) and  iBLogix (Waltham, MA)  Dollar values for the awards were not disclosed. N12 is commercializing advanced materials technology at MIT ...  iBLogix is developing building information software that employs data-aggregation and analysis technology, with the aim of commercializing a system developed to remotely profile the energy performance of buildings. ... U-Launch is partially funded by a three-year, $1.1 million award from the U.S. Department of Energy’s Innovation Ecosystem Development Initiative.  [Kyle Alspach, Mass High Tech, Mar 15, 11]

IBT Laboratories (Lenexa, KS)

ViraCor Laboratories (Lee’s Summit, MO; $1.5M SBIR) and IBT Laboratories (Lenexa, KS; no SBIR) officially merged Tuesday and have a combined work force of more than 200 employees.  [Kansas City Business Journal, Jul 1, 09]

Icagen (Research Triangle Park, NC)

Icagen ($700K SBIR in 1997) announced a definitive agreement to acquire Sanofi's ultra high-throughput biology, screening and chemistry capabilities and research facility in Oro Valley, Arizona (near Tucson), to collaborate in a multi-year services contract for long term discovery services.  Icagen will retain the majority of the talented scientists working at the Tucson site in the transition.   [Icagen press release, Jun 27, 16] Last year, XRpro Science announced its acquisition of assets related to the ion channel biology platform from Pfizer  that had previously been obtained as part of Pfizer's 2011 [$56 million] acquisition of Icagen.  ... is re-launching the Icagen brand and will provide comprehensive services for ion channel and transporter drug discovery, combining Icagen's industry-leading scientific expertise and extensive portfolio of assays and cell lines with XRpro Sciences' proprietary, label-free X-ray fluorescence technology.  [company press release, Jul 2, 15]

Icagen (Durham, NC) is expanding its capabilities to search for new drugs by bolting on a Sanofi research site in Arizona and gaining access to the lab’s library of compounds.  ... says it has a definitive agreement to acquire the Sanofi research site in Oro Valley, AZ. The companies disclosed no financial terms   [FrankVikkuan,, Jun 30, 16]

Icagen (formerly XRpro Sciences, Cambridge, MA; $700K SBIR) ion channel drug discovery firm , is moving its headquarters to Durham [NC], where it will consolidate with the company’s existing R&D site. In July, XRpro bought Icagen from Pfizer  [Frank Vinluan,, Oct 6, 15]

XRpro Sciences (Cambridge, MA; no  SBIR) announced it is relaunching the biotechnology company Icagen (Research Triangle Park; $700K SBIR, acquired by Pfizer for $56 million in October 2011) after acquiring its employees and technology from Pfizer....  Icagen was founded in 1992 by CEO P. Kay Wagoner, who took the company public in 2005.  [David Bracken, Raleigh News & Observer, Jul 2, 15]

Icagen is operating under a new name: Neusentis.  The Durham biotechnology company became a wholly owned subsidiary of pharmaceutical giant Pfizer when it was acquired for $56 million at the end of October  [David Ranii, Raleigh News & Observer, Mar 21]

Icagen is now a wholly owned subsidiary of Pfizer. Icagen's stock ceased trading  [Raleigh News & Observer,Nov 1, 11]

Icagen down 23% [Jul 20, 11]  which was once one of the Triangle's most promising drug-development companies, has agreed to be bought by its larger partner Pfizer for about $56 million. The price of $6 per share disappointed Wall Street investors who had expected more. ...   In 2007, Icagen halted research on an experimental treatment for sickle-cell disease because of disappointing results in clinical tests. It also ran into regulatory hurdles with an epilepsy treatment. Icagen began a partnership with Pfizer in 2007 to develop experimental medicines to treat pain, an agreement that provided much-needed money for further research. The drugs are based on blocking so-called sodium channels and reducing the body's ability to feel pain.   [Alan Wolf, Raleigh News & Observer, Jul 21]

Icagen up 164% [Jun 27, 11] in talks with the pharmaceutical titan  [Pfizer], which already holds a 14.2% stake

Icagen (Durham, NC;$700K SBIR) drug-development company that has struggled financially, is in discussions about a possible takeover by its much-larger partner Pfizer. ...  began a collaboration with Pfizer in 2007 to develop new pain medicines. As part of that partnership, Pfizer has paid Icagen millions of dollars in milestone fees. It also bought more than 1 million Icagen shares and is the company's largest investor, owning a 14.2 percent stake.   [Alan Wolf, Raleigh News & Observer, Jun 24,11]

Icagen up 13% [Feb 1, 11]

Icagen up 30% [Jan 19, 11]

Icagen up 14% [Jan 18, 11]

Icagen shares jumped today after the company announced it has selected an experimental compound for further testing as a potential pain treatment. Icagen is researching pain treatments under a partnership with larger partner Pfizer. Picking the compound for additional clinical testing triggers a $1 million milestone payment from Pfizer, giving Icagen more cash. [Alan Wolf, Raleigh News & Observer, Nov 30, 10]

Icagen developing treatments for pain and epilepsy has received a $3 million payment from larger partner Pfizer. ... Icagen's shares, which began trading publicly in 2005, have fallen sharply as investors worry about the company's financial health and whether it will be able to develop a successful drug [Alan Wolf, Raleigh News & Observer, Jul 29, 10]

Icagen  (Durham, NC; $700K SBIR) hit another setback when its experimental pain medicine didn't help patients during a small test in Britain. ... reported late Monday that the drug did not reduce pain in 24 healthy volunteers who were given simulated sunburns or injected with capsaicin, the active ingredient in chili peppers. ... has seen several experimental drugs run into regulatory roadblocks. ... risks being delisted by the Nasdaq if it doesn't trade above $1 for 10 consecutive days by May. [IPO] 2005 at $8, but have never lived up to investors' expectations. [Alan Wolf, Raleigh News & Observer, Mar 2, 10]

Icagen down ?/% on news that the company plans to stop development of senicapoc due to the asthma drug’s failure in a clinical trial. [Triangle Business Journal, Oct 27, 09]

Drug development company Icagen (Durham, NC; $700K SBIR a decade ago) posted a $3.6 million loss in the third quarter as revenue from its research partners plummeted. [Raleigh News & Observer, Nov 7, 08]

Icagen down 14% [Oct 6, 08]

Icagen ($700K SBIR) is developing three compounds for the treatment of pain disorders, and now Pfizer has obtained exclusive worldwide product rights. Pfizer has already paid Icagen $38 million, including $15 million in equity investments, with a potential $359 million in total periodic payments. [Gene Marcial, Business Week, Mar 10]

Icagen (one Phase 2 SBIR) said it hopes to begin testing an experimental treatment for epilepsy on healthy male volunteers by the end of September. ...  no products on the market and lost about $25M last year ... IPO Feb 05.  [Raleigh News & Observer, Jul 25]

Icagen down 10% [Feb 26, 07]

Icagen rose 21% [Feb 21, 07]

iCardiac Technologies (Rochester NY)

Many of the people laid off by the large companies [Kodak, Xerox, GM, Bausch & Lomb] in Rochester [NY] are highly trained engineers who have started their own companies and live in the upscale neighborhoods of Pittsford, Penfield and Brighton. Some have left the engineering world behind as they made the transition from company man to entrepreneur.  ...  iCardiac Technologies (Rochester NY; no SBIR) which measures cardiac side effects of prescription drugs, has grown to 50 employees and receives a steady stream of resumes during these times of high unemployment nationwide, many from current and former Kodak employees.   ....  private-equity firm Trillium Group has helped fund a number of start-ups, including iCardiac and Thermal Gradiant (Rochester, NY; no SBIR), a molecular diagnostic company started in 2004 by two people who worked at a Kodak spinoff bought by Johnson & Johnson. [Dana Mattioli, Wall Street Journal, Dec 24, 11]  If Congress really wanted a jobs engine, it would seriously re-structure SBIR to push more awards to such start-ups with economic potential and away from SBIR junkies that have a semi-permanent relationship with the large agencies.

Ichor Medical Systems (San Diego, CA)

Ichor Medical Systems (San Diego, CA; $9.2M SBIR) said it has partnered with Janssen Pharmaceuticals to develop DNA-based vaccines. ... can earn up to about $85 million under the contract, along with royalties on any product sales.  ...  will work on developing vaccines for chronic hepatitis B using Ichor's TriGrid electroporation technology to deliver the vaccines. Electroporation uses brief electrical pulses to temporarily make cell membranes permeable. Ichor will deploy the technology to get Janssen's DNA vaccine inside cells to provoke an immune response.    [Bradley Fikes, utsandiego,com, Apr 13, 15]

Iconic Therapeutics (Atlanta, GA and San Francisco, CA)

BioMed startup Iconic Therapeutics (South San Francisco, CA; no SBIR) raised $40 million in Series C funding for clinical trials and talent acquisitions. [for macular degeneration treatments]  [Gina Hall, Silicon Valley Business Journal, Jan 11, 16]    to develop a new approach to retinal disease and cancer. Our lead product candidate, ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of acute vision loss in AMD. By addressing inflammation and angiogenesis together, ICON-1 may potentially alter the course of this leading cause of blindness. ...  broad intellectual property portfolio was exclusively licensed from Yale University, one of the first institutions where TF was cloned and characterized.  [company website]

Iconic Therapeutics (Atlanta, GA to South San Francisco, CA this year; no SBIR) pulled in $20 million in venture capital as it preps to take on Genentech with a potential new treatment for a blinding eye disease.  [Ron Leuty, San Francisco Business Times, Apr 16, 14] Moving to the industry heart.

Iconic Therapeutics (Atlanta, GA and San Francisco, CA ; no SBIR) completed a $20 million round of funding ...  develops therapeutics for serious eye disorders, has completed a successful Phase 1 clinical trial on a therapeutic that binds tissue factor to promote key processes like inflammation that underlie the mechanisms of age-related macular degeneration.  [Ellie Hensley, Atlanta Business Chronicle, Apr 16, 14]


David Blech was the initial financial force behind the industry giant Celgene, the rare-disease specialist Alexion Pharmaceuticals  ($1.8M SBIR), and the cancer-drug developer Ariad Pharmaceuticals ($600K SBIR), not to mention Icos (no SBIR), which developed the impotence pill Cialis. In the early 1990s, Blech was worth about $300 million and made the Forbes list of 400 wealthiest Americans.  Now, however, he is about to begin a four-year prison term, is about $11 million in debt, and is mainly an afterthought to the industry he helped foster. [Andrew Pollack, New York Times, Sep 9, 13]

Icosavax (Seattle,WA)

 (Seattle, WA; no SBIR) announced the launch of the company with a $51 million Series A financing, ... founded on computationally designed self-assembling virus-like particle (VLP) technology developed at the Institute for Protein Design (IPD) at University of Washington School of Medicine ...  to advance the company’s first vaccine candidate, IVX-121, for respiratory syncytial virus (RSV) for older adults through Phase 1b clinical studies [company press release, Oct 3, 19]

ICx Technologies

FLIR Systems to provide surveillance equipment and technology to the Customs and Border Protection Division working to stiffen the border between Mexico and the United States.
The big prize was a five-year contract worth up to $101.9 million to a FLIR subsidiary via a recent acquisition
, ICx Technologies (Arlington, VA).  ....  Also this week, the Defense Department said it had awarded FLIR a $15.9 million, one-year contract to provide 36 night-vision systems and training classes to the Army Aviation & Missile Command [, Jan 6, 11]

Homeland-security products maker ICx Technologies (no SBIR) rose 14% after saying it has agreed to be acquired by large-cap Flir Systems for about $274 million. [Wall Street Journal, Aug 17, 10]

Idaho Technology (Salt Lake UT)

Idaho Technology (now in Salt Lake UT) has gone from 37 to 160 employees in response to anthrax threats since 2001. Idaho Technology's story began in the 1980s when company co-founder Carl Wittwer, then a graduate student at Utah State University, hired student Kirk Ririe as an undergraduate research technician. Wittwer eventually accepted a research position at the University of Utah while Ririe took over the management of Agparts, his father's potato equipment company in Idaho Falls, Idaho. It was in the corner of the factory that the first rapid detection prototypes were built. [Dawn House, Salt Lake Tribune, Oct 6]  Idaho has had at least six Phase 2 SBIRs.

Ideal Power Converters (Austin,TX)

Photovoltaic inverter developer Ideal Power (Austin, TX; no SBIR) [IPO] posted a strong showing ...  founded in 2007 as Ideal Power Converters, joined the Austin Technology Incubator in October 2008. The company has nine employees.  [Christopher Calnan, Austin Business Journal, Nov 22, 13]

Ideal Power (Spicewood, TX; no SBIR) has filed for an [IPO] that could raise up to $16.1 million, according to [SEC] documents ...   founded in 2007, makes power converters that are designed to lower system costs and improve efficiency in solar and wind energy systems, motor drives and electric vehicles. [Lori Hawkins, Austin American Statesman, Nov 18, 13]

Photovoltaic inverter developer Ideal Power (Spicewood, TX; no SBIR, founded 2007) completed a $750,000 financing ... December 2012, the company received a $4 million convertible debt financing .... In 2011, it received a $2.5 million grant from ARPA-E ... In December 2010, the company received a $1 million grant from the Texas Emerging Technology Fund. [Christopher Calnan, Austin Business Journal, Aug 13, 13]

When startup FireFly LED Lighting (Austin, TX; no SBIR) was accepted into the Austin Technology Incubator two years ago, its LED bulbs were still prototypes.  Since then, the company has launched its product line, signed customers including Kerbey Lane Cafe and the University of Texas and received $3.4 million from backers including the Central Texas Angel Network and the Texas Emerging Technology Fund.....  Since its founding in 1989 by legendary business leader George Kozmetsky, ATI has worked with more than 200 startups, helping them raise nearly $1 billion in investment capital.  [Lori Hawkins, Austin American Statesman, Jan 26, 12]  Graduates: Agile Planet,  Atomometrics, Axelo, Calxeda, Dorsan Biofuels, Famigo, GameSalad, Ideal Power Converters, Itzbig, Nitero, Notice Technologies, Open Algae, Qcue, RFMicron, RRE Solar,  Savara Pharmaceuticals, Spredfast, Terapio ($500K  SBIR), Unwired Nation, 

Ideal Power Converters (Spicewood, TX; no SBIR) received a $2.5 million [DOE] grant ... as part of a $156 million package to encourage cutting edge energy research and projects nationally. ... joined the Austin Technology Incubator in October 2008, develops inverters designed to lower system costs and improve energy efficiency ... received a $1 million grant from the Texas Emerging Technology Fund  [Christopher Calnan, Austin Business Journal, Sep 30, 11]

Photovoltaic inverter developer Ideal Power Converters (Austin, TX; no SBIR) has received a $1 million grant from the Texas Emerging Technology Fund. The Austin-based company is expected to use the capital to accelerate the commercialization of its large-scale photovoltaic inverters, [Austin Business Journal, Dec 30, 10]

IdeaPaint (Boston, MA)

Startup IdeaPaint (Boston, MA) has taken in $5 million in its first venture funding ... has created a patented paint that makes any flat surface into a dry-erase writing surface once applied. ...  Coming out of Babson College’s entrepreneur program [Mass High Tech, Nov 12, 08]

Ideaya Biosciences (South San Francisco, CA)

IDEAYA Biosciences down 17% [Nov 20, 19]

IDEAYA Biosciences (South San Francisco, CA; no SBIR) up 47% [Nov 13, 19] announced financial results and that financial results and significant progress on our Phase 1/2 tissue-agnostic basket trial evaluating IDE196 in patients with solid tumors harboring GNAQ or GNA11 (GNAQ/11) mutations, including metastatic uveal melanoma (MUM), cutaneous melanoma and colorectal cancer. [company press release, Nov 13, 19]

Ideaya Biosciences (South San Francisco, CA; no SBIR) filed for a $70 million IPO to fund early-stage studies of lead drug IDE196 in solid tumors with particular genetic mutations. [Alex Lash,, May 3, 19]

Ideaya Biosciences (South San Francisco, CA; no SBIR), committed to the discovery of breakthrough synthetic lethality medicines and immuno-oncology therapies, announced the successful completion of a $94 million crossover Series B financing.  [company press release, Mar 15, 18]

Cyteir Therapeutics (Cambridge, MA; no SBIR, founded 2012) just raised $29 million  [with its] approach to treating cancer is based on research showing how cancer cells behave differently than healthy ones.... Cyteir is the latest company to emerge with the goal of broadening synthetic lethality beyond PARP.  Tango Therapeutics (Cambridge, MA; no SBIR, Series A 2017) unveiled a $55 million in funding last year to back its synthetic lethality research in cancer. Repare Therapeutics (Boston, MA and Canda; no SBIR, founded 2016) raised $68 million last year to support its work. Ideaya Biosciences (South San Francisco and La Jolla, CA; no SBIR, founded 2015), which raised $46 million in 2016, is also in the mix. [Frank Vinluan,, Mar 8, 18]

Biotech startup Ideaya Biosciences  (South San Francisco, CA; no SBIR) founded by executives who sold Flexus Biosciences (San Carlos, CA; no SBIR) last year for $1.25 billion, raised $46 million to further its cancer treatment research.  .....  co-founded by CEO Yujiro Hata, who was chief operating officer at Flexus [Gina Hall, Silicon Valley Busines Journal, May 4, 16]

Idera Pharmaceuticals (Exton, PA)

Idera Pharma down 16% [May 7, 19]

Idera Pharma up 17% [May 3, 19]

Idera Pharma up 17% [Jan 4, 19]

Idera Pharma up 27% [Jan 2, 19]

Idera Pharmadown 40% [Dec 14, 18] presented Clinical Safety and Efficacy Update from the ILLUMINATE-204 Trial of the Combination of Tilsotolimod and Ipilimumab for Unresectable or Metastatic Melanoma Following Failure of PD-1 Inhibitor Treatment [company press release, Fec 14, 18]

Idera Pharma up 28% [Nov 7, 18]

Idera Pharma up 13% [Sep 24, 18]

Idera Pharma up 18% [Aug 13, 18]

Idera Pharma down 15% [Aug 10, 18]

Idera Pharma up 27% [Aug 9, 18]

Idera Pharma down 11% [Aug 3, 18]

Idera Pharma down 13% [Jul 31, 18]

BioCryst Pharmaceuticals (Durham, NC) is ending a plan to merge with Idera Pharmaceuticals and form a single company focused on rare diseases. ... following a meeting that saw shareholders vote overwhelmingly against the proposal. [Frank Vinluan,, Jun 10, 18]

BioCryst Pharmaceuticals (Research Triangle Park, NC; $1.4M SBIR) and Idera Pharmaceuticals (Exton, PA; no SBIR) announced that they have signed a definitive merger agreement to form a new enterprise focused on the development and commercialization of medicines to serve more patients suffering from rare diseases. The combined company will be renamed upon closing [joint companies press release, Jan 22, 18]

iDevices (Avon, CT)

[The] company that makes a Bluetooth-enabled meat thermometer has received a $100,000 grant a $250,000 loan from the state in the latest round of Small Business Express aid packages  iDevices (Avon, CT; no SBIR), launched the iGrill meat thermometer [that] can communicate with an iPhone or iPad through a wireless Bluetooth connection, and let its user know when the meat is ready.  ....  Grow Home Organics (Guilford, CT;  no SBIR) which makes products for outdoor kitchens and gardens, is receiving a matching grant of $83,800, ... Connecticut Valley Bindery (New Britain, CT; no SBIR) is receiving a matching grant of $50,000. ....Wethersfield Offset (Rocky Hill, CT;  noSBIR), a commercial printer, is receiving a matching grant of $55,721 ... Fire Alarm Specialty Design (Windham, CT;  SBIR) which designs fire and security alarm systems for healthcare, educational, municipal, commercial, and industrial uses, is receiving a $100,000 matching grant and a loan of $100,000. [Hartford Courant, Jul 11, 12]  Even though states complain of financial distress, they continue to put public money into private enterprise with little hope of economic return to preserve jobs. It's all politics. So what happens next year when the grants expire and such investment is still uneconomic for private investment?

ID Genomics (Seattle, WA)

startup ID Genomics (Seattle, WA; no SBIR) has developed technology to identify bacteria in 30 minutes, giving doctors all the information they need to prescribe the best treatment.  The goal is to identify the bacteria’s exact “fingerprint” while the patient is still in the clinic, so doctors can choose a narrowly targeted antibiotic.  ...  For several years, Sokurenko and the 10-person ID Genomics team has been creating a database of different strains of E. coli bacteria, which causes the majority of urinary-tract infections. Each strain has distinct characteristics.   “It’s sort of like a bar code,” said Sokurenko [Rachel Lerman, Seattle Times, Apr 24, 17]

ID Genomics (Seattle, WA; no SBIR) has developed technology to identify bacteria in 30 minutes, giving doctors all the information they need to prescribe the best treatment while a patient is still in the clinic. [Seattle Times, Apr 23, 17]  received $3M NIH grant in 2016. [company website]  announced the formation of a national consortium of clinical partners to help increase the rapidity and accuracy of infectious disease diagnosis and antibiotic treatment through the company’s novel DNA-based “bacterial fingerprinting” diagnostics system. The initial consortium was formed under [NIH] grant  [company press release, Jan 11, 17]

IDx LLC (Coralville, IA)

[FDA] last week announced the first approval of artificial intelligence–based disease screening software that doesn't need a clinician to interpret the results. The computer program, developed by IDx LLC  (Coralville, IA; no SBIR, founded 2010), analyzes digital images of a patient's retina to detect diabetic retinopathy, a common complication of diabetes that is the leading cause of blindness in U.S. adults. [Science, Apr 20, 18] total funding $3.6M []

iFirst Medical Technologies (Honolulu, HI)

“NASA iTech is an innovation incubator that brings together the right people to the right place and time, giving entrepreneurs an opportunity to present their technologies as a future commercial market product solution for both Earth and NASA,” said Kira Blackwell, program executive for the Space Technology Mission Directorate at NASA Headquarters.  Blackwell, also said the top 18 companies that have previously participated in NASA iTech have reported raising more than $50 million in private investments over the last 12 months.  The top ten competitors for the grand prize:  BioVirtua (San Francisco, CA; no SBIR)  Humanizing Telehealth in Four Dimensions;  FGC Plasma Solutions (Argonne, IL; no SBIR) Novel Fuel Injectors to Enable Clean, Compact Propulsion ; Germfalcon (Los Angeles, CA; no SBIR)  Germicidal UVC Emitting Robot for Commercial Aircraft; H2 Energy Now (Boalsburg,PA; no SBIR)  New Technology for H2 Generation from Water in Space by Use of Electromagnetic Waves;  Hyperloop Tansportation Technologies (Los Angeles, CA; no SBIR, 500-1000 employees) Augmented Voyage;  iFirst Medical Technologies (Honolulu, HI; no SBIR, founded 2016) The iFirst Analyzer: Handheld Laboratory-grade Diagnostics Platform for Extreme Environments;  Million Concepts (Lemont, PA; no SBIR) The Arisian Lens: A Novel Solution for Low-cost, Lightweight Microscopy;  New Frontier Aerospace (Livermore, CA; no SBIR, founded 2015) Affordable, Powered​ ​Recovery​ ​for​ ​Small​ ​Launch​ ​Vehicles;  Rice Technology (Milwaukee, WI; no SBIR) Smart Real-Time Multipurpose Sensor - Dissolved and Suspended Solids, Bacteria, Phosphorus and Viruses;  Somatic Labs (Phoenix, AZ; no SBIR, founded 2015) Tactile Interfaces for Augmented Reality to Enhance Communication.

IFM Therapeutics (Cambridge, MA )

IFM Therapeutics (Cambridge, MA; no SBIR, founded 2015) is hiving off its NLRP3 stable into a subsidiary dubbed IFM Tre. The new unit, which starts out with $31 million in series A funding, expects to bring its lead asset into phase 1 in 2019.  [Amirah Al Idru,s Fierce Biotech, Jul 19, 18] total funding $27M []

IFM Therapeutics (Cambridge, MA; no SBIR) disclosed a $27 million Series A .... Swiss pharma giant Novartis also chipped in on the round for IFM, which was incubated within Atlas and aims to develop drugs for cancer and inflammatory diseases. [Ben Fidler,, Jun 22, 16]

Igenica Biotherapeutics (Burlingame, CA)

The Column Group, the David Goeddel-led VC firm whose investments include up-and-coming companies like Igenica Biotherapeutics  (Burlingame, CA; no SBIR) , Immune Design  ( Seattle, WA; no SBIR) and NGM Biopharmaceuticals  (S San Francisco, CA; no SBIR) has raised $176 million toward a projected $250 million fund.  ....  Goeddel was the first scientist hired by Genentech and eventually went on to cofound Tularik (S San Francisco, CA;  $500K SBIR), which was sold to Amgen 10 years ago for $1.3 billion.  [Ron Leuty, San Francisco Business Times, Apr 17, 14]

IGM Biosciences (Mountain View, CA)

IGM Biosciences (Mountain View, CA; no SBIR) up 52% [Sep 18, 19] announced the pricing of its [IPO] to raise $175M ... develops antibodies for the treatment of cancer [company press release, Sep 17, 19] prior funding $142M []

IGM Biosciences (Mountain View, CA; SBIR) a global leader in [R&D of engineered IgM antibodies for therapeutic use, nnounced the closing of its $102 million Series C financing. [company press release, Jul 12, 19]

Ignyta (Sorrento Valley, CA)

Igynta  (born 2012 as NexDx, San Diego, CA; no SBIR) developer of cancer treatments, said it is raising $75 million in a public stock offering.  The biotech is developing drugs in tandem with diagnostics to find patients best suited to its therapies. The therapies target the genetics of cancer, homing in on cancer-causing genes and molecular pathways for specific cancers.  ... held another public offering in March of last year, raising $55 million. Ignyta became publicly traded in 2013 through a reverse merger with an already public company.  [Bradley Fikes,, Jun 9, 15]

Ignyta (Sorrento Valley, CA; no SBIR) raised $5.5 million to help develop its personalized medicine tests for rheumatoid arthritis, lupus and other autoimmune diseases. .... brings the total raised in its equity financing to $6 million, the company said. [Bradley Fikes,, Jan 2, 13]

II-VI (Saxonburg, PA)

II‐VI announced that it signed a strategic partnership agreement with LITE-ON Technology, a global leader in optoelectronic components, to partner in the volume manufacturing and commercialization of packaged semiconductor lasers for mass-market light detection and ranging (LiDAR). [company press release, Sep 12, 19]

II-VI up 14% [Jan 31, 19]  reported good earnings 

II-IV down 19% [Nov 9, 18] II-VI and Finisar, a global technology leader in optical communications, announced that they have entered into a definitive merger agreement under which II-VI will acquire Finisar in a cash and stock transaction with an equity value of approximately $3.2 billion. [joint companies press release, Nov 9, 18]

II-VI up 20% [Nov 1, 18] announced it will inaugurate its new II-VI Asia Regional Headquarters and expand its manufacturing footprint in Fuzhou, China to meet increasing global demand. [company press release, Oct 31, 18]

II-VI up 13% [Aug 7, 18]

II‐VI (Saxonburg, PA; $3M SBIR, market cap $2.7B), a leading provider of solutions for optical networks, today announced that in order to address increased demand for its differentiated product portfolio, it plans to expand the capacity of its 980 nm pump laser production lines, including wafer fab and chip on carrier assembly in Zurich, Switzerland and in Calamba, Philippines, and pump laser module assembly in Shenzhen, China. [company press release, Jul 9, 18]

II-VI announced its intent to acquire CoAdna, Holdings, (Sunnyvale, CA; no SBIR, founded Y2K) in a [$85m] cash transaction ... CoAdna is a global leader in wavelength selective switches (WSS) based on its patented LightFlow™ liquid crystal platform and II -VI’s micro-optics. [II-VI press release, Mar 26, 18]

II-VI down 10% [Feb 5,18]

First billion.  II-VI (Saxonburg, PA; $2.5M SBIR in 1980s and early 90s, market cap $2.6B, 10000 employees) confirmed that it is on the brink of a final deal for a long-term lease in the soon-to-be-former Westinghouse office space ...  [Commo chief]Mark Lourie  said the company reported record quarterly earnings and booked more than $1 billion in business for the year for the first time. [Tim Schooley, Pittsburgh Business Times, Oct 3, 17]

II‐VI (Saxonburg, PA; $2.5M SBIR before 1993), a leader in engineered materials and optoelectronic components, announced its acquisition of Kaiam Laser Limited, a 6-inch wafer fabrication facility [300,000 square foot facility with a 100,000 square foot clean room] in the UK. The purchase price was $80 million, and paid for from cash reserves. [company press release, Aug 7, 17]

II-VI , a leader in engineered materials and optoelectronic components, announced the acquisition of Integrated Photonics (Hillsborough, N.J; $3M SBIR, a 2000 spinout of AT&T Bell Labs) in a $45m cash  transaction.  Integrated Photonics  is  a leader in  engineered magneto-optic materials that enable high-performance directional components such as optical isolators for the optical communications market.   [II-VI press release, Jun 19, 17]

II-VI down 16% [May 2, 17]

II-IV up 15% [Jan 24, 17]

II-VI (Saxonburg, PA; $2.5M SBIR 1984-2002) is planning to expand a division that it acquired in February.  II-VI said that its II-VI EpiWorks Division has broken ground on a state-of-the-art facility that produces compound semiconductor epitaxial wafers. It will have a lab as well as production space and represents four times more capacity for the current facility when it opens in the middle of next year.  [Paul J. Gough, Pittsburgh Business Times, Dec 1, 16]

II-IV down 10% [Apr 27, 16]

II-VI said it had completed its acquisition of a manufacturer of semiconductor wafers. ...paid $43 million in cash for EpiWorks (Champaign, IL, $2.4M  SBIR) and could pay another $6 million in earn out if goals are achieved over the course of three years. [Paul J. Gough, Pittsburgh Business Times, Feb 1, 16]

II-VI up 16% [Jan 26, 16]

II‐VI (Saxonburg, PA; $4.3M SBIR) announced that it signed agreements to acquire two businesses that will expand its technology platforms and production capacity for semiconductor lasers with a scalable 6‐inch epitaxial growth and wafer fabrication platform.    These acquisitions will further position the company to serve fast‐growing markets addressed by Vertical Cavity Surface Emitting Lasers (VCSELs). ...  EpiWorks  (Champaign, IL; $2.4M SBIR), global leader in high volume epitaxial growth of compound semiconductor wafers ....   ANADIGICS (Warren, NJ; $600K SBIR)  a high volume foundry unmatched in the production of 6‐inch gallium arsenide (GaAs) wafers. [II-VI press release, Jan 19, 16]

II-VI up 10% [Aug 5,15]

II-IV  up 16% [Jan 27, 15]

 II-VI saw its second-quarter net earnings nearly triple [Sam Kusic, Pittsburgh Business Times. Jan 27, 15]

II-VI plans to buy back $20 million of its stock. [Paul J. Gough, Pittsburgh Business Times,  Feb 7, 14]

II-VI announced that it has signed an asset purchase agreement to acquire Oclaro Inc.'s fiber amplifier and micro-optics division for $88.6 million.  ....  will complement the semiconductor laser business of Oclaro that it acquired in September. [Justine Coyne, Pittsburgh Buiness Times, Oct 11, 13]

II-VI   down 12% [Apr 23, 13]

II-VI has bought a California precision-optical system manufacturer for $31 million.  The acquisition of the outstanding shares of privately held LightWorks Optics (Tustin, CA;  $1.5M SBIR), includes the possibility of $4 million more depending on LightWorks' future financial performance. LightWorks makes visible, infrared and laser-based systems for defense, aerospace and industrial markets. [Paul Gough, Pittsburgh Business Journal, Dec 21, 12]

II-VI down 10% [Jan 22,13]

II-VI will buy Oclaro (no SBIR)'s thin film filter and interleaver product lines for $27 million.  [Pittsburgh Business Journal, Nov 26, 12]

II-VI said it acquired all outstanding shares of M Cubed Technologies (Monroe, CT and Newark, DE; $3M SBIR) in a $71.4 million cash deal. [Malia Spencer, Pittsburgh Business Times, Nov 2, 12]

II-VI down 12%  [Jun 15, 12]

II-VI up 11% [Dec 20, 11]

II-VI down 11% [Oct 25, 11]

II-VI up 10% [Aug 11, 11]

II-VI down 12% [Aug 8, 11]

II-VI down 13% [Aug 2, 11]

II-VI up 23% [Apr 26, 11] after its quarterly results easily topped Wall Street expectations.  ... Fueled by its recent acquisition of near-infrared optics maker Photop Technologies (no SBIR) [Motley Fool, Apr 26]

II-VI is acquiring Philadelphia-basedMax Levy Autograph (no SBIR), a supplier to one of II-VI’s subsidiaries, the company said Tuesday morning. Terms of the deal were not disclosed.  ...II-IV reported 83% percent jump in sales for the first quarter ended Sept. 30, with profit of $18.4 million [Malia Spencer, Pittsburgh Business Times, Dec 7, 10]

Co-founder of optics manufacturer II-VI Carl J. Johnson is retiring from the day-to-day operations of the company he started nearly 40 years ago, but he will remain Chairman of the board  .... under Johnson’s direction, the company went from a few thousand dollars in revenue to sales of $292 million last year and has gone from two employees to 6,000 worldwide.  [Pittsburgh Business Times, May 18, 10]

II-VI  inked a $40 million multi-year agreement with Lockheed Martin to supply components for the Joint Strike Fighter, F-35 Lighting II, the company said .... will be supplying sapphire windows [Malia Spencer, Pittsburgh Business Times, Feb 11, 10]

II-VI made an unsolicited proposal to buy Middlefield, Conn.-based Zygo (Middlefield, CT; one SBIR) according to a release from Zygo. ... Earlier this week, II-VI, which makes specialty optics, closed a deal to acquire the Chinese optics firm Photop Technologies and issued updated guidance for its year-end figures that could see the company break $300 million in profits. [Pittsburgh Business Times, Jan 7, 10]  II-IV had just under $3M SBIR starting in 1984 with 112 employees and ending in 1992 with 220 employees. It now has 1900 employees, revenue of $270M, and a market cap of $930M.

Forbes's 2009 list of best 200 small companies includes Aerovironment, American Science and Engineering (paying a dividend and with nearly $600M market cap), Argon ST, Hittite Microwave, II-IV, Meridian Bioscience, Neogen, NVE, and Synaptics

II-VI  up 10% [Apr 9, 09]

II-VI up 20% [Jan 21, 09]

II-IV down 20% [Dec 3, 08]

II-VI up 15% [Oct 13, 08]

Forbes 200 Best Small Companies list for 2008 had several "SBIR involved" companies: Hittite Microwave 12, II-IV 23, Synaptics 33, NVE 39, ATMI 114, Cymer 166. 

Business Week's Hot Growth Class of 2006 has fared relatively well. Weighted by market value, the companies have returned 4.7% over the past two years. That tops the small-cap Russell 2000 index, which dipped 3.9% during the same period. Ninth highest two-year return was II-VI at 71%. [Business Week, Jun 9, 08]

Market pundit Jack Hough likes II-IV as having impressive return on equity and promising growth prospects [Wall Street Journal, May 8, 08]

II-VI down 11% [Apr 22, 08] despite growing profits. Revenue from infrared optics rose 21 percent, while that from military and materials was up 69 percent.  [Reuters, Apr 22]

II-IV named as bargain growth stock on prospects of 20% profit growth in 2008. [Jack Hough, WSJ, Mar 27]

Forbes's annual list of the best 200 small companies had several SBIR awardees: Ceradyne #12, Flir Systems 37, II-IV 58, ATMI 69, ViaSat 90, Surmodics 105, Micrel 149, OPNET Tech 167.

II-VI up 21% after posting a quarter's profit and a gain in yearly profit. [Aug 7, 07]

Among Business Week's 100 hot growth companies were Ceradyne  and  II-VI. [Jun06]

Minor stumble. big overreaction says Motley Fool about II-VI's 17% plunge even though sales were up 25% and profit up 70% and a rough book-to-bill ratio of 1.14 as both numbers fell just short of their targets. ... Looking ahead, the future for lasers is still glowing brightly. Lasers are increasingly replacing machine tools in manufacturing, and new applications in medicine and consumer goods are continually coming online. Not only are more lasers being used but also they are getting more powerful. These new stronger lasers require more valuable optics, and they consume them faster, a good thing indeed for II-VI. [Motley Fool, Jan 20]

"if only" not convincing. Profits up, sales up, so what?  II-VI said, However, orders for near-infrared optics used in semiconductor manufacturing have not yet recovered. If demand from that industry were to improve .. blah, blah. The market was not listening and the stock took a 15% nose dive when the earnings didn't measure up to expectations. Stock prices. after all, are not about present earning, but about future earnings. When a company lets Wall Street raise its expectations, the stock price sinks when the company cannot produce the expected result. So, private companies that don't care about their shareholders getting rich can stay private and work for the 6% profit on government R&D contracts in sheltered political programs like SBIR. 

II-VI avoids telecom battering ram. Eighteen months ago, shares of II-VI were white hot, irrationally buoyed in part by a limited foray into the telecommunications market. They've cooled since then, as telecommunications stocks tanked and the economy headed south. Shares hit a high of $37 in March 2000 and closed Friday at $15.74, ... The company last week posted record fourth-quarter earnings and set new highs for revenue and earnings for its fiscal year ended June 30.... "Our telecom exposure for the next two to four quarters is not good," Chairman Carl Johnson told analysts last week. For the year, II-VI earned $9.5M on revenue of $123M. ... Since late April, II-VI has reduced its work force by about 10% to 1,100 [Len Boselovic, Pittsburgh Post-Gazette, Aug 12]

II-VI makes components for lasers. One is zinc selenide crystals, which are used to make optics that redirect laser beams in carbon dioxide laser systems, a workhorse light source capable of cutting everything from flesh to metal. These lasers are used for industrial applications like cutting fabric or welding metal. II-VI recently bought rival Laser Power, which gave the company a good business supplying the military with parts for missile guidance and infrared imaging devices. At $15, II-VI's shares go for a high 22 times trailing earnings. But we expect earnings per share to grow 29% this year. [Forbes, Jun 11]

II-IV Rockets. II-IV (Saxonburg, PA) jumped 67% to 44 Friday with the only news being a new strong buy recommendation form another broker. II-VI designs, manufactures and markets optical and electro-optical components, devices and materials for infrared, near-infrared, visible light, x-ray and gamma-ray instrumentation and has recently announced new products to serve the telecommunication industry. It has traded between 11 and 74 in the past 12 months.

II-VI made $7M profit for the year, down from $9.5M the previous year. Although revenues were down less than 10%, making a decent profit at all is an accomplishment for a chipster in the info-tech downwash. The stock price is down only a third from its 12-month high. [date??]

II-VI apparently surprised Wall Street with 35% higher earnings, of $2M for the quarter.on record revenues of $19.8M. The trading price jumped 30% in a record NASDAQ up-day. II-VI (Saxonburg, PA), an SBIR minor beneficiary, makes and and sells optical and electro-optical components, devices and materials for infrared, near-infrared, visible light, x-ray and gamma-ray instrumentation and has recently announced new products to serve the telecommunication industry. [company press release, Apr 18, ??]

II-VI ups offer for competitor. , II-VI Inc. turned up the gas this week in its bid to acquire a San Diego competitor. II-VI, (Saxonburg, PA) optical sensor manufacturer formally made a stock-and-cash offer of $4-$5 a share for Laser Power Corp. This offer followed the announcement three days earlier that Laser Power had agreed to merge into Union Miniere S.A., a Brussels-based nonferrous metal producer that already owns almost 10 percent of the Laser Power. One of Laser Power's most attractive features is its military contracts, since military work accounts for less than 10 percent of II-VI's business. II-VI's advantage in the market is that it manufactures its own raw materials, principally zinc selenide, used to make the optics. According to II-VI, acquiring these materials accounts for 10 percent to 15 percent of Laser Power's costs. Imagine that: an SBIR-funded company in a bidding war to acquire a company that adds military business of which it has too little.

II-VI Zooms Yesterday's zoomer was II-VI (Saxonburg, PA) which gapped up 71%.on news of a strong buy rating by a brokerage. Such new recommendations in the info-tech industry seem to work at least temporary miracles. II-VI had about $3M in military SBIR through the 80s starting when it was already a firm over 100 employees. The five Phase 2 projects were relatively modest improvements, or even defensive research, on existing processes. DOD likes to trumpet II-VI as an SBIR success story even though its contribution was clearly minor. OK, victory has a thousand fathers. The company electro-optics products make a nice annual profit for a decade of about 10% net margin on sales that have been steadily rising. Profits per share have declined year-to-year though in 98 and 99.

Ikaria (Clinton, NJ)

Start-up Wisconsin.  A start-up [NitricGen] with a patent pending on a portable device to treat chronic diabetic foot ulcers won first place in the Wisconsin Governor's Business Plan Contest.  .... founded in Madison in 2011 by Duncan Bathe, Frederick Montgomery and two others. Bathe and Montgomery previously created a Middleton medical device company called Sadasis LLC (no SBIR) that they sold to Ino Therapeutics (no SBIR), which was in turn bought by Ikaria (no SBIR), a critical-care company based in New Jersey. The pair has 19 patents and seven medical devices in use, Montgomery said.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jun 5, 13]

Ikaria  (Clinton, NJ; no SBIR) withdrew its IPO [Nov 11, 10] after cutting its size and estimated price range. [Wall Street Journal, Nov 12, 10] ... a fully integrated biotherapeutics company  ... we are positioned to develop and deliver innovative therapeutics and interventions to meet the needs of critically ill patients [company website]

Ikonisys (New Haven, CT)

Ikonisys (New Haven, CT; one SBIR) diagnostics device firm, has raised $3.8 million of a planned $12 million ... Founded in 1999, Ikonisys has developed its CellOptics platform as the basis for automated cell-based diagnostic products. ...  two years ago the U.S. Food and Drug Administration granted approval for the company’s oncoFISH (Fluorescence In Situ Hybridization) HER2 test, intended for the detection of the more aggressive HER2 form of breast cancer.    [Michelle Lang, Mass High Tech, Aug 5, 10] Diagnostics device firm Ikonisys (New Haven, CT; one SBIR) received [FDA] clearance for its oncoFISH (Fluorescence In Situ Hybridization) HER2 test, intended for the detection of the more aggressive HER2 form of breast cancer. ... Founded in 1999, closed a $30 million Series E round of financing in October 2007, bringing the total amount raised by the company to $67.5 million. [Mass High Tech, Oct 29, 08]

Diagnostics device maker Ikonisys  (New Haven, CT; one SBIR) got a $30M VC finance deal. Since its start in 1999, it has raised $67M.  [Mass High Tech, Oct 17, 07]

Illinois Superconductor (Evanston, IL)

Illinois Superconductor (Mt Prospect, IL) completed installation of 15 RangeMaster Systems for Southwestern Bell Mobile Systems, one of the largest cellular providers in the US, which operates in 10 regions and has 5.5 million subscribers. ISCO claims to be a leading supplier of very high performance filters for the wireless telephony industry. The stock market, though, takes a dim view of ISCO's prospects as it trades down near 20% of its 1993 IPO price. Not that any SBIR superconductor company that went public is doing well either. ISCO had a BMDO SBIR, after its VC backing, for a gadget not related to the cellular phone equipment.

Darkness on ISCO(May 1) With little in the way of solid fundamentals, we are suspending coverage of Illinois Superconductor , said the one Wall Street firm, Grunthal, watching ISCO. Grunthal has recommended selling since last November. The stock has been from 1 to 15 in the twelve months and now rests below 3. ISCO got a start with a BMDO SBIR after it already had VC backing; it has had an imbroglio lately between management and an actively disappointed shareholder.

Diluted or Dead. Shareholders in Illinois Superconductor (Mt Prospect, IL) will have to choose whether to accept the money from new shares sold at way below the IPO price or running out of money. Charges and lawsuits are flying as the firm reports another quarterly loss over $2M.

Illinois Rockets
(Mar 16) Illinois Superconductor stock rose 60% Friday on 2.8M shares (daily average 231K) on top of Thursday's a 119% rise after S&P Equity Group upgraded its prospects. The Dow Jones story, though, said, One industry observer, however, warned of the superconductive electronic device maker's controversial financing agreements and high cash burn rate, or spending on overhead before generating positive cash flow from operations. Nobody's perfect, and 3.5 is still a long haul from the $11 of the 1993 IPO. Back in 1993, superconductors were cool.

Another loss also for Superconductor Technologies. $3.5M in both '96 and '97. The 1988 promise of superconductors has yet to show much economic benefit. The SBIR investments 1988-1992 made sense to give a new technology a chance. But now superconducting has reverted to the long pull of research for which SBIR is not suited.

Never Satisfied
(Nov 24) Illinois Superconductor's largest shareholder filed [another] lawsuit Friday against the company and its directors over a series of recent financing agreements. News of the suit drove down Illinois Superconductor shares nearly 32 percent on the Nasdaq. [Chicago Tribune, Nov 22]

Illinois Superconductor (Mount Prospect, IL) in a dive, down 80% from its high over the last 12 months after a loss of $3M for the quarter. ATMI (Danbury, CT), trading again as ATMI, a lot better off, now 2.5 times its low for the 12 months, even though it is down 20% from the high.

Illinois Super Gets $5M (Nov 3) Illinois Superconductor (Mt Prospect, IL) got $5M in equity financing for working capital and general corporate purposes. The company said it will use the funds primarily to support sales of its wireless telecommunications filter products. [Chicago Tribune, Nov 1]

 New Illini Super Product  (Sep 11) Illinois Superconductor (Mt Prospect, IL) unveiled its low-loss personal communications services transmit filter/duplexer as part of its SpectrumMaster line of filters for wireless communications. IS said the PCS transmit filter/duplexer handles over 20 watts of radio frequency power with acceptable intermodulation distortion levels. The company said it plans to begin shipping product in early 1998. [J Fitzgerald , Chicago Tribune, Sep 10] IS got its first SBIR (and one of very few) from SDIO soon after the venture backed company started.

Illinois Superconductor Hires Salomon (Aug 6) Illinois Superconductor (Mt Prospect, IL) under pressure from its biggest shareholder to lift its share price, hired investment banker Salomon Brothers to evaluate alternative strategies, including selling the firm and strategic alliances. ISC started in 1990 with financial help from the State of Illinois and BMDO SBIR to exploit high temp superconductivity. Lots of firms got such help in the HTSC optimism of 1988-1992. The firm's HTSC radio-frequency filters have been used by several cellular phone firms to reduce interference problems in difficult locations such as O'Hare Airport. But 7.7% shareholder Sheldon Drobny, says, "There is a strong perception right now that they're having trouble selling product. I believe that's untrue, but they are losing the propaganda war." Drobny has been energized by the drop in stock price from $24 to $9. Two other BMDO SBIR HTSC companies, Conductus and STI, have suffered similar shrinkage. [Story by Jon Van, Chicago Tribune, Aug 5]

ISCO's 7.7% Solution A holder of 7.7% of Illinois Superconductor common arranged a kicking upstairs of the CEO. The vocal investor wants management with "extensive operational experience and a Wall Street orientation" now that ISCO has advanced beyond the tech start-up stage. [Wall Street Journal, Jul 9] Out of that nursery.

Raising Another $17M Illinois Superconductor (Evanston, IL) will sell 1M shares in a secondary offering plus another possible 15% if the underwriters exercise their over-allotments. The going price of is around $17. ISCO went public at $11 after getting its first (and almost only) SBIR from BMDO. /p>

An Illinois Filter, Too While STI shows its HTSC (high temperatures are still cold by human standards) at the big Wireless 97 (where not having something is featured) show in San Francisco, Illinois Superconductor (Evanston, IL) will be showing its filter, too. (You show me yours, I'll show you mine) Indeed two filters that allow20% more coverage by a base station (which at the present rate of expansion will be on every roof) and 25% cell site range extension in networks. ISC got its first SBIR from BMDO for an unrelated HTSC item, a current control switch.

Year's Top Product SpectrumMasterTM was named one of 12 top products by Microwaves & RF, a telco industry journal. The Illinois Superconductor (ISCO, Evanston, IL) product competed with 5000 new products for the honor. Announced criteria (like SBIR judging) were design practicality, innovative use of technology, and greatest good for the greatest number (the classic utilitarian goal) of industry participants. The product allows (but does not mandate) fewer ugly towers in neighborhoods (NIMBY) because it lets through 35% more voice signal and reduces interference 10,000 times. Product is shipping. Whether neighborhoods see fewer towers is problematical when competition and not technology rules. Illinois had a BMDO Phase 2 SBIR for a current limiting switch (which doesn't seem to generate such press). [Source: Business Wire]

Superconductor Loss  Losses of $2M for the quarter and $4.5M for the half were in line with the Company's business plan. How comforting. "In July we achieved the most significant milestone in the Company's history when Southwestern Bell Mobile Systems placed the first commercial order for SpectrumMaster filters". It's at least good to know that someone is benefiting from superconductivity that was the technological rage in 1988. Illinois Superconductor (Evanston, IL) got its first (and one of few) SBIRs from BMDO.

Illumigen Biosciences (Seattle, WA)

Kineta (Seattle, WA; no SBIR) is trying a new approach. ... plans to fund its research step by step, relying on revenue-generating deals to undertake the next step in research. ... started the company last December but unveiled it publicly only this month.  Their new venture quickly came after the $9 million sale of their previous company, Illumigen Biosciences ($2M SBIR)... If Illumigen's research and commercial potential fully pans out, its shareholders could get up to $330 million in additional payments from Cubist. ... Kineta has so far partnered with Cubist for early-stage work on a hepatitis C drug, and has received funding from the National Institutes of Health. But it is also pitching itself to investors.  [Angel Gonzalez, Seattle Times, Dec 23, 08]

Cubist Pharmaceuticals  (Lexington, MA; $5M+ SBIR) lowered its previously reported fourth-quarter earnings to reflect a hefty acquisition charge [relating to buying] Illumigen Biosciences (Seattle, WA; $2M SBIR). [Boston Globe, Feb 13, 08]

Cubist Pharmaceuticals (Lexington, MA; $5+M SBIR) bought Illumigen Biosciences (Seattle,, WA; $2M SBIR) for $9M cash and planned milestone payments.  Cubist, of , will make up to $75M in development payments for Illumigen’s lead product, IB657, now aimed at treating hepatitis C. Development of the compound for other uses could trigger payments of up to $117M. [Boston Globe, Dec 27]

Illumina (San Diego, CA)

researchers from Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center and Dana-Farber Cancer Institute have joined forces with DNA sequencing giant Illumina and its liquid-biopsy spinoff Grail to develop a new assay. According to results published in the journal Annals of Oncology, they've come up with a method that can detect mutations in NSCLC patients’ blood with high sensitivity. [Angus Liu, Fierce Biotech, Mar 20, 19]

Illumina received its first official approval in China for its MiSeqDx benchtop sequencer, allowing it to directly market NGS testing in the country. [Conor Hale, Fierce Biotech, Aug 29, 18]

Illumina up 12% [Jul 31, 18]

Illumina announced that it acquired Edico Genome (San Diego, CA; no SBIR, founded 2013), the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results. [company press release, May 15, 18] the deal is reportedly worth $100 million [Chris Jennewein., May 16, 18]

Illumina announced that it acquired Edico Genome (San Diego, CA; no SBIR, founded 2013), the leading provider of data analysis acceleration solutions for next-generation sequencing (NGS). Edico Genome’s DRAGEN® Bio-IT Platform (DRAGEN) uses field programmable gate array (FPGA) technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results. [Illumina press release, May 15, 18] for $100M ;total Edico funding $32M []

Illumina Ventures reeled in $130 million in new funding, bringing its genomics-ventured fund to $230 million.  [Amirah Al Idrus, Fierce Biotech, Oct 16, 2017]

Illumina up 15% [Aug 2, 17]

Genomics startups are increasing in number and quality, so much so that three-year-old Illumina Accelerator has expanded with its latest class to accommodate five of them.  ... provides genomics-focused startups with capital, lab space at Illumina Accelerator’s offices in San Francisco, access to Illumina’s sequencing equipment and expertise, and advice on developing a business from legal experts, recruiting professionals, and Illumina executives and scientists, says Amanda Cashin, co-founder and head of the accelerator.  ..... takes an 8 percent equity stake ..   Checkerspot: designing advanced physical materials that can be used in industrial applications; Chimera Bioengineering:  aims to improve the efficacy and reduce the side effects of engineered cell therapies for oncology;  Encompass Bioscience:  wants to integrate genetic information into the healthcare system; Mantra Bio: studies exosomes, small lipid vesicles that are excreted from cells and deliver information, aiming to discover new drug targets and therapies;  Solarea Bio: The only company not from the Bay Area, Boston-based Solarea is developing probiotic treatments that are derived from natural sources   ....   Of the previous 13 startups that have completed the program since 2014, a few have already made some funding splashes.  Xcell Biosciences (San Francisco, CA; no SBIR) develops a type of cell culture that can be used in certain types of cell propagation and gene editing, raised a $12 million Series A round of funding in February.  EpiBiome (South San Francisco, Ca) raised a $6 million seed Series A round of funding for its process of engineering microbiomes that might be used against drug-resistant bacteria in early 2016.  Trace Genomics (New York) raised a $4 million seed round in mid-2016 for its work sequencing and analyzing the genomes of soil.     [David Holley,, Jul 26, 17]  

BGI (China) announced the launch of a West Coast Innovation Center, co-located in Seattle and San Jose.  ....   Seven years ago, BGI began its bid to turn China into a DNA superpower by buying 128 of the world’s fastest sequencing machines—then the Illumina HiSeq 200. That made BGI Illumina’s biggest single customer at the time, and an overnight sequencing sensation.  ....  Last March, almost exactly a year after Obama announced a $215 million initiative to sequence 1 million Americans, China finalized its plans for a much bigger, multi-billion dollar project.  [Megan Molteni, Wired, May 18, 17]   A Chinese company [A U.S. subsidiary of BGI-Shenzhen] will buy human genome sequencing company Complete Genomics (no SBIR, IPO 2010) for $113 million and provide $30 million in bridge financing for operations after signing a merger agreement.   [Ron Leuty, San Francisco Business Times, Sep 17, 12]

DNA sequencing giant Illumina marked its latest expansion by dedicating a massive new manufacturing building on its sprawling Golden Triangle campus. The 295,000-square-foot-building houses Illumina’s research, development, oncology, genetics and reproductive health operations.  [Bradley Fikes, San Diego Union Tribune, Jan 24, 17]

Grail (San Francisco, CA; no SBIR) one-year-old startup, spun out from Illumina, is raising a more than $1 billion Series B as it prepares to begin large-scale clinical testing of a blood test designed to detect cancer in its earliest stages.  [Luke Stangel, Silicon Valley Business Journal, Jan 9, 17]

Illumina  up 17% [Jan 10, 17]

DNA sequencing giant Illumina introduced a powerful new line of its instruments, bringing down the average time of sequencing a human genome to one hour — from more than one day just a couple of years ago. ... [CEO] DeSouza said, the company’s NovaSeq line is expected to reduce the cost of sequencing to $100 per human genome. That would be one-tenth the figure that Illumina announced in 2014, when it achieved the milestone of $1,000 per genome. A decade ago, the expense was about $10 million.  [Bradley Fikes, San Siego Union Tribune, Jan 9, 17]

Illumina down 25% [Oct 11, 16]  cut its third-quarter revenue guidance and gave a dour view for the current quarter on a bigger-than-feared decline in sales of its high-volume sequencing instruments.  [Tess Stynes, Wall Street Journal, Oct 11, 16]

Nanopore lawsuit settled. In March, genetic sequencing giant Illumina  sued Oxford Nanopore Technologies (UK) for patent infringement (Science, 4 March, p. 1010). Illumina claimed that Oxford's sequencing platforms rely on its patented Mycobacterium smegmatis porin (Msp) protein. Last week, the two companies reached a settlement, according to a U.S. International Trade Commission document dated 18 August. Oxford has agreed not to import or sell any product containing a pore with an amino acid sequence at least 68% similar to Msp and to destroy any inventory of such products. The document explicitly states that the restriction doesn't affect Oxford's ability to use CsgG, a different pore that the company unveiled shortly after the suit was filed, and which underlies its newest line of sequencers. Whether Oxford ever did rely on Msp is still a mystery.  [Science, Aug 26, 16]

San Diego County is noted as fertile ground for innovative start-ups[with] local biotech cluster that excels at bringing creative new ideas to market. It all began at UC San Diego and adjacent biomedical research institutions on the Torrey Pines Mesa. .... In the late 1970s, Hybritech (before SBIR) pioneered the use of monoclonal antibodies as diagnostics. Today, Illumina leads the world in developing advanced technology for sequencing DNA and Ionis Pharmaceuticals  leads the pack in using a broad method called antisense to create drugs that alter the effects of targeted genes. ... And this summer, the for-profit Synthetic Genomics (La Jolla, CA; no SBIR) unveiled a potential replacement for the workhorse bacterium E. coli, an engineered bacterium that replicates far faster, speeding up experiments and production of biotech products such as drugs.   [Bradley Fikes, San Diego Union Tribune, Sep 13, 16]

One firm in particular has been at the heart of this nascent genomic-data industry. Illumina (San Diego,CA) is the main provider of the machines that sequence genetic information. Its dominance, and its role in reducing costs (see chart), has led to comparisons with Intel’s grip on chipmaking. It controls 70% of a market worth $3.3 billion in 2015, according to Research and Markets, a research firm. As its customers, now mainly researchers, expand to include medical practitioners, that market could grow to between $12 billion and $20 billion by 2020.

Illumina down 23% [Apr 19, 16] scraping near 52-week lows after the company pared its revenue-growth target amid weaker-than-expected sales in Europe.  [Wall Street Journal, Apr 19, 16]

10X Genomics (Pleasanton, CA; no SBIR) raised $55 million in a Series C venture round to push ahead with its sequencer upgrade technology. The company makes a box that connects to Illumina machines and provides a better way to interpret short-read sequencing data, its officials say. The round adds to the $80 million in funding 10x announced at its debut last year. [Alex Lash,, Mar 18, 16]

For the first time, consumers can get their entire genome sequenced and analyzed for less than $1,000, a service that could reveal possible medical threats and help people to live healthier lives.  But the $999 program introduced by Veritas Genetics (Boston, MA; no SBIR) is raising questions about whether consumers can grasp and deal with disturbing news that comes from a genetics company.  There’s also debate about whether companies like Veritas and San Diego’s Illumina are doing the right thing in requiring customers to get a doctor’s approval for whole-genome sequencing. [Gary Robbins, San Diego Union Tribune, Mar 4, 16]

Illumina is like the Standard Oil of the genome age. Except instead of oil it pumps DNA.  More than 90 percent of all DNA data is generated by machines Illumina sells, ....  explains why Illumina said today it would try to block commercial sales of a disruptive new DNA sequencing instrument developed by a high-flying British rival, Oxford Nanopore.  [Antonio Regalado,, Feb 24, 16]

Cancer diagnostic maker Grail, spinout of Illumina, named top Google executive Jeff Huber as its first CEO. Grail launched a month ago with ambitions to develop a blood test that detects early stage cancer in seemingly healthy people. [Bruce Bigelow,, Feb 12,16]

Gene-sequencing machine maker Illumina, seeking to build on its strength in DNA sequencing, is launching a new company [called Grail] that will develop and market a test to detect genetic evidence of cancer in the blood. ...  with initial financing of more than $100 million joins race to develop ‘liquid biopsy’ [Ron Winslow, Wall Street Journal, Jan 10, 16]

Illumina down 11% [Oct 6,15]

Pathway Genomics  (San Diego, CA; no SBIR, founded 2008), known for pushing the boundaries of direct-to-consumer genetic testing, will launch a cancer screening test designed to detect bits of cancer DNA in the blood of otherwise healthy people.  ...  a first in the rapidly developing field of "liquid biopsies," which use gene sequencing technology to screen blood samples for trace amounts of DNA associated with different cancers. ... The cost to consumers begins at $299 to periodically check for DNA in their blood ... Guardant Health and Personal Genome Diagnostics Inc already offer blood tests for cancer patients. Roche-backed Foundation Medicine Inc, Genomic Health Inc, Illumina Inc and Sequenom Inc say they have similar tests in the works. [Julie Steenhuysen, Reuters, Sep 9, 15]

Illumina and [two] investment firms plan to announce  that they have created a new venture named Helix that is meant to serve as a hub for a constellation of analytic businesses.  ....   investing about $100 million in Helix, and Illumina’s [CEO] will serve as the venture’s chairman. ... an unusual move that its backers say is meant to help support the genetic analysis ecosystem. [MICHAEL J. de la MERCED, New York Times, AUG. 18, 2015]

Baebies (Durham, NC; no SBIR) raised $13 million to develop technologies to advance newborn screening worldwide. ...  Pamula and CEO Richard West founded Baebies after the sale of Advanced Liquid Logic (Research Triangle Park, NC; $10M SBIR) to Illumina (in 2013 for undisclosed amount) and licensed its core technology, digital microfluidics, from Illumina. In addition to a technology license in newborn screening that does not include sequencing, Baebies also received equipment, contracts, and other consideration in exchange for a share of ownership in the new company.  [Jason deBruyn, Triangle Business Journal, Jul 28, 15]

Among the Technology Review fifty smartest companies: Illumina ($5M SBIR plus acquired firms), Alnylam ($600K SBIR), DNAnexus (one SBIR).  The other quadrillion SBIR winners haven't been as smart as the best. To make the list, a company must have truly innovative technology and a business model that is both practical and ambitious, with the result that it has set the agenda in its field over the past 12 months. [, Jun 29]

Illumina, the market leader in DNA sequencing technologies, will open a 13,000 square foot manufacturing facility in Madison [WI].  The facility will house a fermentation suite and specialized processing labs to produce specialty enzymes used in DNA sequencing and related technologies for life sciences research, the company said. ... At full capacity, it will employ more than 80 people, a spokeswoman said.  Illumina was named the world's smartest company by MIT Technology Review. {Kathleen Gallagher, Milwaukee Journal Sentinel, Jun 11, 15]

Synthetic DNA startup Twist Bioscience (San Francisco, CA; no SBIR,  founded 2013) raised $37 million in Series C funding to accelerate commercialization efforts.  Gene-sequencing company Illumina led the round ... synthetic DNA production for specialty chemical compounds and drug development. The company claims its platform has the potential to greatly accelerate the development of personalized medicine  [Cromwell Schubarth, Silicon Valley Business Journal, Jun 11, 15]

Adaptive Biotechnologies (Seattle, WA; no SBIR), a leader and pioneer in next generation sequencing (NGS) of T-cell and B-cell receptors in the immune system, announced today the completion of Adaptive’s Series F financing round with a $195 million investment to support several strategic growth initiatives. ... Adaptive is also backed by industry-leading strategic investors Illumina, Celgene, BD Biosciences and LabCorp. [company website, May, 6, 15]

Graduates of Illumina's life sciences technology accelerator in Mission Bay could pocket $1 million to $5 million in matching capital, thanks in part to a $40 million injection into a fund by a deep-pocketed investment firm [Viking Global Investors] ...  The Illumina Accelerator, part of a growing community of company-sponsored spaces for startup companies in the Bay Area, invests $100,000 in convertible notes and provides a $20,000 unsecured equity line as well as access to instruments and legal, licensing and other support.  [Ron Leuty, San Francisco Business Times, Feb 27, 15]

Graduates of Illumina Inc.'s life sciences technology accelerator in Mission Bay [CA] could pocket $1 million to $5 million in matching capital, thanks in part to a $40 million injection into a fund by a deep-pocketed investment firm [Viking Global Investors]  ... The fund will match, dollar for dollar, what each accelerator graduate raises during a six-month funding cycle that aligns with the companies' stays at the facility.    [Ron Leuty, San Francisco Business Times, Feb 26, 15] 

Illumina will take 360,000 square feet of lab and office space in BioMed Realty Trust's Lincoln Centre development in Foster City with the option for another 160,000 square feet.  ... to consolidate most of its Bay Area operations   [Ron Leuty, San Francisco Business Times, Jan 5, 15]

Sequenom up 13% [Dec 3, 14]   Illumina and Sequenom settled their patent and intellectual property disputes, [they said] Ending the disputes will allow the companies to collaborate and grow their markets, analysts said. The companies will pool their patents regarding noninvasive prenatal testing.  [Bradley Fikes,, Dec 3, 14]

Edico Genome (La Jolla, CA; no SBIR, founded 2013) took first place [in The Scientist top ten innovation list] for its Dragen Bio-IT Processor. The add-on card accelerates the analysis of genomic data by a factor of 30, says Pieter van Rooyen, Edico's president and chief executive.  ....  Genome sequencers from Illumina took second and third place   [Bradley Fikes,, Dec 1, 14]  Other winners: BioNano Genomics, RainDance Technologies  (Lexington, MA; $1.1M SBIR) , Leica Microsystems, Organovo  (San Diego, CA; $300K SBIR), Haplogen Genomics, Immucor, Sciencescape.    [The Scientist, Dec 1, 14]

US and China agreed a big trade deal, Information Technology Agreement announced in Beijing, subject of course to a US Senate ratification if they can take time out from running against Obama and dialing for dollars, that would eliminate roughly $1 trillion in tariffs on a range of products including medical equipment, software, GPS technology and other high-tech goods. ...  “One local example is Illumina competing with (Beijing Genomics Institute) in China,” [Eric Topol, director of the Scripps Translational Science Institute] said. “Taking down the tariffs could help Illumina compete in what is a ginormous market.”  [Paul Sisson, utsandiego, Nov 11]

Illumina revealed the first three companies admitted to its six-month accelerator program in San Francisco for genomics-related startups. The three companiesEncoded Genomics  (San Francisco, CA; no SBIR), Xcell Biosciences (San Francisco, CA; no SBIR), and EpiBiome  (Union City, CA; no SBIR) —get full access to Illumina’s next-generation gene sequencing systems.  [Alex Lash,, Oct 17, 14]

Given that the size of a computer has gone from filling a room to filling a back pocket, ...  [DEC founder Ken] Olsen's doubt may also serve as a lesson for investors to never underestimate the possibilities of breakthrough innovations. ...  particularly valuable when applied to genomics, because if genomics proves as game-changing as the computer, Illumina may someday become a blue-chip company like IBM. ....  the average all-in cost to sequence a genome fell to less than $5,000 earlier this year from nearly $100 million in 2001. Those costs, which are paid by sequencing centers that receive funding from NHGRI, are likely to continue falling as more facilities shift to Illumina's latest sequencer, the HiSeq X Ten.  ...   Illumina's real blue-chip opportunity may not be in building increasingly less expensive machines, but in leveraging the genomic information that these machines are producing.   Illumina is already moving in this direction by offering bioinformatics solutions such as BaseSpace, a software service that automates workflow prep for sequencing, provides analysis and storage of genomic data, and gives users a real time interface for charting and viewing genomic data.  If Illumina successfully embeds itself into customer's daily routine with an easy to use UI and increasingly relevant analytics, it would be reminiscent of technology bellwethers Microsoft, which locked millions of users up with its Office suite, and Apple, which did the same thanks in large part to iTunes.  [Todd Campbell, Motley Fool, Oct 13, 14]

Medical College of Wisconsin Human and Molecular Genetics Center received a $2.5 million grant to analyze the genes of patients with undiagnosed diseases in collaboration with Illumina  [Milwaukee Journal Sentinel, Sep 29, 14]  Illumina also recently announced that the leading maker of DNA sequencing equipment, is partnering with Sanofi , AstraZeneca , and Johnson & Johnson  to create a test for more mutations in dozens of genes that will be used first in clinical trials and, eventually, to help decide which patient should get which marketed drug. [Matthew Herper, Forbes, Aug 21, 14]

A record 228,000 human genomes will be completely sequenced this year by researchers around the globe, said Francis de Souza, president of Illumina, the maker of machines for DNA sequencing. ... The price of sequencing a single genome has dropped from the $3 billion spent by the original Human Genome Project 13 years ago to as little as $1,000, he said. ... the company’s growth has rested sometimes precariously on two curves. One has been the collapsing price of sequencing. The other is the soaring demand from genome scientists and funding agencies.  [Antonio Regalado,, Sep 24, 14]

Cypher Genomics  (San Diego, CA; no SBIR, founded 2011, 10 employees) biotech startup has signed a sales partnership with DNA sequencing giant Illumina and brought on board some prominent industry veterans. ...  Illumina's sales force will sell Cypher Genomics's service which analyzes genomes to discover clinically important information. The software uses all the genome, including the great majority lacking genes that code for proteins but that still may contain sequences that influence health, said Ashley Van Zeeland   [Bradley Fikes, utsandiego. com, Jul 24, 14]

Michael Farr, president of Farr, Miller & Washington, which manages about $1.1 billion, said that in January he trimmed a stake in Illumina that was considered a small-cap stock when he purchased it. The stock almost doubled in price last year, giving the stock an outsize position in Mr. Farr's portfolio.  "The small caps have done fabulously well for a long time," he said. "We're really trying to protect against the downside." [Wall Street Journal, Jul 21, 14]

The British government says that it plans to hire the U.S. gene-sequencing company Illumina to sequence 100,000 human genomes in what is the largest national project to decode the DNA of a populace.... picked as the “preferred partner” for the £100 million project ... ct ....  llumina [released] a new system, the Hiseq X Ten, which it says would be able to sequence genomes for $1,000 each, crossing a long-anticipated price barrier [ Antonio Regalado,, Jul 11, 14]

Illumina is adding to the Bay Area's long list of incubators, with help from legendary investor Yuri Milner. .... will create the world's first genomics incubator, aimed at accelerating the number of entrepreneurs, startups and early-stage companies working on next-generation sequencing applications.  .... the Russian entrepreneur and venture capitalist, who is offering $100,000 to each company in the facility in exchange for convertible notes [Ron Leuty, San Francisco Business Times, Feb 12, 14] 

Illumina the smartest. Almost 25 years after the Human Genome Project launched, and a little over a decade after it reached its goal of reading all three billion base pairs in human DNA, genome sequencing for the masses is finally arriving. It will no longer be just a research tool; reading all of your DNA (rather than looking at just certain genes) will soon be cheap enough to be used regularly for pinpointing medical problems and identifying treatments. This will be an enormous business, and one company dominates it: Illumina  (San Diego, CA; $10M SBIR). ...  sells everything from sequencing machines that identify each nucleotide in DNA to software and services that analyze the data. In the coming age of genomic medicine, Illumina is poised to be what Intel was to the PC era—the dominant supplier of the fundamental technology. [Eilene Zimmerman ,,  Feb 18, 14]  Other SBIR companies among 50 smartest:  Cree (Durham, NC; $10M SBIR), Qualcomm (San Diego, CA; $1.5M SBIR), Arcadia  Biosciences (Davis, CA, $200K SBIR).

Hoping to speed adoption of genomics technology and expand its customer base, DNA sequencing giant Illumina is setting up what it calls the world’s first genomics incubator.  Called the Illumina Accelerator Program, the San Diego company described it Wednesday as a business accelerator to help entrepreneurs and young companies develop uses for next-generation sequencing (PDF), a market Illumina dominates.   [Bradley Fikes,, Feb 12, 14]

The dramatic rise in Illumina stock reached another milestone. For the first time, the DNA sequencing giant has surpassed $20 billion in market value. [, Feb 10, 14]

In a follow-up to Illumina’s announcement last week that it had cracked the $1,000 human genome barrier, the DNA sequencing giant unveiled detailed marketing plans for its DNA sequencing machines. ... said it intends to set the standards by which the growing flood of genomic data is collected, interpreted and made useful for medical care.   [Bradley Fikes,, Jan 20, 14]

The cost of sequencing a human genome has been brought below $1,000, San Diego DNA sequencing giant Illumina said, opening the door to bringing the full benefit of 21st-century genomic medicine to the public. [Bradley Fikes,, Jan 14, 13]

Illumina received FDA approval last week to sell its new next-generation sequencer for clinical use. .....  Increasingly powerful DNA sequencers have uncovered a mountain of data on how changes in the human genome affect health and disease. These “next-generation” instruments have greatly speeded up genome sequencing, while bringing down the price from hundreds of millions to as little as $5,000.   .... that knowledge will now be brought directly to patients as part of normal medical care.    [Bradley Fikes,, Nov 26, 13]

[FDA] approved four "next-generation" gene-sequencing devices with the potential to make faster and more precise diagnoses of cystic fibrosis, the chronic disease afflicting about 30,000 patients just in the U.S.  Two of the four tests have potential, too, to be used in the diagnosis and treatment of certain genetically identifiable cancers, according to the FDA. The tests are produced by Illumina. [Thomas Burton, Wall Street Journal, Nov 20, 13]

Illumina up 10% [Oct 22, 13]

Advanced Liquid Logic (Morrisville, NC; $10M SBIR) startup creating “Lab on a Chip” diagnostics, has been acquired by Illumina ....  Its microfluidics technology will enable Illumina to advance more efficient next-generation sequencing (NGS).  Financial terms were not disclosed. .... the North Carolina Biotechnology Center, responding to a 25 percent budget cut, counts ALL among its portfolio companies, having granted the startup four loans totaling $468,100. N.C. Biotechnology Center spokesperson Robin Deacle confirms that the loans have been repaid. ALL has nabbed other investments over the past few years, including $6 million from angel investors, $30 million in federal research grants and $20 million in strategic partner funding, she notes. [Lauren Ohnesorge, Triangle Business Journal, Jul 23, 13]

Illumina up 11% [Jul 24, 13] on a strong earnings report []

DNA sequencing giant Illumina has been ordered by a federal court to pay Auburn, Wash.-based Syntrix Biosystems  (Auburn, WA; $13.7 M SBIR) $115.1 million in a patent infringement case. ....  for technology using silica beads that pick up specific DNA sequences  [Bradley Fikes,, Jun 19, 13]

[post-merger internal reshuffling is] bad news for Life Technologies’ autonomous Ion Torrent Systems unit, the No. 2 player in the high-speed DNA sequencing industry. And bad news for Ion Torrent is good news for Illumina the unrivaled No. 1 in this fast-emerging and important market. [Luke Timmerman,, Apr 29, 13]

Illumina  up 13% [Apr 23, 13]

A federal jury in Tacoma found that Illumina, a maker of genetic-analysis equipment with $1.15 billion in sales last year, infringed Syntrix Biosystems’ (Auburn, WA; $12.7M SBIR) patent on synthetic matrix and array technology. ...  the biggest patent-infringement verdict in state history, though the $95.8 million judgment likely will be appealed.  [Drew Desilver, Seattle Times, Mar 15, 13]

SynapDx (Lexington, MA; no SBIR) currently developing diagnostics for the earlier detection of autism, said it has formed an alliance with Illumina that specializes in life sciences tools. A goal of the alliance is to combine SynapDx’s proprietary autism technologies with Illumina’s sequencing platform to develop early detection tools for autism spectrum disorders. [Chris Reidy,  Boston Globe, Mar 8, 13]

Illumina will buy prenatal test company Verinata Health (no SBIR) for $350 million and up to $100 million in milestone payments through 2015, the companies said [Ron Leuty, San Francisco Business Times, Jan 6,13]

Illumina, the leading manufacturer of DNA sequencing machines, said hat it would buy the privately held Verinata Health (Redwood City, CA; no SBIR) for at least $350 million in cash to expand its push into the diagnostics business.  Verinata sells a test that uses a blood sample from a pregnant woman to determine whether her baby will have Down syndrome or some other chromosomal abnormalities [Andrew Pollack, NY Times, Jan 7, 12]

Moderna Therapeutics,stealthy startup (Cambridge, MA) subject of their considerable brainpower and experiments. the company is finally emerging from stealth, having raised $40 million to dateSince the first sequencing of the human genome was completed in 2003 at a price tag of over $2 billion, the speed, price and accuracy of the technology have all improved. Illumina has dropped its price for individual readouts to $5,000; earlier this year, Life Technologies introduced a sequencer it says can map the human genome for $1,000. The smallest machine is now desktop-size. [Amy Dockser Marcus, Wall Street Journal, Dec 29, 12]

Illumina says it can now sequence a person's entire genome in as little as two weeks, a service meant to help physicians diagnose and treat disease. But for the short term, at least, the test will be of limited use. In 2009, the American Medical Association surveyed more than 10,000 doctors and found that almost 75 percent of them had no significant education in genetic testing.  [Gary Robbins,, Sep 11, 12]

Having trouble sifting through all that DNA data gathered in a gene sequencing test?  There’s an app for that.   Illumina, a maker of machines that map genes, said that it’s setting up a software marketplace around its BaseSpace gene sequencing service.  Called BaseSpace Apps, the marketplace is a genomics version of Apple’s Apps Store, and it aims to break a bottleneck around software for analyzing genetic information.  [, Apr 27, 12]

Illumina, the market-leading maker of DNA sequencing instruments, said it is creating an open platform for genomic software developers to make apps for scientific customers who want to slice and dice through DNA data. This new initiative is called Basespace Apps, and will enable researchers to store their data on cloud computing infrastructure provided by Amazon Web Services, and then make it possible to download various genomic software “apps” to analyze and interpret the data.  [Luke Timmerman,, Apr 25, 12]

Swiss drugmaker Roche said it would not extend a $6.8 billion hostile offer for genetic specialist Illumina as the U.S. group's shareholders blocked its move to appoint new directors.  [Reuters, Apr 18, 12] Having had $8M SBIR by 2006, the company now disdains $6.8B.  If it remains independent, we shall see how well it swims the shark filled waters of open global competition.

Illumina said its board of directors had adopted a poison pill shareholder rights plan that could allow existing shareholders to purchase more shares at a discount under certain conditions.  The move, which is fairly common in hostile takeover bids, could potentially make it much more expensive for Roche to gain control of Illumina – thus thwarting the takeover.  [Mike Freeman,, Jan 26, 12]

Illumina up 55% [Jan 25, 12]

Roche Holding AG is offering $5.7 billion in cash to buy U.S. gene sequencing company Illumina  in a hostile takeover bid that marks a major play by the Swiss drugmaker into the gene technology field.  ....  Companies such as Illumina, Affymetrix and Life Technologies get 20-40 percent of their revenue from U.S. government-backed research and may take a hit from any government funding cut.  [Reuters, Jan 25, 12]  Illumina enjoyed about  $10M SBIR 1999-2010, and a $4.6B market cap before the Roche gambit. Founder David Walt now owns less that 1% of the shares. Employees: 1200.

Illumina will reduce its global workforce by nearly 9 percent by laying off about 200 employees as part of a restructuring  Keith Darce, [, Oct 27,11]Illumina down 32% [Oct 7, 11] fell the most ever after dropping its profit forecast because of concerns that research funding will be reduced, sending shares of rival equipment makers down.  .... The weakness in demand may continue as the U.S. government, looking to curtail spending, mulls the research budget for agencies  [Bloomberg, Oct 7]  Indeed, the companies that subsist on federal funding will have a problem as long as deficit reduction is the plat du jour. If SBIR is lucky, Congress won't notice that SBIR's economic return is incalculable (that means nobody knows what it is, if anything).

Illumina down 18% [Jul 27, 11]  investors had very high hopes for screaming growth from the company

Illumina, maker of genetic testing tools, said that it will open on office in Sao Paolo, Brazil, on Feb. 1. [signonsandiego,com, Jan 18, 11]

a French scientist tells me he is moving his startup, Portable Genomics, to San Diego. ...  based on the assumption that it will be possible in another year to completely sequence an individual human genome for less than $1,000—and within three years, for less than $300. This is the promise of the recent announcements coming out of Life Technologies, Illumina, and Complete Genomics, as the speed of genetic sequencing increases and costs plummet. [Bruce Bigelow,, Jan 14, 11]

Illumina and Life Technologies [make the machines that separate DNA from samples of saliva, blood, skin and other tissue for genetic analysis. ] both cut their genomics teeth on DNA testing products and sequencing machines designed mainly for human medical research. However, agriculture-related business has become increasingly important to the companies in recent years, executives said.  Crop and livestock customers generated $100 million in sales for Illumina in 2009, or 12 percent of total revenue, said Tristan Orpin, a senior vice president and chief commercial officer ....  Illumina now offers separate commercial chips for testing cows, dogs, pigs, sheep, horses and corn. Each chip sells for between $195 and $295, and the largest one (for cows) tests for 500,000 markers.  In November, Life Technologies began selling a genetic testing kit for quicker detection of viral diarrhea in cows, a costly disease that can spread rapidly in a herd and reduce the body weight, and value, of sick animals. [Keith Darce,, Dec 21, 10]

Life Technologies took a step toward lowering the cost of genetic sequencing and expanding the availability of the revolutionary technology by launching its new Ion Torrent Personal Genome Machine. ... acquired the machine in August when it purchased the device’s creator, Ion Torrent (Guilford, CT, no SBIR), in a $725 million deal. .....  among several, including Illumina of San Diego, that are racing to introduce new ways of sequencing genes that expand the use of the technology  [, Dec 17, 10]

Sage Science (Beverly, MA; no SBIR), a developer of laboratory and research-related technologies, has taken in $2.02 million in an equity offering ...  Founded in 2005, Sage Science signed a co-marketing deal with Illumina in October to promote sample preparation use of Sage Science’s Pippin Prep in conjunction with Illumina’s DNA sequencing platforms. ... last raised a $2 million round of venture capital funding, with 16 investors, in March. [Michelle Lang, Mass High Tech, Dec 2, 10]

Illumina (San Diego, CA; $9M SBIR) was 130th on the new Deloitte Fast 500 list of fastest-growing technology companies [Mike Freeman, signonsandiego, Oct 21, 10]

Illumina rose 10 percent in after-hours trading after the company reported first-quarter earnings that topped Wall Street estimates. [signonsandiego, May 4]

Illumina up 13% [Apr 29, 10]

Companies to Watch in personalized medicine. Affymetrix, Life Tech, Illumina, Helicos Biosciences, Metabolon.  Among the fifty most innovative:  A123 Systems, American Superconductor, Alnylam, Illumina, iRobot, Novomer, BIND Biosciences.  [MIT Tech Review, M/A10]

Illumina has found a famous early adopter for a futuristic personal genome-sequencing service it offers.  The company said Thursday that movie and television star Glenn Close had her genome sequenced last fall, one of about 10 people to have their genetic data compiled since the company introduced the service in June.  While it’s expensive, at $48,000, Illumina says it believes the cost will quickly become a realistic option for many people (with a spare $48K).  [Thomas Kupper, San Diego Union Tribune, Mar 11, 10]

Affymetrix down 14% [Jan 13, 10]  The technology that Affymetrix develops is quickly becoming obsolete, or so analysts believe. ... increased pricing pressures from competitors as its technology becomes quickly outdated by new genetic analysis technology such as Illumina’s sequencing technology. [Lisa LaMotta,, Jan 13, 10]

Illumina unveiled new technology yesterday that it says will bring the cost of sequencing a human genome below $10,000. It was the latest milestone in the advancement of genetic analysis, from the $3 billion Human Genome Project a decade ago to current systems that can run a person’s genome for around $50,000.  [Thomas Kupper, San Diego Union Tribune, Jan 13, 10]

Illumina up 16% [Jan 12, 10]

Illumina said its board has approved a plan to buy back up to $100 million of the San Diego company’s stock. The buyback program follows a $75 million stock repurchase plan the company announced in August and has recently completed. [, Nov 26] 

Illumina down 20% [Oct 28, 09] It swung to a profit, but warned its fourth quarter and year will disappoint. [Wall Street Journal, Oct 29]

Illumina  down 12% [Jul 2, 09]  said revenue for its second quarter would fall below Wall Street estimates after falling short in the first quarter as well. [Wall Street Journal, Jul 3]

Illumina is launching a futuristic service that will give consumers the chance to get their DNA sequenced. But it's not cheap: $48,000. The company, which specializes in DNA research tools for scientists, thinks consumer gene sequencing could become widespread within a few years. That could give patients quick access to personalized information as the role of specific genes in disease becomes better understood.  [Thomas Kupper, San Diego Union Tribune, Jun 11, 09]

Illumina  up 10% [Mar 23, 09]

Illumina   up 21% [Feb 4, 09]

Illumina up 11% [Oct 30, 08]

Illumina down 22% [Oct 22, 08]

Illumina up 10% [Oct 13, 08]

Illumina down 11% [Oct 6, 08]

Illumina (San Diego, CA; $9M SBIR) sold more 4 million shares to the public to raise $343M. [San Diego Union Tribune, Aug 13, 08]

an up kind of day for genetics analysis company Illumina (San Diego, CA; $9M SBIR).  report of a 66% jump in revenue and a $6.1 million increase in quarterly profits. ... would acquire genetics sequencing company Avantome for $25 million upfront and contingent payments of up to $35 million. ... a 2-for-1 stock split. [Terri Somers, San Diego Union Tribune, Jul 23, 08] If the Congress wants to know where and why SBIR seems to succeed, it should explore why most of the economic success stories come from the life sciences and little from the mission agencies - NASA and DOD which have the lion's share of the SBIR money. 

Illumina was up 26% last week and up 79% for 52 weeks. [Jan 14, 08]

Illumina jumped 16% to a record high [Jan 10, 08] after the company settled a patent lawsuit with Affymetrix Inc.

Steady growth and the departure of top executives have driven Illumina (San Diego,CA; $9M SBIR) that does genetic analysis, to reorganize into two operating units. ... As the science at biotechnology companies has progressed over the past few years, there have been increasing demands for the genetic analysis and products developed by Illumina. Meanwhile, technology advances have made the tests performed by Illumina much more affordable. ...  Revenue for the first nine months of 2007 was $254M [San Diego Union Tribune, Jan 5]

Illumina fell 10% despite better earnings. [Feb 2, 07]

Illuminating Diagnostics (Buffalo, NY))

Perseverance.  Sarah Scouten was born in Western New York and built a family here, including four children, while finally finishing her Ph.D in biochemistry at the University at Buffalo in 2009.  ...  Two years later, she was hired by local startup AndroBioSys, and worked at the company until it folded in 2014. Newly unemployed, Scouten looked around at the things happening in Buffalo, including the 43North business competition and Start-Up NY tax breaks program. She decided it was time to start her own company, based on an idea she'd had several years before when she contracted a serious MRSA infection. ....  Her solution is an invention based on Scouten's expertise in molecular and microbiology and genetics, for which she has gained a provisional patent. The company, Illuminating Diagnostics (no SBIR), was one of 113 semifinalists at 43North and recently gained entry into Start-Up NY, and has been accepted into UB's Biosciences incubator at the Clinical and Translational Research Center on the Buffalo Niagara Medical Campus. [Dan Miner,  Buffalo Business First, Jan 15, 15]

IlluminOss Medical (East Providence, RI)

IlluminOss Medical (East Providence, RI; no SBIR) that has developed a bone stabilization system for treating fractures, said Thursday that it has secured a $28 million Series C round of venture capital financing.[Chris Reidy, Boston Globe, Sep 27, 12]

IlluminOss Medical (East Providence, RI; no SBIR, founded 2007), has taken in a $4 million debt financing round, the company noted   ...  develops its Photodynamic Bone Stabilization System used in stabilizing and treating bone fractures. The photodynamic polymer system is intended to replace traditional screws, plates and pins used to stabilize fractured bones. It has been approved in Europe for use in low load bearing bones. [Michelle Lang, Mass High Tech, Nov 30, 11]

IlluminOss Medical  (East Providence, RI; no SBIR) raised $11M in Series B funding, according to published reports. ... develops medical devices for the treatment of bone fractures. [Mass High Tech, Apr 4]

Illumitex (Austin, TX)

Illumitex (Austin, TX; no SBIR, founded 2005, 60 employees) maker of high-tech [LED] lights used in offices and by indoor farmers, has completed a $16 million Series C-1 round of funding. ... increases to $76.8 million the amount of investment capital Illumitex has raised since launching  [Christopher Calnan, Austin Business Journal, Aug 11, 15]

Lighting developer Illumitex (Austin, TX; no SBIR) received $3.8 million of a planned $8 million financing from four investors. [Austin Business Journal, Apr 15, 13]

Illumitex(Austin, TX; no SBIR, founded in 2005) received $2 million in debt securities, according to a securities filing. The company develops and sells high brightness LEDs for the general lighting market, including residential, commercial and industrial uses. .... has raised a total of about $41 million. [Lori Hawkins, Austin American Statesman, Mar 29, 12]

Illumitex (Austin, TX, no SBIR; founded 2007)  has received $13.5 million of a planned $25.2 million financing. ... develops light-emitting diode, or LED, technology  [Cristopher Calnan, Austin Business Journal, Jun 13, 11]<

The experts say light-emitting diodes are creating the biggest change in the lighting industry since Edison. And a little-known Illumitex, (Austin, TX; no SBIR) says it has developed a way of making LEDs that is more energy efficient than previous methods. The 5-year-old startup unveiled its first LED product line Thursday and said it is working with an array of lighting system manufacturers that like its promise of delivering more highly directed light from smaller diodes that consume less energy. [Austin American Statesman, Apr 1, 10]

Illumitex (Austin, TX; no SBIR) has received $4.3 million of a planned $10 million round of financing. ... develops light-emitting diode technology ... founded in 2007, has been operating in stealth mode ... In June, the company was reportedly in beta production  [Austin Business Journal, Oct 14, 09]

Imagen Energy (Milwaukee, WI)

Imagen Energy (Milwaukee, WI; one SBIR) [developing] an advanced energy storage system consisting of an extremely compact 150kW high frequency 3-Level inverter, an integrated 48kWhr compact Li-ion battery system, proprietary battery management systems and internet communications capability. [company website, Oct 24, 17] The Wisconsin Economic Development Corp. and the University of Wisconsin-Extension’s Center for Technology Commercialization launched the SBIR Advance matching grant program in 2014, and have now awarded $4.15 million to 56 Wisconsin companies.  ...  The other companies receiving up to $75,000 grants are: GoDx (Madison, WI), Stem Pharm (Fitchburg, WI), Microscopy Innovations (Marshfield, WI), -based Photonic Cleaning Technologies (Platteville, WI) and Proteovista LLC (Madison, WI).  [Molly Dill, Milwaukee Biz Times, Oct 10, 17]

ImageVision (Anna,TX)

The Dallas Angel Network has a new $1.1 million fund and already has granted its first of three investments to a North Texas startup - ImageVision (Anna, TX;  no SBIR) with its first $340,000 allotment.    [Danielle Abril,  Dallas Business Journal, Dec 11, 13]

Imaging Biometrics (Elm Grove, WI)

Imaging Biometrics (Elm Grove, WI; $200K SBIR) medical imaging software firm received an $800,000 [NIH SBIR] grant ... to develop and distribute its software to neuroradiologists, oncologists and surgeons [Kathleen Gallagher,  Milwaukee Journal Sentinel, Sep 22] Funding low technical risk projects to reduce business risk does not meet a market failure croterion for government market intervention.  But it does make politicians and beneficiaries happy. 

ImagineOptix (Raleigh, NC)

ImagineOptix (Cary, NC; no SBIR), NC State spinout, scores $9M in funding [Lauren K. Ohnesorge, Triangle Business Journal, Dec 20, 18] prior funding $6M; commercializing patented optical thin-films and related products []

Researchers from NC State and ImagineOptix (Raleigh, NC; no SBIR) have unveiled a new polarization-conversion system (PCS) that makes liquid-crystal (LC) based projectors (such as many picoprojectors) almost twice as efficient. The device does this by separating light into its two polarization components, rotating one component 90° to line up with the other, then using all the light (minus any optical inefficiencies) [John Wallace, Laser Focus World, Jul 17, 12]

Imago Scientific Instruments (Madison, WI)

Ametek (Paoli, PA, annual sales of $2.1 billion) announced that it has acquired  Imago Scientific Instruments (Madison, WI; $900K SBIR) manufacturer of three-dimensional atomic probe microscopes. "Imago is a pioneer in the development of 3-D atom probe technology, which is used in advanced materials science to conduct atomic level imaging and analysis. Imago provides us with additional technical capabilities, significantly broadens our customer base and strengthens our global leadership in this high-end technology," said Frank A. Hermance, Ametek's chairman and CEO. Ametek manufactures electronic instruments and electromechanical devices, and reports. [Don Walker, Milwaukee Journal Sentinel, Apr 9, 10]

Imanis Life Sciences (Rochester, MN)

LifeScience Alley, the regional trade association that represents life science and health technology companies, announced that 10 organizations will be exhibiting cutting-edge products as part of the association’s New Technology Showcase at the 2013 LifeScience Alley Conference, Nov. 20 at the Minneapolis Convention Center.   Featured will be:  (Rochester, MN;  no SBIR), developing a cancer-selective virus particularly suited to destroy relapsed or metastatic cancer cells; Omnis PharmaRebiotix (Roseville, MN; no SBIR), which will present something called Microbiota Restoration Therapy, which delivers live, human-derived microbes to patients’ intestinal tracts to restore balance and treat certain diseases; and (Naperville, IL; no SBIR) will demonstrate its remote patient monitoring and predictive analytics system, which converts patient vital signs into information to aid in care.    VGBioCogCubed (Minneapolis, MN;  no SBIR) will exhibit an approach to diagnosing and treating cognitive health by analyzing game play data; Datuit (Roseville, MN; no SBIR) will display a platform allowing patients, family and clinicians to confidentially share medical information; Imanis Life Sciences   (Rochester, MN; no SBIR) will show a gene-based platform for promoting non-invasive, long-term imaging technologies in living beings; Mednology Solutions (Excelsior, MN;  no SBIR) will exhibit a system designed to improve efficiency in the management of medical emergencies; NanoVault Medical (St. Paul, MN; no SBIR) will show a cellular and biotherapeutic delivery technology to treat autoimmune diseases. ReMind Technologies of Houston, Tex., will exhibit a smartphone-based medication dispensing device and Skyline Medical, Inc. of Eagan will show an automated surgical fluid disposal device with unlimited capacity and real-time fluid volume data. For more information.  [James Walsh, Minneapolis Star Tribune, Sep 25]

Imbed Biosciences (Madison, WI)

Imbed Biosciences (Fitchburg, WI; $3M SBIR), announced it has closed its Series A Preferred Stock equity financing, which was expanded to $4 million due to investor demand. [company press release, Nov 7, 19]

Imbed Biosciences (Fitchburg, WI; $2M SBIR, founded 2010), that makes medical devices for wound care, reported raising $1.05M, which is part of an overall $3.5M round [WisconsinInno, Nov 15. 18] prior funding $4M []

Imbed Biosciences (Fitchburg, WI; no SBIR, founded 2010) has raised a funding round of nearly $1.6 million, which the startup plans to use to begin selling an ultra-thin wound dressing material [nanofilm technology that uses silver’s antimicrobial properties to kill infection-causing pathogens] later this year, CEO Ankit Agarwal says. [Jeff Buchanan,, Jan 2, 18]

Imbed Biosciences  (Fitchburg, WI;  SBIR), which is developing an ultra-thin dressing material that it says has much lower levels of silver than conventional dressings. ... has raised $600,000 from three investors, according to a regulatory filing ... will likely support Imbed in its effort to commercialize its Microlyte Ag technology—the name refers to silver’s periodic table symbol—which the FDA recently cleared Imbed to sell   [Jeff Buchanan,, Aug 18, 16]

Imbed Biosciences  (Fitchburg, WI; no SBIR) which is seeking to commercialize an ultra-thin wound dressing material invented in a lab at the University of Wisconsin-Madison, received FDA clearance to market the dressing for human use, the university said.   [Jeff Buchanan,, Aug 8, 16]

Imbed Biosciences (Madison, WI; no SBIR) raised $683,000 of a planned $1 million funding round  [Milwaukee Journal Sentinel, Sep 5, 14]      a spin-off from the University of Wisconsin-Madison  ...  developing novel and patent-pending technologies for imbedding bioactive molecules in wound dressings and surgical implants.  ... and ideally reduce the overall cost of managing surgical and chronic wounds, a $3 billion market opportunity in the U.S. and Europe  [company website] 

Imbed Biosciences (Madison, WI; $500K SBIR) received a [NIH SBIR] grant of $1.5 million to continue developing biologic dressings [containing silver nanoparticles that allows closure of hard-to-heal wounds without infection or silver toxicity] that could be used to prevent wound infections and promote cell growth and healing. [Kathleen Gallagher, Milwaukee Journal Sentinel, Jul 28, 14] first product platform is antibacterial silver nanofilms ...  co-founder [one of five] Nicholas Abbott is Professor and Chairmain of the Chemical Engineering Department at the University of Wisconsin-Madison. Dr Abbott has 20 years of experience in colloid and surface science, and is an internationally recognized leader in the field. He is the cofounder of Platypus Technologies (Fitchburg, WI; $9M SBIR), a nanotechnology company.  [company website]

Eight Wisconsin biotech companies have been selected as winners of the BioForward 2013 Emerging Company Showcase:  ABL Technologies LLC   (Greenfield, WI; no SBIR); Co-D Therapeutics (Madison, WI; no SBIR); Imbed Biosciences (Madison, WI; no SBIR)  medical device company developing novel and patent-pending technologies for imbedding bioactive molecules in wound dressings and surgical implants [company website]; Insert MRI  (no SBIR) developing a platform technology for encapsulating workflow 'apps' to interactively guide magnetic resonance (MR) image-guided surgical procedures [company website]; Microscopy Innovations  (Marshfield, WI; no SBIR) New Capsule-based System for  preparing Microscopy Specimens  [company website]; Regenerative Medical Solutions (Chicago/Madison; no SBIR) develop a protocol to grow healthy and resilient pancreatic stem cells [company website]; Stealth Therapeutics (Madison, WI; no SBIR) less invasive medical devices [company website]; and XenoGen Biosystems ( Madison, WI; no SBIR)  Mathematical Modeling and Computing for the Life Sciences [company website]. ... represent "a cross section of emerging companies in our industry sector that we feel are going to make an impact down the road," said Bryan Renk, BioForward's executive director.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 4, 13]

Imbed Biosciences (Madison, WI;  no SBIR) has received a $326,000 [SBIR] to continue developing biologic dressings that could be used to prevent wound infections and promote cell growth and healing.  {Kathleen Gallagher, Milwaukee Journal Sentinel, Apr 13, 12]

iMetalx Group (Pittsburgh, PA)

iMetalx Group ( Pittsburgh, PA; no SBIR) awarded $2.68 million [from ARPA-E] to develop an advanced electrochemical system to produce titanium from titania using domestic ore. [Justine Coyne, Pittsburgh Buiness Times, Sep 20, 13]

Imiplex (Newtown, PA)

BioAdvance, operator of the Biotechnology Greenhouse Corp. of Southeastern Pennsylvania, said it made commitments of $2.4 million to seven new life science companies:  RMH Sciences  (Philadelphia, PA; no SBIR) which is developing antibacterial agents for the treatment of resistant gram negative and gram positive infections; Ossianix  (no SBIR), which is developing single domain antibodies based on the shark VNAR structure to treat immunological, inflammatory, musculoskeletal, neurologic, and other disorders; Merganser Biotech (Newtown Square, PA; no SBIR) which is developing hepcidin peptides for the treatment of hemoglobinopathies such as sickle cell anemia and diseases of iron overload; Anakim Biologics (Exton, PA; no SBIR) which is developing efficiencies and improvements in biologics manufacturing; Enzium (Philadelphia, PA; no SBIR) which is developing highly sensitive biosensor methodologies for the testing of proteases and other enzymes; Imiplex (Newtown, PA; two SBIRs) which is developing the TriPol platform, engineered from proteins, designed to provide a flexible system for constructing diverse nanostructures; Cool-Bio (Wayne, PA; no SBIR) which is developing platelet-inhibiting technology geared specifically to activation during the cooling process of cardiac bypass.  [John George, Philadelphia Business Journal, Jun 20, 12]

Immco Diagnostics

Immco Diagnostics Amherst NY)(Amherst NY; $1.3M SBIR, 90 employees) Founded as a research lab at the University at Buffalo in 1971 ....   has been acquired by an [Irish] company in a $32.75 million deal. ... Trinity Biotech plc, an international diagnostic products company that focuses on the point-of-care and clinical laboratory markets. [Tracey Drury, Buffalo Business First, Aug 23, 13] 


Immersion down 24% [Aug 3, 18] reported earnings

Immersion up 36% [Jan 29,18] announced that the Company has entered into [confidential] settlement and license agreements with Apple.

Immersion up 28% [Nov 30, 17]

Immersion down 10% [Nov 6, 17]

Immersion up 11% [Aug 17, 17]

Immersion up 10% [Aug 9, 17]

Immersion  down 18% [Aug 4, 17]

Immersion down 10% [May 5, 17]

Immersion down 20% [Mar 3, 17]  reported quarterly earnings

Immersion up 17%[Nov 4, 16]

Immersion down 14% [Aug 5, 16]

Immersion  up 11%[Jun 23, 16]

Immersion up 13%[Jun21, 16]

Immersion up 16% [Feb 26,16]

Immersion up 10%[Feb 12, 16]

Immersion down 10% [Jan4, 16]

Immersion  up 17% [Oct 30, 15]

Immersion up 19% [Jul 31,15] reported record revenue

Immersion down 12% [Sep 9, 14]  announced that it has extended its license agreement with Samsung, for the use of TouchSense® and Integrator products in smartphones and other mobile devices  [Business Wire, Sep 8]

Immersion down 23% [Aug 1, 14]

Immersion up 11% [Jul 10,14]

Immersion up 11% [Jun 30, 14]

Immersion up 11% [Apr 30, 14]

Immersion up 13% [May 3, 13]

Immersion up 12% [Apr 16, 13]

Immersion up 16% [Mar 8, 13]

Immersion up 31% [Mar 7, 13]  after it struck a multi-year licensing agreement with Samsung Electronics Co. Ltd and raised its 2013 revenue forecast by over 50 percent. [AP,Mar 7, 13]

Immersion  up 35% [Nov 27, 12] entered into a settlement and license agreement with Google and Motorola Mobility LLC, resolving the patent infringement litigation pending between Immersion and Motorola. []

Immersion up 13% [Nov 13, 12]

Immersion up 10% [Nov 12, 12]

Immersion down 10%  [Jun 25, 12]

Immersion up 10% [Nov 16, 11]

Immersion  down 11% [Nov 7, 11]

Immersion  down 16% [Nov 4, 11]

Immersion up 10% [Oct 4, 11]

Immersiondown 13% [Aug 5, 11]

Immersion up 13% [May 6, 11]  when [sales and profits] numbers exceeded analysts consensus, and were also much stronger than we expected. [Seeking, May 6]

Immersion  up 13% [Dec 30, 10]

Immersion down 10% [Nov 5, 10]

Immersion  up 10% [Sep 30, 10]

Immersion up 10% [Jun 25, 10]

Immersion up 10% [May 10, 10]

Immersion up 11% [Jul 27, 09]

Immersion  down 23% [Jul 1, 09]  is conducting an internal investigation into certain previous revenue transactions in its Medical line of business. [Business Wire, Jul 1]

Immersion   down 10% [May 5, 09]

Immersion  down 10% [Apr 20, 09]

Immersion  up 12% [Mar 23, 09]

Immersion  down 13% [Mar 5, 09]

Immersion down 25% [Mar 3, 09] 

Immersion down 13% [Feb 9, 09]

Immersion down 13% [Jan 20, 09]

Immersion up 14% [Dec 8, 08]

Immersion up 12% [Nov 24, 08]

Immersion down 15% [Nov 14, 08]

Immersion up 10%[Nov 13, 08]

Immersion down 11% [Nov 5, 08]

Immersion up 11% [Nov 3, 08]

Immersion up 12% [Oct 30, 08]

Immersion up 16% [Sep 16, 08]

Immersion down 12% [Aug 1, 08]

Immersion up 15%  [Jun 5, 08]

Immersion up 11% [Apr 29,08]

Immersion climbed 13% amid news that a new CEO and president was appointed [, Apr 25, 08]

Immersion  up 14% [Jan 31, 08]

Immersion up 14% [Sep 27, 07]

Immersion down 10%. [Aug 15,07]

Immersion dropped 16% after an analyst offered cautious comments on the company's shares ... are pricing in "unachievable" growth opportunities beyond his already bullish assumptions. [Jul 16, 07]

Immersion up 17% [Mar 2, 07]

Immtech Pharmaceuticals

Immtech Pharmaceuticals down 46% after the New York pharmaceutical company said it will discontinue all development for a potential treatment for African sleeping sickness, after the development of kidney and liver abnormalities in a subgroup of volunteers in a safety study of the drug.  [Wall Street Journal, Feb 26] 

Immtech Pharmaceuticals up 15% [Feb 5, 08]

Immtech Pharmaceuticals up 15% [Jan 23, 08]

Immtech Pharmaceuticals down 16%  [Jan 16, 08]

Immtech Pharmaceuticals down 20% [Jan 4, 08]

Immtech Pharmaceuticals up 36% [Dec 28, 07]

Immtech Pharmaceuticals down another 25%  [Dec 27, 07]

Immtech Pharmaceuticals down 51%[Dec 26, 07]

Immtech Pharmaceuticals up 14% [Dec 5, 07]

Immtech Pharmaceuticals down 10% despite new scientific support for it product. [Aug 14,07]

Immtech Pharma down 10%. [Mar 5, 07]

Immtech Pharmaceuticals up 19% [Dec 14, 06] after its earlier announcement of a Phase 2 trial of a malarial prophylactic.

Immucell (Portland, ME)

Immucell up 10% [May 4, 18]

Immucell up 11% [May 12,17]

Immucell (Portland, ME; $2.5M SBIR before 2003) down 15% [Oct 18, 16]  a growing animal health company that is developing, manufacturing and selling products that improve health and productivity in the dairy and beef industries, announced private placement of approximately $3.5 million of ImmuCell's common stock.  [company press release, Oct 17, 16]

Immucell (Portland, ME; $2.5M SBIR) down 24% [Jan 29, 16] announced the pricing of its previously announced underwritten public offering  [company press release]

Immucell (Portland, ME; $2.4M SBIR) up 10% [Nov 13, 15]

A skin cancer drug developed in the Bay Area will work with another locally grown drug after federal regulators approved the combination. Cotellic — originally the work of  Exelixis (South San Francisco, CA; no SBIR) before being handed off to biotech giant Genentech Inc. — can be used in combination with Zelboraf, another Genentech drug developed by Plexxikon (Berkeley, CA; $300K SBIR) .  ....  The drugs, which reportedly will cost $17,600 a month, can now be used to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery.     [Ron Leuty, San Francisco Business Times, Nov 10, 15]

Immucell (Portland, ME; $2.5M SBIR) up 18% [Jul 29,15]

Immucell down 11% [May 21, 15]

Immucell (Portland, ME; $2.5M SBIR) up 26% [May 13, 15]  Total sales increased 49% in most profitable quarter since 2003. [company press release]

Immucell (Portland, ME; $2.5M SBIR) up 15% [Mar 26,15]

Immucell  (Portland, ME; $2.5M SBIR)  up 12% [Jan 21, 15]

Immucell (Portland, ME; $1.6M SBIR  1990-2002) up 16% [Dec 11, 14]

Immucell (Portland, ME; $2.5M SBIR) up 12% [Sep 18, 14]

Immucor (Norcross, GA)

Edico Genome (La Jolla, CA; no SBIR, founded 2013) took first place [in The Scientist top ten innovation list] for its Dragen Bio-IT Processor. The add-on card accelerates the analysis of genomic data by a factor of 30, says Pieter van Rooyen, Edico's president and chief executive.  ....  Genome sequencers from Illumina took second and third place   [Bradley Fikes,, Dec 1, 14]  Other winners: BioNano Genomics, RainDance Technologies  (Lexington, MA; $1.1M SBIR) , Leica Microsystems, Organovo  (San Diego, CA; $300K SBIR), Haplogen Genomics, Immucor, Sciencescape.    [The Scientist, Dec 1, 14]

[FDA] Blood Products Advisory Committee voted to recommend approval of Immucor (Norcross, GA; no SBIR) HEA Molecular BeadChip Test as a safe and effective evaluation for blood group typing.  .... The test provides additional information about the composition of donor and patient blood ...   It is currently available for research use only in the United States, though it is commercially available in Europe and other international markets.   [Ellie Hensley, Atlanta Business Chronicle, Mar 19, 14] 

Immune Control (West Conshohocken, PA)

Immune Control (West Conshohocken, PA; no SBIR) and Arginetix (Baltimore, MD; no SBIR) said they are merging to form Corridor Pharmaceuticals Inc., which will develop novel treatments for vascular diseases with an initial focus on pulmonary arterial hypertension. In conjunction with the merger, Corridor Pharmaceuticals completed a $15 million Series A financing involving previous investors in the two companies.  [John George, Philadelphia Business Journal, Jun 17, 10]

Immune Design (Seattle, WA)

Four months after Immune Design (no SBIR)  halted a late-stage study for its lead cancer vaccine and saw its stock price cut nearly in half, the immunotherapy company is now in line to join Merck’s pipeline in a deal worth approximately $300 million. Merck announced that it has agreed to acquire Immune Design [Frank Vinluan,, Feb 21, 19]

Immune Design (Seattle, WA; no SBIR) lays off [20%] workers and shifts course after halting lead cancer vaccine trial [Casey Coombs, Puget Sound Business Journal, Oct 16, 18]

Immune Design up 13% [Mar 8, 18]

Immune Design up 10% [Mar 2, 18]

Immune Design down 11% [Nov 13, 17]

Immune Design up 12% [Oct 30, 17]

Immune Design down 16% [Oct 24, 17]

Immune Design down 16% [Oct 19, 17] announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation for G100, Immune Design's investigational intratumoral therapy, for the treatment of follicular non-Hodgkin's lymphoma.   [company press release, Oct 19, 17]

Immune Design down 20% [Oct 18, 17]

Immune Design down 19% [Oct 17, 17]

Immune Design up 14% [Jun 23,17]

Immune Design down 12% [Jun 22,17] 

Immune Design  up 19% [Jun 21,17]

Immune Design  up 19% [Jun 21,17]

Immune Design up 11% [May 18, 17]

Immune Design up 13% [Mar 9, 17]

Immune Design down 11% [Dec 28, 16]

Immune Design raised $30 million [Casey Coombs, Puget Sound Business Journal, Nov 17, 16]

Immune Design up 22% [Nov 10, 16]

Immune Design up 15% [Nov 9, 16]

Immune Design up 14% [Nov 7, 16]

ImmuneDesign down 17% [Jun 21, 16]

Immune Design down 12% [May 11, 16]

Immune Design up 10% [Apr 13, 16]

Immune Design up 10% [Mar 31, 16]

Immune Design down 12% [Mar 23,16]

Immune Design down 18% [Feb 8, 16]

Immune Design up 10% [Feb 4, 16]

Immune Design up 11% [Jan 20, 16]

Immune Design down 17% [Jan 13, 16]

Immune Design up 17%  [Nov 6, 15]

Immune Design up 10% [Nov 2, 15]

Immune Design up 12% [Oct 15,15]

Immune Design down 13% [Sep 25, 15]

ImmuneDesign up 11% [Sep 2, 15]

Immune Design up 11% [Aug 26, 15]

Immune Design up 11% [Aug 14, 15]

Immune Design up 12% [Aug 12, 15]  announced a partnership with Genentech, the U.S. biotech arm of Swiss drug company Roche, for a clinical trial.  [Annie Zak, Puget Sound Business Journal, Aug 12, 15]

Immune Design down 26% [Aug 11, 15] reversed previous day spike; announced it has entered into clinical collaboration agreements through subsidiaries of Merck, known as MSD outside of the United States and Canada, to evaluate the safety and efficacy of two Immune Design immuno-oncology investigative agents, G100 and LV305 [company press release]

Immune Design up 19% [Aug 10, 15]

Immune Design down 10% [Jul 24,15]

Immune Design up 15% [Jul 10,15]

Immune Design down 10% [Jun 26, 15]

Immune Design, that develops treatments for cancerous tumors, plans to raise $60 million in an offer of its common stock  ... raised $60 million last year when the company went public [Annie Zak, Puget Sound Business Journal, Apr 14, 15]

Immune Design up 10% [Apr 14,15]

Immune Design (Seattle, WA and South San Francisco, CA; no SBIR), said it has begun a Phase 1 trial of its G100 cancer immunotherapy agent, combined with radiation therapy, in patients with metastatic sarcoma.  [Alex Lash,, Feb 12, 15]

Immune Design  down 12% [Jan 20, 15]

Immune Design  up 11% [Jan 13, 15]

Immune Design down 14% [Dec 30, 14]

Immune Design up 20% [Dec 19, 14]

Immune Design up 15% [Dec 18, 14]

Immune Design down 11% [Dec 4, 14]

Immune Design up 11% [Nov 21, 14]

ImmuneDesign  up 17% [Nov 13, 14]

Immune Design up 10% [Oct 29, 14] 

Immune Design up 12% [Oct 21, 14]

Immune Design down 11% [Oct 15, 14] 

Immune Design up 12% [Oct 3, 14]

Immune Design up 11% [Sep 26, 14]

Immune Design up 13% [Sep 11, 14]

Immune Design (Seattle, WA; no SBIR) said its [IPO brought in] $60 million  ... developing immune-based therapies to fight cancer and plans to use the IPO’s proceeds to complete phase 1 clinical trials and advance development of its drug candidates targeting breast cancer, melanoma, non-small cell lung cancer, ovarian cancer, sarcoma or Merkel cell carcinoma.   [Seattle Times, Jul 24, 14]

Immune Design (Seattle, WA; no SBIR) biotechnology company working on immune-based therapies to fight cancer, has filed  [IPO]  .... wants to raise $60 million to complete the phase 1 clinical trials and to support continued development, including into phase 2 clinical trials .... has never been profitable and does not plan on bringing in real revenues in the foreseeable future  ... has raised $93.7 million  [Brandon Brown, Seattle Times, Jun 24, 14]

The Column Group, the David Goeddel-led VC firm whose investments include up-and-coming companies like Igenica Biotherapeutics  (Burlingame, CA; no SBIR) , Immune Design  ( Seattle, WA; no SBIR) and NGM Biopharmaceuticals  (S San Francisco, CA; no SBIR) has raised $176 million toward a projected $250 million fund.  ....  Goeddel was the first scientist hired by Genentech and eventually went on to cofound Tularik (S San Francisco, CA;  $500K SBIR), which was sold to Amgen 10 years ago for $1.3 billion.  [Ron Leuty, San Francisco Business Times, Apr 17, 14]

cancer therapy company Immune Design (Seattle, WA; no SBIR) said it's closed on a Series C financing round that could raise up to $49 million.  ..... to advance Immune Design's cancer immunotherapy product pipeline, including proof-of-concept studies for its lead therapeutic candidates ID-LV305 and ID-G305," Immune Design said  [Ben Miller, Puget Sound Business Journal, Oct 30, 13]  

Investors promised to pump another $49 million into Immune Design (Seattle, WA; no SBIR) as the cancer immunotherapy company pushes three therapies into the clinic next year and opens a clinical development center in the Bay Area. [Ron Leuty, San Francisco Business Times, Oct 30, 13]  

Immune Design (Seattle, WA; no SBIR) took a big step forward as a company in 2010 when it struck a deal to let AstraZeneca’s MedImmune unit test out its proprietary vaccine boosters, or adjuvants. Now, it’s got a bigger goal in mind: using a broad collaboration with two big non-profit organizations to break into the hot field of cancer immunotherapy. .....   formed a partnership with the Ludwig Institute for Cancer Research and the Cancer Research Institute, two New York-based non-profits that support cancer research and sponsor and conduct clinical trials. [Ben Fidler,, Jun 12, 13]

Immune Design   (Seattle, WA; no SBIR), the developer of vaccine technology, said it has pulled in another $11 million through the second tranche of its previously announced Series B venture financing. The company is backed by some prominent VC firms [Luke Timmerman,, Oct 6, 11]

Immune Design (Seattle, WA; no SBIR) said it’s raised $32 million in Series B financing ... developing vaccines and immunotherapies for infectious disease and cancer. ... said it’s raised $50 million since its founding two years ago [Puget Sound Business Journal (Seattle), Jul 26, 10]

Immunetics (Boston, MA)

Rule One: spend the money.   Immunetics (Boston, MA; $9M SBIR) received a $3.7 million, two year [NIH] SBIR contract to support clinical trials of a new blood screening test for Babesia infection.  “Babesia is among the top infectious threats to blood safety and, at present, there is no licensed test available.  [company press release, Sep 10, 12]  Multi-million awards in principle violate the law's provisions for award sizes.  But Congress doesn't seem concerned because, after all, every award of any size has two Senators and Representative with great praise for a brilliant government investment in a constituent company. What Congress won't tolerate is the agency's not spending the legally mandated minimum SBIR total for the year.

Infectious disease testing company Immunetics (Boston, MA; $9.2M SBIR) won a three-year, $2.4 million Phase 2 [NIH] SBIR grant. ... aid in bringing its confirmatory test for Chagas’ disease, a potentially fatal parasitic infection, to clinical trials, Immunetics said [Michelle Lang, Mass High Tech, May 3, 11]

Test developer Immunetics (Boston, MA; $7M SBIR) has been awarded a $2.8 million contract as part of a long-term study of blood safety involving HIV and other complications of blood transfusions. [James Connolly, Mass High Tech, May 18, 10]

Immunetics(Boston, MA;  24 workers; $5.5M SBIR) won two federal grants totaling $1.2M to develop a test for antibiotic resistance in bacteria. [Mass High Tech, Jun 6, 08] Company press release [Jun 4] announced [FDA] approval of its test for anthrax infection

Immune Pharma (New York, NY)

Immune Pharma (New York, NY; no SBIR) up 50% [Apr 20, 17] announced that it has entered into a letter of intent with Pint Pharma GmnH, a pharmaceutical company focused on Latin America and other markets ("Pint"), which binds the parties to seek agreement regarding an exclusive license by Pint of the rights to commercialize Ceplene throughout Latin America  [company press release, Apr 20, 17] after last week's 1-20 reverse split

ImmuneWorks (Indianapolis IN)

ImmuneWorks (Indianapolis IN; no SBIR), a life-sciences startup based at Indiana University's Emerging Technologies Center, has developed a therapeutic product it says can help fight IPF and increase the success rate of lung transplants. ... The company last week secured $300,000 in early-stage funding from BioCrossroads' $6 M Indiana Seed Fund 1, and hopes to begin clinical trials by next summer. [Chuck Bowen, Indianapolis Star, Oct 30]

Immunex (Seattle, WA)

VLST (Seattle, WA; no SBIR) biotech that raised about $50 million in its nine-year history, has wound down all its operations and sold off its remaining assets ....  One buyer has scooped up an antibody drug candidate for cancer that’s being prepped for mid-stage clinical trials. Another buyer has obtained VLST’s proprietary drug discovery engine, preclinical drug candidates, and related intellectual property, [CEO] Simonetti said.  ....  founded 2004 by Immunex veterans Craig Smith and Steve Wiley.  ....  never put a single drug candidate from its discovery group into clinical trials.   [Luke Timmerman,, Aug 7, 13]

Pfizer, the world's largest drug company, has agreed to pay up to $632 million to Theraclone Sciences (Seattle, WA; no SBIR) in a research collaboration on antibody drugs for cancer and infectious disease, the companies said ...  The company is led by Steven Gillis, a scientist and venture capitalist who previously co-founded Seattle biotechnology companies Immunex (Seattle, WA; three Phase I SBIRs) and Corixa (Seattle, WA; $4M SBIR).   Amgen bought Immunex for about $16 billion in 2002; GlaxoSmithKline bought Corixa for about $300 million in 2005.  [Duff Wilson, New York Times, Jan 19, 11]  SBIR advocates should calculate the ROI to the government, and the economy, if the government had taken an appropriate equity share for its capital investment. And then insist that future SBIR be managed in such a way to push the investments to such entrepreneurs instead of the life-style companies with no taste for ROI.

ImmuneXcite (Cambridge, MA)

ImmuneXcite  (Lexington, MA; $300K SBIR) a biopharmaceutical company focused on developing transformative immuno-oncology products that utilize the power of both the innate and adaptive immune response, today announced the completion of an $8.6 million Series A-1 financing ... In 2015, ImmuneXcite established undisclosed early-stage collaborations with two of the leading biopharmaceutical companies in the immuno-oncology space.  [company press release, Mar 30, 16]

biotech startup ImmuneXcite (Cambridge, MA; no SBIR) has taken in $2.48 million in the company’s first institutional funding round, according to a federal document. .... developing a product platform that will cause an excited immune response to things like cancer cells, based on the research of co-founder and chief scientific officer Ifat Rubin-Bejerano, a senior researcher at the Whitehead Institute at MIT. According to the presentation, Rubin-Bejerano discovered a polysaccharide that is found on the cell walls of fungal cells, which triggers the body’s immune response to such cells if there is a fungal infection.  [Rodney Brown, Mass High Tech, Jan 4, 12]

Immunexpress (Seattle, WA)

Immunexpress (Seattle. WA; no SBIR, 14 employees) has won [FDA] clearance for a diagnostics test that could save hospitals billions of dollars. The FDA cleared the Seattle biotech's SeptiCyte LAB analysis that tests for sepsis, a life-threatening immune response to infection.  ....  [CEO] Brandon and four others founded Immunexress in Australia in 2006 and moved its headquarters to Seattle in 2010.   ....  has raised $42.5 million.  [Casey Coombs, Puget Sound Business Journal, Feb 23, 17]

biotech Immunexpress (Seattle, WA; no SBIR, 25 employees, founded 2006 in Australia) is trying to raise up to $40 million in a Series C round that it plans to close by mid-year. ....  designs assays that test for a life-threatening immune response called sepsis ... Over the next 12 to 18 months, will double its workforce  ... To date has raised $42.5 million  [Rachel Nielsen, Puget Sound Business Journal, Mar 2, 16]

Immunic (San Diego, CA)

Immunic down 17% [Sep 4, 19]

Immunic (San Diego, CA; no SBIR) up 71% [Jul 10, 19] a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases ... Its subsidiary, Immunic AG, is based in Planegg-Martinsried, Germany, where the company’s research and development activities are conducted.   [company website]

Immunic down 26% [Jun 25, 19]

Immunic (San Diego, CA; no SBIR), up 91% [Jun 24, 19] clinical-stage biopharm focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, announced that [it] will present previously unpublished data regarding the company's lead program, IMU-838, at the GI Inflammatory Diseases Summit (GIIDS). [company press release, Jun 24, 19]


Immunicon slipped 12% after reporting a bigger loss. [Feb 21, 07]

Immunicon down 12% in a soggy week for its stock. [Dec 14, 06]

Immunitas Therapeutics (Boston, MA

Immunitas Therapeutics (Boston, MA; no SBIR), a single cell genomics-based drug discovery company, announced a $39 million Series A financing .... Underlying the company’s programs is the unique drug development platform crafted by the Immunitas team along with Aviv Regev (Professor of Biology and Core Member of the Broad Institute and Investigator at the Howard Hughes Medical Institute) that dissects the microenvironment of human tumors using single cell genomics-based approaches to identify novel immune targets [company press release, Nov 21, 19]

ImmunoCellular Thera

ImmunoCellular Therapeutics (Calabasas CA;  no SBIR)up 93% [Jan 10, 17] stock price is down 90+% from 2012, after 1:40 reverse split in Nov 2016.

ImmunoCellular Thera down 10% [Nov 23, 16]

ImmunoCellular Thera up 26% [Nov 21, 16]  a week after 1:40 reverse split

ImmunoChemistry Technologies (Bloomington, MN)

Sally Hed recently became the sole owner of  ImmunoChemistry Technologies (Bloomington, MN; $1.2M SBIR, ten employees) that makes biotechnology tools that, since 1994, have helped researchers at places like NIH and the WHO find remedies for a host of maladies and diseases. .... bankruptcy averted only when ImmunoChemistry earned its first major patent and sold it in 2014 plus royalties, the company is cash-flowing on about $3 million in revenue.  [Neal St. Anthony, Minneapolis Star Tribune, Aug 7, 16]


Presage Biosciences (Seattle, WA; no SBIR) has been named one of FierceBiotech ’s “Fierce 15” of 2013.  ... a spinoff company of the Fred Hutchinson Cancer Research Center  .... patented a novel method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single tumor while that tumor is still in a patient.  .... FierceBiotech evaluates hundreds of private companies from around the world each year before selecting the 15 it considers the most innovative, creative and promising.   The other Fierce 14 are:   Acetylon Pharmaceuticals;   AnaptysBioCytomX  (Santa Barbara, CA; $500K SBIR); FibroGen  (South San Francisco, CA; $1.3M SBIR);  Immunocore; Jounce TherapeuticsKala PharmaceuticalsMacroGenics  (Rockville, MD; $2.6M SBIR) ; Moderna Therapeutics; Nimbus Discovery; Scioderm; UltragenyxUniQure; and Visterra.  [Valerie Bauman,  Puget Sound Business Journal , Sep 24] 

ImmunoGen   (Cambridge, MA)

Immunigen up 23% [Nov 5, 19]

Immunogen up 28% [Nov 1, 19]

drugmaker ImmunoGen (Waltham, MA) announced it will reduce its workforce by approximately 220 employees, after an operational review. [company press release, Jun 27, 19[

Immunogen down 32% [May 15, 19] announced the [FDA] has recommended that the Company conduct a new Phase 3 randomized trial to evaluate the safety and efficacy of mirvetuximab soravtansine in patients with high folate receptor alpha (FR)-positive, platinum-resistant ovarian cancer as part of a Type C meeting held this week. [company press release, May 15, 19]

Imunogen up 15% [May 6, 19]

A phase 3 trial of ImmunoGen’s antibody-drug conjugate mirvetuximab soravtansine has missed its primary endpoint. The ADC failed to extend progression-free survival by more than chemotherapy. [Nick Paul Taylor, Fierce Biotech, Mar 1, 19]

Immunogen down 20% [Feb 27, 19]

Immunogen up 14% [Feb 6, 19]

Immunogen down 16% [Oct 22, 18]

Immunogen down 11% [Oct 4, 18]

Immunogen down 15% [Mar 27, 18]

Immunogen up 18% [Feb 12, 18]

Sanofi has dropped (PDF) an anticancer antibody-drug conjugate it licensed from ImmunoGen. The French pharma gained full control of the anti-LAMP1 drug as part of a recent deal but has now removed the asset from its pipeline. ImmunoGen first teamed up with Sanofi to work on ADCs against the target in 2013. [Nick Paul Taylor, Fierce Biotech, Feb 7, 18]

Immunogen down 13% [Feb 5,18]

Immunogen up 10% [Jan 31,18]

Immunogen up 10% [Jan 9, 18]

Immunogen up 12% [Dec 13, 17] 

Immunogen  down 13% [Nov 1, 17]

Immunogen up 10% [Oct 27, 17]

Immunogen down 10% [Oct 5, 17]

Immunogen down 11% [Sep 12,17]

Immunogen up 12% [Aug 30, 17] Jazz Pharmaceuticals (Ireland) and ImmunoGen, announced that the companies have entered into a collaboration and option agreement granting Jazz Pharmaceuticals exclusive, worldwide rights to opt into development and commercialization of two early-stage, hematology-related antibody-drug conjugate (ADC) programs, as well as an additional program to be designated during the term of the agreement. [joint companies press release, Aug 29, 17]    ImmunoGen lists 11 compounds in development with 10 partners, among them Eli Lilly, Novartis, and Takeda Pharmaceutical. Its last partnership came in May when Switzerland-based Debiopharm International paid $25 million up front for rights to non-Hodgkin lymphoma drug candidate in Phase 2 testing.  [Frank Vinluan,, Aug 29, 17]

Immunogen up 17% [Aug 29, 17]

Immunogen down 15% [Jul 31, 17]

Immunogen up 14% [Jul 28, 17]

Immunogen up 12% [Jul 24, 17]

Immunogen up 13% [Jun 26,17]

Immunogen  up 11% [Jun 21,17]

Immunogen up 10% [Jun 20,17]

ImmunoGen got $30 million from Sanofi to amend a 2003 deal and give up its right to co-promote a group of experimental cancer drugs in the U.S.  [Ben Fidler,, Jun 2, 17]

Debiopharm International SA (Switzerland) and Immunogen (Waltham, MA, $1.6M SBIR in 1990s, founded 1981), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, announced that Debiopharm has acquired  ImmunoGen's IMGN529/DEBIO 1562, a clinical-stage anti-CD37 ADC for the treatment of patients with B-cell malignancies, such as non-Hodgkin lymphomas (NHL).  ... ImmunoGen received a $25 million upfront payment for IMGN529/DEBIO 1562 and is entitled to a $5 million milestone payment to be paid after completion of the transfer of ImmunoGen technologies related to the asset, which the parties expect to achieve by the end of 2017. In addition, ImmunoGen is eligible for a second success-based milestone payment of $25 million upon IMGN529/DEBIO 1562 entering a Phase 3 clinical trial.  [joint companies press release, May 23, 17] 

Immunigen up 14% [May 18, 17]

Immunogen up 11% [May 15,17]

Immunogen down 10% [May 8,17]

Immunogen up 17% [Apr 20, 17]

Immunogen up 10% [Apr 19, 17]

Immumogen up 21% [Feb 27,17]

Immunogen down 29% [Jun 14, 16]

Immunogen down 19% [Apr 29, 16]

Immunogen down 16% [Sep 21, 15]

Immunogen up 14% [Sep 17, 15]

Immunogen up 13% [Jul 16,15]

Immunogen   up 16% [Jul 13,15]

Immunogen (Waltham MA; $1.6M SBIR) up 72% [Jun 1, 15] after the biotechnology company told the American Society of Clinical Oncology meeting that one of its drugs showed promising results in the treatment of ovarian cancer.  []

Immunogen down 11% [Apr 27,15] 

A deal with Japanese biotech Takeda Pharmaceuticals worth potentially $440 million sent shares of ImmunoGen (Waltham, MA; $1.6M SBIR in the 1990s) up to their highest point since a failed drug trial in December sent them crashing.   ....  a 300-employee drug developer with one approved drug through a partnership with Roche and a slew of others in the pipeline, today announced that Takeda — best known locally as the owner of the Cambridge company formerly called Millennium Pharmaceuticals — has paid $20 million up front to license ImmunoGen’s antibody-drug conjugate technology.  ...  in addition to the money, the Takeda deal also provides some much-needed validation to ImmunoGen’s scientific approach to fighting cancer. [Don Seiffert,  Boston Business Journal, Mar 23, 15]  Bubble blowing?  In the 168 weeks since the beginning of 2012, the NASDAQ Biotech Index has advanced 250%. In the 168 weeks leading up to the peak of the dot-com bubble, the NASDAQ Composite gained 290%. []

Immunogen up 17% [Mar 23, 15]

Immunogen up 23% [Jan 30, 15]

Immunogen down 44% [Dec 19, 14]   Roche Holding AG said a late-stage study of its breast cancer drug Kadcyla failed to yield superior results to an existing treatment, damaging the outlook for stronger sales in one of its key drug markets. .... Kadcyla includes a proprietary cancer-killing agent that is produced by ImmunoGen, according to the company’s website. ImmunoGen said the results would have no impact on its financial guidance for the year.   [ Neil Maclucas and Shirley S. Wang, Wall Street Journal, Dec 19, 14] 

Eli Lilly exercises its rights under its Multi-Target Agreement with ImmunoGen (Cambridge, MA; $1.6M SBIR) for exclusive licenses to develop and commercialize anticancer products to two undisclosed targets utilizing ImmunoGen's antibody-drug conjugate technology. Lilly has now taken all licenses afforded under the contract.  ImmunoGen will record $15.6M in fiscal Q2 revenue as a result of Lilly's action. It will also be eligible to receive up to $200M in milestones plus commercial sales-based royalties under each license.  [Douglas W. House,, Dec 15, 14]

Immunogen down 10% [Apr 25, 14]

Immunogen up 11% [Mar 16, 14]

Immunogen up 10% [Nov 11, 13]

Immunogen’s efforts to prove it can create a successful drug that combines a targeted antibody with an extra-potent toxin, without the help of a partner, took a big step backward this week. One of Immunogen’s internally-developed drug candidates for small cell lung cancer flopped in a mid-stage study. An independent data monitoring committee found Immunogen’s experimental drug, IMGN901, ineffective, and also saw that patients on treatment had higher rates of infection-related deaths than those getting standard treatments alone. The company responded by halting the clinical trial. [Ben Fidler,, Nov 8, 13]

Immunogen  down 19% [Nov 5, 13]  is stopping a study of an experimental drug for the treatment of small-cell lung cancer. [Chris Reidy, Boston Globe, Nov 5]

ImmunoGen entered into a licensing agreement with Eli Lilly... granted exclusive use of IMGN's maytansinoid-based TAP technology to create and market "products directed to a specific antigen target." ....  entitled to receive as much as $200M in milestone-related payments plus royalties on any future commercial sales. [, Aug 28, 13]

Immunogen down 10% [Apr 12, 13]

ImmunoGen   ($1.6M SBIR in the 1990s), but the drug is being marketed by its partner, the Genentech division of Swiss drugmaker Roche AG, under the brand name Kadcyla   [Robert Weisma, Boston Globe, Feb 22, 13]

ImmunoGen  surged 17 percent in early trading after partner Roche Holding AG said its experimental breast cancer drug significantly extended the lives of patients when compared with standard therapy. [Boston Globe, Aug 27, 12]

Immunigen down 10%  [Aug 3, 12]

Immunogen  up 12% [Jan 27, 12]

ImmunoGen added yet another collaboration deal, this time working with Eli Lilly and Co. to develop anticancer therapeutics under an agreement that could bring in up to $200 million or more to ImmunoGen.  Staring with an up front payment from Lilly of $20 million, ImmunoGen will apply its Targeted Antibody Payload (TAP) technology to monoclonal antibodies from Lilly’s library to make these new antibody-drug conjugate (ADC) cancer-fighting therapies, the companies said   [Rodney Brown, Mass High Tech, Dec 20, 11]

Immunogen  up 10% [Nov 30, 11]

Immunogen up 11% [Nov 28, 11]

ImmunoGen is pulling in more milestone payments from Amgen, raking in its second $1 million pay from the company this month.[Mas High Tech, Nov 15, 11]

Immunogen up 13% [Aug 23, 11]

Immunogen up 10% [Aug 9, 11]

Immunogen down 10% [Aug 8, 11]

Immunogen< down 11% [Aug 4, 11]

Immunogen up 10% [Jul 6, 11]

ImmunoGensaid that it has earned a $2 million milestone payment after its partner in a licensing agreement, Bayer HealthCare Pharmaceuticals, submitted an investigational new drug application.  [Boston Globe, Jun 15, 11]

ImmunoGen has priced a public stock offering of 7 million shares of common stock at $12 per share, expected to bring in gross proceeds of about $84 million [Mass High Tech, May 20, 11]

Immunogen up 27% [Apr 7, 11] on news that its potential therapy for breast cancer achieved positive phase 2 trial results.  [Julie Donnelly, bizjournals,com, Apr 7]

ImmunoGen said it has initiated a randomized Phase I/II clinical trial to evaluate its proprietary product candidate, IMGN901, for first-line treatment of small-cell lung cancer in patients with extensive disease. [Boston Globe, Nov 30, 10]

ImmunoGen has agreed to work with Novartis on targeted anticancer therapeutics developed using ImmunoGen’s Targeted Antibody Payload (TAP) technology, in a deal potentially worth nearly $250 million – and potentially much more. [Mass High Tech, Oct 11, 10]

Immunogen up 10% [Aug 30, 10]

ImmunoGen  plunged 38% yesterday after US regulators rebuffed a bid to gain fast-track status for a breast cancer drug it is developing with the Genentech unit of Swiss pharmaceutical giant Roche Holding AG. [Boston Globe, Aug 28, 10]

ImmunoGen said it will receive a $1 million milestone triggered by the start of a clinical trial by sanofi-aventis, a global drug maker. [Boston Globe, Jun 25, 10]

Immunogen up 10% [Jun 17, 10]

ImmunoGen said it raised $77.6 million through a stock offering after deducting expenses. [Boston Globe, May 11, 10]

ImmunoGen expanded its planned stock offering, and now expects to raise $67.4 million in net proceeds. [Boston Globe, May 7, 10]

Immunogen  down 12% [May 6, 10]  announced plans to offer at least 8.5 million shares of common stock. [WSJ, May 7]

ImmunoGen reports the [FDA] and the EU Committee for Orphan Medicinal Products has granted orphan drug status to an ImmunoGen compound used to treat Merkel cell carcinoma (MCC).  The compound, IMGN901, has shown effectiveness in treating MCC, a rare aggressive neuroendocrine cancer of the skin that typically occurs on the head/neck, most often in individuals of European ancestry, according to the company.  [Mass High Tech, Mar 10, 10]

Roche and ImmunoGen reported on a "guided missile" combination drug called T-DM1 that shrank tumors by 30% or more in one-third of critically ill, advanced breast cancer patients in a trial. The therapy combines Roche's Herceptin with a second, potent cancer-killing drug from ImmunoGen, with Herceptin acting as the guidance system, using its ability to home in on cancer cells to deliver the treatment directly to its target. [, Dec 17, 09]

ImmunoGen announced a second license granted to Amgen Inc. for its maytansinoid Targeted Antibody Payload technology for an undisclosed target. The deal promises a $1 million upfront payment to ImmunoGen, with up to $34 million in milestone payments and additional royalties [Mass High Tech, Nov 20, 09]

Immunogen down 11% [Oct 30, 09]

ImmunoGen ($1.6M SBIR in the 1990s) today priced its public offering of 5 million shares of common stock and expects proceeds of $33 million. [Boston Globe, Jun 19, 09]

ImmunoGen (Waltham, MA; $1.6M SBIR) has raised $24.7 million through a purchase of 7.8 million shares of common stock. [Mass High Tech, Jun 23,08]

ImmunoGen (Cambridge, MA; $1.7M SBIR) earned a $1.5 million milestone payment in connection with a drug candidate for treating certain types of tumors.  [Boston Globe, Feb 2]

Immunome (Philadelphia, PA)

Immunome (Philadelphia, PA); $300K SBIR) a biotechnology company focused on developing transformative immunotherapies to treat cancer, announced it has closed on an aggregate of $10.2 million in 2016 Series A Preferred Stock investments. An additional $2 million is committed to be funded by June 30, 2017.  ...  to further develop and scale up Immunome’s discovery engine and pipeline of cancer therapeutics [originally developed at MIT].  [company press release, Oct 6, 16]

Immunomedics ((Morris Plains, NJ)

Immunomedics up 17% [Sep 10, 19]

Immunomedics down 26% [Jan 18, 19] announced it has received a Complete Response Letter (CRL) from [FDA] for the Biologics License Application (BLA) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease. [company press release, Jan 17, 19]

Immunomedics down 20% [Dec 20, 18]

Immunomedics up 10%  [Jun 4, 18]

Immunomedics (Morris Plains, NJ; $11M SBIR, markat cap $1.6B) up 16% [Dec 7, 17]  announced that a blinded, independent review by an adjudication team of radiologists has determined an ORR of 31%, including six complete responses (CRs) and 28 partial responses (PRs), in 110 patients with mTNBC after receiving treatment with sacituzumab govitecan, the Company's lead investigational antibody-drug conjugate (ADC), in a Phase 2 study. [company press release, Dec 6, 17]

Immunomedics up 13% [Dec 6,17]

Immunomedics down 14% [Dec 4, 17]

Immunomedics down 19% [Nov 13, 17]

Immunomedics up 19% [Nov 10, 17]

Immunomedics up 10% [Sep 25, 17]

Immunomedics up 14% [Aug 28, 17]

Immunomedics up 10% [Aug 24, 17]

Immunomedics up 18% [May 5, 17]

Seattle Genetics announced that it has agreed to terminate its license agreement with Immunomedics for sacituzumab govitecan (IMMU-132) and settle the related litigation. The license agreement had not yet closed due to legal action brought by an Immunomedics stockholder challenging the transaction. The termination and settlement remain subject to court approval. [Seattle Genetics press release, May 5, 17]  Meanwhile, Immunomedics is charting its own path forward, raising $125 million in a stock sale to private investors to support development of the drug that SeaGen had hoped to bring to market. [Frank Vinluan,, May 5, 17]

Immunomedics down 13% [Apr 21, 17]

Immunomedics up 19% [Mar 9, 17]

Clinical holds placed last December on the Seattle Genetics leukemia drug vadastuximab talirine following four patient deaths were lifted this week after the Bothell, WA-based biotech made changes to the trials to “enhance patient safety.”   [Ben Fidler,, Mar 10, 17]

A proxy fight at Immunomedics shifted control of the biotech’s board to directors backed by investment firm venBio. The firm criticized the deal Immunomedics management struck to license the company’s lead cancer drug to Seattle Genetics. On Thursday, a Delaware judge halted the transaction.  [Ben Fidler,, Mar 10, 17]

Immunomedics (Morris Plains, NJ; $14M SBIR) up 22% [Feb 10, 17]  Seattle Genetics is to pay $250 million upfront for the rights to Immunomedics'  solid tumor asset IMMU-132. The deal could swell to $2 billion, puts Seattle Genetics in charge of filing for accelerated FDA approval of IMMU-132 in metastatic triple-negative breast cancer (TNBC) while also advancing the drug in other indications. ...  frees Immunomedics from up to $100 million in near-term development costs and gives it a partner that is potentially capable of ironing out lingering concerns manufacturing issues could hold the drug up.  [Nick Paul Taylor, FierceBiotech, Feb 10, 17]

Immunomedics up 10% [Jan 12, 17]

Immunomedics up 10% [Dec 6, 16]

Immunomedics down 14% [Jun 9, 16]

Immunomedics down 14% [Jun 6, 16]

Immunomedics down 15% [Jun 3, 16]

Immunomedics up 11% [Apr 27, 16]

Immunomedics down 17% [Jul 29,15]

Immunomedics down 31% [Jul 28,15]

Immunomedics down 10% [Jun 9, 15]

Immunomedics up 16% [Jun 8, 15]

Immunomedics down 18% [Feb 5, 15]

Immunonmedics down 22% [May 2, 14]

Immunomedics up 12% [Apr 22, 14]

Immunomedics up 10% [Feb 7, 14]

Immunomedics up 18% [Jan 10, 14]

 Immunomedics up 10% [Dec 31, 13]

Immunomedics up 14% [Nov 22, 13]

Immunomedics  down 12% [Nov 5, 13]

Immunomedics up 12%  [Oct 23, 13]

Immunomedics down 12% [Oct 18, 13]

Immunomedics down 12% [Oct 8, 13]

Immunomedics (Morris Plains, NJ; $4M SBIR) up 10% [Oct 1, 13]

Immunomedics up 16% [Jun 21, 13]

Immunomedics (Morris Plains, NJ; $12M SBIR) up 13% [May 30, 13]

DisperSol Technologies (Georgetown, TX; no SBIR) received $612,000 of a planned $1 million financing. ...  founded in 2007, develops a drug-polymer composite system designed to improve the solubility of drug compounds.   [Christopher Calnan, Austin Business Journal, May 30, 13]

Immunomedics   up 10% [Apr 19, 12]

Immunomedics  up 13% [Feb 17, 10]

Immunomedics  down 11% [Jan 26, 10]

Immunomedics up 24% [Jan 8, 10]

Immunomedics up 13% [Oct 29, 09]

Immunomedics down 11% [Oct 1, 09]

Immunomedics down 15% [Aug 28, 09]

Immunomedics ($4M SBIR) rose 61% after announcing with partner UCB SA that a midstage trial comparing their treatment with placebo for treating lupus over 12 weeks showed "meaningful treatment effect."  [Wall Street Journal, Aug 28, 09]

ImmunoMolecular Therapeutics (Boston, MA)

ImmunoMolecular Therapeutics (Boston, MA; $200K SBIR) a clinical-stage company developing personalized therapies for autoimmune disease, raised $10M in Series A financing [Rowan Walrath, BostInno, Oct 9, 19]

Immunomic Therapeutics (Rockville, MD and Lancaster, PA)

Immunomic Therapeutics (Rockville, MD; $600K SBIR, founded 2005) raised $315K in a funding round in SEC filings. The clinical-stage biotech company studies nucleic acid immunotherapy platforms. It has previously raised more than $14M. [Kieran McQuilkin, DCInno, Aug 3, 18] 

Immunomic Therapeutics (Rockville, MD and Lancaster, PA; $1.5M SBIR, 20 employees) has developed a cutting-edge technology for DNA vaccination. The Company is commercializing LAMP-Vax, a breakthrough immunomodulation platform that has the potential to transform the rapidly growing allergy and cancer immunotherapy markets. By 2020, the allergy immunotherapy market is expected to be valued at $50 billion and cancer immunotherapy is expected to be valued at $60 billion.  ITI has already executed three commercial partnerships - two with Astellas Pharma and one with Geron/Asterias.    [company website, Jul 28, 16] reached a $300 million deal licensing its technology to Japanese company Astellas Pharma.  [Baltimore Sun, Oct 9, 2015]

Immunophotonics (St. Louis, MO)

Immunophotonics (St. Louis, MO; no SBIR) biotech startup that has its eye on curing cancer, has added an additional $600,000 to its most recent Series A financing, which now sits at $2.48 million. ... is developing inCVAX, a therapeutic cancer vaccine to help treat metastatic cancer via immunotherapy, which according to the American Cancer Society is treatment that uses your body's own immune system to fight cancer. ...  moved to St. Louis from Columbia, Mo, in 2013 after the company received a non-equity $50,000 grant from Arch Grants. ... was already a portfolio company of the Missouri Technology Corporation, which invested more than $200,000   [Brian Feldt, St. Louis Business Journal, Jan 26, 15]

Cultivation Capital has invested just short of $11 million of the $20 million tech fund it created in 2012.   ...  started out as a tech fund, created its life sciences fund in 2013 with plans to invest some $30 million over five years.  ....  its portfolio: Immunophotonics (Columbia, MO; no SBIR) developed a cancer vaccineMolecular Sensing  (Nashville, TN; no SBIR) commercializing a label-free molecular interaction assay system based on Back-Scattering InterferometryAdarza BioSystems (WEST HENRIETTA, NY; $1.8M SBIR) early stage medical diagnosticsCardialen (Minneapolis, MN; no SBIR) developed a treatment to keep the heart in a normal rhythm for people suffering from atrial fibrillation (AF)Euclises Pharmaceuticals (St Louis, MO; no SBIR) developing pain and cancer medications; Mobius Therapeutics (St Louis, MO; no SBIR) commercial stage venture focused on ophthalmic surgery solutions; Pulse Therapeutics (St. Louis, MO; no SBIR) developed a new approach to accelerate the concentration and delivery of physician-selected agents within the vasculature; Galera Therapeutics (Malvern, PA; no SBIR) focused on the development of breakthrough drugs targeting the oxygen metabolic pathways.  [Brian Feldt, St. Louis Business Journal, Oct 27, 14]   

Immunophotonics (St Louis, MO; no SBIR) is engaged in the development of a vaccine that may help treat cancer by using a patient's own immune system. ... Clinical trials have been conducted in Latin America.  ... More than $7 million has been invested to develop the vaccine, with significant investments coming from organizations within the St. Louis startup ecosystem ... With its $50,000 Arch Grant, Alleruzzo said the company moved from Columbia, Missouri, to St. Louis, and with the move gained valuable partnerships with medical researchers at Washington University, St. Louis University and biotech related organizations in St. Louis.   [Jim Bafaro, St. Louis Business Journal, Oct 28, 14]   Moved from the university nursery to the money, the talent, and the facilities.

Immunophotonics (St. Louis, MO; no SBIR) biotech startup that has its eye on curing cancer, has completed a $1.8 million Series A financing round ...  developing inCVAX, a therapeutic cancer vaccine that can help treat metastatic cancer via immunotherapy  [Brian Feldt,  St. Louis Business Journal, Sep 3, 14] 

ImmuRx (Lebanon, NH]

ImmuRx (Lebanon, NH) vaccine developer for cancer and chronic infections, has pulled in $250,000 in seed funding ....  brings additional funding to the $329,000 SBIR grant from the NIH [Mass High Tech, Jun 18, 08]

ImmusanT (Cambridge, MA)

ImmusanT (Cambridge, MA; no SBIR, founded 2011) a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™(ESIT™) platform to deliver first-in-class peptide-based immunomodulatory vaccinetherapies to patients with autoimmunediseases,has discontinued thePhase 2 global study for its lead candidate,Nexvax2®, intended as a treatment forceliac disease. The results from aninterim analysis revealed Nexvax2 did not provide statistically meaningful protection from gluten exposure for celiac disease patients when compared with placebo. [company press release, Jun 25, 19] total funding $73M []

ImmusanT (Cambridge, MA; no SBIR, founded in America 2010) has raised a Series A round of funding, bringing in $20 million ...  should bring the company’s celiac disease vaccine Nexvax2, to a proof-of-concept stage, along with the supporting diagnostic and monitoring technology ImmusanT is developing. The vaccine triggers an immune response that is intended to allow celiac disease to be treated like a simple allergy with regular injections. [Rodney Brown, Mass High Tech, Dec 13, 11]

Born from research in Australia, ImmusanT (Cambridge, MA; no SBIR) has launched to commercialize a therapy that aims to treat celiac disease like a simple allergy with regular injections of a therapy. [Mass High Tech, Mar 15, 11]  ...  The company, which said in a press release that it has secured seed financing from angel investors, is calling its drug candidate vaccine Nexvax2. Celiac disease is a lifelong autoimmune disorder that is triggered by foods containing gluten, the main protein in wheat, rye, and barley. [Boston Globe, Mar 15]

Immusoft (Seattle, WA)

Immusoft (Seattle, WA; $300K SBIR, founded 2009) developing technology to genetically reprogram patients’ B cells outside the body to produce therapeutic proteins, said it raised $20 million from investors. [Jeff Buchanan,, Jan 4, 19] prior funding $12M []

Immusoft (Seattle, WA; no SBIR) announced  it has closed a $3M initial tranche of a Series B financing. ....   to complete its Phase I/II clinical trial in MPS-I (Mucopolysaccharidoses type I) and advance its pipeline, which uses its proprietary Immune System Programming (ISP™) approach to B cell modification for treating diseases. [company press release, Jan 5, 18]

Biotech startup Immusoft (Seattle, WA; no SBIR) gene therapy company closed on $2.74 million of a $3 million fundraising round   ...  [CEO says] positions the company well as it moves forward with clinical and business operations and to its Series B. [company press release, Nov 1, 16]

gene therapy biotech startup Immusoft (Seattle, WA; one SBIR, founded 2009) has acquired Discovery Genomics  (Minneapolis, MN; $5.5M SBIIR).  With the acquisition, Immusoft gets a license to use Discovery Genomics’ Sleeping Beauty Transposon System, which can deliver genes into cells without using a virus, which is less expensive and more scalable than using a virus, said Matthew Scholz, CEO and founder  [Greg Lamm, Puget Sound Business Journal, Mar 9, 16]

biotech startup Immusoft (Seattle, WA;  SBIR) raised $2.37 million from investors ...  to scale up research, including approaching the [FDA] about doing human clinical trials  ...  betting on finding a way to tap into and modify information stored in human cells to fight diseases. The process has been described as programming a person’s own cells to become miniature drug factories.   [Greg Lamm, Puget Sound Business Journal, Aug 21, 14]

Impact Biomedicines (San Diego, CA)

Celgene [one of the biggest U.S. biotech companies] is in talks to buy Juno Therapeutics [market cap $5.5B, founded 2013]  just days after announcing another major deal to bolster its portfolio of blood-cancer drugs [by buying Impact Biomedicines for $1.1B].   [Jonathan D. Rockoff, Dana Cimilluca, and Dana Mattioli, Wall Street Journal, Jan 16, 18]

Celgene  and Impact Biomedicines (San Diego, CA; no SBIR, founded 2016) announced the signing of a definitive agreement in which Celgene will acquire Impact Biomedicines , which is developing fedratinib for myelofibrosis and polycythemia vera.   Celgene will pay approximately $1.1 billion upfront and up to $1.25 billion in contingent payments based on regulatory approval milestones for  myelofibrosis. [joint companies press release, Jan 5, 18]  Impact was formed after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib... with $22M Series A funding.  [company press release, Oct 2017]

Impact Proteomics (Pittsburgh, PA)

Impact Proteomics (Pittsburgh PA; no prior SBIR) received a $225,000 Phase I [NSF] SBIR to apply their patent pending technology to develop a fast, high yield proteome sample preparation and cleanup kit that can be easily automated, with the ultimate aim of standardizing sample preparation for the proteomics field. [company press release, Jan 1, 19]

Impact Science Technology [Nashua, NH]

Bombs Away.  Impact Science & Technology [Nashua, NH] won the contract for the production and support of 1,100 "vehicle-mounted counter-radio-controlled IED electronic-warfare systems," according to the U.S. Department of Defense. The technology is expected to be produced quickly for use in the field by U.S. troops in Iraq and Afghanistan. [Mass High Tech, Apr 16] No SBIR, and not be confused with Impact Technologies (Rochester, NY) which has at least 30 SBIR Phase 2s in the last decade. IS&T is also now a subsidiary of EDO.

Impel Neuropharma (Seattle, WA)

Impel NeuroPharma (Seattle, WA; $600K SBIR) raised $21 million from investors to continue to develop drugs and devices for central nervous system disorders. ... specializes in treatments that can be given through the nose, and has created devices that enable people to take medication in that way.   [Rachel Lerman, Seattle Times, Dec 2, 16]

Impel NeuroPharma (Normandy Park, WA; $600K SBIR) announced that it has raised $4 million, the first portion of a $12 million Series B funding ...  is developing a technology that helps drugs more easily reach the brain and central nervous system  [Annie Zak, Puget Sound Business Journal, Oct 14, 15]

Impel Neuropharma (Seattle, WA; $500K SBIR, University of Washington spinoff) has been working for five years to show it can quickly deliver drugs through the nose, directly to the brain, for the treatment of central nervous system disorders. The animal data so far has been encouraging, but now the company has got key confirmation that it can do its thing in human beings.  ....  has gotten this far on about $1.5 million in investment from friends, family, and angel investors, plus about $3.5 million in grants from the National Institutes of Health, Department of Defense, and the state of Washington’s Life Sciences Discovery Fund. The company has struck a series of small research collaborations with seven pharmaceutical and medical device manufacturers that are developing central nervous system drugs, [CEO Michael] Hite says.   [Luke Timmerman,, Apr 17, 13]

Imperium Renewables (Seattle, WA)

Imperium Renewables formally withdrew its proposed $345 million initial public offering this morning, blaming "unfavorable market conditions." The Seattle-based company, which operates the largest biodiesel facility in the U.S  [Angel Gonzalez, Seattle Times, Jan 3]

Imperium Renewables in Seattle, which is armed with $145 M in VC and private equity funding. Imperium buys practically every drop of oil U.S. algae startups are producing. ... expects startups to be making 100 million gallons a year. At that point, Tobias reckons, the price per gallon will fall to $1.70, from as much as $20 today. [Gail Edmonson, Business Week, Dec 3]

Impinj (Seattle, WA )

Impinj (Seattle, WA; no SBIR) radio frequency identification technology (RFID) company ...  filed for a $60 million [IPO]  ...  formed in 2000 in part from University of Washington research, has raised more than $130 million from venture-capital and private-equity firms, according to Crunchbase    [Rachel Lerman, Seattle Times, Jun 2, 16]

Impinj  (Seattle, WA ; no SBIR) a technology company that designs and sells RFID chips used for tracking everything from pants to prescription drugs, filed to raise up to $100 million [IPO]. ... founded 2000 ... has never been profitable [Sanjay Bhatt, Seattle Times, Apr 21, 11]

Implant Sciences (Wakefield,MA)

Two companies are hoping they can make your 1980s dreams finally come true for the defense market with an [hoverboard] idea for land surfing commandos. Defense News reports that Implant Sciences (Wakefield, MA; $9M SBIR) is looking to buy a French company, Zapata Industries SAS, and its Flyboard Air hoverboard in hopes of pitching it to the Pentagon and special operations world. Board riders can go as fast as 60 miles per hour for up to two miles. [Defense One, Aug 5, 16]  [Implant recemtly] signed a letter of intent to acquire Zapata Industries SAS of Marseilles, France, a profitable and debt-free company with commercial, defense, and homeland security technology applications. [company website]

As the use of explosive devices by terrorist organizations grows, so does the need for explosive trace detection technology, which is fueling the sales and research and development activities of Implant Sciences ... developer of ion mobility spectrometry systems used to detect minute traces of explosives ... president and CEO Glenn D. Bolduc said “we are penetrating international markets by working with local distributors…who know their market (and) have the requisite relationships with decision makers. We’ve been anticipating increased demand for our Quantum Sniffers™ in Nigeria and throughout Africa.  [Jim Schakenbach, Mass High Tech, Aug 15, 12]

Implant Sciences announced a contract totaling approximately $6 million for its Quantum Sniffer(TM) QS-H150 Portable Explosives Detectors and associated support. ... by the Government of India, for use by the Ministry of Defence (MoD) in Force Protection and Public Safety applications throughout the country. [company press release]

Implant Sciences disclosed Tuesday it missed a $7.65 million payment on its convertible promissory notes and is working with its lender to negotiate the financing of the loans. ... for the fiscal year ended June 30 ...,it generated $8.7 million in revenue and $12.8 million net loss. [Jackie Noblett, Boston Business Journal, Dec 23, 09]

Implant Sciences reports it has landed $1.2 million from a government agency in China for its explosive detection technology.  Under the deal, the Wilmington-based defense and homeland security sensor maker will deliver its Quantum Sniffer QS-H150 Portable Explosives Detectors to be used for transportation security applications throughout China. [Brendan Lynch, Mass High Tech, Aug 14, 09]

Implant Sciences raised $5.6 million in a note and warrant sale on condition that two board members be replaced, including David Eisenhaure, founder of Sat Con Technology. [Mass High Tech, Dec 17, 08]

Implant Sciences reports that its wholly owned subsidiary, Core Systems, has been sold to the group’s management in a $3 million deal.  ...  has been gradually shedding parts of its business since the beginning of the year.  [Mass High Tech, Nov 17, 08]

Implant Sciences has retained the services of an M&A advisory firm to help with “strategic alternatives,” one day after Implant reported a fourth quarter loss of $2.46 million. [Mass High Tech, Oct 16, 08] The stock traders have already marked the company way down below the buck despite its most recent Phase 2 SBIR.

Implant Sciences continues to shed medical IP business assets, this time announcing a sale to Best Medical International The definitive agreement, closing on September 18, ensures that Best pay $100,000 initially to acquire Implant’s intellectual property from its former brachytherapy products business. [Mass High Tech, Jul 30,08]

Implant Sciences reports it has sold equipment used to make coatings for medical products for $750K as part of a plan to withdraw from the medical coatings business.  [Mass High Tech, Jul 3, 08]

Implant Sciences got $2.7 M in contracts for its portable explosives detection systems  [Mass High Tech, May 29,08]

Implant Sciences reports plans to sell Core Systems, the company's wholly owned semiconductor subsidiary. [Mass High Tech, Feb 21]

Implant Sciences is reaching for world markets in its appointment of Richard Meyerhoff as its new Vice President of Sales and Service in the Security Division. He holds a BA in Economics from Universidad Catolica Argentina and an MBA from the University of Michigan. Mr. Meyerhoff speaks several foreign languages and has had responsibility for leading and managing sales operations, distributor networks and business units in the U.S., Middle East, Asia-Pacific, Europe and Latin American regions. [company press release, Nov 26, 07] Notably, the company has five directors: its two founders, two from SatCon Technology, and a former CEO of a medical products company.

Implant Sciences shipped six units of the company's Quantum Sniffer BTS benchtop bomb-finding system to Beijing for the Olympics.

Pulling Up Seeds. Implant Sciences completed the first phase of its plans to get out of the radioactive prostate seeds business. [Mass High Tech, Jul 2, 07] 

Implant Sciences is down to 10% of its stock price three years ago. [Jun 07]

Implant Sciences got a patent for a device used in an automated explosives detector capable of desorbing trapped explosives vapors at speeds of less than 1 millisecond.. [, Apr 3, 07]

Implant Sciences got a service contract that could be worth up to $1.5M from a big tech company. [Mass High Tech, Jan 31]

Implant Sciences up 10% on news that its quantum sniffer would show up in a prime-time TV show. [Nov 20, 06]

Implant Sciences up 11% [Oct 25, 06] and down 7% the next day.

Implant Sciences jumped 17% after saying it expected a big revenue jump. [Sep 06]

Sniffer Orders Flowing.  Over the past several weeks [Implant Sciences] has received domestic orders from public agencies and private companies that plan to use the detectors for shipboard, cargo and overnight delivery security The latest is New Jersey which brings orders to $20M in the past 12 months. [Mass High Tech, Jun 19]  Unfortunately, all those sales led to a $7M loss. Now if they could make it up in volume.

Implant Sciences shot up 11% Wednesday (Apr 13, 06) on news of a Chinese order for another twenty quantum sniffers.

101 Noses.  Although chemo-explosive detectors don't do as well as dogs, China is buying 101 Quantum Sniffers from Implant Sciences for several million dollars. The stock traders loved it and ratcheted the price up an enthusiastic half before dropping back to +10%.  Implant Sciences led the AMEX percentage gainers with 10%. [7/20/05]

Implant Sciences ships product and wins patents but the stock traders don't seem impressed. two more Quantum Sniffer handheld explosives detection devices overseas to exclusive sales agents in Italy and Kuwait ... a fourth patent for its trace explosives detection technology. The patent, titled “Virtual Wall Gas Sampling for an Ion Mobility Spectrometer,” covers a special form of gas sampling vortex in which a large space is enclosed by spinning air.  [Mass High Tech] Meanwhile, the stock price is down to 20% of its roller-coaster high. 

Implant Sciences got a patent for its explosives detection system's vortex air sampling system used in its Quantum Sniffer explosives detection systems. [Apr 05]

Implant Sciences paid $11.3M to acquire Accurel Systems International - a Silicon Valley commercial laboratory specializing in Failure Analysis Microscopy, Transmission Electron Microscopy and Focused Ion Beam Circuit Repair Services. The unimpressed stock traders hit the stock another 10%, driving the price to below half of its year-ago price. [Mar 10, 05]

Implant Sciences sold $7.8M of stock plus warrants to unnamed institutional investors.CEO Tony Armini said the proceeds will be used for an acquisition.  [Mass High Tech, Mar 9, 05]

Implant Sciences sold a Quantum Sniffer (QS) explosives detection devices to the Pakistan Airport Security Force. [Mass High Tech, Nov 29, 04]

Buying cash flow. Implant Sciences is buying Core Systems (Sunnyvale, CA) to provide a steady cash flow to fund new explosive detection products without needing to dilute shareholders by raising money in the capital markets, says CEO Tony Armini Core and Implant compete in semiconductor wafer processing which has become almost a sideline for Implant as it tries to cash in on new explosive detection technology. Sounds like Implant thinks it can get a better return for its $2M cash than simply buying Treasury bonds as semiconductor stocks are wallowing. [Mass High Tech, Oct 14]

Sniffing a Market. Implant Sciences sold a dozen trace explosive sniffers to the Army as the first order for commercial quantities of the Quantum Sniffer. That follows a $1.7M Navy production. contract. The market liked the news and put the stock up 32% last week. [Jun 04]

Implant Sciences up 15% for the week even though the quarterly earnings report emphasized government R&D contract revenue and a $1.1M loss (buried in the fourth paragraph) blamed on the expense of performing those contracts. 

Implant Sciences,  got a $1.7M Navy contract for a test buy of three explosive sniffers. Implant's stock is up 40% in the past month and has quintupled in a year. In a demonstration that a small company with a new technology doesn't need SBIR to succeed, and may be actually held back in development by SBIR, Implant got the Navy attention with a TV appearance of its Quantum Sniffer. Once alerted that there was publicly known technology that seemed to work and that the politicians would soon be badgering the military about it, the Navy instantly found the money for a contract. The moral is that if your gizmo works, get as public a demonstration of it as you can muster. High noon in Times Square if you can arrange it. All the bureau talk about budgeting and program limits and such and such will disappear in a New York minute. The downside is that you take all the R&D risk but then you own the intellectual property and the world will rush to your door in the classic better mousetrap. For those with no money and no courage, keep applying in 25 pages or less to the government for money to develop your unproved ideas such that the government takes all the risk. SBIR is perfect for mediocrity of both company and government.  

Implant Sciences got a $600K deal with TSA to demonstrate its table-top explosive sniffer with the promise (governmental promise, of course) for $400K more if all goes well.  TSA desperately needs  an explosives detection device that can be used in a wide variety of security screening applications, including screening luggage, passengers, cargo or vehicles. Especially cargo. [Oct 03]

Implant Sciences> stock has doubled this summer even though the company is still not profitable. Its "Quantum Sniffer" has attracted government attention with a Marine Corps SBIR (Phase 1 only so far)  and live demos at  the ASIS International show for security professionals. The Quantum Sniffer  uses proprietary laser ion mobility spectrometry technology which electronically detects minute quantities of explosive vapor molecules in the air.

The stock price of Implant Sciences has taken a drubbing this year, Friday's 7% decline brought the price to about half its Jan 1 (2003) price. The last good news was a Phase 1 SBIR for $70K in December. Press releases for Phase 1s are not the stuff of confidence.

Implant Sciences got $2.5M convertible financing and an invitation to show its prototype explosives detector at DOT laboratories whereafter it got test and evaluation processing. Since DOT is probably buried in security gizmos, don't wait up for a volume procurement.

Half a minute for a whole company. Implant Sciences says it will become an explosive detector company with its two prototype explosives detectors being readied for a queue of customers. Its laser ion mobility spectrometer sucks up particles from a suitcase and looks for traces of explosive in 5-10 seconds, a practical improvement over 47 seconds per scan. Half an airport minute saved for the frenetic business traveler. CEO Tony Armini says the company is in discussions with government (so are zillions of other potential contractors with new gizmos). [facts by >Matthew French, Mass High-Tech, Aug 5] TSA has a long queue in the waiting room with detectors sure to solve the explosive detection problem. Just send money. Implant has been around for 16 years, the last few years as a public company with a variety of sub-critical products on which it can lose a little money. The stock traders were not impressed by the announcement as the stock went down on a big up day.

Implant Sciences finished developing its handheld explosives detection product and plans commercially availablility by 2003. Nevertheless, the soggy NASDAQ market has bit a fourth from the market cap.

More Revenue, Less Loss, says Implant Sciences as revenue rose 37% and losses decreased fir nine months. The press release prattles about the relatively good news nine-month results before getting to the latest quarter in which losses grew to $1M rather than shrunk. With only $1.6M in cash, how much longer can it keep trying to make up in volume what it loses in transactions?

An Explosive Sniffer(Dec 11)Implant Sciences shot up by half, and led the AMEX percentage gainers, when it said on Dec 4 that it had developed a prototype explosives sniffer. Implant said that the sniffer could detect vapor from at least five types of explosives, at airborne concentrations measured in parts per trillion. The system is 100 to 1000 times more sensitive than the capabilities of explosive-sniffing dogs. Which is good because the dogs are getting tired everywhere since Sept 11. Implant has had no Phase 2 SBIRs that sound like the source of this sensor although it has had a smattering of Phase 1s over the decade.

Implant Sciences reported sales up 58% and losses down 42% thanks to the growing sales of I-Plant(TM) radioactive seeds for the treatment of prostate cancer.

More Implant Workers. (Sep 12) Implant Sciences said it would immediately increase its production workforce by half to keep up with growing demand for its radioactive seeds used to treat prostate cancer. It said that demand for its I-Plant Iodine-125 brachytherapy seeds has grown at a compounded rate of 27% per month since it became commercially available last November. With that kind of growth in sales, it might even start to make a profit.

Implant Sciences took in 44% more revenue for the quarter to just equal the loss of $700K in the same quarter last year.CEO Tony Armini said We are extremely pleased with the significant progress .

Implant Deal on Stent  (Mar 23)Implant Sciences (Wakefield, MA) which develops products for the radiation oncology, interventional cardiology and orthopedic markets, announced it has entered into a joint development agreement with CardioTech International to begin a new research program to develop a porous polymer covered vascular stent. This joint research and development program will utilize CardioTech's proprietary porous polymer biocompatible coating technology as a platform for Implant Sciences' proprietary radioactive brachytherapy technology. The total vascular stent market is estimated today to be in excess $2B. The polymer covered stent is expected to reduce restenosis after balloon angioplasty by providing means for either local radiation delivery, drug delivery or gene therapy within the polymer. This porous polymer could also provide a platform for CardioTech's endothelial cell seeding technology. [company press release, Mar 21,00] CEO Tony Armini made the usual cooing noises.

Mass Says OK to Implant Sciences  (Jan 13)Implant Sciences (Wakefield, MA) says that Massachusetts OK'ed a license to make and sell its I-Plant(TM) Iodine-125 brachytherapy seeds that are good for radiation oncology, interventional cardiology and orthopedic marketplaces (love those multi-syllable words). Implant says Permanent implant of radioactive seeds for the primary treatment of prostate cancer is a relatively new technique that is rapidlygaining acceptance as a method of treating early stage prostate cancer. The market liked it, pushing IMX up 11% - back above its IPO price from which it had lost 50% only a few months ago. No, no info-tech involved unless you count the new BMDO SBIR for the world's first ion implanted blue light emitting diode (LED) produced from gallium nitride. Implant has had almost no SBIR support since its founders split from Spire which has had tons of SBIR support.

Implant Moves to AMEX  (Sep 9) An SBIR stock moves to a bigger pond as Implant Sciences (Wakefield, MA) moves to the AMEX. All SBIR companies heretofore have stayed on NASDAQ after going public. CEO Tony Armini, a 1980s escapee from Spire Corp said, The Amex will provide Implant Sciences with heightened visibility, a potentially larger investor base and a more liquid auction market. Which seems an old view in the face of the huge market cap corporations like MSFT and INTC on NASDAQ and likely to stay there. Inmplant's market cap is only $35M but visibility counts for a lot in the capital game.

Implant Comes Out  (Jun 25) After a delay caused by the original underwriter's failure to buy the shares, Implant Sciences (Wakefield, MA) started trading. Priced at 7.50,the stock closed at 8.125 after the first day of trading. Implant has had precious little SBIR even though the firm its founders came from, Spire has had a ton but is now looking for a savior. Tony Armini and Steve Bunker developed a real commercial business in ion implantation to compete with Spire. Officially, Implant's main business is developing medical radiation therapy implant devices. In the line of future business, it has a new Phase 2 SBIR from BMDO for a new version of gallium nitride for blue lasers.

Implant Sciences IPO
(May 4) Implant Sciences (Wakefield, MA) first went public and then pulled it the next day before trading started due to market conditions It had priced 18% of the company at $7.8M. Implant, formed by two escapees from Spire (Bedford, MA), has had 25 Phase 1 SBIRs and one Phase 2 (1991, Army). BMDO just picked Implant for its second Phase 2, no doubt with substantial co-investment by real business partners. Implant has been on the brink of an IPO for months waiting for the right moment.

Implant Sciences IPO Due  (Feb 15) Implant Sciences (Wakefield, MA) is scheduled for IPO this week to raise $8M. Although Implant has had only one Phase 2 SBIR, it is the type of company that would do something commercial with a decent result because SBIR is clearly NOT its business focus. Its founders split from an SBIR multi-multi user, Spire, to do ion implantation its own way.

The IPO of Implant Sciences (Wakefield, MA) to raise $8M for 19% of the equity has been put off to January. The firm plans to make radioactive seeds (awaiting FDA approval) to treat prostate cancer; it also wants to sell coronary stents, catheters, and other devices with radioactive coatings that make them visible when X-rayed. The company currently uses proprietary ion implantation techniques to alter the surfaces of semiconductors and orthopedic devices (thus minimizing friction and wear). [Hoover's] Implant Hopes for IPO
(Nov 9) Implant Sciences (Wakefield, MA) filed Sep 29 for an IPO to raise $7.8M. Says Hoover's Implant Sciences hopes to counter the growth of cancer with the seeds of science. The firm plans to make radioactive seeds (awaiting FDA approval) to treat prostate cancer; it also wants to sell coronary stents, catheters, and other devices with radioactive coatings that make them visible when X-rayed. The company currently uses proprietary ion implantation techniques to alter the surfaces of semiconductors and orthopedic devices (thus minimizing friction and wear). Sales to Biomet and Stryker account for some 48% of sales. Chairman, president, and CEO Anthony Armini will own nearly 27% of the company after it goes public; VP and chief scientist Stephen Bunker will own 14%. Implant has used some SBIR, not enough to get dependent - a little over $1M 1993-97 all Phase 1s.

Impossible Foods (Redwood City, CA)

Impossible Foods (Redwood City, CA;no  SBIR, founded 2011) has raised a total of $182M for its meatless burgers and intends a rollout in New York and San Framcisco. [Silicon Valley Business Journal, Jun 20, 16] We start with plants – such as grains, greens and beans – and separate proteins, fats, and other nutrients from each one, selecting those that give our foods desirable flavors and textures. We then combine these proteins with vitamins, amino acids, and fats, all from plants, to make our meats and cheeses. [company website]

Imprimis Pharmaceuticals (San Diego, CA)

Imprimis Pharmaceuticals (San Diego, CA; no SBIR, market cap $37M) announced the release of data from a peer-reviewed study of patients receiving Imprimis' proprietary Dropless Therapy® following cataract surgery. The study evaluated 1,541 eyes from 922 patients and demonstrated that in nearly 92% of cases, supplemental medication was not required after surgery.  [company press release. Oct 25, 16]  ...  announced the availability of a significantly lower-cost compounded alternative to Valeant's Calcium Disodium Versenate (edetate calcium disodium injection, USP), commonly used to stabilize and treat patients exposed to lead poisoning.   [company press release. Oct 18, 16]

Imprimis Pharma up 11% [Dec 1, 15]

Imprimis Pharma up 23% [Nov 20, 15]

Imprimis Pharma up11% [Oct 26,15]

Commoditization.  Turing Pharmaceuticals (no SBIR) sparked nationwide outrage and government investigations when it raised the cost of a generic drug used for AIDS and cancer from $13.50 to $750 a capsule. Today, [Imprimis Pharmaceuticals (San Diego, CA; no SBIR)]  introduced a competitor to that drug that sells for $1 a capsule. Moreover, the company plans to compete against other manufacturers who sell generic drugs far above their cost. .... There's a limitation, Baum said: The formulation is not FDA-approved, and can legally only be sold through a doctor's prescription to a specific individual.    [Bradley Fikes, San Diego Union Tribune, Oct 22, 15]

Imprint Energy (Alameda,CA)

Imprint Energy  (Alameda,CA; no SBIR) startup is developing flexible, rechargeable batteries that can be printed cheaply on commonly used industrial screen printers.  ...  has been testing its ultrathin zinc-polymer batteries in wrist-worn devices and hopes to sell them to manufacturers of wearable electronics, medical devices, smart labels, and environmental sensors. .... recently secured $6 million in funding  [Daniel Lovering,, Jul 18]

Impulse Monitoring (Columbia, MD)

San Diego spine surgery device maker NuVasivesaid that it will acquire [Impulse Monitoring (Columbia, MD; no SBIR)] neurological monitoring company for $80 million in cash and stock ...  Impulse currently accounts for 5 percent of a highly fractured outsource neuro-monitoring market, which is expected to generate $260 million in sales this year, the chief executive said.  [Keith Darce,, Sep 29, 11]

Imricor Medical Systems (Burnsville, MN)

Imricor Medical Systems (Burnsville, MN; $900K SBIR, founded 2006) is wrapping up a clinical trial needed to start selling its system in Europe.  [Katharine Grayson, Minneapolis / St. Paul Business Journal , Oct 3, 17]  joined forces with Siemens Healthineers to develop an integrated solution that combines the clinical benefits of real-time MRI scans with 3D-guided cardiac ablation. [company press release, May 9, 2017]

Imris (Minnetonka, MN)

Med-tech company Imris (Minnetonka, MN; no SBIR) which moved its headquarters from Canada to the Twin Cities two years ago, has filed for Chapter 11 bankruptcy  ... which makes MRI-guided surgical systems, said high research and development expenses and delayed product installations contributed to its bankruptcy  [Katharine Grayson, Minneapolis / St. Paul Business Journal, May 26, 15]

ImThera Medical (San Diego, CA)

Houston’s Cyberonics, which makes an implantable neurostimulation device used to treat epilepsy and depression, says today it’s making a $4 million investment in San Diego startup ImThera Medical (San Diego, CA; no SBIR). Cyberonics says its investment could eventually total $12 million, providing that ImThera meets certain milestones. ... has been developing technology that fits neatly with Cyberonics’ core expertise in neuromodulation.  [Bruce Bigelow,,, Oct 56, 11]

ImThera Medical  (San Diego, CA; no SBIR) developer of a neuro-stimulation device for treating sleep apnea, has raised $1 million of a planned $2.2 million round of equity financing,  [Ryan McBride,, Nov 19, 10]

i-Nalysis (Concord, MA)

i-Nalysis (Concord, MA; no SBIR) has landed a six-figure round of angel funding and its first customer for the company’s handheld materials analyzer ... X-ray Fluorescence Spectrometer  is a small, light and inexpensive device that identifies the elemental analysis “of almost anything,”  [Mass High Tech, Dec 22, 09]

Inari Agriculture (Cambridge, MA)

biotech startup Inari Agriculture (Cambridge, MA; no SBIR, founded 2016) is being introduced today with the mission to transform agriculture and its impact on society and the environment by developing a more personalized plant breeding approach. [Cindy Zimmerman,, Jul 18, 18]

InCarda Therapeutics (Newark, CA)

InCarda Therapeutics (Newark, CA; no SBIR, founded 2009) completed an oversubscribed $42 million Series B financing ... developing first-of-their-kind inhaled therapies for cardiovascular diseases, [company press release, Nov 7, 18] prior funding $6M []

INCELL (San Antonio, TX)

INCELL (San Antonio, TX; $1.3M SBIR) biotech, entered into a joint venture with a Belgian investment group to form a new company called BioTurnKey. The new firm plans to accelerate the development and manufacturing of regenerative and personalized medicine products and services.   [W. Scott Bailey,San Antonio Business Journal, Jun 7, 16]

INC Research (Raleigh, NC)

A private equity firm and a Canadian pension fund have agreed to acquire INC Research, (Raleigh, NC; no SBIR) that assists drugmakers with clinical trials.  [Raleigh News & Observer, Aug 20, 10]

Incelldx (Menlo Park, CA)

In its first round of venture funding, medical test maker Incelldx (Menlo Park, CA; no SBIR) raised $3 million. ... led by CEO Bruce Patterson, M.D., who started it after about a decade of research at both Northwestern and Stanford universities. [Stephen EF Brown, San Francisco Business Times, Jun 8,10]

Incitor (now XF Technologies)Albuquerque, NM)

XF Technologies (formerly Incitor, Albuquerque, NM; no SBIR) raised another $1.5 million to continue to develop its biofuels ...  makes a fuel additive from biomass that has some unique properties, said company president Len Rand. ... raising more than $5 million last year and building a new plant’s biomass chemicals are turning out to be good replacements for both chlorinated solvents as well as plasticizers, which are chemicals in plastics that are banned in many countries. ... Since 2012 XF has raised more than $8.3 million  [Dan Mayfield, Albuquerque Business First, Jun 24, 15] using a novel catalytic process  [company website] 

Incodema3D (Freeville, NY)

Subsidies lose favor. As New York's state Senate Republicans propose shutting down Start-Up NY, business leaders involved in the program say it's too early to call it quits. Start-Up NY, created by Gov. Andrew Cuomo in 2013, exempts qualifying businesses from taxes for 10 years when they expand or relocate to select college and university campuses. ... program approved 67 businesses in 2017. [Liz Young, Albany Business Review, Feb 20, 18] a number of legislative leaders and the state’s news media have been underwhelmed with the 408 jobs created by the program ... A case: Dr. Greg Galvin, cofounder of Incodema3D (Freeville, NY; no SBIR, founded 2001, a $10 million start-up investment financed mostly locally [Ijdavidhill, Ithaca Journal, Jan 21, 2015]) the first company certified within the Start-Up NY Program in 2014. The young company has grown from four initial employees to a staff of 30 over the past two years. ... Did Start-Up NY actually influence your decision to start Incodema3D? Dr. Galvin hesitated: “We would have started the company with or without Start-Up NY. But it certainly helped us succeed.” [Andrew Levine, Forbes, Aug 11, 16]

InControl Medical (Milwaukee, WI)

Eight start-up companies have been certified as qualified new business ventures by the Wisconsin Economic Development Corp., the agency said.  With the certification, the companies' financial backers will be eligible for a 25% tax credit on the amount they invest in the company.  The start-ups include:  InControl Medical LLC (Milwaukee, WI; no SBIR) has developed an FDA-cleared device designed to treat female urinary incontinence; NitricGen (Middleton, WI; no SBIR) has developed a medical device that uses plasma technology to electronically generate gaseous nitric oxide from the air and helps speed the healing process for individuals with chronic diabetic foot ulcers; SpeechTails (Elm Grove, WI; no SBIR) has an online speech therapy and learning system; Whole Trees (Stoddard, WI; no SBIR) has a technology for digitally engineering timber to make affordable commercial construction materials that can be substitutes for concrete, steel or milled lumber.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Aug 1, 12]

InCube Labs (San Antonio, TX)

InCube Labs (San Antonio, TX; no SBIR), a multi-disciplinary life sciences R&D lab, announced that it has been awarded a subcontract from the University of Pittsburgh to help develop an implantable neuromodulation therapy to restore bladder function for spinal cord injury (SCI) patients.  As part of a multi-year, potential $10 million [DOD] contract awarded to the University of Pittsburgh, a primary goal of the subcontract is submission to the FDA for an Investigational Device Exemption (IDE). [company press release, May 24, 16]

Incyte  (Wilmington, DE)

The surprising failure last month of a large clinical trial of a promising cancer immunotherapy drug from the biotech company Incyte (no SBIR) has quickly reverberated across the pharmaceutical industry. Three companies have canceled, suspended, or downsized 12 other phase III trials of the compound, epacadostat, or two similar drugs, together slated to enroll more than 5000 patients with a variety of advanced cancers. The two other companies: Bristol Myers Squibb and NewLink Genetics. [Ken Garber, Science, May 11, 18]

NewLink Genetics down 43% [Apr 6, 18] after Merck and Incyte said their trial testing a combination including a type of cancer drug called an IDO inhibitor had failed. NewLink has focused its research and development on IDO as a target for its cancer drugs, and its two lead therapies -- indoximod and NLG802 -- target the IDO pathway. [Emma Court, MarketWatch, Apr 6, 18]

Incyte down 23% [Apr 6, 18] said its experimental cancer drug failed in a closely watched clinical trial that paired it with Merck’s Keytruda, striking a blow to combination therapies [Peter Loftus, Wall Street Journal, Apr 6, 18]

Eli Lilly is laying a $90 million bet on an arthritis drug developed by Incyte (Wilmington, DE; no SBIR)  [Jeff Swiatek, Indianapolis Star, Dec 22, 09] Incyte's last five years highly variable revenue with losses totaling $600M against which it has raised $800M from securities sales. [Thomson Reuters]

InCytu (Lincoln, RI)

Medical technology firm InCytu (Lincoln, RI; no SBIR), has taken in $1.86 million in a new equity funding round, federal documents show. ...  based on the Cellarium platform technology first developed by David Mooney of Harvard University. Cellarium uses a biopolymer scaffold the size of a vitamin pill that is implanted to function as a micro-factory, drawing in naturally occurring cells, reprogramming them to fight cancer or grow new tissue in a damaged area, then targeting the newly programmed cells to those areas, according to the company’s website.  [Rodney Brown, Mas High Tech, Jan 13, 12]

Indalo Therapeutics (St. Louis, MO)

Indalo Therapeutics (St. Louis, MO; no SBIR) has raised nearly $9 million of a planned $25.99 million equity offering.   [Brian Feldt, St. Louis Business Journal, Aug 2, 17]  formed by the October 2016 merger of  Antegrin Therapeutics and Cascadia Therapeutics dedicated to developing novel therapies to treat fibrotic diseases.   [company press release]

biotech startup Antegrin Therapeutics (St. Louis, MO; no SBIR) merged with a similar  Cascadia Therapeutics (Seattle, WA; no SBIR) to form Indalo Therapeutics (St. Louis, MO) -  a biotechnology company dedicated to developing novel therapies to treat fibrotic diseases. ... unites Antegrin’s robust portfolio of small-molecule integrin antagonists with the strong drug-development expertise, seasoned executive experience, and proven track record of success of Cascadia. [Indalo press release, Oct 17, 16]

Indiana Nanotech

 "I knew nothing about teeth." A year-old life-sciences company .. six months away from bringing its first product to market. .. Robert Karlinsey earned a doctorate by studying the way nanoparticles behave when water turns to ice. One day, while waiting for some test samples to freeze, he got to thinking about new applications for his work. By looking at calcium, fluoride and other chemicals at a molecular level, Karlinsey found he could combine them to form a substance with unique properties. [that] actually does a better job than its individual elements of protecting people's teeth from decaying. Indiana Nanotech [no SBIR], founded in October 2006, has raised $300,000 in seed money, [and] hopes to have its first product, a fluoride mouth rinse, to market by February. [Chuck Bowen, Indianapolis Star, Sep 11]

InDi Molecular (Seattle, WA)

InDi (Seattle, WA; no SBIR) , aka Integrated Diagnostics, is planning to graduate from startup mode this year and start selling its first product, a diagnostic test that spots lung cancer in a tiny sample of blood. But before it does that, it has decided to spin out some of its key intellectual property into a new startup called InDi Molecular. The spinoff has secured a $1.5 million seed investment  [Luke Timmerman,, Sep 20, 13]

Industrial Heat (Raleigh, NC)

Cold-fusion still heating.  Italian inventor Andrea Rossi is suing two Raleigh [NC] investors, along with their companies, alleging both the venture and its investors owe him $89 million for a cold-fusion invention he insists he's validated.  [Lauren K. Ohnesorge, Triangle Business Journal, Apr 7, 16]   Rossi claims that he has developed a tabletop reactor that produces heat by an as-yet-not-fully-understood LENR process.  Rossi has gone well beyond laboratory demonstration; he claims that he and the private firm Industrial Heat (Raleigh, NC; no SBIR) have actually installed a working system at an (undisclosed) commercial customer’s site.   [David H. Bailey,LBNL (retired) and UCal Davis and Jonathan M. Borwein, Laureate Professor of Mathematics, University of Newcastle, Australia,, Aug 28, 15]

Industrial Perception (Palo Alto, CA)

Over the last half-year, Google has quietly acquired seven technology companies in an effort to create a new generation of robots. ....  not something aimed at consumers. Instead, the company’s expected targets are in manufacturing ....  Among the companies are Schaft, a small team of Japanese roboticists who recently left Tokyo University to develop a humanoid robot, and Industrial Perception  (Palo Alto, CA; no SBIR), a start-up here that has developed computer vision systems and robot arms for loading and unloading trucks. Also acquired were Meka (San Francisco, CA; no SBIR) and Redwood Robotics  (San Francisco, CA; no SBIR), makers of humanoid robots and robot arms, and Bot & Dolly  (San Francisco, CA; no SBIR), a maker of robotic camera systems that were recently used to create special effects in the movie “Gravity.” A related firm, Autofuss  (San Francisco, CA; no SBIR), which focuses on advertising and design, and Holomni  (Mountain View, CA, no SBIR) a small design firm that makes high-tech wheels. The seven companies are capable of creating technologies needed to build a mobile, dexterous robot. Mr. Rubin said he was pursuing additional acquisitions.  [John Markoff, New York Times, Dec 4, 13]  Note that all the US companies live around San Francisco Bay with the hotbed of innovative venture capital. And none needed SBIR to attract major investment. 

InEnTec (Bend, OR)

InEnTec (Bend, OR; no SBIR) Receives $26,250,000 New Financing Round...  technology, called the Plasma Enhanced Melter or PEM, uses the power of plasma to break materials apart into their elemental components (such as hydrogen, carbon, and oxygen) and then transform those elements into synthesis gas which is one of the basic blocks of the chemical and energy industries. [, Apr 6, 12]

InfaCare Pharmaceutical (Trevose, PA)

InfaCare (Trevose, PA; no SBIR) specializing in medicine for infants raises $5.5M  ....  lead new drug candidate is a neonatal jaundice treatment  [John George, Philadelphia Business Journal, Nov 12, 16]

InfaCare Pharmaceutical (Trevose, PA; no SBIR) raised $12.1 million in a private stock sale. ... focuses on developing proprietary products to treat neonatal and pediatric diseases. [John George, Philadelphia Business Journal, Jul 15, 15]

InfaCare Pharmaceutical (Trevose, PA; no SBIR) which specializes in developing treatments for neonatal and pediatric patients, will get $750,000 ..... The company's lead product, Stanate, is the only in-development treatment for infantile jaundice currently in development. The cash, part of InfaCare's $20 million Series C round, will go toward funding the Phase 2B trial currently underway in babies.  [Lauren K. Ohnesorge, Triangle Business Journal, Jun 5, 14]

Infarct Reduction Technologies (Waldwick, NJ)

Infarct Reduction Technologies  (Waldwick, NJ; no SBIR, founded 2010)  is developing a device, the LifeCuff, to deliver an ischemic pre-conditioning protocol. Ischemic pre-conditioning has been found to improve outcomes in heart attack, stroke, sepsis and other conditions. The only other method of providing this protocol is manually by intensive care, surgical or emergency medical staff   [Lauren Hertzler, Philadelphia Business Journal, Jan 16, 15]   $400 Thousand in 1 Round, Aug 2014   []   A competitor in infarct reduction is TherOx  (Irvine, CA; $500K SBIR), [which] seeks $25 million for the final push to bring its treatment to increase the quality of life for heart attack patients. [, Nov 29, 13]


Infinera down 27% [May 9, 19] missed Wall Street’s revenue expectations by about 6% while reporting a narrower loss than analysts had expected. [, May 9, 19]

Infinera up 17% [Feb 1, 19] announced the expansion of its portfolio of metro packet-optical solutions with the introduction of the Infinera 7100 PSX-3S platform. The compact, high-density 1 rack unit (1RU) 7100 PSX-3S platform enables cost-effective access and aggregation of diverse metro traffic types, including high-speed Ethernet and 10 gigabits per second (Gb/s) and 100 Gb/s wavelength-division multiplexing (WDM). [company press release, Jan 30, 19]

Infinera down 15% [Oct 1, 18]

Infinera down 11%  [May 29, 18]

Infinera down 20%  [May 10, 18]

Infinera up 30% [Feb 8,18]  "In Q4 we made some difficult but necessary decisions to reposition the company for crisper execution and increased focus on our go to market strategy," said Tom Fallon, Infinera's Chief Executive Officer.  [company press release, Feb 8, 18]

Infinera down 27% [Nov 9, 17] announced a plan to restructure its worldwide operations to reduce its expenses and establish a more cost-efficient operating structure. [company press release, Nov 8, 17]

Infinera  down 17% [Aug 4, 17]

Infinera up 27% [Feb 10, 17]

Infinera down 14% [Oct 27, 16]

AXT down 10% [Oct 27, 16]

Infinera down 34% [Jul 28, 16]  demand is softening in certain areas of our business and we face a difficult near-term revenue outlook," said [CEO] Tom Fallon  [company press release, Jul 28, 16]

Infinera down 23% [Apr 28, 16]

Infinera up 15% [Oct 28, 15]

Infinera down 12% [Aug 20, 15]

Infinera up 31% [Oct 23, 14]

Infinera up 12% [May 19, 14]

Infinera   up 15% [Mar 12, 14]

Infinera up 29% [Jan 30, 14] after an impressive quarterly earnings report.

Infinera up 23% [Apr 25, 13]

Infinera  up 11% [Nov 26, 12]

Infinera  up 15% [Feb 3, 12]

Infinera down 11% [Oct 19, 11]

Infinera up 10% [Aug 1, 11]

Infinera down 18%  [Jan 28, 11]

Infinera down 35% [Oct 19, 10] following lowered guidance from the company [Forbes, Oct 19]

Infinera up 31% [Jul 23, 10]

Infinera up 10% [Jul 22, 10]

Infinera down 19% [Jul 20, 09]

Infinera up 10% [Jun 4, 09]

Infinera  down 15% [Apr 22, 09]

Infinera up 11% [Mar 12, 09]

Infinera up 15% [Mar 10, 09]

Infinera  down 18% [Jan 30, 09]

Infinera down 13% [Dec 15, 08]

Infinera  down 16% [Dec 1, 08]  On a stock bloodbath day

Infinera up 10% [Nov 26, 08]

Infinera up 13% [Nov 24, 08]

Infinera up 10% [Nov 17, 08]

Infinera up 14% [Oct 16, 08]

Infinera down 16% [Oct 15, 08]

Infinera up 15% [Oct 10, 08]

Infinera down 14% [Oct 2, 08]

Infinera up 18% [Sep 19, 08]

Infinera down 13% [Sep 9, 08]

Tools for An all-optical Internet. one-centimeter-square chips built at Infinera (Sunnyvale, CA). Each chip contains more than 40 optical devices that are important to managing the transmission of data on light beams; due to be commercialized this summer, they can replace individual components within Internet hubs. And this fall Luxtera (Carlsbad, CA) is commercializing a chip that integrates 100 optical components on silicon. [MIT Tech Review, J/A08]

Infinera up 10% [Jul 23, 08]

Infinera down 26% after it cut its full-year revenue forecast and projected third-quarter sales well below analysts' expectations. [Wall Street Journal, Jun 18, 08]

Infinera down 18% [Apr 23, 08]

Infinera down 10% [Mar 10, 08]

Infinera down 10% [Feb 29, 08]

Infinera up 44% [Feb 1, 08] on losing a lot less than expected.

Infinera up 10% [Jan 23, 08]

Infinera down 10% [Jan 15, 08]

Infinera down 12% [Jan 4, 08] on a day of NASDAQ pain that puts it at half its first day price last summer. Intel was down 15% for the week and one wag opined pushed small-capitalization stocks to the brink of a bear market

Infinera expects to raise $240M this week with a secondary. [Oct 07]

Infinera up 12%. [Jun 28, 07]

Infinera up 12% after a big commo provider picked its Digital Optical Network for its regional network.  [Jun 15, 07]

Infinera was up 28% after shooting up 52% the day before above its IPO price. [Jun 8, 07]

Infinera ($2M SBIR) filed to go public. [Feb 07]

David Welch, looking younger than he did a decade ago, graces the story on his new photonic integrated circuit at his start-up Infinera. [story by Kate Greene, MIT Tech Review, J/F 07] David was chief at R&D at SDL which sold itself for uncounted zillions to JDS Uniphase near the top of the IT bubble. He has had at least $1.3M in SBIR to supplement his apparent re-cycling of his profit from SDL.

Infinia (Kennewick, WA)

Infinia (Kennewick, WA; $3.6M SBIR) is raising another truckload of money. ... backed by Paul Allen and Vinod Khosla, has snapped up $11.5 million in new equity financing out of a round that could bring in as much as $75 million over time, according to a regulatory filing. ... developing solar-powered [Stirling] engines to generate large amounts of electricity in a renewable way  [, Feb 5, 10]

Infinia (Kennewick, WA; $3.5M SBIR)  which is using Stirling Engines to convert the sun’s rays into electricity, has raised $14 million in debt financing, according to a filing with the SEC. ...  part of a $50 million capital raise — follows a massive $50 million venture round  [John Cook, Puget Sound Business Journal, May 22. 09]

Infinite Electronics (Irvine, CA)

Infinite Electronics (Irvine, CA; no SBIR), a leading global supplier of electronic components serving the urgent needs of engineers through a family of highly recognized and trusted brands, has announced today its acquisition of Integra Optics (Latham, NY; no SBIR, founded 2007), a leading provider of high-quality optical transceiver products and solutions. [Infinite press release, Jun 9, 19]

Infinity Pharmaceuticals (Cambridge, MA)

Infinity Pharmaceuticals (Cambridge, MA; no SBIR)  announced 100 layoffs, more than half its workforce, after it terminated its partnership with AbbVie around the cancer drug duvelisib. Despite disappointing duvelisib data a few weeks ago, Infinity still aims to press on with more trials [Alex Lash,, Jul 1, 16]

Infinity Pharmaceuticals got a new lease on life in 2014 when pharma giant AbbVie plunked down $275 million to see if the company’s blood cancer drug, duvelisib, could stand out in a crowded field. The answer came back negative today, and Cambridge, MA-based Infinity has decided to gut its workforce as a result.  [Ben Fidler,, Jun 14, 16]

Infinity Pharmaceuticals (Cambridge, MA; no SBIR), a cancer drug discovery and development company, said that it has "elected to terminate" a trial of a drug candidate called IPI-504 in patients with refractory gastrointestinal stromal tumors.   [Boston Globe, Apr 16, 09]

Infinium (Boston, MA)

Infinium (Boston, MA; no SBIR) , a startup spun out of Boston University that’s been operating quietly since 2008 is now ready to go to market with its first products—the “rare earth” metals neodymium and dysprosium.  .... The ceramic material Powell showed me—which is made of zirconium oxide—replaces the carbon electrode and eliminates those [CO2] emissions. Researchers have been trying to replace carbon for many years, but the molten salts have corroded the alternatives. The key advance for Infinium was developing alternative molten salts that don’t react with the zirconium oxide, so that it can last long enough to be practical.  [Kevin Bullis,, Jun 4, 14]

Inform Genomics (Boston, MA)

Inform Genomics (Boston, MA; no SBIR, founded 2010) reports it has secured an undisclosed amount of funding from angel investors and individuals, including company founders and members of the board of directors. ....  to move along development of its molecular diagnostic product called ONPART, which uses genomics to predict what side effects a specific cancer patient might encounter with chemotherapy treatments.  [Rodney Brown,  Mass High Tech, Dec 1, 11]

Infoscitex (Waltham, MA; once Foster-Miller)

Ball Aerospace and Infoscitex (Dayton, OH; $50+M SBIR) won a shared contract with a combined potential value of $135M to perform research and development services to support the U.S. Air Force’s efforts to improve situational awareness and decision-making. [Brenda Marie Rivers,, Nov 22, 19] Infoscitex is not the only SBIR company camped around a DOD flagpole and winning huge contracts after piles of SBIR.  Congress could wrestle with the question of whether those piles of SBIR to such companies nurtures new technology with a market future. Unlikely.

Infoscitex (formerly Foster-Miller SBIR champ, now a wholly owned subsidiary of DCS Corporation, Beavercreek, OH) won a $70 million project at Wright-Patterson Air Force Base. [Dayton Business Journal, Jun 29, 17] .... has partnered with the United States Air Force Research Laboratory to create and operate a world class biodynamics and impact laboratory. [joint website of company and AFRL, 2014]

Infoscitex (Waltham, MA;  former overall SBIR award champion $150M SBIR as Foster-Miller, now a subsidiary of Alexandria, Va.-based DCS) landed a $98 million contract from Air Force Research Laboratory.   ...   to provide aerospace systems technology development. ... The work will be performed at Wright-Patterson Air Force Base during the next seven years.   [Joe Cogliano, Dayton Business Journal, Dec 19, 14]

Infoscitex (Waltham, MA; $tens of millions SBIR) and Ball Aerospace and Technologies will split a $60 million U.S. Air Force research and development contract.    ...   for the 711th Human Performance Wing  [Joe Cogliano, Dayton Business Journal, Mar 3, 14]

Infoscitex develops technology solutions in a number of fields, ranging from oceans to outer space. A multi-year Larta CAP participant, Infoscitex has previously received funding from both the NIH and TATRC, and recently announced that it will be acquired by DCS Corp and become a wholly owned subsidiary. Infoscitex’s extensive experience with research and development for defense agencies like the DoD and TATRC, including an $85 million, five-year contract with the Air Force Research Laboratory and Aeronautical Systems Center, will complement the technology solutions services DCS Corp provides to government agencies within the national security sector.  [LARTA Vox, Aug 30, 12]  Infoscitex is the residue of Foster-Miller that did not merge with Qinetiq (Europe’s largest science and technology solutions company, says Robotic Trends 2004)

Database management systems and integration, visualization and support products maker Infoscitex (Waltham, MA; $50M SBIR since 2005; founded 2000) has been acquired by Alexandria, Va.-based DCS Corp. [creates innovative technology solutions for our customers in the national security sector.: company website] for an undisclosed amount. .... Last month, DCS said it acquired OptiMetrics (Ann Arbor, MI; $5M SBIR) which provides chemical, biological, radiological, Nuclear and Explosives (CBRNe) defense, training and simulation, and combat vehicle survivability for the Department of Defense.   [Mass High Tech, Aug 10, 12]  How would the government like to explain the wealth creation it fostered by "investing" $50 million of technology nursery money in a government support contractor, no matter how technically excellent?

Infoscitex (formerly Foster-Miller (says SBA), or at least some part thereof, $13M++ SBIR from at least 87 projects since 2005 (SBA database crashes just trying to spit out the data))  landed $49.5 million from the USAF ....   will create modeling, simulation, and analysis tools and techniques for research and engineering for the Air Force...   [Mass High Tech, Mar 19]    Vision and Mission go beyond simple elevator-pitch statements. Our values are the underpinning of our culture and these core values are the primary reasons for our success.   got that?  ...currently employs 80 professionals throughout the U.S. and anticipates revenue of $17 Million in 2008.[company website] got that?


Inframat and its sister company, US Nanocorp...  are idea labs. In 2003 the companies pulled in $3M in revenue, only 10% from commercial sales. The bulk was government research money, the main source of the $20M grants and contracts Reisner has sucked up since 1996, when he started out, from the likes of the Navy, NASA, the National Institutes of Health and other agencies. Private capital abhors abstruse products that can take years to reach the market. Besides, he says, "We would have had to give away half the company for a few hundred thousand dollars."  ...  Reisner, who has three children, quit his job and lived off the income of his wife, who has an ob-gyn practice. ... cranking out nanopowder by the ton. At $35 a pound the stuff will help pay the salaries of all those Ph.D.s. (Some of whom "understand when we miss the payroll by a few days," says Hsiao.) Powder sales have totaled $100K in the last three years. [Thomas Kellner, Forbes, Jun 21] Another SBIR company living on government money until the happy day when the commercial world (or military procurement) cottons on to nanostuff. Could be a long haul to his retirement or bankruptcy. Moral: if you're going to depend on SBIR for your advanced technology dream, marry a doctor with a practice. Meanwhile, the government SBIR people may tout your technology for their commercialization reports without giving you any money. Especially if your payoff to their programs is far in the future.

Infraredx (Burlington,MA

 Infraredx (Burlington, MA; no SBIR, founded 1998) enrolled its first patient and invested more than $10 million into what it says is the first and largest study of treatment of Lipid core plaque in patients' major arteries.  ....  said its PROSPECT II study, which will enroll 900 patients at 16 cardiac catheterization labs in Scandinavia ...  applied for approval in Japan in February 2013 with its Japanese partner Nipro, the giant medical device company. Nipro agreed to distribute Infraredx’s TVC imaging system to both diagnose and treat coronary artery disease. In addition, Nipro will maintain the systems and teach doctors how to use them. The exclusive deal, worth $50 million, will last five years. ... Nipro also invested $25 million in Infraredx in last August   [Patricia Resende, Boston Business Journal, Jun 30, 14]

InfraReDx (Burlington, MA; no SBIR) landed a $10 million senior secured multi-draw term loan ...  has developed the TVC Imaging System, an intravascular imaging system based on ultrasound and near-infrared spectrum that can identify plaque within the interior of a blood vessel. ....  In June, InfraReDx raised $24.1 million in a new equity offering, which was to be used for expanding manufacturing operations and commercial infrastructure.   [Rodney Brown, Mass High Tech, Dec 7, 11]

Infraredx (Burlington,MA& Infraredx (Burlington,MA) said it has raised $24.1 million from the sale of equity to existing InfraReDx shareholders. Some of the funding will be used to support the recent launch of a coronary imaging system that can detect coronary plaques. [Boston Globe, Jun 28, 11]

InfraReDx(Burlington, MA, no SBIR) medical device company, said it has gotten a regulatory clearance to market a coronary imaging system. [Boston Globe, Sep 1, 10]

Until last October, InfraReDx (Burlington, MA; no SBIR) considered itself a symbol of the kind of science-based innovation that creates durable healthcare industry jobs. Now, InfraReDx represents the perils of the recession for small companies working on promising medical technologies that hospitals and insurers see as experimental. The company, which makes a laser-scanning system that locates signs of heart disease, has been through two rounds of layoffs, reducing its work force to 72 from 92. It would have run out of money this month if its investors had not agreed to a new round of investment.  [Barnaby Feder, NY Times, Apr 5, 09]

US regulators approved the first device that lets doctors see fat buildup inside coronary arteries to gauge heart attack risk. ... made by InfraReDx (Burlington, MA; no SBIR).  [Boston Globe, May 1, 08]  a privately-funded, early-stage medical device company with expertise in photonics and medicine. ... founded in 1998 ... to develop novel, photonic-based medical devices that will help improve the diagnosis and treatment of various diseases [company website]

InfraScan (Philadelphia,PA)

Infrascan (Philadelphia, PA; $1M SBIR) signed a $3.7 million, multi-year contract with the U.S. Marine Corps/Navy to develop a next generation version of the company’s Infrascanner brain  [John George, Philadelphia Business Journal, Jun 12, 15]

Nearly three years have passed since Infrascan (Philadelphia, PA; $1M SBIR) secured [FDA] approval for its Infrascanner, a portable imaging device that uses near infrared technology to detect bleeding in the brain. ... now working on a third generation Infrascanner while also looking to add military and nonmilitary customers in the United States and abroad.  "The focus on the company is the military market," said [CEO] Ben Dor, noting the handheld device is ideal for making diagnoses on the battlefield   [John George, Philadelphia Business Journal, Nov 28, 14] 

InfraScan (Philadelphia, PA; $1M SBIR) has signed a $2 million  [SBIR Commercialization Pilot Program] contract with the U.S. Marine Corps to create a portable device to detect traumatic brain injuries on battlefields and other operational environments. Head wounds, according to military officials, lead to nearly 50 percent of combat deaths. .... The Infrascanner has obtained European marketing clearance and is marketed in Russia, Italy, Romania, Saudi Arabia, Panama, Turkey and India. An application to sell the product in the United States is currently under FDA review   [John George, Philadelphia Business Journal, Jul 19, 10]

INF Robotics (Fairfax, VA)

INF Robotics (Fairfax, VA; no SBIR,five employees), is looking for a new headquarters to expand its robot manufacturing business and hopes to have a new home by this summer.  .... “What interests me most about Baltimore is they’re very supportive of hardware companies relocating,” Nunez said. “Hardware companies bring jobs. ... developing a robot that could help elderly or individuals with limited mobility care for themselves so they can stay at home  [Sarah Gantz, Baltimore Business Journal, Mar 13, 14]

Infusion Medical (Morrisville, NC)

Infusion Medical (Morrisville, NC; no SBIR, founded 2013) raised $3.2 million from private investors, but wants to keep a low profile. ... developing a new way to deliver a local anesthetic, but would not give details  [Jason deBruyn, Triangle Business Journal, Aug 28, 14]

Ingeneus (Milwaukee, WI)

General Dynamics, DRS Technologies and others will discuss their needs this week at the Resource Rendezvous, an event organized to help state companies increase their chances of winning federal grants and research agreements with defense contractors. Seventeen companies from the Upper Midwest also have been selected to pitch their science and technology-based products at the event  .... Presenting companies include Ingeneus (Milwaukee, WI) formed in August that is developing a tool for DNA analysis of hypertension; Isomark (Madison, WI; no SBIR)  with a technology for detecting infection as soon as two hours after onset; and Matrix Product Development  (Sun Prairie, WI;  SBIR) with a technology using battery-operated tags for hazardous waste material tracking. ....  To register or get more information, visit or call Joy Sawatzki at (608) 442-7557.   [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 16, 13]

Ingeneron (Houston, TX)

Stem-cell technology developer InGeneron (Houston, TX; no SBIR) added another $23 million to a Series D financing it announced in 2017, bringing the total of the funding round to $43 million for a clinical study in rotator cuff tendinopathy, a swelling of the tendons and muscles that support the shoulder joint. [David Holley,, Jun 11, 19]

Ingeneron (Houston, TX; no SBIR) developer of a stem cell-based technology, announced it has raised $20 million from strategic partner Sanford Health -  a large hospital chain based in Sioux Falls, SD, is conducting a small, 18-patient safety study of Ingeneron’s system, known as Transpose RT, being used to heal orthopedic ailments like torn shoulder rotator cuffs..  I...  In total, the company has raised $38 million from unspecified family offices and high net-worth individuals in both the United States and Germany. [Angela Shah,, Mar 6, 17]

Ingeneron (Houston, TX; no SBIR, founded 2006) stem cell research company raised $4.5 million, according to [SEC] filing   .... creates cell-based research for health care, veterinary and life science research, according to its website. Among other technology, the company researches the use of regenerative cells, which includes stem cell research, and how it can impact treatment for disease, cosmetic and orthopedic injuries.   [Joe Martin. Houston Business Journal, Jul 12, 16]

Inhibitex (Alpharetta, GA)

Great innovation, who will buy it? Big pharmaceutical companies increasingly demand evidence that a drug will have a paying market. But many of their erstwhile biotech partners aren’t getting the message, according to a new industry report [by Ernst & Young]. ...“When we ask [most biotechs], is demonstrating the value of your product important, of course everyone said, yes it is,” Giovannetti said. “Then we asked, are you putting expertise on your team, and we got a much lower response.”   [Bradely Fikes,, Apr 23]  Big Pharma companies, for their part, often feel like they’ve been snookered a few too many times by overpaying for biotech companies that didn’t deliver on their promise. (Ask Merck about Sirna Therapeutics (San Francisco, CA; no SBIR), or Bristol-Myers Squibb about Inhibitex (Alpharetta, GA; one SBIR).  [Luke Timmerman, xconomy,com, Apr 22] NIH is one federal agency whose SBIR forces the proposer to answer such questions as who will buy and who will invest. Whether the peer reviewers know enough to judge the proposer's predictions is another question. But the track record of economic activity from NIH SBIR is phenomenal, especially when measured against the big money SBIR programs at DOD and NASA.

Biota Pharmaceuticals  (Rockville, MD; no SBIR) is moving to Alpharetta, GA. ... focuses on the development of anti-infective products to prevent and treat potentially life-threatening viral and bacterial infectious diseases, ... also has an advanced program for the treatment of human rhinovirus infection.  ...will initially employ up to 20 ....  has an R&D operation in Melbourne, Australia and an office in Oxford, England.   Biota is led by two former executives at Inhibitex (Alpharetta, GA; one SBIR in 1999)  clinical-stage drug development company acquired by Bristol-Myers Squibb Co. [Urvaksh Karkaria, Atlanta Business Journal, Apr 15, 13]

Inhibitex up 140% [Jan 9, 12]

Drug maker Bristol-Myers Squibb is buying hepatitis C drug developer Inhibitex (Alpharetta, GA; one Phase I SBIR in 1999)  for about $2.5 billion, paying a premium to become a bigger player in the growing business of treating the potentially fatal virus. ...  focuses on treatments for bacterial and viral infections. The small company has had an up-and-down history, with its shares falling in late 2010 after Inhibitex posted disappointing trial results for its FV-100 shingles treatment. Near the end of 2011, the stock price hit a 52-week high of $16.49 due to interest in the company's hepatitis C treatment INX-189. By contrast, the shares recorded a 52-week low of $2.15. [JD Rockoff, A Das, and G Chon, Wall Street Journal, Jan 9, 12]

Inhibitex  down 20% [Dec 16, 11]

Inhibitex up 20% [Nov 29, 11]

Inhibitex up 93% [Nov 21, 11]

Inhibitex up 14% [Nov 7, 11]

Inhibitex up 116% [Nov 4, 11]  after the company released promising new data on its hepatitis C drug candidate. []

Inhibitex up 13% [Oct 17, 11]

Inhibitex  up 11% [Aug 15, 11]

Inhibitex up 31% [Apr 1, 11] after reporting positive top-line safety and antiviral data from its multiple ascending dose Phase 1b clinical trial of INX-189, an oral nucleotide polymerase inhibitor being developed to treat chronic infections caused by hepatitis C virus (HCV). [Business Wire]

Inhibitex up 12% [Mar 31, 11]

Drug developer Inhibitex (Alpharetta, GA; one SBIR a decade ago) down 24% [Dec 13, 10] following news that its potential shingles medication did not test well in a mid-stage clinical trial. [Atlanta Business Chronicle, Dec 14, 10]

Inhibitex (Alpharetta, GA; one SBIR) was dogged again in the third quarter by higher research and development costs. ...  ... a net loss of $4.5 million [Atlanta Business Chronicle, Nov 6, 09]

Inhibkase Therapeutics (Atlanta, GA and Cambridge, MA)

Inhibkase Therapeutics (Atlanta, GA and Cambridge, MA; no SBIR)  young pharmaceutical company just got the green light from the U.S. Food and Drug Administration to treat a rare side effect of drugs given for autoimmune diseases.  ...  develops products to treat infectious diseases with little or no resistance. The company received Orphan Drug Designation for its product imatinib, which is designed to treat Progressive Multifocal Luekoencephalopathy (PML).   [Ellie Hensley, Atlanta Business Chronicle, May 21, 14]

Inhibrx (La Jolla, CA)

Inhibrx (La Jolla, CA; SBIR, founded 2010), developer of protein drugs targeting cancer and other diseases, has raised $40 million as the biotech steers several programs through early-stage clinical trials. [Sarah de Crescenzo,, May 24, 19]

INI Power(Cary,NC)

ADS  (Virginia Beach, VA; no SBIR). announced today that it has won[a $25M] contract to supply the U.S. Marine Corps One Man Portable Battery Charger Requirement Program of Record. ADS. will utilize INI Power Systems (Morrisville, NC; $800K SBIR)’s One Man Portable Generators featuring OMNIVORE™ Engine Technology (GSA Advantage: INI POWER) to meet 1MPG Single Fuel Forward requirements.  INI’s One Man Portable Generators provide the real-time solution to bridge the power and energy capability gaps required to generate 1kW of electrical power using JP-8 in support of GREENS and One-Man Portable Battery Chargers.  [ADS Press Release, Jan 8, 2015]

Burns any fuel. The U.S. Army will test four of INI Power (Morrisville, NC; $800K SBIR in Illinois)’s fuel omnivores this year... little dynamo can burn: gasoline, ethanol, diesel, kerosene, jet fuel, methanol, grain alcohol, rum, paint thinner, hydrogen. Any liquor that’s 151-proof and stronger will do in a pinch. .... a decade-long struggle for a breakthrough. The company has burned through $20 million in private investment and federal grants, Markoski said. For the past three years, the 10-employee business has been “self-funded”  [John Murawski, Raleigh News & Observer, May 6, 12]

INI Power Systems (Cary, NC; $800K SBIR while in IL) raised $4M VC as the company moves closer to marketing methanol-powered fuel systems that could replace batteries in portable electronic devices [Raleigh News & Observer,  May 31]

Inland Labs (Austin, TX)

BioPhysical (Austin, TX;  $1.1M SBIR, founded 1982, 53 employees)  raised $4.1 million of a $5 million round of funding that it will use to pay for an office expansion in Houston and Austin in 2015. ... has yet to turn a profit  [Chad Swiatecki, Austin Business Journal, Nov 14, 14]  manages and markets biomarker-based health assessments direct to consumers and corporations ...  provides the most comprehensive blood-based assessments of an individual's health. ... history: 1982 Inland Labs (no SBIR) is founded; 1995 Luminex ($1.1M SBIR) is formed from Inland Labs; 2002 Rules Based Medicine (no SBIR) is formed from Inland Labs; 2005 Biophysical forms from Rules Based Medicine.  [company website]

Inmobly (Columbus, OH)

the Ohio Third Frontier Commission approved more than $84.9 million to support promising startups, new cutting-edge technologies and getting innovative ideas to the marketplace.  Two Cincinnati companies are to receive $100,000 grants:   Sense Diagnostics (Cincinnati, OH; no SBIR) will use the money to enable commercialization of a device named SENSE, a noninvasive radio frequency sensor that detects changes in the brain – including seizures, hemorrhage and increased swelling/edema.      Standard Bariatrics (no SBIR) will use the money to further develop and commercialize a stapler guide. It will improve surgical procedures that reduce the volume of the stomach to help morbidly obese patients lose weight. [Barrett J. Brunsman, Cincinnati Business Courier, Jun 18, 14]  Other Central Ohio entities receiving Third Frontier funds:     EWI:$4.9 million as part of its matching funds toward a federal award creating a $148 million high-tech manufacturing research institute near Detroit in collaboration with Ohio State and the University of MichiganCardiox (Columbus, OH; no SBIR) :$1.7 million loan toward commercializing its device that detects abnormal blood flow from the earInmobly (Columbus, OH; no SBIR):$1 million loan for scaling up the spread of its technology that helps stop broadband traffic logjams from video downloads. [Carrie Ghose, Columbus Business First, Jun 23, 14]  Third Frontier seems a standard subsidy program with metrics that don't really measure the impact against the investment.  But political programs usually work that way: fanfare for the handouts and no public ROI rerports and no control group for comparison.

InnAVasc Medical (Durham,NC)

InnAVasc Medical (Durham,NC; $1.2M SBIR), founded by Duke University surgeons and scientists, recently reported a $500,000 fundraising round for costs associated with going into clinical trials.An arteriovenous graft modification that bills itself as the “first error proof dialysis graft” is the company’s primary technology.  [, Oct 16, 18]

NCBiotech announced last week that it had awarded $1,060,352 through 17 grants and loans in the first quarter of its 2016-17 fiscal year. In total, four Triangle firms snagged funding.  InnAVasc Medical (Durham, NC; no SBIR), 410 Medical Innovation  (Durham, NC; no SBIR), UVision360 (Research Triangle Park, NC; no SBIR), and EpiCypher  (Research Triangle Park, NC; no SBIR) each received a $250,000 small business research loan for applied research, NCBiotech said.   [Jennifer Henderson, Triangle Business Journal, Oct 20, 16]

InnerPulse (Research Triangle Park,NC)

A recent beneficiary of venture capital is InnerPulse, a Research Triangle Park [NC] medical device company that is developing a defibrillator for reviving a heart. A group of venture capitalist firms invested $15.1M in the company in late 2003, even though its technology was unproven. Now, InnerPulse has 40 employees and is on track to test its device -- which would be implanted like a pacemaker -- in humans next year. The company has raised $85M in financing. [David Ranii, Raleigh News and Observer, Mar 21]  No SBIR.

InnerOptic Technology (Hillsborough, NC)

InnerOptic Technology (Hillsborough, NC; $500K SBIR), working on ultrasound equipment that promises to help surgeons, has raised up to $370,000 from private investors and CatoBioventures. [Raleigh News&Observer, Dec 20]  Launched in 2003, InnerOptic is a spin-off of the University of North Carolina at Chapel Hill's pioneering Computer Graphics Department. [company website]

Innocrin Pharmaceuticals (Durham, NC)

Innocrin Pharmaceuticals (Research Triangle Park, NC; no SBIR)  raised $6 million, according to an SEC filing [Jennifer Henderson, Triangle Business Journal, Jul 14, 17]  ...  focuses  on  the  discovery  and  development of    best-­‐in-­‐class,  small   molecule CYP17  lyase inhibitors,  a  [2014]  spin-­‐out    of  Viamet    Pharmaceuticals  ...  for the  treatment  of  castration--­‐resistant prostate  cancer  (CRPC)  [company press release, Oct 22, 14]

Innocrin Pharmaceuticals (Durham, NC; no SBIR) drug-development company that spun out of Viamet Pharmaceuticals last fall, has raised $28 million.  ... to develop its experimental treatments for breast and prostate cancer. The company doesn’t have any products on the market.  [Raleigh News & Observer, Apr 15, 15]

Innocrin Pharmaceuticals  (Durham, NC; no SBIR), which recently spun out of Viamet, raised $8 million and has commitments for another $6 million from existing investors. ... to develop a treatment for both prostate and breast cancer. [Jason deBruyn, Triangle Business Journal, Dec 18, 14]

Innography (Austin, TX)

Austin startup Innography Inc. has raised $6.5 million in venture capital to expand the marketing of its software, which helps companies manage, protect and leverage their patents. The company was founded by Tyron Stading, who filed two dozen patents during his five years as a software engineer and industry solutions manager at IBM Corp. in Austin. [Austin American-Statesman, Aug 18]

InnoPad (Peabody, MA)

InnoPad (Peabody, MA; no SBIR), a maker of material used in semiconductor manufacturing, has raised $2.7 million in a new funding round that is targeting a top end of $5 million ... launched in 2006 when its predecessor company Innovent Technologies LLC purchased the innoPad intellectual property from a German firm. The company makes pads used to polish the alternating layers of semiconductor material and insulators in the creation of a semiconductor chip.  [Rodney Brown, Mass High Tech, Sep 14, 11]

InnoPad (Peabody, MA; no SBIR) maker of material used in semiconductor manufacturing, has closed on $1.7 million of a planned $3.4 million funding round, the company confirmed [Mass High Tech, Apr 6, 10]

Innotec (E Lansing,MI)

Forbes magazine list of 25 best US small companies included  Innotec  (E Lansing, MI; $900K SBIR) and  Torch Techonolgies (Huntsville, AL; $5M SBIR)


Chemical giant DuPont announced Monday that it has acquired Innovalight (Sunnyvale, CA; $900K SBIR in Texas) startup that makes "solar ink" for leading solar manufacturers. ... the latest sign that established corporate players with cash on hand are seeking a bigger stake in renewable energy, particularly solar  [San Jose Mercury News, Jul 25, 11]

Chinese solar manufacturer Yingli Solar announced it has signed a technology, research and production agreement with Innovalight (Sunnyvale, CA; $900K SBIR in Texas). It's Innovalight's second major deal with a Chinese solar manufacturer. Earlier this month, JA Solar signed an agreement to buy inks from Innovalight for three years. ....  In 2008, Innovalight was one of six companies to be awarded a competitive, $3 million grant from the Department of Energy that aims to make solar energy cost-competitive with conventional forms of electricity by 2015.  [Dana Hull, San Jose Mercury News, Jul 26, 10]

Innovalight (Sunnyvale, CA; $900K SBIR in Texas) which sells silicon ink-based high efficiency solar cell materials and technology, said it raised $18 million in new capital. ... the fourth round of funding was led by EDB Investments of Singapore.  [Silicon Valley/San Jose Business Journal, Jan 7, 10]

NanoReturn. Will any of this stuff translate into an economic windfall for Minnesota? So far, the U has licensed nanotechnology to three companies, two of them local, with mixed results.  Nanocopoeia (St. Paul , MN; $1M SBIR) is trying to divest its original medical device coating business to focus on pharmaceuticals. Rushford Hypersonic (no SBIR) next month will open the world's first hypersonic plasma particle disposition plant in southeastern Minnesota. Innovalight, (Austin, TX to St. Paul, MN to Sunnyvale, CA; $900K SBIR in TX), which originally focused on light bulbs, is now making solar cells. ...  The U's uneven experience with nanoscience mirrors corporate America's teasing and often frustrating flirtation with a technology that's failed, so far, to match hype with reality. Despite millions of dollars in government research money and venture capital, making big bucks off nanotechnology remains an elusive dream. [Thomas Lee, Minneapolis Star Tribune, Jun 28, 09]  Nanostuff, GaAs, CVD diamond, SiC substrates, and such, are the kind of futures that SBIR should invest in until economic barriers show that it has only a long term possible future. Then it should be turned over to long term investors with long green, not slogged away in a small high tech nursery program. SBIR's goal should be economic visibility for a technology, not long term development a few bucks at a time in life-style companies.

We have embarked upon . . . a new frontier of silicon Innovalight (Santa Clara CA; $0.9M SBIR in Texas) has silicon ink, a secret nanotechnology recipe it developed that the company says lets it make solar cells that are more efficient than current models, at a lower price.  Another $28M of VC, this time led by Norway (with all that North Sea oil money stashed away). [story San Jose Mercury News, Oct 15] It may be a secret formula for commercial markets, but the government's SBIR rights could cause some trouble in selling it for obscene profit to the government.

Korgel and Johnston, placed bits of silicon in a pressurized titanium chamber. They poured in a brew of solvents and then heated it to 932F. What emerged from this pressure cooker were itsy-bitsy crystals of silicon, visible only under the most powerful microscopes. But something was very peculiar about silicon at this atomic scale. It wasn't its usual sandy self. Far from it. These so-called nanocrystals, when hitched to electrical current, emitted steady light. That glow attracted venture capitalists. [S Baker and A Aston, Business Week, Oct 11] There's always at least one VC who will invest in almost anything new. Korgel's UT spinoff InnovaLight attracted five VC firms plus "investments"  from the government: AF STTR, DOE, and NSF (SBIR). MIT Tech Review (Oct 04) highlights three top nano startups: Quantum Dot (two HHS SBIRs), AmberWave(an Army SBIR), and Neah Power Systems.  Two of those startups are the brainchild of two of the top 100 innovators under 35.

Innovari Energy Austin, TX)

Innovari Energy (Austin, TX; no SBIR) raised $4 million in venture backing, according to a securities filing.  [Austin American Statesman, Jun 2, 11]

Innovate Biopharmaceuticals (Raleigh, NC)

Innovate BioPharma up 38% [Dec 10, 18]

Innovate Biodown 14% [Nov 14, 18]

Innovate Bio down 11% [Oct 5, 18]

Innovate Biopharma up 15% [Sep 24, 18]

Innovate Biopharma down 15% [Sep 6, 18]

Innovate Biopharma down 14% [Sep 5, 18]

Innovate Biopharma up 26% [Sep 4, 18]

Innovate Biopharmaup 36% [Aug 31, 18]

Innovate BioPharma down 14% [Aug 13, 18]

Innovate Biopharma down 11% [Aug 10, 18]

Innovative Biopharma up 24% [Aug 8, 18]

Innovate Biopharma down 20% [Jul 30, 18]

Innovate Biopharma up 13% [Jul 25, 18]

Innovate Biopharma up 25% [Jul 24, 18]

Innovate Biopharma down 14% [Jul 23, 18]

Innovate BioPharma down 12% [Jul 18, 18]

Innovate BioPharma down 66% [Jul 16, 18] apparently spurred by a filing related to a proposed stock offering. Innovate filed a securities registration statement amendment [Motley Fool, Jul 16, 18]

Innovate Biopharma up 14% [Jul 9, 18]

Innovate Biopharma down 10% [Jul 6, 18]

Innovate Biopharma down 12% [Jul 5, 18]

Innovate Biopharma up 13% [Jul 2, 18]

Innovate Biopharma up 11% [Jun 26, 18]

Innovate Biopharma up 39% [Jun 25, 18]

Innovate Biopharma up 22% [Jun 22, 18]

Innovate Biopharmadown 13%  [Jun 11, 18]

Innovate Biopharma up 13%  [May 2, 18]

Innovate Biopharma down 15% [Apr 23, 18]

Innovate BioPharma down 16% [Apr 19, 18]

Innovate BioPharma down 17% [Apr 18, 18]

Innovate Biopharma up 14% [Apr 12, 18]

Innovate Biopharma down 10% [Apr 11, 18]

Innovate BioPharmadown 19% [Apr 6, 18]

Innovate Biopharma  up 42% [Apr 3, 18]

Innovate BioPharma  up 19% [Apr 2, 18]

Innovate Biopharma up 12% [Mar 29, 18]

Innovate BioPharma down 16% [Mar 28, 18]

Innovate Biopharma up 20% [Mar 23, 18]

Innovate Biopharma up 18% [Mar 22, 18]

Innovate Biopharman up 23% [Mar 19, 18]

Innovate BioPharma up 13% [Mar 16, 18]

Innovate BioPharma down 21% [Mar 15, 18]

Innovate Bipharma down 10% [Mar 13, 18]

Innovate Biopharma down 10% [Mar 7, 18]

Innovate Biopharma down 16% [Mar 6, 18]

Innovate Biopharmaceuticals (Raleigh, NC; no SBIR, founded 2012,market cap $9M) up 82% [Mar 5, 18] developing novel medicines for autoimmune and inflammatory diseases with unmet needs. went public Jan 2018 by reverse merger, reverse stock split, and concurrent financing of $21 million. [company website]

Innovate Biopharmaceuticals (Raleigh, NC; no SBIR) is poised to become a public company through a reverse merger with California-based Monster Digital  [Jennifer Henderson, Triangle Business Journal, Jun 20, 17]   Innovate’s lead drug candidate, larazotide acetate (INN-202), is the only drug which has successfully met its primary endpoint in an efficacy clinical trial for celiac disease. [Monster press release]

Innovative Design Labs (Minneapolis,MN)

Innovative Design Labs (Minneapolis, MN; no SBIR) is using grants from NIH to develop and commercialize a system to detect the potential for falls in elderly people. [Holly Dolezalek, Minneapolis / St Paul Business Journal, Jun 28, 13] exclusively a research and development company focused on creating new and innovative electronic products [company website]

Innovative Microplate (Chicopee, MA)

Seahorse Bioscience’s (no SBIR) local expansion has been so successful, the company made a second in-state acquisition, of BioProcessors (Woburn, MA; $500K SBIR) in March 2009. The Woburn company creates an instrument that helps biologic makers decide how to design their manufacturing process to maximize cell yield.... Founded in 2001, [Seahorse] has grown from around 60 employees two years ago to about 100 now, through hiring and acquisitions.... acquisition of  Innovative Microplate (Chicopee, MA; no SBIR). five years ago has led to continued hiring through the recession and an expansion of the manufacturing facility there, to 25,000 square feet from 14,000 square feet. Seahorse’s lead product is a bench-top scientific instrument that measures the energy production activity of cells.  [Julie Donnelly, Mass High Tech, Jun 23, 10]

Innovative Pulmonary Solutions (Bellevue, WA)

Innovative Pulmonary Solutions (Bellevue, WA; no SBIR), a stealthy medical device startup, has raised more than $10 million in venture capital and recruited a new CEO with experience selling a couple of other startups,  .... sold his previous companies, Lutonix (no SBIR) and Velocimed (no SBIR), to C.R. Bard and St. Jude Medical, respectively. [Luke Timmerman,,  Sep 20, 12]

Innovative Pulmonary Solutions (Bellevue, WA; no SBIR), a stealthy medical device startup, has raised more than $10 million in venture capital and recruited a new CEO with experience selling a couple of other startups,  .... sold his previous companies, Lutonix (no SBIR) and Velocimed (no SBIR), to C.R. Bard and St. Jude Medical, respectively. [Luke Timmerman,,  Sep 20, 12]  

Innovative Scientific Solutions (Beavercreek, OH)

Innovative Scientific Solutions (Beavercreek, OH; $20M SBIR) and Taitech (Beavercreek,OH; $7M SBIR) were named to the seven-year contract to continue work on the Technology for Sustained Supersonic Combustion program [Joe Cogliano, Dayton Business Journal, Oct 29, 13] The "innovation" objective is to make the Air Force even smarter about scramjets. No doubt the SBIR advocates will find the contracts as fine examples of "commercialization" even though the market impact will be about nil.

Innovative Scientific Solutions (Beavercreek, OH; $17M SBIR) landed a spot on a $44.5 million U.S. Air Force support deal.  ....     for advanced propulsion concepts and cycles program work. The contract is structured to include a short-list of companies eligible to bid on individual tasks.  [Joe Cogliano, Dayton Business Journal, Mar 1, 13]  the firm's web site claims providing innovative and unique solutions in the areas of Fluid Dynamics, Aerodynamics, Combustion Analysis, and Pressure/Force Measurement. Gathering around the sponsor's flagpole is called industry cluster, and provides easy access to the honeypot.

Innovention Technologies (Pittsburgh, PA)

Cardiorobotics (Newport, RI (originally founded in 2005 as Innovention Technologies, Pittsburgh, PA); no SBIR) has landed $5 million in venture capital ... makes the cardioARM, a snake-like, remote-controlled robotic probe intended to minimize incisions necessary for surgical procedures. ... In June, raised a Series A round of $11.6 million  [Mass High Tech, Jan 21, 10]

Innov-X Systems  (Woburn, MA)

Innov-X Systems (Woburn, MA; no SBIR, founded 2001) , maker of handheld chemical and elemental analyzers, has landed a $4.5 million investment ... a three-pound portable X-ray fluorescence (XRF) device that can determine the presence of elements such as lead or mercury ....  received $27 million in venture funding [Rodney Brown, Mass High Tech, Jun 24, 09]

Innov-X Systems (Woburn, MA) got $27 M in venture funding for its 3-pound gadget that detects cadmium and mercury. [Mass High Tech, Jan 8, 07]

Innovative Silicon (Santa Clara, CA)

Innovative Silicon (Santa Clara, CA; no SBIR) developer of Z-RAM,  raised $25M for ultra-dense memory. far reached licensing deals with Hynix Semiconductor and Advanced Micro Devices [Matt Marshall, Venture Beat, Nov 7]

Innovative Spinal Technologies (Mansfield, MA)

Innovative Spinal Technologies (Mansfield, MA; no SBIR) that ceased operations in February, has officially filed for Chapter 7 bankruptcy protection.  ... focused on minimally invasive spine surgery and motion preservation  [Mass High Tech, Jun 1, 09]

Innovative Spinal Technologies (Mansfield, MA; no SBIR) has shut down its website and did not return calls seeking comment. .... originally spun off from the Texas Back Institute ....  had raised $75 million in funding and had as more than 100 employees as its peak in 2007  [Boston Globe, Feb 3, 09]

Innovative Technologies (Dayton, OH)

Defense contractor Innovative Technologies (Dayton, OH; no SBIR) was awarded $17M in punitive damages  in a lawsuit that alleged three employees used trade secrets and confidential company data to set up their own competing company. ... used the trade secrets and confidential information to start their own firm, Kenton Trace Technologies LLC, in 2000 while still Innovative Technologies employees. The three then worked with a Washington, D.C.-based contractor, Advanced Management Technologies , to take away a major federal contract from Innovative Technologies, according to the case. [Dayton Business Journal, Jan 4,08]

Innovative Trauma Care or iTraumaCare (San Antonio, TX)

Innovative Trauma Care, or iTraumaCare, has completed a convertible debt financing round which has netted the early-stage medical device firm $3 million.  .... to support the commercialization of its first product, the iTClamp Hemorrhage Control System, in North America and Europe.  The iTClamp is designed to control severe bleeding in a matter of seconds by sealing the edges of a wound.  [W Scott Bailey, San Antonio Business Journal, Jun 26, 13]

InnovaWave (Austin, TX)

Start-up InovaWave (Austin, TX) says it might double in size, adding 20 employees by the end of this year, thanks to a $7.2 million venture capital investment as well as heavy customer interest in a forthcoming software product. The Austin company, which is only 16 months old, has attracted interest from large corporations because its software enables servers in large corporate data centers to run more efficiently. [Austin American-Statesman, Jul 17]

Innoviva (Brisbane, CA)

Innoviva (Brisbane, CA; no SBIR) down 16% [Oct 25, 17] "We had a very successful third quarter of 2017 that included strong commercial performance of RELVAR/BREO ELLIPTA and ANORO ELLIPTA, positive regulatory outcome in the U.S. and Europe for TRELEGY ELLIPTA, a successful refinancing of our 9% non-recourse term notes, and completion of the Board of Directors expense review," said [CEO] Michael W. Aguiar. [company press release, Oct 24, 17]

Innovolt Atlanta, GA)

Innovolt (Atlanta, GA;  no SBIR) raised nearly $2.6 million of a planned $9 million equity raise, according to [SEC] filing.  .....   developed technology, it says, guards against damage from 99.5 percent of power interruptions and extends the life span and reliability of electronic devices.  .... The Georgia Tech spinoff has designed a microprocessor — about half the size of a business card — that can be embedded in electronic devices. The chip is able to detect abnormalities in the electrical flow and evens out the current, or shut off the device before damage occurs.  [Urvaksh Karkaria, Atlanta Business Chronicle, Jul 16, 13]

Innovolt (Atlanta, GA; no SBIR) raised $3 million according to [SEC] filing  ...   developed technology, it says, guards against damage from 99.5 percent of power interruptions and extends the life span and reliability of electronic devices.  Georgia Tech spinoff has designed a microprocessor — about half the size of a business card — that can be embedded in electronic devices. The chip is able to detect abnormalities in the electrical flow and evens out the current, or shut off the device before damage occurs. [Urvaksh Karkaria, Atlanta Business Journal, Jul 13, 12]

Inocucor (Denver, CO)

Inocucor (Denver, CO; no SBIR), developer and producer of biological crop inputs for high-value produce and row crops, announced the final close of its Series B funding round at $15.9 million ... Earlier this week, Inocucor acquired ATP Nutrition (Canada), a producer of science-based plant nutrients. [company press release, Apr 19, 18]

Inocucor (Denver, CO; no SBIR) a developer and producer of biological crop inputs for high-value produce and row crops, announced the $9.5 million USD ($12.1M CAD) second close of its Series B financing round. Funds raised to date in its Series B round now total $38.5 million [to] accelerate its commercialization activities, through the increased production and marketing of its first- and second-generation biostimulant products, Synergro® and Synergro Free™   [company press release, Jan 8, 18]

Inorganic Specialists (Miamisburg, OH)

DOE gave Inorganic Specialists (Miamisburg, OH; $2M SBIR) $2M for research aimed at helping produce low-cost batteries to help development of plug-in hybrids and electric vehicles.  [William Hershey, Dayton Daily News, Oct 27, 09]

Inotek Pharmaceuticals (Beverly,MA)

Inotek Pharma up 10% [Jan 3, 18]

Inotek Pharma up 12% [Jan 2, 18]

Inotek Pharma down 14% [Oct 17, 17]

Inotek Pharma down 14% [Oct 6, 17]

Inotek Pharma up 48% [Oct 5, 17]

Two months after [Inotek Pharmaceuticals (Lexington, MA; $24M SBIR)] shares cratered following the second conclusive failure of its lead glaucoma drug — scuttling its share price — the biotech has become a reverse merger shell for a gene therapy, [Rocket Pharmaceuticals (NYC, NY; no SBIR, raised about $25 million in May 2017 ) developing treatments for a variety of rare blood diseases.   [John Carroll,, Sep 12, 17]

Inotek Pharma (Lexington, MA; $22M SBIR) down 71% [Jan 3, 17] first big Phase 3 test of an experimental glaucoma drug fell far short, leaving the fate of the drug, known as trabodenoson, unclear. [Ben Fidler,, Jan 3, 17]

Inotek Pharma down 10% [Dec 28, 16]

 Inotek Pharma up 12% [Dec 6, 16]

Inotek Pharma down 13% [Nov 3, 16]

Inotek Pharna  up 13%  [Sep 14, 16]

Inotek Pharma down 29% [Aug 1, 16]

Inotek Pharma down 17% [May 11, 16] on report of bigger loss

Inotek Pharma up 13% [Apr 6, 16]

Inotek Pharma up 13% [Mar 14,16]

Inotek Pharma up 13% [Mar 11,16]

Inotek Pharma  up 15% [Feb 17, 16]

Inotek Pharma down 12% [Jan 13, 16]

Inotek Pharma up 10% [Nov 9, 15]

Inotek Pharma up 11% [Oct 15,15]

Inotek Pharma  down 10% [Sep 29,15]

Inotek Pharma up 12% [Sep 15, 15]

Inotek Pharma up 14% [Sep 2, 15]

Inotek Pharma up 15% [Aug 5,15]

Inotek Pharma down 15% [Jul 30,15]

Inotek Pharma (Lexington MA; $14M SBIR) up 15% [Jul 24,15]

Inotek Pharma (Lexington MA; $14M SBIR) up 194% [Jul 22,15] top percentatge gainer  announced the Phase 3 development strategy of its lead glaucoma drug, trabodenoson, a first-in-class selective adenosine mimetic designed to restore the eye's natural pressure control mechanism. Based on feedback from a recent End of Phase 2 meeting with the US Food and Drug Administration (FDA), Inotek is in final preparation stages to commence its first Phase 3 trial to support a New Drug Application (NDA) for trabodenoson. [company press release]

Inotek Pharma (Lexington MA; $25M SBIR) up 18% [Apr 24, 15]

Inotek Pharmaceuticals (Lexington, MA: $51M SBIR) has boosted its latest funding round by nearly $10 million, closing the round out at $23.6 million, according to a federal document. ...  Just one week after announcing the first tranche last month, Inotek began dosing in a multiple-dose Phase 2 clinical trial for INO-8875 in glaucoma patients. In June 2009, the drug candidate returned positive results from its Phase 1/2 trial, when the researchers found INO-8875 reduced intraocular pressure by a statistically significant amount. Intraocular pressure is a risk factor for vision loss associated with glaucoma and is thought to be one of the causes of the disease. [Rodney Brown, Mass High Tech, Jul 20, 11]<

Inotek Pharmaceuticals (Lexington, MA; $25+M SBIR) which is developing drug candidates for diseases of the eye, today said it has closed an $18 million preferred stock financing. ...  to advance Inotek’s novel eye-drop INO-8875 through multiple-dose Phase 2 clinical trials in glaucoma. [James Connolly, Mass High Tech, Jun 11,10]

the increasingly prominent role big pharmaceutical companies are taking during the recession — both to help get new biotech firms off the ground and to prop up those companies with promising technologies, but few financing options. .... MedImmune Ventures, an arm of MedImmune Inc., which is a subsidiary of AstraZeneca plc. The venture arm has $300 million under management and has invested $200 million, including investments in Hydra Biosciences (Cambridge, MA; $250K SBIR) and Inotek Pharmaceuticals (Lexington, MA; $20+M SBIR)    [Mass High Tech, Aug 14, 09]

Inotek Pharmaceuticals (Beverly, MA) said it has shuttered several international offices, including its manufacturing plant in Israel, and shed 85 of its 120 employees over the past three months. [Todd Wallack, Boston Globe, Apr 9, 08]

Inotek Pharmaceuticals (Beverly,MA; 82 Phase 1 SBIRs and $25M in Phase 2s) closed a third round of venture capital $19M as the drug developer looks to generate more data on its product candidates,  [Mass High Tech, Aug 24]

Ino Therapeutics

Start-up Wisconsin.  A start-up [NitricGen] with a patent pending on a portable device to treat chronic diabetic foot ulcers won first place in the Wisconsin Governor's Business Plan Contest.  .... founded in Madison in 2011 by Duncan Bathe, Frederick Montgomery and two others. Bathe and Montgomery previously created a Middleton medical device company called Sadasis LLC (no SBIR) that they sold to Ino Therapeutics (no SBIR), which was in turn bought by Ikaria (no SBIR), a critical-care company based in New Jersey. The pair has 19 patents and seven medical devices in use, Montgomery said.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jun 5, 13]

Inova Labs

startup Inova Labs (Austin, TX; no SBIR), a medical device maker, has agreed to be acquired by  ResMed, a developer of oxygen therapy delivery systems  [Christopher Calnan, Austin Business Journal, Jan 11, 16]

Inova Labs (Austin, TX) (Austin, TX;  no SBIR) completed a $12 million round of financing.  ....  launched in 2002, develops portable oxygen concentrators, according to the company website  [Christopher Calnan, Austin Business Journal,  May 22, 13]

Inovio Biomedical (San Diego, CA)

Inovio Pharma spinout Geneos Therapeutics (Plymouth Meeting, PA; founded 2016) closed a $10.5 million first-round financing that will help launch its R&D in neoantigen-targeting cancer immunotherapies. [Phil Taylor, Fierce Biotech, Feb 22, 19]

Inovio Biomedical (San Diego, CA; no SBIR) said it got the go-ahead to begin human trials of a preventive vaccine for H5N1 avian flu in Korea.  [San Diego Union Tribune, Mar 3, 10]

Inovio Biomedical announced plans to team up with the National Institutes of Health's vaccine-research center to create influenza vaccines and expedite development of an H1N1 vaccine. [Wall Street Journal, Aug 11, 09]

Inovio Biomedical quadrupled [Jul 29, 09] to a market cap of $140M. The developer of DNA vaccines said animal studies showed its experimental H1N1 vaccine provided 100% protection against the current strain of the virus. The vaccine was tested on laboratory mice and pigs. [, Jul 29, 09]

Inovio Pharmaceuticals (Blue Bell, PA)

AstraZeneca (UK) is starting to look at cutting some of the fat from its external pacts, and Inovio Pharmaceuticals is in the crosshairs. AstraZeneca's biologics arm MedImmune and Inovio have a long history, penning a deal back in 2015 worth $27.5 million upfront and up to $700 million in milestones for work on Inovio's cancer vaccines. [Ben Adams, Fierce Biotech, May 29, 19]

Inovio Pharmaceuticals (Plymouth Meeting, PA; $1.4M SBIR) and CEPI – the Coalition for Epidemic Preparedness Innovations (Norway) – announced a partnership under which Inovio will develop vaccine candidates against Lassa fever and Middle East Respiratory Syndrome (MERS). CEPI will fund up to $56M to support Inovio’s pre-clinical and clinical advancement through Phase 2 of INO-4500, its Lassa fever vaccine, and INO-4700, its MERS vaccine. The shared goal of Inovio and CEPI is for the Lassa and MERS vaccines to be available as soon as possible for emergency use. [joint press release, Apr 11, 18]

Inovio Pharmaceuticals (originally Genetronics, Plymouth Meeting, PA; no SBIR, market cap $366M ) announced that [it] is collaborating with The Wistar Institute to advance two novel SynCon® vaccine programs against tuberculosis (TB) and malaria, fully funded by more than $4.6 million in total grants from the Bill & Melinda Gates Foundation and [NIH]. [company press release, Feb 12, 18] received awarded an appropriation of approximately $1 million by the United States Department of Defense for the development of its gene delivery electroporation technology for application to vaccination against infectious diseases, including potential bioterrorism agents. [company press release, Sep 13, 2005] receive an appropriation of $1.1 million from the United States Department of Defense to develop applications of its electroporation-based gene delivery technology for vaccination against infectious diseases [company press release, Oct 19, 2006] contract is for $1.9 Million over 12 months. Under the contract, VGX will demonstrate in vivo efficacy of novel vaccines derived from DNA plasmid-based pox virus antigens delivered using a skin micro-electroporation system. [company press release, Sep 10, 2007] a contract for $933,000 from the Department of Defense (US Army) to continue research and development of DNA-based vaccines delivered via its proprietary electroporation system [company press release, Sep 23, 2008] merged with VGX Pharmaceuticals July 2008 ... contract, titled “Development of Improved DNA Vaccines and Electroporation Delivery Devices for Prophylactic HIV Vaccines”, provides [VGX Pharma] $23.5 million of funding over seven years [company press release, Oct 1, 2008] sold $30M in shares Oct 2009 .... a $3.5 million grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of its next generation DNA vaccine delivery device capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation. [company press release, Apr 10, 2013] ... Closes $63.3 Million Underwritten Financing March 2014 ... raised $15M in common stock March 2013 ... Closes $87.4 Million Underwritten Financing May 2015 .... Inovio Pharmaceuticals Awarded $6.1 Million Sub-grant Through Wistar Institute to Develop DNA-based Monoclonal Antibodies Against Zika Virus Dec 2016 .. raised $75M in pubic offering July 2017 ... reported quarterly net loss of $34M in Sep 2017

Inovio Pharma  down 11% [Jan 24,18]

Inovio Pharma up 23% [Jan 23,18]

Inovio Pharmaceuticals (Plymouth Meeting, PA; no SBIR) announced it has received a milestone payment from MedImmune as MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination with durvalumab (MEDI4736) satisfactorily completed the phase 1 safety review portion of the study and has advanced to the phase 2 efficacy stage of the trial. As part of a $700 million 2015 license and collaboration agreement, MedImmune, the global biologics research and development arm of AstraZeneca, is evaluating MEDI0457 in combination with durvalumab, its PD-L1 checkpoint inhibitor, in patients with recurrent/metastatic HPV-associated head and neck squamous cancer (HNSCC) in a clinical trial with an estimated enrollment of 50 patients.  [company press release, Jan 8, 18]

Inovio Pharma down 16% [Oct 24, 16] announced that FDA placed a clinical hold on its proposed phase III clinical program for VGX-3100. [company press release, Oct 24, 16]

On 26 July, Inovio Pharmaceuticals (Plymouth Meeting, PA) began the first human trials of a Zika vaccine. The biotech's DNA vaccine is being tested in a phase I study on 40 healthy people for safety and its ability to trigger immune responses.  ... But Neil Ferguson, a mathematical modeler at Imperial College London, thinks the epidemic is racing so fast through Latin America that many people may have been exposed and become immune by the time efficacy trials begin, leading to a drop in transmission rates that, in turn, make it far more difficult to see the benefit of a vaccine.  [Jon Cohen, Science, Aug 5, 16]

Inovio Pharma up 11% [Jun 28, 16]

Inovio Pharma down 10% [Jun 27, 16]

Inovio Pharma up 16% [Jan 29, 16]

Inovio Pharmaceuticals (Plymouth Meeting, PA; no prior SBIR) announced [Jan 20, 16] it has been awarded a $500,000 [Army SBIR] grant to further advance the development of Inovio’s next generation delivery device capable of simultaneously administering multiple vaccines via a skin-surface, needle-free electroporation delivery.  ... Our DNA immunotherapies activate the body’s immune system to break the body’s tolerance of cancerous cells and protect against diverse, changing strains of infectious diseases.  [company website]

MedImmune [$3.4M SBIR, now the biologics research and development arm of U.K. pharmaceutical giant AstraZeneca] and the National Institute of Standards and Technology  unveiled a five-year joint agreement to research tools to develop new drugs or therapies, or make existing therapies more effective.  ...  MedImmune will provide the first-year funding for seven NIST postdoctoral scientists focused on projects such as developing a new, sensitive form of Raman spectroscopy  .... the latest in a number of partnerships MedImmune began in the last year. In October, MedImmune joined a project with Inovio Pharmaceuticals (no SBIR) and the University of Pennsylvania on monoclonal antibody-based infectious disease treatments under a $12.2 million DARPA award. In June, MedImmune, AstraZeneca and a handful of other pharma companies and health groups announced a broad lung cancer trial, looking to use patients' genomic profiles to match them with therapies.    [Tina Reed, Washington Business Journal, Feb 20, 15] 

Inovio Pharmaceuticals  (Plymouth Meeting, PA; no SBIR), the University of Pennsylvania, and MedImmune (Gaithersburg, MD; $3.7M SBIR in the 1990s) are set to collaborate on monoclonal antibody-based infectious disease treatments under a $12.2 million DARPA award, Inovio announced  ...  the latest in MedImmune's recent partnering frenzy ...  MedImmune is [now] owned by U.K. pharmaceutical giant AstraZeneca  [Bill Flook, Washington Business Journal, Oct 21, 14]

Inovio Pharma down 14% [Jun 10, 14]

Inovio Pharmaceuticals (Blue Bell, PA; no SBIR) entered into a licensing deal worth up to $422.5 million with [Swiss giant] Roche. [John George, Philadelphia Business Journal, Sep 10, 13]

NIAID (NIH) awarded a $3.5 million grant to Inovio Pharmaceuticals (Blue Bell, PA; no SBIR, 53 employees, listed NYSE) ...  to advance the development of its next generation DNA vaccine delivery device, which is capable of simultaneously administering multiple synthetic vaccines via skin surface electroporation.  [John George, Philadelphia Business Journal,  Apr 10, 13]

Inovise Medical (Newberg, OR)

medical device developer Viscardia (Portland, OR; no SBIR) says it has completed a Series B financing round while obtaining "assets and technology rights" for a local heart monitor developer [Inovise Medical, Newberg, OR; $1M SBIR]  for $12.5 million.   ...  Inovise is a 20-year-old company that landed $5 million in 2011   [Andy Giegerich, Portland Business Journal, Feb 2, 17]

Inozyme Pharmaceuticals (Cambridge, MA)

Inozyme Pharma (Boston, MA; no SBIR, founded 2017) developing novel medicines to treat rare, debilitating, and life-threatening mineralization disorders, announced raised $67 million in a Series A2 financing .... has to date raised $116 million in venture capital. [company press release, Apr 10, 19]

Inozyme Pharmaceuticals (Cambridge, MA; no SBIR, founded 2016 ith technology licensed from Yale University), developing novel medicines to treat rare diseases of calcification, affecting soft tissues and bone, announced it has raised a $49 million Series A financing.  [company press release, Nov 15, 17]

InPhase (Longmont, CO)

A conventional DVD stores data only on its surface. But holographic storage encodes data as three-­dimensional patterns embedded inside a disc, vastly expanding its storage capacity. A long-awaited holographic drive from InPhase (Longmont, CO, one SBIR) is due out late this year; geared to Hollywood studios and large archives, it will cost $18,000. But a few companies, such as General Electric and Sony, are working on holographic storage systems that could be more compatible with existing technologies.  [David Talbot, MIT Tech Review, J/F 09]

Inphi (Santa Clara, CA)

Inphi (Santa Clara, CA; no SBIR) closed 28% above its IPO price.  ... designs high-speed analog semiconductors to help eliminate bandwidth bottlenecks in telecommunications and computer networks. Its products are used in data center and enterprise servers, telecom transport systems, computer storage systems, test and measurement equipment, and military systems. [Wall Street Journal, Nov 12, 10]

Inpria (Corvallis, OR)

Inpria (Corvallis, OR; $1.3M SBIR)  ..a spinoff of Oregon State University ... secured $4.6 million funding round, according to [SEC] documents ... developing high-performance, thin-film technology that can be used by many markets including the semiconductor industry. [Malia Spencer,  Portland Business Journal, Dec 30, 13]

Inscripta (Boulder, CO)

Inscripta (Boulder, CO; no SBIR, founded 2015) a leading gene-editing technology company, announced that it has closed a $55.5 million Series C funding [company press release, Feb 28, 18]

Insert MRI

Eight Wisconsin biotech companies have been selected as winners of the BioForward 2013 Emerging Company Showcase:  ABL Technologies LLC   (Greenfield, WI; no SBIR); Co-D Therapeutics (Madison, WI; no SBIR); Imbed Biosciences (Madison, WI; no SBIR)  medical device company developing novel and patent-pending technologies for imbedding bioactive molecules in wound dressings and surgical implants [company website]; Insert MRI  (no SBIR) developing a platform technology for encapsulating workflow 'apps' to interactively guide magnetic resonance (MR) image-guided surgical procedures [company website]; Microscopy Innovations  (Marshfield, WI; no SBIR) New Capsule-based System for  preparing Microscopy Specimens  [company website]; Regenerative Medical Solutions (Chicago/Madison; no SBIR) develop a protocol to grow healthy and resilient pancreatic stem cells [company website]; Stealth Therapeutics (Madison, WI; no SBIR) less invasive medical devices [company website]; and XenoGen Biosystems ( Madison, WI; no SBIR)  Mathematical Modeling and Computing for the Life Sciences [company website]. ... represent "a cross section of emerging companies in our industry sector that we feel are going to make an impact down the road," said Bryan Renk, BioForward's executive director.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 4, 13]

Insight Technology (Londonderry, NH)

Insight Technology has landed $34.1 million from the U.S. Navy to develop imaging technology for night vision goggles  [Mass High Tech, Mar 2, 10]

Defense and security technology firm L-3 Communications said it would acquire Insight Technology (Londonderry, NH; $1.1M SBIR) maker of night vision goggles and other electro-optical equipment.  ...  L3 said Insight is expected to generate $290 million in sales for 2010, and while it would not disclose the purchase price, it is approximately nine times Insight’s 2010 earnings before interest, taxes, depreciation and amortization. The deal is expected to close in the second quarter of this year. Insight employs about 1,100 people. [Mass High Tech, Feb 19, 10]

Insight Technology (Londonderry, NH; $1M SBIR) landed $15 million from the Army for weapon sights  ...Founded in 1988 Insight specializes in target lights and laser guides for handguns and rifles for U.S. Special Operations Forces. [Brendan Lynch, Mass High Tech, Jan 6, 10]

Insight Technology (Londonderry NH) got a $53M Marine Corps contract to develop night-vision weapons sights by the end of 2009. [Mass High Tech, Sep 19, 07]

Insight Technology got an $8.7M Army contract for weapon sight technology. [Aug 10, 07]

Insight Technology (Londonderry, NH; $1M+SBIR)  got a $25M contract to build a handheld targeting system for the U.S. Special Forces. Insight employs 800 workers. Company officials declined to release financial data. [Mass High Tech, Jun 29]  Its most recent SBIR, presumably before it got to 800 workers, sounds like a classic engineering study for using existing technology: Our effort will include the development of mission scenarios, an analysis of the operational and functional requirements, a market survey of the latest available functional modules for each of the functions listed, trade studies to determine the optimal configuration of the system, risk reduction demonstrations or experiments, a preliminary design of the system configuration selected, and a final report. And all for $100K. Innovation? In the eye of the federal beholder.  <

Insight Technology (Londonderry, NH) gets $32M Navy night vision order for night-vision sights for SEALs. [Mass High Tech, Sep 2] It had a handful of SBIRs in the 21st century. 

$25M Insight Engineering.   Insight Technology (Londonderry NH) got a $25M Navy procurement contract for Thermal Night Vision Devices and two Army SBIR Phase 2s in the last two years for what sounds like more of the same. It smells like the military services are using SBIR for final stage engineering of mature concepts. If you ask either Insight or the military, they will claim high innovation which is one of those terms defined each time by the user. 

Insight Technology (Londonderry, NH) won a $1M part of a $43M five-year Army contract. for weapon-mounted laser sights. The night-vision company dates back to the 80s and came to SBIR in 2000 with two Phase 1s and a Phase 2. It has also won a $13M Army for night vision goggles. In typical bureaucratic fashion the Army Phase 2 contract was for $720K despite being with a company with whom the Army intends a long term relationship by committing to $50M+ contracts a year after the Phase 2 started. Sounds like the SBIR was merely a funding vehicle to cover part of the procurement contract's cost.

InSite Vision (Alameda, CA)

Like most biotechnology companies, InSite Vision (Alameda, CA; $500K SBIR) languished for years in a kind of financial purgatory, running up $150M in losses during its two-decade quest to reach the promised land of profitability.  It finally got its first product approved for sale in April, helping InSite earn more than $3M for the first nine months of 2007. ... Northern California's biotech companies are maturing from cash-burning research operations to viable commercial enterprises, according to a new study   [Steve Johnson, San Jose Mercury News, Jan 10, 08]

Insitu (Bingen,WA)

Insitu (Bingen,WA: 3 Phase 1 SBIRs)  got a $4 M earmark (at the Appropriations Committee stage) for the Integrator Unmanned Aircraft System, a low-altitude, long-endurance aircraft designed for intelligence, surveillance and reconnaissance missions, boasts its Senator. [The Oregonian, Sep 13]

InSitu Biologics (St Paul, MN)

InSitu Biologics (St Paul, MN; no SBIR, founded 2017] is raising $1 million after getting encouraging results from pre-clinical tests of a novel non-opiate painkilling gel, [based around the use of its proprietary Matrix BioHydrogel as a platform for drug delivery], according to a recent filing. [Don Jacobson, Twin Cities Business, Dec 6, 17]

Insmed (Monmouth Junction, NJ)

Insmed  (Monmouth Junction, NJ; $1M SBIR) up 10% [Mar 31, 14]

Inspire Medical Systems(Maple Grove,MN)

Inspire Medical up10%  [May 14, 18]

Inspire Medical Systems (Maple Grove, MN; no SBIR) jumping 56% from its [IPO raising $108M] .... maker of implantable electric stimulators to treat sleep apnea. [Joe Carlson, Minneapolis Star Tribune, May 3, 18]

Inspire Medical Systems (Maple Grove, MN; no SBIR) has closed on $40 million in venture capital ....  two weeks after  announced it received regulatory approval to sell its implantable device for treating sleep apnea [Katharine Grayson, Minneapolis / St. Paul Business Journal, May 15, 14]

Inspire Medical (Minneapolis, MN; no SBIR, spun out of Medtronic in 2007, funded by prominent medical technology investment firms) medical device for treating sleep apnea improved breathing in roughly two-thirds of patients participating in a key clinical trial, according to research released.   .... makes a pacemaker-sized implantable device that treats obstructive sleep apnea [Katherine Grayson, Minneapolis / St Paul Business Journal, Jan 9, 14]

of two Twin Cities startups developing implantable devices to treat sleep apnea. ...  Inspire Medical Systems, is still in business and recently submitted its device for Food and Drug Administration approval, CEO Tim Herbert said in an interview. ...  spun out of Medtronic and raised $14.5 million in funding last year.  [Katherine Grayson,  Minneapolis / St Paul Business Journal, Aug 2, 13]

Inspire Medical Systems (Maple Grove, MN; no SBIR) a Medtronic spinoff company, has received the go-ahead from the Food and Drug Administration to conduct a large-scale trial with a device to treat a common sleep disorder that causes breathing difficulty. [Wendy Lee, Minneapolis Star Tribune, Nov 29, 10]

Inspire Pharmaceuticals (Durham, NC)

Inspire Pharmaceuticals  (Raleigh, NC; no SBIR, 240 employees) dropped 60% [Jan 3, 11] One of the Triangle's most promising drug-development companies suffered a major setback Monday when it announced that an experimental treatment for cystic fibrosis failed to improve patients' health in a two-year clinical trial.  Officials said they are reviewing strategic options.  ...  Analysts said Inspire is likely to scrap the 10-year research program in which it has invested $120 million. [John Murawski, Raleigh News & Observer, Jan 3, 11]

Inspire Pharmaceuticals (Durham, NC; no SBIR) has scrapped a partnership with a Spanish drug company, after an experimental allergy pill that both companies were working on hit regulatory roadblocks. ...  not the first setback for Inspire, which shifted to selling other companies' drugs after its own products failed to win regulatory approval. An experimental dry eye treatment called Prolacria has been held in regulatory limbo at the FDA for years. [Alan Wolf, Raleigh News&Observer, Jan 15] In July it sold $75 M of exchangeable preferred stock to Warburg Pincus, a leading global private equity investor. [company website]

Inspired Solar Technologies (Rocklin, CA)

Inspired Solar Technologies (Rocklin, CA; no SBIR) closed a Series A round raising $500,000. In all, IST has raised about $4 million, said founder and CEO Ken Oosting .... invented a high-tech solar tracker that promises to help the solar industry achieve grid parity — where the cost of generating a kilowatt-hour of electricity using solar power meets or beats the cost to generate the same amount of electricity through traditional technologies such as oil or gas. [Melanie Turner, Sacramento Business Journal, Feb 1, 13]

Insulet (Bedford, MA

Shareholders of Insulet (Bedford MA; no SBIR), maker of insulin-management systems, sold $113M in stock in a public offering. founded in 2000, produces an insulin-delivery device called the OmniPod for people with insulin-dependent diabetes. The firm reported a 2006 net loss of $36M  on revenue of $3.7 M [Mass High Tech, Nov 7, 07]

IntAct Labs (Cambridge, MA)

No fewer than four groups in Massachusetts are racing to bring so-called microbial fuel cells to market through a variety of applications. None has been commercialized yet, but industry insiders say microbial fuel cells hold the potential to become a major part of the renewable energy equation. ...  Hy-SyEnce (Fall River, MA; no SBIR)is working to generate large-scale power from the wastewater of food-processing plants, while IntAct Labs LLC (Cambridge, MA; no SBIR)  is applying its technology to similar industrial applications, as well as the possibility of generating power and recycling waste products during space missions.  A research group out of Harvard University, on the other hand, is hoping to provide power for lighting and other systems in developing nations, while Derek Lovley’s Geobactor Project at UMass Amherst is looking to create organic batteries that could one day power computers or even vehicles.  [Mass High Tech, Aug 22]

Intact Vascular (Wayne, PA)

Intact Vascular (Wayne, PA; no SBIR, founded 2011), a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the first commercial use of its Tack Endovascular System® in multiple hospitals within Germany. A novel therapy for dissection repair following balloon angioplasty, the Tack® implant is a first-of-its kind device for patients with peripheral arterial disease (PAD) and/or critical limb ischemia (CLI). [company press release, Jan 8, 19] total funding $90M []

Intact Vascular (Wayne, PA; no SBIR, founded 2011) developer of medical devices for minimally invasive peripheral vascular procedures, today announced that it closed a Series C financing totaling $20 million [to] fund the Company through Pre-Market Approval (“PMA”) of the Tack Endovascular System for the treatment of post-angioplasty dissections above the knee. [company press release, Apr 16, 18] total funding $89M []

Intact Vascular (Wayne, PA; no SBIR) series B financing has grown to $46 million  ... for a “host of product development initiatives aimed at expanding the utility of [its] Tack Endovascular System for the treatment of peripheral artery disease.” The system features a minimal metal implant that is designed to improve peripheral balloon angioplasty results. ...  Another medical device company being spun out Intact Vascular, Vesper Medical  (Wayne, PA; no SBIR)[John George,  Philadelphia Business Journal, Jan 3, 17]    Vesper raised $9 million in a private stock sale in November [2016], according to [SEC]documents [, Nov 4, 16]

Intact Vascular  (Wayne, PA; no SBIR) , a developer of medical devices for minimally invasive peripheral vascular procedures, today announced that [FDA] granted staged approval for the Company’s Investigational Device Exemption (IDE) application to begin its Tack Optimized Balloon Angioplasty II BTK (“TOBA II BTK”) clinical study. The study will examine the safety and efficacy of the Tack Endovascular System when used to repair dissections (or tears) in the arteries below the knee (BTK) following percutaneous transluminal angioplasty (PTA) as a treatment for critical limb ischemia (CLI) [company press release, Oct 31, 16]

Intact Vascular (Wayne, PA; no SBIR), developing technology to improve vascular repair procedures, raised $38.9 million in a [Series B] venture capital financing ... to accelerate the development of its Tack Endovascular System. The system features a minimal metal implant that is designed to improve peripheral balloon angioplasty results in patients treated for peripheral artery disease.    [John George, Philadelphia Business Journal, May 14, 15]

Medical-device developer Intact Vascular (Wayne, PA; no SBIR) raised $3 million in a debt financing, according to [SEC] documents  ... focused on developing medical devices for minimally invasive peripheral vascular procedures. Its lead product candidate is the Tack Endovascular System, a minimal metal implant that is designed to improve peripheral balloon angioplasty results in patients treated for peripheral artery disease. ...  CEO Bruce Shook said the funds will be used to support late-stage testing of Tack Endovascular System. Shook took over as CEO last summer after previously leading Neuronetics (no SBIR), another suburban Philadelphia medical-device company.  [John George, Philadelphia Business Journal, Mar 20, 15]

Medical device manufacturer Intact Vascular  (Wayne, PA; no SBIR), which is out to improve balloon angioplasty surgery with its technology, raised $4.7 million in a debt and equity financing. .... specializing in the development of products used in minimally invasive peripheral vascular procedures. Its lead product is the Tack-It Endovascular System, an endovascular stapling device containing a minimal metal implant.  ... September, Intact Vascular raised $15.5 million in a venture capital financing   [John George, Philadelphia Business Journal, Dec 23, 13]


Brilliant Start-Up Gone Wrong They had a kick-ass product, cash in the bank, and eager customers. In the scrappy world of Silicon Valley start-ups, they were about to be eaten alive. Read Tim Barkow's gripping story of Intaglio, a start-up gone wrong in Wired Oct 96. Full text on-line


Ismael Ghalimi started software-maker Intalio with a solid business plan and leading-edge technology. But like many software entrepreneurs, Ghalimi is finding that isn't enough.  After six years without showing a profit, company executives decided it was time for plan B: rather than sell customers pricey, high-end software, Intalio decided to sell open-source software instead, cutting the price from about a half-million dollars to zero. The company would charge for support and a license fee when its software is deployed on closed-source databases and middleware.  [Martin Lamonica, CNET News, Jan 12, 06 ]

Intarcia Therapeutics (Boston, MA)

Intarcia Therapeutics (Boston, MA; no SBIR) announced the first closing of a major equity financing [$215M] that puts the company in a strong strategic and financial position over the next 2-3 years as it prepares for the potential approval and launch of ITCA 650 late next year, and the parallel progression of several novel pipeline programs in major chronic diseases like diabetes, obesity and auto-immune/inflammation. .... Intarcia’s novel technology platform, The Medici Drug Delivery System™, is a proprietary subcutaneous delivery system comprised of three unique technologies:     a matchstick-sized osmotic mini-pump that is placed just beneath the skin to deliver a continuous and consistent flow of medication;      a placement technology designed for a simple, relatively quick and highly reliable user experience; and,     a stabilization technology for proteins, peptides, antibody fragments, and other high-potency small molecules.  [company press release, Sep 15, 16]

Boston biotechnology firm Intarcia said it acquired Phoundry Pharmaceuticals  (Research Triangle Park, NC; no time for SBIR), a 7-month-old spin-out from GlaxoSmithKline, for an undisclosed sum. Phoundry was spun out of GSK in February after 6 years of research-and-development in GSK’s Enteroendocrine Discovery Performance Unit, developing peptides for treatment of diabetes and obesity. Intarcia is developing an implantable pump with a proprietary medication for Type II diabetes patients. ... Intarcia said it will retain all nine Phoundry employees in RTP and expects to double the newly acquired unit’s headcount over the next 12 to 18 months.  [John Murawski, Raleigh News & Observer, Sep 24, 15]

Intarcia Therapeutics announced a $225 million investment which will go largely to pay for a planned trial of its once-a-year ITCA 650 pump and drug combination device aimed at revolutionizing the market for type 2 diabetes, establishing it as the standard of care.  [Don Seiffert, Boston Business Journal, Apr 28, 15]

Intarcia Therapeutics (Boston, MA and Hayward, CA;  no SBIR, founded 1995 as BioMedicines) announced that it's forged a license deal with Servier (French) for sales outside the U.S. The deal is worth $171 million up front, plus three near-term milestones totaling $230 million, and another $650 million in development, regulatory and sales milestone payments.  ... has been developing a tiny pump to be inserted under the skin of patients with type 2 diabetes, a global market which has been estimated at $50 billion.    [Don Seiffert, Boston Business Journal, Nov 12, 14

p> A diabetes drug delivered continuously from a small implantable pump resulted in a marked and sustained reduction in blood sugar in patients in two studies, potentially setting the stage for a once-a-year treatment option to manage the disease.  The matchstick-size pump, called the ITCA 650, is being developed by closely held Intarcia Therapeutics (Boston, MA and manufacturing facilities in Hayward, CA; no SBIR) startup, which is releasing details of the studies  ... The two studies are among four Phase 3 or late-stage studies Intarcia is conducting with a plan of filing for approval for six-month and 12-month pumps with the U.S. Food and Drug Administration by early 2016. The company also is mounting head-to-head studies against both oral and injectable treatments with the aim of proving the pump superior to the conventional treatments.   [Ron Winslow, Wall Street Journal, Oct 1, 14]

Intarcia Therapeutics (Boston, MA; no SBIR), working on a treatment for type 2 diabetes, raised $200 million. ...  is testing a once-a-year treatment for type 2 diabetes that uses a matchstick sized pump under the skin.   [Steven E.F. Brown, San Francisco Business Times, Apr 2, 14]


IntegenX (no SBIR) has raised $15.6 million in a second round of funding and acquired nearly all of the stock in GenVault Corp. ...  with participation from existing investors [including] In-Q-Tel  [John Sailors, San Francisco Business Times, Feb 7, 11]

Integral Molecular (Philadelphia, PA)

[NIH]awarded Integral Molecular (Philadelphia, PA; $13M SBIR) a five-year, $3.5 million contract to study the human immune response to Ebola and hepatitis C.  ... to better understand how human antibodies protect, or fail to protect, people against such viruses.  ....  hopeful that the mapping will help researchers develop treatments for the viruses.  [John George, Philadelphia Business Journal, Nov 14, 14]

Integral Molecular (Philadelphia, PA; $12M SBIR) was awarded $5.5M by the National Institutes of Health to study Ebola antibodies as part of an effort to aid in the discovery of a vaccine for the virus.   ...   to expand its efforts to discover antibodies that work against the Ebola virus and to identify how the different antibodies bind to the viral surface to prevent Ebola virus infection.  [John George, Philadelphia Business Journal, Oct 16, 15]

Integrated Diagnostics InDi (Seattle, WA)

biotech Integrated Diagnostics (Seattle, WA; no SBIR, founded 2009) (not to be confused with same name company in Baltimore, MD) said it has raised $47.25 million for its "breakthrough, molecular diagnostic blood test."   ....  to commercialize its Xpresys Lung molecular diagnostic blood test, which could allow patients with benign lung nodules to avoid invasive surgery.  [Ben Miller, Puget Sound Business Journal,  Apr 29, 14]

Integrated BioTherapeutics (Gaithersburg, MD)

 A race to detect Ebola:

  • [FDA] authorized emergency use of BioFire (Salt Lake City, UT; no SBIR)’s FilmArray system to diagnose Ebola in U.S. hospitals and military labs.   ...  uses PCR [polymerase chain reaction] technology, but can deliver results in about one hour on the premises of any treatment facility that has one of the machines, which cost around $39,000 apiece.  ...  Many U.S. hospitals already have the machines, which were approved to diagnose pathogens including those causing gastrointestinal and respiratory diseases.   
  • Corgenix Medical (Denver, CO; $600K SBIR) is speeding up development of a portable Ebola test kit designed to deliver results from a drop of blood in about 10 minutes, said [CEO] Doug Simpson. It uses so-called “lateral-flow” technology, which is similar to that found in a home pregnancy test, and doesn’t require electricity or a machine to process the sample. A paper strip displays one blue line if no virus is detected, two blue lines if virus is detected, and no lines if the test didn’t work properly.  ...  Corgenix is working with Tulane University in New Orleans and other partners in the Viral Hemorrhagic Fever Consortium, with funding from the NIH. ..  Researchers are testing the Corgenix device, including in West Africa, but haven’t yet gathered enough data to apply for approval by either FDA or WHO, said Mr. Simpson.  
  • Chembio Diagnostics Systems (Medford, NY; no SBIR) maker of rapid diagnostics for HIV and syphilis, this week formed a partnership with another company, Integrated BioTherapeutics (Gaithersburg, MD;  $1.1M SBIR), to develop a point-of-care test for Ebola. Chembio plans to use substances known as “reagents,” developed by Integrated BioTherapeutics, for the test. Chembio hopes to begin testing the tool in Africa within months, said Chief Executive John Sperzel. 
  • Genalyte (San Diego, CA;  no SBIR) developing an Ebola diagnostic that uses a silicon chip to test a drop of blood drawn with a pinprick. The chip is processed through a 15-inch-wide machine that delivers results in about 10 minutes, said Genalyte Chief Executive Cary Gunn.  
  • OraSure Technologies (Bethlehem, PA; no SBIR), maker of an oral test for HIV, is exploring whether it can develop a rapid oral test for Ebola, said Chief Executive Douglas Michels. Chembio’s Mr. Sperzel said his company also would consider developing an oral Ebola test.     [Peter Loftus, Wall  Street Journal, Nov 5, 14]

Integrated Diagnostics (Baltimore, MD)

Fifty Nifty Techno-Innovators as judged by Technology Review magazine [Apr 12]. In the company of investment magnets like Facebook and Google are a few companies and ideas that would be fit for a realistic SBIR program intent on seeding technically uncertain innovation with a future if it can be shown to work.  
Alta Devices
(no SBIR) high-efficiency gallium arsenide–based solar cells provide a way to lower the cost of solar power.  Can economically produce robust cells that use only small amounts of the expensive semiconductor.
 Integrated Diagnostics
(Baltimore, MD; $1M SBIR)  By reducing the cost of diagnostic tests, it has allowed the monitoring of more disease markers. Its synthetic antibodies replace more expensive antibodies widely used in diagnostics.   
Suntech (no SBIR) Has developed a low-cost way of making better silicon solar cells. Its new panels are more efficient because they reflect less light and use thinner electrodes that block less light.   
(no SBIR) Its high-energy batteries, which will first appear in consumer devices, could make electric cars cheaper and improve their range.  Making batteries without the flammable liquid found in conventional electric-car batteries means they can store more energy. 
(no SBIR) Makes fuel and chemicals from the carbon monoxide produced by processes such as steelmaking.  Genetically engineered organisms turn the gas into ethanol and other useful chemicals. 
First Solar
  (Toledo, OH; $750K SBIR) It is reducing the cost of utility-­scale photovoltaic installations.  constrains costs with vertical integration of everything from plant construction to the manufacture of high-efficiency cadmium telluride cells. 
Wildcat Discovery (no SBIR) Has used high-speed methods to find materials that improve the performance of batteries. Identified a pair of materials that could increase energy density by 25 percent in batteries for cars and portable electronics. 
Siluria  (no SBIR) Its catalytic process is able to convert cheap and abundant natural gas into ethylene, a commodity chemical used to make plastic.  Developed a family of catalysts that selectively cause methane to react to form ethylene.
  (San Diego, CA; $260K SBIR) Its three-dimensional artificial tissue structures can be used for drug testing and are likely to find therapeutic applications. A printing process methodically deposits layers of cells and gel material to build up new tissues.    Cellular Dynamics International (Madison, WI; $500K SBIR) Using human iPS cells in drug screening could accelerate the development of new therapies.  Its new product derived from iPS cells is meant for use in vascular targeted drug discovery, tissue regeneration, and life science research.
Foundation Medicine 
(no SBIR)  Its new diagnostics exploit a growing understanding of the molecular basis of cancer.   It has developed a comprehensive cancer diagnostic test and is partnering with pharmaceutical companies to use the test in drug development.

Integrated DNA Technologies (Coralville, IA)

Integrated DNA Technologies (Coralville, IA; $1.2M SBIR) purchased roughly 25 acres of land in Research Triangle Park (NC) for north of $3.4 million, according to county records. [Jennifer Henderson,  Triangle Business Journal, Dec 30, 16]

Integrated Fuel Cell Technologies (Burlington, MA)

Army's venture venture.  The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs;  Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries;  Integrated Fuel Cell Technologies  (Burlington MA; no SBIR) next generation fuel cell systems for portable devices;  Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates,   PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets;  Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell” SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell.  []  No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout. 

Integrated Photonics (Hillsborough, NJ)

II-VI , a leader in engineered materials and optoelectronic components, announced the acquisition of Integrated Photonics (Hillsborough, NJ; $3M SBIR, a 2000 spinout of AT&T Bell Labs) in a $45m cash  transaction.  Integrated Photonics  is  a leader in  engineered magneto-optic materials that enable high-performance directional components such as optical isolators for the optical communications market.   [II-VI press release, Jun 19, 17]

Integration Associates (Mountain View,CA)

Austin's Silicon Laboratories will buy a small California company with chip technology that complements its own product lines. Silicon Labs agreed to pay $80 million for Integration Associates (Mountain View, CA; no SBIR), which employs more than 100 people and has quarterly revenue of about $8 million.  [Austin American-Statesman, Jun 25, 08]

Integra Group (St. Paul, MN)

Two Minnesota startups are joining forces to debut what they claim is a faster and more effective way to test drug-coated stents at the nation's premier biotechnology conference this week.  Nanocopoeia (St. Paul, MN; $0.9M SBIR)  and the Integra Group (Brooklyn Park, MN; no SBIR)  will announce today a new company called NanoInterventions whose core technology is a mouse-based testing system for drug-coated stents. [Minneapolis Star Tribune, Jun 17, 08]


Intelect Medical (Boston, MA)

Boston Scientific has acquired Intelect Medical (Boston, MA; no SBIR) developing technologies for deep brain stimulation for $60 million in cash. ... deep brain stimulation involves using implantable devices to target therapies to the brain using electrical impulses. Boston Scientific estimates the current worldwide market for DBS at $400 million with projections to grow to more than $1.5 billion by 2020. .... founded in April 2005 based on intellectual property developed at Cleveland Clinic's Center for Neurological Restoration and its Lerner Research Department of Biomedical Engineering.   [Julie Donnelly, Boston Business Journal, Jan 6, 11]

Intelleflex (Santa Clara, CA)

Intelleflex (Santa Clara, CA; no SBIR) said on Tuesday it has raised $11.5 million in an extension of its Series A funding. ...  to boost sales and marketing of its low-cost, temperature-sensitive RFID tags.  [Silicon Valley / San Jose Business Journal, Dec 14, 10]

Intellia Therapeutics (Cambridge, MA)

Intellia Thera up 13% [Mar 14, 18]

Intellia Thera up 10% [Mar 8, 18]

Intellia Thera down 10% [Feb 2,18]

Intellia Thera up 11% [Jan 22,18]

Intellia Thera down 12% [Jan 8, 18]

Intellia Thera down 10% [Dec 11, 17]

Intellia Thera up 12% [Oct 3, 17]

Intellia Thera up 19% [Aug 28, 17]

Intellia Thera up 10% [Aug 21, 17]

Homology (Bedford, MA; no SBIR) wrapped up an $83.5 million Series B round ... making the bold claim that its underlying science, technology it calls AMEnDR, is a better version of existing gene editing methods, among them the CRISPR-Cas9 technology that has taken the scientific research world by storm and has led to the formation of three now publicly traded companies, Editas Medicine (Cambridge, MA; no SBIR), Intellia Therapeutics (Cambridge, MA; no SBIR), and CRISPR Therapeutics (Switzerland). [Ben Fidler,, Aug 1, 17]

Stock prices of Editas MedicineCRISPR Therapeutics (Switzerland), and Intellia Therapeutics (Cambridge, MA; no SBIR) dropped sharply after the publication of a Nature Methods article that described unintended effects stemming from the use of CRISPR-Cas9 gene-editing technology. But as Xconomy noted two years ago, the possibility of “off-target effects” from use of these tools have long been a concern. [Ben Fidler,, Jun 2, 17]

Intellia Thera  up 11% [Oct 21, 16]

Intellia Therapeutics (Cambridge, MA; no SBIR)  up 23% [May 6, 16], which owns rights to an important but disputed piece of the CRISPR-Cas9 gene editing technology, .... raised $108 million by IPO.  ....  joins Editas Medicine, Cellectis (France), and Sangamo Biosciences as publicly traded biotechs using gene editing to develop their main products.  [Alex Lash,, May 5, 16]

Intellia Therapeutics (Cambridge, MA; no SBIR) filed papers to go public, and simultaneously cut a deal with Tarrytown, NY-based Regeneron Pharmaceuticals  to develop a group of CRISPR-Cas9 drugs—the first being for a rare liver disease called transthyretin amyloidosis.  [Ben Fidler,, Apr 14, 16]

Editas Medicine  up 14% [Feb 3, 16]  faces a numberof hurdles ... no such therapy has been approved for clinical use in either the U.S. or Europe.  More importantly, Editas doesn’t even know for sure whether it even has the right to use CRISPR. ... already faces competition from two other startups, Intellia Therapeutics (Cambridge, MA; no SBIR) and CRISPR Therapeutics  (Swiss) [which] recently announced a $300-million joint venture with Bayer AG to develop new drugs for a range of illnesses.  [Michael Reilly,, Feb 3, 16]

IntelliCyt (Albuquerque, NM)

Sartorius, a Germany-based international pharmaceutical and laboratory equipment provider that had 1.1 billion euros in sales last year, announced in a press release that it acquired IntelliCyt (Albuquerque, NM; no SBIR, 55 e,ployees) for $90 million cash  that uses flow cytometry in medical instrumentation, process, and software. [Joe Cardillo, Albuquerque Business First, Jun 28, 16] 

St. Louis-based Prolog Ventures participated in a $7.4 million financing deal for New Mexico-based IntelliCyt (Albuquerque, NM; no SBIR), a provider of integrated platforms to accelerate drug discovery, antibody discovery and immunology.  ... According to CrunchBase, the IntelliCyt deal was Prolog’s fifth of 2015 — the company also participated in Veran Medical Technologies’ (no SBIR) $41.7 million round in September; Benson Hill Biosystems (no SBIR) $7.3 million deal in August; and EndoStim (no SBIR) $2.5 million funding in May.   [Brian Feldt, St. Louis Business Journal, Oct 23, 15]

IntelliCyt (Albuquerque, NM; no SBIR) said that it has completed an $8 million round of financing. The life science firm sells products that screen molecules for drug discovery. [Dennis Domrzalski, Albuquerque Business First, May 6, 13]

Intelligent Automation (Rockville, MD)

Cryptonite (Rockville, MD; no SBIR) with its new product, rolled out officially, the company focuses on not only preventing an attack from breaching the network, but also on preventing an attack from hopping from one computer to another in the same network — something that could’ve been useful in the Yahoo! or Target breaches in the last couple of years. In 2015, Cryptonite quietly spun out of federal contractor Intelligent Automation (Rockville, MD; 480 SBIR projects), with only the technology and a few key employees following it. Since then, they’ve been in stealth mode. The team has been quietly testing its product with key clients, and they’ve landed a total of $5M in funding. Today, with the key research and development completed, they’re making their product launch official. [DC Inno Beat, Oct 26, 17]  That's in the neighborhood of $250M in SBIR for this "federal contractor" over thirty years of SBIR.  Any idea of the ROI from such investment?  The agencies buying the R&D services don't ask such questions.

Loving Experience.   Scientific Systems (Woburn,MA; $50M+ SBIR) won a NASA JPL Phase 2 SBIR for Distributed Formation State Estimation Algorithms Under Resource and Multi-Tasking Constraints. Creare (Hanover NH; $120M SBIR) won four NASA JPL Phase 2 SBIRs. Intelligent Automation (Rockville MD; $100M SBIR) won three NASA JPL Phase 2 SBIRs. Physical Optics (Torrance, CA; $200M SBIR) won one NASA JPL Phase 2 SBIR. Radiation Monitoring Devices (Watertown, MA; $90M SBIR) won one NASA JPL Phase 2 SBIR. Etc, etc, etc. A zillion start-ups all over America got letters saying there was not enough money to nurture their ideas.

Advanced materials. The challenge comes not from overseas competition but the possibility that US companies will fail to reach their innovation potential because of insufficient support for the physical sciences and engineering, lack of capital for small start-ups and uncompetitive tax credits. [Technology Business, N-D98] "What's the best advice for entrepreneurs seeking SBIR funding? Be tenacious", says Jeff Bond. "If you don't submit, you can't get selected." BMDO selects one in every three Phase 1 proposals because it is willing to take greater risks on questionable technologies with significant marketplace potential. [FM Corso, Technology Business, N-D98]
Corso's longish piece on SBIR in the rah-rah Technology Business has the wrong reason for BMDO's high acceptance rate. The risk-taking is right, but the high acceptance rate comes from discouraging hopeless proposals. After all, if BMDO got all bad proposals it would still have to fund about 200 Phase 1s a year while holding its nasal appendage. The one success story Corso uses shows the problem with evaluating SBIR (where data seems the plural of anecdote). He fawns over Intelligent Automation (Rockville, MD) which has milked the SBIR for uses of its Fuzzy CMAC technology. Of its 59 SBIRs, the latest crop 1993-1997
  1993 1994 1995 1996 1997
Phase 1 7 6 4 9 23
Phase 2 2 3 4 1 1
Note the declining ratio of Phase 2 to Phase 1. Trouble in River City for agencies looking for something tangible. For one agency in that pack, BMDO probably will not see IAI as its kind of entrepreneur worthy of high-risk finance.

Intelligent Bio-Systems (Waltham, MA)

Intelligent Bio-Systems Waltham, MA; $5.3M SBIR) has been sold for an undisclosed price to Quiagen N.V., a large life sciences research tools company.  Kegonsa Seed Fund, a Madison [WI] venture capital fund, is one of three funds that are shareholders of the  company. Kegonsa is making more than three times its original investment, said Ken Johnson, the fund's managing director. IBS makes a laptop DNA sequencing machine. "They make equipment that can sequence DNA in hours at a cost of $1,000, which will help enable personalized medicine," Johnson said.  [Kathleen Gallagher, Milwaukee Journal Senitnel, Jun 26, 12]  If SBIR is a capital investment program, such an acquistion countys as a success.  If SBIR is a life-style company support program for small govdernment contractors, the SBIR market-dead multiple awardees will moan to their Congressional sponsors.

Some Bay State largesse.  The Massachusetts Life Sciences Center, a quasi-public agency tasked with implementing the state’s ten-year, $1 billion Life Sciences Initiative, today announced the awarding of $2.2 million in loans [$750K each] to three early-stage life sciences companies. Intelligent Bio-Systems, (Waltham, MA; $6.3m SBIR)  DNA sequencing company with a patented, higher performance, lower cost, DNA sequencing instrument and consumable system; Allurion Technologies,(Wellesley, MA; no SBIR) company that is developing a novel medical device designed to induce significant weight loss by displacing volume in the stomach. The device can be delivered without surgery and it can be eliminated via an orally available, non-toxic dissolution agent; and Paragonix Technologies,(Cambridge, MA; no SBIR) company that is commercializing first-in-class, single-use and highly portable organ preservation and transport devices called ‘Sherpas.’ Paragonix has begun with a Sherpa for kidney transport, but is planning to expand their ‘Sherpa’ product line for other organs.  [DC Dennison, Boston Globe, Dec 28, 11]

Intelligent Epitaxy Technology (Richardson, TX)

Intelligent Epitaxy Technology (Richardson, TX; $800K SBIR) a manufacturer of semiconducting epi wafers for electronics — plans to relocate and consolidate its North Texas corporate operations into two, yet-to-be-build facilities totaling 100,000 square feet in Allen.  In all, the firm is investing $20 million in relocating and consolidating more than 50 employees from its headquarters and other offices in Dallas-Fort Worth. ... Allen Economic Development Corporation has offered the company an economic incentive package for the relocation and consolidation. The details of the incentives were not immediately disclosed   [Candace Carlisle, Dallas Business Journal, Nov 24, 15]

Intelligent Medical Devices (Cambridge, MA)

Intelligent Medical Devices (Cambridge, MA; $200K SBIR), which makes technology that fights superbug infections, has pulled in $3 million ... In November 2007, [it] told Mass High Tech after years of silence it had raised a total of $15 million from angel investors [Mass High Tech, Jun 23, 09]

Intellimedix (Atlanta, GA)

Intellimedix (Atlanta, GA; no SBIR) molecular-profiling startup, raised $2.3 million to use gene-analysis technology to identify drugs to treat cancer, Alzheimer's Disease and the Ebola virus.  [Urvaksh Karkaria, Atlanta Business Chronicle, Feb 27, 15]


Purdue University says it helped launch 10 startup companies from July 2007 to June 2008, including GreenTech America, Intelliphage and Nutrabiotix. All use Purdue-licensed technologies. Purdue Research Foundation's Office of Technology Commercialization also reported more than $4.1 million in royalties for that time frame.  [Indianapolis Star, Jul 29]

IntelliRad Control  (Radnor, PA)

IntelliRad Control  (Radnor, PA; no SBIR)  new medical-device company that is developing products to significantly reduce the doses of medical radiation needed for diagnostic and interventional procedures has raised $5.3 million in its first round of equity financing.....  to commercialize technology developed by researcher [Drexel U prof]  Allon Guez, who in July received a patent for his radiation control and minimization system.  [John George, Philadelphia Business Journal, Sep 21, 12]

Intellisense (Wilmington, MA)

Corning Gobbles Intellisense(May 23) Corning moved again to absorb optical switching companies in buying the last 67% of Intellisense (Wilmington, MA) for $500M in Corning stock. That means a $750M valuation for a company that started getting DOD SBIR in 1992 (Air Force) at five employees for a miniature navigation system using micromachining technology and stopped in 1998 at 12 employees with six Phase 2s from AF, Navy, and BMDO. It now has 50 employees which makes them worth about $15M each. The 1998 Navy award was for a typical military project - packaging technology that is an extension of IntelliSense's previously developed fiber to waveguide packaging techniques. If the government as pseudo-VC had taken a proportionate share of equity for its contribution of Intellisense's capital needs, it might today have $100-200M of Corning stock for under $6M of SBIR. $800K in a five person company makes a huge contribution and if SBIR is to be jump-start program (instead of just decent R&D) it has to seek out the Intellisense-like situations. For a whole lot less SBIR money and whole lot more Intellisenses, SBIR would be a decent venture program it claims to be instead of mostly an ordinary government R&D program which it actually is.

IntelliSense (Wilmington, MA) and Corning will collaborate on MEMS development under a joint development agreement to focus on the design,development and fabrication of optical-communications products based on MEMS (Micro-Electro-Mechanical Systems) technology. In the deal Corning took a piece of equity. an equity. Says SPIE Intellisense had about $5M in DOD SBIR in the 90s as it grew from 5 to 12 people by 1997. Which suggests that DOD could claim a large hypothetical equity value from its investments in Intellisense. Will it go public? Or will Corning just buy it? Who knows at this stage, but MEMS is a hot market topic.

Little Gyro, Little Firm, Big Plans The micro-machined opto-electronics resonator has two new features: sensitive measurement and unique material processing, says IntelliSense Corp (Wilmington, MA).The resonator should lead to a tiny gyroscope, less than 5 cc volume (like a pencil eraser for those who still remember pencils) and ten grams weight, that would last 100,000 hours (about 12 years, which is important for military munitions that sit patiently on shelves waiting for a war). GEC-Marconi Electronic Systems Corp wants to buy so many that it teamed with founder Fariborz Maseeh for the Phase 2 SBIR and beyond. Market studies have estimated a $2B+ market for micro-machined inertial sensors in 2000 after a present $160M. The technology core, that the SBIR funded, is the ROPE - resonant optical photonic element - based in fine optical waveguides deposited on micro-machined silicon, not a process for heavy thumbs. But if it works, it has the potential as an optical filter for WDM and very sensitive sensors for environments that are quite sensitive to particular invaders. (Now there's a competitive and conveniently theoretical market for SBIR proposers, the perfect fig-leaf for agencies winking at commercialization.) The acid test of whether this start-up can make good in the big-time will probably be in its unit-cost after the cost-insensitive military market is served. BMDO's SBIR gave it a free-money chance to prove itself....

Intelomed (Wexford, PA)

Intelomed (Wexford, PA; no SBIR, 15 employees) medical device firm, has raised$3.85 million from investors, all high-net-worth individuals most of whom are based outside the region, President and CEO Frank Amoruso said. ... developed a noninvasive device that can detect in real time if a patient is about to go into cardiovascular collapse or shock. [Patty Tascarella, Pittsburgh Business Times, Jul 24, 14] 

Intematix (Fremont, CA)

LED light materials maker Intematix (Fremont, CA)(Fremont, CA; $1.3M SBIR) has raised another $16 million in funding [Lindsey Riddell, San Francisco Business Times, Mar 16, 12]

Inter-4 (San Francisco, CA)

Air Force (USAF) selected Sierra Nevada (Sparks, NV; $1M SBIR, founded 1963, 2500 employees) and its partner Embraer (Brazil) Defense and Security for its Light Air Support (LAS) program.  ...   deemed the A-29 Super Tucano aircraft, and the overall solution offered by SNC, to be the superior choice for this critical mission. The initial $427.5 million delivery order is to supply the USAF with 20 A-29 Super Tucano aircraft.    ...  for. light air support, reconnaissance and training capabilities to the Afghanistan military. As such, it is a vital element of the United States’ Afghan withdrawal strategy   .. work will be in Jacksonville, FL  [company press release Feb 27, 13] over the years it has gathered up companies:  Space Dev (Poway, CA; $5M SBIR) ;MicroSat Systems (Littleton, CA; $11M SBIR) ; Straight Flight  (Denver, CO; no SBIR) ; Waveband (Torrance, CA; $17M SBIR); Aviation Resources Delaware (no SBIR); Inter-4 (San Francisco, CA; no SBIR); Turtle Mountain Communications (no SBIR) ;  Plano Microwave (Plano, TX; no SBIR) ; Spectral Systems (Beavercreek, OH; no SBIR) ;Advanced Countermeasure Systems (Sacramento, CA; no SBIR) . 

Interactive Supercomputing (Waltham, MA)

Microsoft  has acquired the technology assets of Interactive Supercomputing (Waltham, MA; one SBIR) for an undisclosed sum, various websites such as New England Tech Wire and are reporting. [Boston Globe, Sep 24, 09]

Interdigital (King of Prussia, PA )

InterDigital down 13% [Feb 23,17]  present subsidiary Interdigital Telecom $300K SBIR in 1990s

Interdigital ($300K SBIR)  down 12% [Jul 1, 13] said an administrative law judge overseeing patent-infringement claims against Nokia , Huawei Technologies, and ZTE  found that one of the wireless-technology company's patents were infringed but that the patent was invalid and that another six patents weren't infringed.   [Dow Jones wire]

Interdigital up 14%  [Aug 1, 12]

Interdigital up 26%  [Jun 18, 12]

down 14% [Apr 26, 12]

Interdigital (King of Prussia, PA, nearly $3M SBIR in New York as SCS Telecom and Interdigital Telecom) down 20% [Jan 23, 12] after the developer of wireless technology said it plans to focus on growing rather than on getting bought. [Peter Kay, Philadelphia Business Journal, Jan 24, 12]

Interlace Medical (Framingham, MA)

medical device startup Interlace Medical (Framingham, MA; no SBIR; founded 2006). has announced raising $20.5 million in Series C funding ... commercializing Myosure, its treatment for removing intrauterine fibroids and polyps. [Mass High Tech, Jun 16, 09]

Intermagnetics General

Philips Medical Systems MR, formerly Intermagnetics ($5M SBIR in the 1990s), announced that the company planned to keep SuperPower under its wing for the "foreseeable" future. ... Philips has invested $10M in the plant since the acquisition in 2006. ... SuperPower was celebrating the re-energizing of its high-temperature superconducting wire project being operated between two National Grid substations in Albany and Menands. [Larry Rulison, Albany Times-Union, Feb 22] The government's $5M in a new technology attracted an international giant which is now owns the technology in which it is investing serious money. That's what SBIR was supposed to do.

Bigger.  Philips Medical Systems MR, formerly Intermagnetics General, has received town approval for a 48,000-square-foot expansion to its MRI magnet manufacturing plant in Latham, NY. ...  The expansion was planned before Intermagnetics was purchased last month by Dutch electronics giant Royal Philips Electronics NV for $1.3 billion.  [Larry Rulison, Albany Times-Union, Dec 22, 06]

Intermagnetics General sold itself to Philips Electronics for $1.3 B.  The maker of high-field superconducting magnets had seven Phase 2 SBIRs 1986-1993.

Intermagnetics General jumped 15% on a good earnings report and a $10.7M DOD contract [Jan 4, 06]  IMGC has some SBIRs including seven Phase 2s back in the 80s and 90s, starting with ... you guessed it, BMDO ... although at the time it already had 200 employees. It now has 1000+ employees.


Intermolecular down 10% [May 20, 14]

Intermolecular up 39% [May 19, 14]

Intermolecular  down 14% [May 7, 14]

Intermolcular down 31% [Feb 28, 14]  

Intermolecular (San Jose, CA; $2M SBIR) down 10% [Dec 31, 13]

Intermolecular up 13% [Apr 17,13]

Intermolecular up 10%  [Jun 29, 12]

Intermolecular   up 12% [Mar 21, 12]

Intermolecular  down 15% [Feb 27, 12]

Intermolecular down 10% [feb 15, 12]

Intermolecular ($2M SBIR) is pricing its IPO today at $13 to raise $130 M. It's VC-funded, with ATMI [one of its customers, and a huge SBIR successs story] owning 10.6 percent, ... and Symyx owning 10.9 percent...  does have very intriguing science, but the firm is not a product company and borders on being a materials company with a big licensing component. The markets are not always appreciative of that model.  [ blog, Nov 17, 11]  ATMI was co-founded by Gene Banucci, PhD chemistry, once R&D chief of American Cyanimid, and transitioned from scientist to CEO of emerging tech company for 19 years and Chairman for 24 years. ATMI went public in 1992 and now has 800 employees in various countries.  Gene is now actively retired in two states, a good and avid golfer, and never seems to sit down. A model for aspiring SBIR company founders and CEOs.

Intermolecular (San Jose, CA; $2M SBIR) plans to price its IPO this week to raise $130M. [Wall Street Journal, Nov 14, 11]

Intermolecular  (San Jose, CA; $2M SBIR) which helps semiconductor and clean-energy companies accelerate R&D through combinatorial chemistry, has raised $15 million out of a potential $25 million in a sale of equity and securities, according to a regulatory filing. [Wade Roush, francisco, Mar 14, 11]

Intermolecular a "secretive" new Silicon Valley company has raised $36M and has worked with “a large logic manufacturer” to synthesize a unique molecule that will be used in copper interconnects at the 32 nm node. “This is a molecule that doesn’t exist anywhere else on Earth today, engineered to have properties of interest to that application,” [chief exec David] Lazovsky said.[Matt Marshall,, Jul 17]


InterMune wins FDA OK for lung-scarring disease drug at center of Roche deal ... an $8.3 billion buyout of [InterMune] by drug giant Roche — won regulatory approval [Ron Leuty, San Francisco Business Times, Oct 15, 14] 

InterMune up 35% [Aug 25, 14] 

Roche Holding AG has agreed to buy U.S. biotech company InterMune (Brisbane, CA; $300K SBIR) for $8.3 billion in cash.  [Reuters, Aug 24, 14]   Fodder for SBTC's claim that SBIR deserves more money since there have been so many M&A transactions.  Actually, SBTC is right for one agency, and only one agency - NIH.  All the mission agencies that will use the SBIR-funded technology have a completely different scale of values that does not weigh financial success or even broad public adoption. Note also that these pages are full of economic news from NIH companies and  little from DOD- and NASA-funded companies. 

 Intermune up 14% [Aug 13, 14]

Intermune up 13% [May 19, 14]

Intermune up 11%  [Mar 7, 14]

Intermune down 15%  [Feb 26, 14]

Intermune up 170%  [Feb 25, 14]  said its experimental drug for lung disease succeeded in a late-stage trial, raising expectations that the treatment could be eventually be approved by the FDA  [Wall Street Journal , Feb 25, 14]

Intermune up 11% [Feb 10, 14]

Intermune down 11% [Feb 3, 14]

Intermune down 18% [Jan 31, 14]

InterMune  up 10% [Jan 9, 14]

Intermune up 15% [Jul 25, 13]

InterMune ($300K SBIR) will net more than $228 million from the sale of convertible senior notes and shares of common stock.[San Francisco Business Times, Jan 16, 13]

Intermune  up 11% [Nov 16, 12]

InterMune up 17% [Nov 8, 12]

Intermune Pharma up 16% [Oct 17, 12]

Intermune down 15%  [Jul 23, 12]

Intermune up 10% [May 1, 12]

Intermune  down 16% [Apr 9, 12]

Intermune up 12% [Mar 8, 12]

Intermune up 11% [Jan 9, 12]

InterMune up 10% [Jan 5, 12]

InterMune  down 13% [Dec 16, 11]

InterMune  down 30% [Dec 15, 11]

Intermune up 13% [Oct 24, 11]

Intermune down 12% [Aug 8, 11]

Intermune up 145% [Dec 17, 10]  after a European regulatory committee recommended approval of its medicine Esbriet to treat a fatal lung disease. [Bloomberg]

Intermune  down 10% [Jul 28, 10]

Intermune down 75% [May 5, 10]  after the FDA declined to approve Esbriet, company's proposed lung drug, and requested another clinical trial. [Wall Street Journal, May 6]

Intermune up 13% [May 3, 10]

InterMune surged 65%, after an FDA panel recommended the agency approve pirfenidone, a lung drug developed to treat a type of pulmonary fibrosis. [Wall Street Journal, Mar 11, 10]

Intermune  up 59% [Mar 5, 10]  as Wall Street took a favorable view of briefing documents for next week's panel that will review the Brisbane, Calif., biotechnology company's lung-disease treatment and recommend whether the Food and Drug Administration should approve it. While the documents aren't overtly positive, they leave the door open to approval in early May.  [Wall Street Journal, Mar 6, 10]

Intermune  down 16% [Nov 17, 09] said it would discontinue a high-dose of its experimental Hepatitis C treatment in a study because of potential liver damage. [AP, Nov 17, 09]

Intermune up 11% [Nov 3, 09]

The former chief executive of Intermune (Brisbane, CA; $300K SBIR) was found guilty last week of fraudulently promoting the drug Actimmune for treatment of a fatal lung disease. Dr. W. Scott Harkonen, who left the company in 2003, faces up to 20 years in prison and $250,000 in fines, according to the U.S. Attorney's Office. The San Francisco federal jury acquitted Harkonen on a misbranding charge. However, the grand jury found Harkonen guilty of wire fraud. ...  In 2006, Intermune agreed to pay $37 million to settle the government's civil case related to Actimmune's marketing.   [Erin Allday, SF Chronicle, Oct 4, 09] 

InterMune   up 36% [Feb 3, 09]

Intermune up 12% [Jan 21, 09]

Intermune up 10% [Jan 16, 09]

InterMune down 10% [Dec 11, 08]

InterMune  up 12% [Dec 2, 08]

InterMune up 19%  after the company said its hepatitis C drug candidate met safety goals in an early-stage study and appeared to be effective. [AP, Apr 1, 08]

Intermune  up 16% [Mar 24, 08]

Veteran Bay area biotechnology executive Dr. W. Scott Harkonen was indicted Tuesday on charges that he fraudulently promoted the drug Actimmune for a fatal lung disease while he was the chief executive for the drug's manufacturer, Intermune (Brisbane, CA; $300K SBIR). ... The criminal case is part of a drive in recent years by both state and federal prosecutors to crack down on company promotion of their drugs for off-label uses - that is, for diseases not indicated on a drug's FDA-approved label. Actimmune is approved for two rare diseases afflicting children, but the Food and Drug Administration never approved it for idiopathic pulmonary fibrosis. In general, companies have been forbidden to market medicines for unapproved uses, though doctors are legally free to prescribe drugs off-label if they think scientific evidence warrants it. [SF Chronicle, Mar 20, 08]

InterMune up 14% [Jan 7, 08]

InterMune (two SBIRs) fell 21% when it ended a Phase III clinical trial that it did no better than a placebo for mortality rates from a lung disease. 

International Stem Cell

In a step toward one-size-fits-all stem cell therapies, an Oceanside biotechnology company said yesterday that it has developed cell lines that could potentially be used by many different people and races without fear of transplant rejection. Scientists at International Stem Cell (no SBIR) said the four embryonic stem cell lines have a simple genetic profile in critical areas of DNA that code for immune system rejection, making them easy to “immune match” with large numbers of patients.  published yesterday in the online edition of Cloning and Stem Cells Journal  [Penny Crabtree, San Diego Union Tribune, Dec 20]

International Stem Cell (formerly BTHC III) up 17%.[Feb 23, 07]  Its trading symbol is the same one once held by Illinois Superconductor. 

Interrad Medical (Plymouth, MN)

InterRad Medical (Plymouth, MN; no SBIR) looks to raise $6 million in equity financing according to [SEC] filing ...  filing indicates that the company has not yet raised any of the money that it seeks in its latest round of financing.   InterRad’s product is the SecurAcath device. During a hospital stay, a patient may have a catheter inserted into his or her arm for the delivery of fluids or medication. The small SecurAcath device can be snapped onto a catheter to improve stability of the line and reduce incidences of catheters becoming dislodged. InterRad received clearance from the U.S. Food and Drug Administration for the device in 2010. [Burl Gilyard, Twin Cities Business, Sep 28, 16]

Interrad Medical (Plymouth, MN; no SBIR) which makes an anchor-like medical device that holds catheters in place, has closed on $7.5 million in financing  ...  to open a European headquarters in Cardiff, Wales   ... raised $10 million from individual investors three years ago.  The company's product, SecurAcath, is an alternative to sutures and adhesives that are now used to keep catheters from dislodging during lengthy treatments.  [Katharine Grayson, Minneapolis / St. Paul Business Journal, Dec 1, 14]

&IntersectENT (Menlo Park, CA)

Intersect ENT (Menlo Park, CA; no SBIR) dedicated to transforming care for patients with ear, nose and throat conditions, announced [FDA] approval for the SINUVA™ (mometasone furoate) Sinus Implant , a new targeted approach to treating recurrent nasal polyp disease in patients who have had previous ethmoid sinus surgery. [company press release, De 12, 17]

Intersect ENT priced its IPO at $11, the low end of its target range, raising $55 million. The stock then traded near the top of the range on its Nasdaq debut, closing up about 17 percent. [Cromwell Schubarth, Silicon Valley Business Journal, Jul 28, 14]

A trio of Bay Area life sciences companies Tobira Therapeutics  (South San Francisco, CA; no SBIR, founded 2006, backed by Danish drug developer Novo A/S ), Zosano Pharma (formerly Macroflux,  Fremont, CA; no SBIR, founded 2006) and IntersectENT (Menlo Park, CA; no SBIR) — will seek more than $200 million in upcoming IPOs. [Ron Leuty, San Francisco Business Times, Jun 24, 14]

&Intersense (Burlington,MA)

Motion-tracking technology company InterSense (Burlington, MA;$2.5M SBIR) landed a Phase 2 SBIR from the Air Force to develop an autonomous training system designed to work with commercially available wearable computers. [Mass High Tech, Aug 3, 09] High innovation or incremental engineering? Only the AF knows and it is not telling.


Virginia's Four Points Technology LLC will use InterSystems' database as part of its $31.4 contract with the Department of Veterans Affairs.... Founded in 1978, InterSystems develops and markets a post-relational database, software and a health information exchange platform. The company operates offices in 22 countries and has customers in 88 countries. [Mass High Tech, Dec 1] Intersystems (New York NY) had at least eight Phase 2 SBIRs for what sound like interesting but commercially fundable software projects.

InterValve (Minnetonka, MN)

A med-tech startup InterValve (Minnetonka, MN; no SBIR) aiming to profit off a wave of new heart valve technologies poised to hit the market has raised about $2.6 million ... has developed a device that simplifies transcatheter valve replacement procedures, plans to use the funding for working capital. It's aiming to raise a total of $3.5 million, according to a regulatory filing.  ...  completed a $4.7 million round of financing in 2011   [Katherine Grayson, Minneapolis / St Paul Business Journal, Jul 15, 13]

InterVene (South San Francisco, CA)

InterVene (South San Francisco, CA ; no SBIR, founded 2011) secured $15 million to validate its catheter-based treatment for correcting failed one-way valves in the veins of the legs, which can lead to backflows of blood, pain and swelling.  [Conor Hale, Fierce Biotech, Jun 25, 19] prior funding $21M []


Intevac (Santa Clara, CA;  $5M SBIR) down 27%  [May 1, 18] continued to make good progress in our Thin-film Equipment growth initiatives, which support the future revenue growth trajectory of our company  [company press release, Apr 30, 18]

Intevac up 10% [Mar 28, 18]

Intevac up 12% [Oct 27, 17]

Intevac (Santa Clara CA; $2,5M SBIR) up 17% [Jan 24, 17]

Intevac up 11% [Dec 29, 16]

Intevac up 12% [Aug 2, 16]

Intevac up 11% [Mar 18,16]

Intevac down 10% [May 8, 14]

Intevac ($2.5M SBIR) up 10% [Dec 6, 13]

Intevac  up 12% [Jun 27, 13]

Intevac  up 12% [Dec 5, 12]

Intevac  up 16% [Nov 30, 11]

Intevac down 13% [Nov 1, 11]

Intevac up 15% [Oct 20, 11]

Intevac down 10% [Oct 3, 11]

Intevac up 11% [Aug 23, 11]

Intevac down 11% [Aug 5, 11]

Intevac up 19% [Nov 2, 10]

Intevac said that its photonics business received a multi-year, $18 million purchasing agreement for its digital night vision module.  [Silicon Valley/ San Jose Business Journal, Mar 9, 10]

Intevac  up 22% [Jan 4, 10]

Intevac  down 10% [Jul 2, 09]

Intevac  up 10% [Jul 1, 09]

Intevac up 12% [May 21, 09]

Intevac  down 11% [May 13, 09]

Intevac   down 11% [May 7, 09]

Intevac  up 12% [Apr 28, 09]

Intevac down 10% [Mar 20, 09]

Intevac up 17% [Mar 12, 09]

Intevac  up 16% [Mar 6, 09]

Intevac  up 12% [Dec 2, 08]

Intevac  down 20% [Dec 1, 08]  On a stock bloodbath day

Intevac down 13% [Nov 12, 08]

Intevac down 12% [Nov 5, 08]

Intevac up 13% [Oct 16, 08]

Intevac down 18% [Sep 29, 08]

Intevac up 23% [Sep 18, 08]

Intevac up 11% [Jun 4, 08]

Intevac down 14% [Apr 29, 08]

Intevac said Citigroup agreed to supply it $20M in credits secured by some of Intevac’s holdings in its Citigroup accounts, according to a filing with the SEC. [Jack Davis, San Jose Mercury News, Mar 10]  Those accounts include Intevac's cash in "auction-rate" securities which at least temporarily have no liquid market. Is it likely that Intevac knew the risk of auction-rate instruments? I doubt it since the tech company probably relied on Citibank's advice in reaching for higher returns.

Intevac down 11% [Feb 4, 08]

Intevac down 10% [Aug 9, 07]

Intevac fell 16% on bad news of profit forecast stemming from a delay in orders from a major customer. [Jul 31, 07]

Shares of disk sputtering equipment maker Intevac tumbled 11% after a Goldman Sachs downgraded the company, predicting its orders will decline. [AP, Apr 18, 07]

Intevac soared 28% after it said that surging sales led to a doubled fourth-quarter profit.[Feb 7, 07]

Intra-Cellular Therapies (New York, NY)

Intra-Cellular Therapies up 10% [Apr 10, 18]

Intra-Cellular Therapies (New York, NY; $4M SBIR) up 21% [Mar 2, 18] reported a larger net loss and larger R&D expenses and  Following guidance received from [FDA] in 2017, we intend to submit a new drug application (NDA) for lumateperone for the treatment of schizophrenia by mid-2018. [company press release, Mar 1, 18]

IntraCellular Therapies up 12% [Jan 4, 18]

Intra-Cellular Therapies announced the completion of its previously announced underwritten public offering of approximately $150 million [company press release, Oct 2, 17], which will help it prepare for an FDA filing for lumateperone in schizophrenia next year.  [Phil Taylor, FierceBiotech, Oct 3, 17]

Intra-Cellular Therapies down 13% [Sep 27, 17]

Intra-Cellular Therapies up 17% [Sep 7, 17] announced positive topline data from the first part of an open-label safety switching study in which 302 patients with stable symptoms of schizophrenia were switched from standard-of-care antipsychotic medications to lumateperone (ITI-007 60 mg) with no dose titration of lumateperone required for a 6-week treatment duration, then switched back to standard-of-care. [company press release, Sep 7, 17]

Intra-Cellular Therapies up 15% [Aug 30, 17]

IntraCellular Thera up 10% [Aug 24, 17]

Intra-Cellular Therapies up 28% [Aug 23, 17]

IntraCellular Therapies up 14% [May 10,17]

Intra-Cellular Therapies said the FDA has raised questions relating to certain findings observed in nonclinical animal toxicology studies of lumateperone and has requested additional information to confirm that the nonclinical findings are not indicative of a safety risk associated with long term exposure in humans.  [company press release, May 1, 17]

Intra-Cellular Therapies  down 10% [May 2, 17]

 Intra-Cellular Thera down 24% [May 1, 17]

IntraCellular Thera up 12% [Mar 27, 17]

Intracellular Therapies up 12% [Mar 1,17]

Intra-Cellular Therapies up 18% [Nov 9, 16]

BlackThorn (South San Francisco, CA; no SBIR) is making its first formal announcement. It’s closed a $40 million Series A round, with participation from the venture arm of Johnson & Johnson ....  disclosed plans to develop drugs for neurobehavioral diseases—such as obsessive compulsive disorder, depression, and schizophrenia—and test them in a way that its executives believe can help overcome some of the field’s notorious roadblocks. ....  This year alone, antipsychotic drugs developed by Alkermes, Intra-Cellular Therapies , and the now-defunct Forum Pharmaceuticals have failed Phase 3 trials, and all three cited a high level of placebo effect in the control group as a significant problem.   [Ben Fidler,, Oct 19, 16]

Intra-Cellular Therapies down 64% [Sep 29, 16] said its lead drug candidate had a similar rate of effectiveness to placebo in a Phase 3 schizophrenia trial.  [Josh Beckerman, Dow Jones Newswire, Sep 28, 16]

IntraCellular Therapies up 14% [Apr 6, 16]

IntraCellular Therapies up 10% [Feb 26, 16]

Intracellular Therapies  down 12% [Feb 5, 16]

Intracellular Therapies  down 10% [Feb 2, 16]

Intra-Cellular Therapies down 12% [Sep 25, 15]

Intra-Cellular Therapies down 12% [Sep 22, 15]

Intra-Cellular Therapies up 20% [Sep 17, 15]

Intra-Cellular Therapies up 87% [Sep 16, 15]  said a higher dose of its lead drug was found to be effective in reducing the severity of schizophrenia symptoms in a late-stage study.  [Reuters, Sep 16, 15]

Intra-Cellular Therapies  down 10% [Jul 20,15]

Intra-Cellular Therapies up 10% [Jul 6, 15]

IntraCellular Therapies up 12% [Jun 22, 15]

 Capital prediction. RBC Capital Markets recently started Intra-Cellular Therapies ($4M SBIR) as Outperform with a price target of $41. The stock closed at $23.02 ahead of the call. ...  focused on small molecule drug development to treat neuropsychiatric and neurodegenerative diseases and other disorders of the central nervous system. The last formal call we saw was from JMP Securities, starting it as Outperform back in December, with a $26 price target, versus a $17.03 share price back then.   [, Apr 20, 15]

Intra-Cellular Therapies  up 12% [Feb 18, 15]

Intra-Cellular Therapies  up 10% [Feb 13, 15]

Intra-Cellular Therapies  up 12% [Feb 12, 15]

Intra-cellular Therapies (New York,NY; $3.9M SBIR)  up 10% [Jan 16,15]

Intra-Cellular Therapies (NYC, NY; $4M SBIR)   up 12% [Jan 14, 15]

Intra-Cellular Thera (New York, NY; $3.9M SBIR) up 11% [Sep 26, 14]

Intra-Cellular Therapies (New York, NY; $4M SBIR) down 10% [Aug 20, 14]

Intra-Cellular Therapies (New York, NY; $4M SBIR) up 11% [Aug 13, 14]

Intra-Cellular Therapies (New York, NY; $3.9M SBIR) up 11% [Jun 4, 14]

Intra-Cellular Therapies (New York, NY; $4M SBIR)  up 11% [Apr 9, 14]


IntraLase rose 12% to the price for which it is being bought by Advanced Medical Optics. [Jan 8, 07]

Intralytix (Baltimore, MD)

Intralytix (Baltimore, MD;  at least $2.5M SBIR)  announced that it received $17.5 million in new equity funding from Lesaffre, a French family group. ... marks the beginning of a close collaboration between both companies to develop and commercialize bacteriophage-based products, for various benefits in human health and in other areas of mutual interest.   [company press release,  Jul 24, 17]

Intralytix (Baltimore, MD; $1.4M SBIR, founded 1998) raised $17.5 million in new funding ... has created products designed to kill food-borne bacteria including listeria, E. coli and salmonella.  [Morgan Eichensehr, Baltimore Business Journal, Jun 2. 17]  using its core bacteriophage technology to develop safe and effective products based on naturally-occurring bacteriophages, for use in food production and processing, environmental cleanliness, veterinary applications, and human therapy.  [company website]

Intrepida Bio (San Diego, CA)

Intrepida Bio (San Diego, CA; no SBIR), a company formed around a preclinical antibody developed by Italian pharmaceutical company Biouniversa. ... backed by $9.5 million ... launched last week, plans to advance work by Biouniversa’s Maria Caterina Turco, who studied a protein, BAG3, that is overexpressed by some cancer tumors—especially pancreatic tumors. [Sarah de Crescenzo,, Nov 4, 19]

Intrepida Bio (San Diego, CA; no SBIR) debuts as a company dedicated to the discovery and development of medicines that modulate the innate immune system to fight cancer and other diseases. An initial $9.5 million equity investment will fund investigational new drug (IND) application-enabling studies of Intrepida’s lead oncology program. [company press release, Oct 2, 19]

Intrexon (Germantown, MD)

Bioengineering company Intrexon (no SBIR) will have access to up to $100 million of new capital through a deal with an affiliate company controlled by its founder and chairman, Randal "RJ" Kirk. Intrexon announced the company entered into what it called a preferred stock equity facility with Kapital Joe LLC, an entity managed by Third Security LLC, a venture capital firm founded by Kirk. (Washington Business Journal)

An investor in genetherapy company GenVec (Gaithersburg, MD; $9.5M SBIR) sued the company and its board following a deal inked earlier this year to be acquired by Intrexon (Germantown, MD; no SBIR) ... alleges GenVec issued misleading disclosures in [SEC] filing on March 17 [Washington Business Journal, Apr 17, 17]

Fibrocell Science (Exton, PA; no SBIR) an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs, and Intrexon (Germantown, PA; no SBIR) , a leader in synthetic biology, today announced an Exclusive Channel Collaboration (ECC) for the development of genetically-modified fibroblasts to treat chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions.  According to the Centers for Disease Control and Prevention, arthritis—characterized by joint inflammation, pain, and decreased range of motion—is the United States’ most common cause of disability affecting more than 52 million adults as well as 300,000 children at a cost exceeding $120 billion. [joint companies press release, Jan 4, 16]

biotech  Intrexon (Germantown, MD; no SBIR) will receive an upfront payment of $115 million in a new collaboration and licensing agreement with Merck Serono, the biopharmaceutical business of German drug giant Merck. ...  went public in 2013, and raised $116 million in a secondary stock offering in January  [Jeff Clabaugh, Washington Business Journal; Mar 30, 15]

Intrexon (Germantown, MD; no SBIR, listed on NYSE) a synthetic biology company, plans to raise up to $150 million though a secondary offering of common stock, the company said ...   for general corporate purposes as well as strategic acquisitions or investments.  Intrexon relies heavily on partnerships to build products based off of its core technology.  [Tina Reed,Washington Business Journal, Jan 21, 15]

Intrinsic Therapeutics

Late-stage medical device startup Intrinsic Therapeutics (no SBIR, founded Y2K) raised $38.8M in a $41.7M funding round, according to a [SEC] filing. [Srividya (Sri) Kalyanaraman, BostInno Beat, Apr 24, 19]  develops therapies to treat disc herniations in the spine for discectomy patients. ..  prior funding $219M []

Intrinsity (Austin, TX)

Long-time chip designer Intrinsity  (Austin, TX; no SBIR) raised $4 million in a new round of funding. ... from 11 investors ..  founded 1997 ... employed more than 100 workers in early 2008. [Austin Business Journal, Feb 12, 10]

Introgen Therapeutics

the [Texas] A&M system had entered into an agreement to develop vaccines with a therapeutics manufacturing firm called Introgen this put the firm in a position to benefit from the new center. Introgen’s founder, David Nance, is a close friend of [Gov] Perry’s. He contributed $100,000 to Perry over the decade, he had previously served on the advisory committee of the tech fund awarding the $50 million, and Perry’s son, Griffin, owned Introgen stock between 2001 and 2004.  Introgen had its main drug rejected by the FDA and declared bankruptcy shortly before the $50 million award  [Alec McGillis, The New Republic, Sep 28]

The ETF’s Regional Center of Innovation and Commercialization, which typically reviews grant applications as the initial step of the process, was reportedly skipped over in August before a 17-person statewide board approved a $4.5 million grant for Convergen (Austin, TX; no SBIR) Lifesciences Inc. Information about Convergen is scarce, and the company doesn’t operate a website. It was reportedly founded by biotech entrepreneur David Nance, who — along with his now-bankrupt company Introgen Therapeutics (Houston, TX; $1.6M SBIR). — contributed $80,000 to Perry’s camp in the past decade.  [Austin Business Journal, Oct 22, 2010]

Introgen Therapeutics filed for bankruptcy, the latest difficult chapter for the struggling drug development company.  [Austin American Statesman, Dec 4, 08]

Introgen Therapeutics chief executive and founder David Nance resigned, along with three other top executives. The company is cutting from 45 to 15 employees  [Austin American-Statesman, Nov 27, 08]

With its cash dwindling, Introgen Therapeutics said that it has hired an adviser to pursue strategic options, including a possible sale. The news came as the Austin-based biotechnology company reported a third-quarter net loss of $6 million [Austin  American-Statesman, Nov 12, 08]

Introgen Therapeutics has been notified by the Nasdaq composite index that its shares could be delisted because its market value has fallen below the $50 million minimum. [Austin American-Statesman, Sep 6, 08]

Introgen Therapeutics fell nearly 40% after the company disclosed that the U.S. Food and Drug Administration had refused to accept the application for its cancer-fighting drug Advexin.  [Lilly Rockwell, Austin American-Statesman, Sep 3, 08]

Introgen Therapeutics saw its stock price plummet about 20% [Jul 14, 08] , the same day a report from was published questioning the effectiveness of the company's much-touted cancer drug Advexin. [Austin Business Journal]

Introgen Therapeutics became the first to apply for FDA approval of a gene therapy drug to treat recurring head and neck cancers. But it could be early 2009, at best, before a decision on whether it can market the drug, Advexin, on which it has been working for 14 years. [Boston Globe, Jul 1]

Introgen up 13% [Feb 20, 08] on announcement of starting a randomized, controlled study of INGN 225.

Introgen Therapeutics bolstered its cash position by selling its entire stake in a European biotechnology company for $7.5M.  [Austin American-Statesman, Jan 18]

Introgen Therapeutics down 28%  [AP, Dec 20, 07] after the company said it will expand the amount of tissue samples in a late-stage study in order to boost the strength of the results.

Introgen Therapeutics up 11% [Dec 19, 07]

Introgen Therapeutics up 12% as it and Moffitt Cancer Center announced plans to begin a phase 2 randomized, controlled study of INGN 225, Introgen's investigational immunotherapy product in patients with metastatic small-cell lung cancer (termed extensive stage SCLC). [press release, Sep 6, 07]

Introgen Therapeutics Up 19% [Aug 7, 07]

Introgen Therapeutics said European regulators have certified its production facilities for Advexin, a gene-based treatment for cancer. [Austin Statesman-American, Apr 17]

Introgen Therapeutics said it lost $7.2M in the quarter as revenue fell 84% while awaiting FDA approval on its primary product, Advexin which would be the first gene-based cancer treatment in the United States. [Austin American-Statesman, Mar 9]

Introgen Therapeutics expanded its licensing agreement with the University of Texas, giving the biotechnology company broader rights to a group of patent applications related to INGN 241, an anti-cancer therapy.  The new agreement gives Introgen worldwide, exclusive rights to the patent applications, covering use of INGN 241 in a wide range of treatments, including chemotherapy and more advanced targeted treatments. [Austin American-Statesman, Dec 22]

Introgen Therapeutics said it struck a deal with the M.D. Anderson Cancer Center in Houston giving it exclusive rights for a portfolio of patents that focus on nanotechnology. The patents deal with nanoparticles that can deliver therapeutic bioactive proteins and other compounds to cells, including cancer cells. The goal is for the nanoparticles to increase a treatment's activity and more specifically target cells. Introgen is a drug development company that is waiting for a U.S. Food and Drug Administration decision on its leading product. That product, Advexin, is a gene-based cancer treatment based on research developed at M.D. Anderson. [Austin American-Statesman, Nov 17]

Introgen Therapeutics raised $6.1M in a private placement of stock, about the amount it lost last quarter in trying to market a novel cancer treatment. At least $2.6M in SBIR. [Nov 8, 06]

Intuitive Biosciences (Fitchburg, WI)

Intuitive Biosciences (Middleton, WI; no SBIR, founded 2012, 4 employees), which makes protein analysis tools for the life sciences industry, has raised $1.3 million of a proposed $2.9 million offering, according to [SEC] filing   [Kathleen Gallagher, Milwaukee Journal Sentinel, Jun 8, 15]   [bought] many of the assets of Gentel Biosciences (Fitchburg, WI; no SBIR) [which had] bought GlaxoSmithKline’s protein chip technology. [Judy Newman, Wisconsin State Journal, May 16, 2012 ]

Intuitive Biosciences (Fitchburg, WI; no SBIR) that makes protein analysis tools for the life sciences industry, ...  in 2012 acquired certain assets and businesses of Gentel Biosciences  (Madison, WI; no SBIR) biotechnology company. The company has raised $487,000, according to [SEC] filing.  [Kathleen Gallagher , Milwaukee Journal Sentinel, Aug 28, 14]

Intuitive Genomics (St Louis, MO)

NewLeaf Symbiotics (St Louis, MO; no SBIR) announced  the close of a $24MM series C financing round, accelerating plans to convert proven applications of its biotechnology into products for large-scale agriculture. ... The company is tripling the size of its R&D and pilot production facility in St. Louis and is expanding its proprietary Prescriptive Biologics Knowledgebase™ bioinformatics platform.  [company press release, Jul 10, 17]  acquired Intuitive Genomics (St Louis, MO; no SBIR, founded 2010) in 2013

Intuitive Surgical

Intuitive Surgical, known for its da Vinci systems for robotically assisted surgery, has unveiled a study showing its new flexible robotics platform could be used safely to take lung tissue samples for biopsy.  [Amirah Al Idrus, Fierce Biotech, Nov 3, 17]

Transenterix  up 93% [Oct 16, 17]  after the company gained FDA clearance for its Senhance surgical robot. The company was previously denied clearance from the FDA for its SurgiBot System back in April 2016.  According to the company, Senhance is now the first new market entrant in abdominal surgical robotics since 2000, when Intuitive Surgical, gained clearance for its da Vinci Surgical System.  [Wayne Duggan Benzinga, Yahoo Finance, Oct 16, 17]  Meanwhile, Intuitive Surgical purchased a 60,000-square-foot building in the Triangle Business Center in Durham [NC] for just shy of $6 million. [Jennifer Henderson, Triangle Business Journal, Oct 16, 17]

Intuitive Surgical executed a 3:1 stock split. [Oct 5, 17]

Intuitive Surgical split its stock 3:1.

Auris Surgical Robots (San Carlos, CA; no SBIR for stealth) raised $280 million in a Series D round ... Auris last raised capital nearly two years ago, a $149.5 million round ..... has raised a total of $530 million. ....  company [webite]  says its first target is lung cancer.  ...   led by co-founder and CEO Frederic Moll, a serial entrepreneur who might best be known for his role with Intuitive Surgical  he co-founded in 1995. Last year, Intuitive reported $2.7 billion in total revenue.  [Frank Vinluan,, Aug 4, 17]

Intuitive Surgical (Sunnyvale, CA; $2.4M SBIR) won FDA clearance for the da Vinci X Surgical System, the latest iteration of its robotic-assisted surgery platform, and will launch it the U.S. later this year.  [Ben Fidler,, Jun 2, 17]

Goldman Sachs told investors to buy Intuitive Surgical shares because robot-assisted procedures will double in the next two years. [Tae Kim, CNBC, May 16, 17]

Intuitive Surgical (Sunnyvale, CA; $2.5M SBIR) announced that it planned to increase the amount it spends on research and development in 2017 by an additional $80 million dollars, a full 30% higher than in 2016. ... it had already increased R&D spending in 2016 by over 20%. ... to produce the company's next generation designed to operate through a small incision and a single port the size of a tennis ball, ... two degrees of greater flexibility than the Xi robot, which already bends farther than the human wrist  [Danny Vena, Motley Fool, Feb 7, 17] Note: Vena and Motley Fool own shares of Intuitive Surgical.

What works will get copied, and improved.  Robots assisted half a million surgeries in the U.S. last year—but a secretive venture by Alphabet and Johnson & Johnson wants to increase that number dramatically. The duo’s company, Verb Surgical, has been developing a new robot for over four years, but only recently announced its plans. And what plans. The current state-of-the-art in robotic surgery is Intuitive Surgical’s da Vinci robot, and Verb plans to best it in virtually every respect. ...  Currently robots leave surgeons to look at a video feed; Verb plans to use AI image analysis to annotate a feed with anatomical data and guidance. That could help provide any surgeon with a level of expertise usually belonging to doctors with thousands of cases under their belts.   [MIT Tech Review, Oct 17, 16]

Intuitive Surgical  (Sunnyvale, CA; $2.3M SBIR), a maker of surgical robots, has been on the receiving end of lawsuits alleging (which the firm denies) that surgeons were inadequately trained to use its machines or that the robots were defective. Machines may get the better of humans in the operating theatre, but the courtroom will also determine how fast they spread.  [The Economist, May 7, 16]

robotics developer TransEnterix said that federal regulators rejected the company’s application to manufacture and sell a surgical robot it has been developing for the U.S. market. ....  The surgical robot industry has been dominated by a single surgical robot, called the [Intuit Surgical's] da Vinci system, for about 15 years.    [John Murawski, Raleigh News & Observer, Apr, 20, 16]

Stealthy startup Auris Surgical Robotics (San Carlos, CA; no SBIR) disclosed that it has raised $150 million ...  the fourth robotic surgery business co-founded by Dr. Frederic Moll. He previously co-founded Intuitive Surgical  ($2.5M SBIR) , Hansen Medical (no SBIR), Endotherapeutics (no SBIR), and Origin Medsystems (no SBIR) ....has now raised a total of $185 million.  [Cromwell Schubarth, Silicon Valley Business Journal, Sep 24, 15]

Google strikes deal with Johnson & Johnson to make robots that can assist surgeons, launching a new challenge to Sunnyvale's Intuitive Surgical.   [Jeremy C. Owens, San Jose Mercuiry News, Mar 27, 15] Success inspires competition.

In the latest study to question the value of robotic surgery, researchers from Columbia University found that the technology costs significantly more and has a higher rate of complications than regular minimally invasive surgery for removing ovaries and ovarian cysts.  ... Intuitive Surgical, which makes the da Vinci Surgical System reviewed in the studies, said surgeons and patients choose to use it “because it can lead to fewer complications and shorter hospital stays.” The company also said the technology is often used on patients “with more complex disease and higher risk factors,” which the latest study didn’t take into account.     [Melinda Beck, Wall Street Journal, Oct 7]  

  Intuitive Surgical up 18% [Jul 23, 14]  reported a decline in its second-quarter earnings and revenue, but results topped expectations. [WSJ, Jul 23]  Meanwhile, A new study finds treating bladder cancer with a surgical robot made by Intuitive Surgical is no better at reducing procedural complications than performing the procedure with traditional surgery.  .... Intuitive Surgical said in a statement that it was "grossly misleading" for the researchers to make a comparison between robotic and open surgery in bladder cancer because the surgeons used the open technique to perform bladder reconstruction in both arms of the study.  [Joseph Walker, Wall Street Journal, Jul 23, 14]

Intuitive Surgical convinced a Washington state jury that it wasn’t negligent in its training of a doctor who performed a robot-assisted surgery on a patient who later died. ....  the first to go to trial of at least 26 lawsuits against Intuitive alleging injuries tied to its da Vinci robotic system, ....The robots, which are in more than 1,300 U.S. hospitals, cost $1.5 million each and were used in 367,000 U.S. procedures in 2012.  [Patricia Guthrie and Joel Rosenblatt, Bloomberg, Jun 10, 14]  Where technology meets humans, the disappointed will sue.

Intuitive Surgical said in a preliminary report that first-quarter revenue declined about 24 percent amid a sharp drop in sales of its robotic surgery system.  [Robert Langreth, Bloomberg, May 12, 14]

Intuitive Surgical down 11% [Apr 23, 14]  after reporting disappointing first-quarter results. [WSJ]

Intuitive Surgical forecast that sales of its da Vinci surgical robots would show a first-quarter decline of 59%, citing weaker demand for some minimally invasive procedures.  .... as doctors took a more conservative approach toward performing some minimally invasive procedures. Concerns about the safety and cost-effectiveness of the company's robots have also hurt sales, analysts said.   [Wall Street Journal, Apr 8]

Intuitive Surgical  up 13% [Apr 1, 14], maker of the da Vinci robotic surgery system, rose the most in more than three years after U.S. regulators cleared a new version of its product that offers a greater range of motion. [Drew Armstrong, Bloomberg, Apr 1, 14][

Reports of adverse robotic events to the Food and Drug Administration are on the rise. Based on a draft analysis of these reports by physicians at Rush University Medical Center, the University of Illinois and the Massachusetts Institute of Technology, there has been a sharp increase in the injury and death rate from robotic surgery to about 50 reports per 100,000 procedures last year from only 13.3 in 2004.  Intuitive Surgical the dominant manufacturer of robotic-surgery gear—disputes this analysis, claiming there isn't any "statistically significant trend."    [Stewart Pinkerton, Wall Street Journal, Nov 18, 13]

A robotic-surgery device called the da Vinci Surgical System [made by Intuitive Surgical] is linked to "an overall increasing trend in the rate of injury and death reports" since 2004, according to a draft analysis of such events reported to the [FDA]. The company disagreed.  [Thomas Burton, Wall Street Journal, Nov 9, 13]

Intuitive Surgical was ranked #8 on Forbes's list of the world's most innovative companies. [Aug 22, 13]

The slide of Intuitive Surgical, maker of the da Vinci robotic systems, continues. Its shares are tanking today after the Sunnyvale company reported second-quarter results that failed to meet expectations, and cut its revenue outlook for the year. Its CEO disclosed that the company has received a warning letter from the FDA over product-safety notifications. Reports of surgical injuries are piling up. Earlier this month, the company recalled 30 devices. [Levi Sumagaysay, Silicon Beat, San Jose Mercury News, Jul 19, 13]

Intuitive Surgical down 16% [Jul 9, 13]

The biggest thing in operating rooms these days is a million-dollar, multi-armed robot named da Vinci [made by Intuitive Surgical (Sunnyvale, CA; no SBIR)] , used in nearly 400,000 surgeries nationwide last year — triple the number just four years earlier.    .... What we thought was impossible 10 years ago is now commonplace," said Dr. Michael Stifelman, robotic surgery chief at New York University's Langone Medical Center.   But now the high-tech helper is under [FDA] scrutiny over reports of problems, including several deaths that may be linked with it and the high cost of using the robotic system. [Lindsey Tanner, AP, Apr 9, 13]

Intuitive Surgical  down 11% [Feb 28, 13]

Intuitive Surgical up 13% [Jan 21, 11]

the robot has its skinny arms buried deep in the patient's abdomen, busily lifting and cutting and cauterizing  ...  The leading manufacturer of surgical robots, Intuitive Surgical  (Sunnyvale, CA; $2.5M SBIR), reports that roughly half of all prostate cancer surgeries in the U.S. in 2008 employed the company's da Vinci robotic system, which is now in use at more than 1,000 hospitals and clinics across the country and another 400 institutions around the world.  [David van Drehle, Time, Dec 13, 10]  The Army funded a 2004 Phase 1 Haptics-Optional Surgical Training System (HOSTS) when the company already had 300 employees and then left the SBIR  field to NIH. Today the company has 1500 employees and a $10B market cap.  By then the company was already public but if the government had taken equity shares for its investment, it would now have ten times the investment. That's even better than bailing out Citigroup or General Motors.

 Technology needs more than an ON-switch. In use at 853 hospitals across the U.S., the da Vinci has become a symbol of medical progress ...  One study published in the Journal of Urology found that a hospital needs to do at least 520 surgeries a year with the robot to bring its costs in line with traditional surgery. That's seven times the number of robotic surgeries Wentworth-Douglass has been averaging. ... Last year, Intuitive Surgical reported profits of $233 million on sales of $1.05 billion. Its stock price has more than doubled over the past year ...  Wentworth-Douglass began leasing its da Vinci in 2006. The 178-bed nonprofit facility competes for patients with six other hospitals located within a 30-mile radius in eastern New Hampshire and southern Maine. None of those hospitals had the robot, so Wentworth-Douglass saw an opportunity to gain a technological edge.  [John Carryrou, Wall Street Journal, May 5, 10]

Intuitive Surgical  up 12% [Jan 22, 10]

Intuitive Surgical up 27% [Jul 23, 09]  Second-quarter net income grew 22% on strong sales of its surgical robots, defying economic headwinds hitting spending at hospitals that buy the systems. Covering of large short positions assisted the gain  [Wall Street Journal, Jul 24]

Intuitive Surgical   up 10% [Apr 24, 09]

Intuitive Surgical  up 11% [Apr 9, 09]

Intuitive Surgical  down 10% [Dec 1, 08]  On a stock bloodbath day

Intuitive Surgical down 17% [Nov 16, 08]

Intuitive Surgical makes the remarkable da Vinci surgical system. Machines cost $1.3 million apiece, plus around $130,000 for yearly service contracts and $2,000 per surgery for items that can't be reused. Demand is strong, since the system's tiny incisions keep healing times and hospital stays short, while its highly scalable movements turn clumsy hands into precise ones. But Intuitive stock is trading at 38 times this year's earnings forecast at a time when low price/earnings ratios are suddenly plentiful.  [Jack Hough, Wall Street Journal, Nov 6, 08]

Intuitive Surgical up 11% [Nov 4, 08]

Intuituve Surgical down 12% [Oct 17, 08]

Intuitive Surgical up 13% [Oct 16, 08]  Even though it posted third-quarter earnings above analysts' views, Oppenheimer said there were high expectations. [WSJ, Oct 18]

Intuitive Surgical down 15% [Oct 15, 08]

Intuitive Surgical down 13% [Oct 6, 08]

Intuitive Surgical up 18% [Jul 23, 08]

Intuitive Surgical down 17% .after its full-year sales forecast missed analyst expectations. Although Intuitive Surgical posted an 88% higher quarterly profit, investors focused on the outlook  [AP, Apr 18, 08]

Intuitive Surgical up 20% [Feb 1, 08]

Intuitive Surgical down 12%. [Jan 29, 08]

CAN INTUITIVE SURGICAL ($2M SBIR) possibly be worth $240 a share? Since its June 2000 debut, the stock is up 13-fold in value. The company is now valued at 19 times trailing 12-month sales. That's more than 10 times the median for the S&P 500 index. ... it introduced the da Vinci surgical system in 1999  (before its SBIRs and 2000 IPO) ...  already sold more than 650 machines (at $1.3M each) ... [, Oct 12,07]  One does wonder, though, why HHS gave it an 2005 Phase 2 STTR for the daVinci robot that was already selling commercially?

Intuitive Surgical up 32% [Jul 20, 07] on news of fat profits and projections. It which makes da Vinci surgical systems for use in urologic, cardiothoracic, gynecologic and general surgeries

Intuitive Surgical jumped 17% seemingly in response to a friendly piece by Motley Fool: the company behind the da Vinci robots used in minimally invasive surgical procedures, is a perfect example of a dynamic company that is still experiencing outstanding growth. Its five-year estimated growth rate is 35%, [Feb 2, 07]

Invenra (Madison, WI)

Invenra (Madison, WI; no SBIR) startup that develops therapeutic antibodies for pharmaceuticals companies and other clients, has raised more than $2.9 million from investors, according to a regulatory filing.  ....  Invenra’s core business involves discovering antibodies and performing related biology work around targets the startup’s partners have identified in advance. Invenra’s collaborators, which include U.K.-based Oxford BioTherapeutics and AgonOx (Portland, OR; $300K SBIR) , are then responsible for taking the drugs forward into the clinic. [Jeff Buchanan,, Oct 5, 17]

Invenra (Madison, WI; no SBIR) has had success developing therapeutic antibodies for its own drug research, and for the research of others. Now has signed on with pharma giant Merck, which hopes Invenra’s antibody expertise can help it develop new drugs. [Jeff Buchanan,, Jul 28, 17]

Invenra (Madison, WI; no SBIR, 18 employees) raised more than $3 million from 27 investors, according to a [SEC] document  ... Invenra’s cell-free protein expression technology allows for the screening of hundreds of thousands of full antibodies, and is much faster than conventional cell-based methods for finding therapeutic antibodies. ... has raised more than $11 million  [Jeff Buchanan,  xconomy,com,  Jul 21, 16]

Invenra (Madison, WI; no SBIR) has raised just over $2 million from investors that it will use to further develop its cell-free protein expression technology, a new SEC filing shows.  ... has now raised $6.2 million total from investors since 2012 ...  one of the companies developing a way to make antibodies without using genetically modified cells such as E. coli or Chinese hamster ovary cells as the factories—a departure from the current standard. Sutro Biopharma (South San Francisco, CA; no SBIR) is another company working on similar technology.   [Jeff Engel,, Jan 29, 15]

Invenra (Madison, WI; no SBIR) maker of pharmaceutical products, raised $2 million, its filing said. That brings to $6.2 million the total amount the company has raised since 2012, according to  Invenra was co-founded by Roland Greene and Emile Nuwaysir, both veterans of NimbleGen Systems (Madison, WI; $1.8M SBIR), which was acquired in 2007 for $272.5 million by the diagnostics arm of Roche Holding AG, the giant Swiss pharmaceutical company.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Jan 29, 15]  Invenra's proprietary technology combines the cell-free expression of full-length antibodies and extreme miniaturization, enabling the screening of unprecedented numbers of full-length antibodies in phenotypic assays. [company website]. If you pay attention to emerging biotech companies, you might have heard of Sutro Biopharma. With a new way of making therapeutic monoclonal antibodies, the Northern California company has raised more than $90 million and just struck a major deal with Celgene. It’s a lot less likely you’ve heard of Invenra. But the Madison, WI-based company says it has a similar technology to Sutro: an antibody production system that doesn’t use genetically modified cells such as E. coli or Chinese hamster ovary cells as the factories, a break from the industry standard.  [Alex Lash,, Nov 15, 14]

Invensense (Sunnyvale, CA)

Motion-sensing chip maker InvenSense (Sunnyvale, CA; no SBIR). stock dropped by as much as 25 percent on Friday after it lowered first quarter sales guidance.  ....  went public in November at $7.50 a share and rose to as high as $23.35 in late March but traded as low as $12.51 on Friday.  [Cromwell Schubarth, Silicon Valley / San Jose Business Journal, May 4, 12]

Invensense (Sunnyvale, CA; no SBIR) raised $75 million in its IPO ... Founded in 2003, the-based company provides motion sensor chips for Nintendo's Wii and consumer electronics such as smartphones and tablets. [ Silicon Valley/ San Jose Business Journal, Nov 16, 11]

Inventev (Detroit. MI)

Inventev (Detroit. MI; no SBIR) cleantech startup  recently landed a $500,000 federal grant, which represents a large chunk of the TechTown-based startup's upcoming seed round. The 4-year-old clean-tech startup has raised $750,000 in seed capital, including the half-a-million-dollar grant, a matching $50,000 grant from the state of Michigan, and $200,000 worth of in-kind contributions. The $500,000 grant is from the ARPA-E agency of the U.S. Department of Energy.  [Jon Zemke,, Feb 7, 16]

Inverness Medical Innovations (Waltham MA)

Inverness Medical Innovations (Waltham MA; no SBIR) closed its IPO for $806M.  [Boston Globe, Nov 24, 07]

Invirsa (Columbus, OH)

Invirsa (Columbus, OH; no SBIR, founded 2016) is developing a new treatment approach. Currently in the preclinical stage, the drug being developed by Invirsa supports the body’s natural immune response to viral infections, while also stimulating the repair of damaged cells. [Courtney Gabrielson and Will Flanagan, Cincy Inno, Jun 28, 18] total funding $700K []

Invertix (McLean, VA)

Invertix (McLean, VA; $1M SBIR) and Near Infinity (no SBIR) are now operating as Altamira Technologies. .....  announced it was teaming up with Ball Aerospace & Technologies to go after one of four prime contractor spots on an eight-year, $960 million deal to support the National Air and Space Intelligence Center at Wright-Patterson Air Force Base. [Joe Cogliano, Dayton Business Journal, Jun 19, 13] 

Invictus Medical (San Antonio, TX)

Early stage San Antonio, TX, startups can again tap into funds provided by the Texas Research & Technology Foundation (TRTF). The McDermott Legacy Fund, which is managed by the foundation’s subsidiary, the Texas Technology Development Center, is reloading a seed fund it operates that invests in early stage bioscience and technology companies with $1 million. The fund made six investments since 2010 in early seed rounds for companies including Invictus Medicine (San Antonio, TX;  ??SBIR, founded 2012) and StemBioSys (San Antonio, TX;  ??SBIR, $8M Series A in 2015 ).  [Angela Shah,, Feb 8, 16]

medical device company Invictus Medical (San Antonio, TX; no SBIR) raised about $3.8 million this year to support clinical trials for its product, according to [SEC] filing ... developed an extracranial pressure relief device for newborn infants that they are calling GELShield. The company recently completed a clinical trial at the Baylor University Medical Center in Dallas and has filed an application with the Food and Drug Administration to seek regulatory approval to begin commercializing the product.  [Mike W. Thomas, San Antonio Business Journal, Dec 19, 14]

medical device company Invictus Medical (San Antonio; TX; no SBIR, founded 2012, five employees) has raised about $3.8 million this year to support clinical trials for its product, according to [SEC]  filing ...  has developed an extracranial pressure relief device for newborn infants that they are calling GELShield. The company recently completed a clinical trial at the Baylor University Medical Center (Dallas) [Mike W. Thomas, San Antonio Business Journal, Dec 16, 14]

Invictus Medical (San Antonio, TX; no SBIR, founded 2011) filed an application with the Food and Drug Administration to seek regulatory approval for the company’s new extracranial pressure relief device for newborn infants. ... has raised more than $4 million in private equity funding  [James Aldridge, San Antonio Business Journal, Sep 16, 14]

Invictus Medical  (San Antonio, TX;  SBIR) a venture launched two years ago by a group of engineering students at the UT San Antonio, is finally starting to build some traction in the commercial market. ... developed a neonatal cranial-support device that should help protect premature infants from developing plagiochephaly, or the shifting of cranial plates. ....expecting to launch its first commercial product in the health care market by this time next year. [Mike Thomas, San Antonio Business Journal, Dec 24, 12]

InView Technology (Austin, TX)

InView Technology (Austin, TX; no SBIR) a two-year-old startup that develops advanced cameras and imaging technology, said that it has received $2 million in funding as part of a second investment round.  ....  investors included In-Q-Tel, which led the company's $4 million first investment round, and the state's Emerging Technology Fund.  .... continue to develop its "compressive sensing," which uses advanced mathematics to take sharp photographic images in low light conditions and can detect images hidden by smoke and fog.  [Kirk Ladendorf, Austin American Statesman, Apr 17, 12]

InViewTech (Austin, TX)The military and spy agencies are looking for better and cheaper cameras, and InView Technology (Austin, TX; no SBIR) plans to make them. It expects to demonstrate its first prototypes by the end of this year and to begin selling camera systems next year.  ... One of its other backers, announced this spring, is In-Q-Tel, an investment company tied to the Central Intelligence Agency. InView is expected to get $1 million, half as a research project and half as an equity investment. It has another research contract worth more than $1 million as a subcontractor to Raytheon Co., a major defense contractor. ... [Founder] Bridge got in the camera business after selling Zilker Labs (no SBIR) to Intersil Corp. for an undisclosed price. [Kirk Ladendorf, Austin American Statesman, Jun 5, 11]

Inviragen   (Ft Collins, CO)

Inviragen, (Fort Collins,CO; $5.6M SBIR) is being sold for $35 million, but the final purchase price could be much higher, the Coloradoan reports. The buyer, Japan's Takeda Pharmaceutical Co., will make milestone payments of as much as $215 million as part of the purchase agreement. Inviragen, which was founded in 2005, is working on vaccines for dengue and hand, foot and mouth disease.  [Denver Business Journal, May 8, 13]

Aldevon (Fargo, ND; no SBIR), maker of DNA and protein products is putting a research and sales operation in [Wisconsin] ....  founded by two ND State U graduates, has more than 70 employees, and provides products and services to pharmaceutical companies and diagnostic test-makers.  ... also welcomed to Wisconsin: RJA Dispersions (no SBIR), VitalMedix (no SBIR) and Rapid Diagnostek (no SBIR), from Minnesota; Flex Biomedical (one SBIR) and Exact Sciences (no SBIR), from Massachusetts; NanoMedex ($1M SBIR), from Florida; and Inviragen ($2M SBIR) from Colorado. Biotechnology is the fastest-growing segment of the Wisconsin economy, with an annualized growth rate of nearly 7%, [Gov] Doyle said in a statement. The sector has 400 companies in the state with 34,000 employees.

Inviragen (Ft Collins, CO; $2M SBIR) developer of vaccines with offices in Madison, has merged with a Singapore company in tandem with a $15 million equity investment from a group of venture capital investors. [Business Journal of Milwaukee, Oct 6, 09]

The Colorado BioScience Association is seeking entries for its annual BioWest Venture Showcase award. Six companies in bioscience technology (biotechnology, medical devices or biofuels) will be chosen to present to a panel of national venture capital investors on Nov. 13 at the 2008 BioWest Conference and Expo, Nov. 13-14 ... Each company will have 15 minutes to present their technologies and business plans. ... Past winners include Apoplogic Pharmaceuticals (Aurora, CO; $700K SBIR) , Inviragen (Ft Collins, CO; $700K SBIR) and ValveXchange. [Denver Business Journal, Sep 4]

InVisage Technologies (Menlo Park, CA

InVisage Technologies (Menlo Park, CA;  no SBIR), a developer of smartphone image sensors, added $15 million to its Series E round announced early this year, bringing it up to $32.5 million. ...  has raised more than $100 million since it was founded in 2006.  ... claims that its QuantumFilm material absorbs light ten times faster than silicon, dramatically improving pictures take in low light.  [Cromwell Schubarth, Silicon Valley Business Journal, Dec 17, 14]

Intel is investing about $26 million in six mobile technology startups ... CloudMade (Menlo Park, CA) startup that provides tools to developers of location-based applications.  ...  InVisage Technologies (Menlo Park, CA) startup that is developing a custom semiconductor material, replacing silicon, for image sensors ... Beijing-based Borqs, New York-based Kaltura, Toronto-based SecureKey Technologies and Reading, England-based VisionOSS Solutions [Frank Russell, San Jose Mercury News, Feb 14]

InvisionHeart (Nashville, TN)

InvisionHeart (Nashville, TN; no SBIR) startup that provides a wireless electrocardiogram system to first responders and health care providers, has raised $1.9 million in a Series A financing round, according to [SEC] filing  .....  to complete the technology build out, seek clearance from the [FDA] and initiate pilot sales   [Eleanor Kennedy, Nashville Business Journal, Jun 4, 14]   A perfectly appropriate private investment of applying established technology to new use with a calculable ROI then depends only on market acceptance. 

Invision Medical (Mountain View, CA)

Stealthy startup nVision Medical  (Mountain View, CA; no SBIR) has raised $12 million in Series B financing, with funds slated to support product development, clinical studies and regulatory submissions to for its micro-catheter technology  [for] cell collection from the fallopian tube and direct visualization of the fallopian tube, the company said. [Fink Densford, Jul 28, 16]

Invitae (San Francisco, CA)

CombiMatrix (Irvine, CA; $1M SBIR, 55 employees) up 42% [Aug 1, 17]  a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announced that it has entered into a definitive merger agreement with Invitae [one of the nation's fastest-growing genetics information companies] to be acquired in an all-stock merger for approximately $33 million  [company press release, Jul 31, 17]

Invitae  up 12% [Feb 18, 15] after IPO

Genetic testing firm Invitae (San Francisco, CA; no SBIR) bucked an IPO tide that has become choppy of late, raising more than expected in a $102 million offering. [Cromwell Schubarth, Silicon Valley Business Journal, Feb 12, 15]

Genetics testing company Invitae (San Francisco, CA; no SBIR) landed a $120 million funding round from CEO Randy Scott, Genomic Health Inc., Chinese investor Decheng Capital and others, the company said, to build out the company’s infrastructure and expand globally.  [Ron Leuty, San Francisco Business Times, Oct 13, 14] 

Genetic diagnostics company Invitae (San Francisco, CA; no SBIR) raised $40 million in a Series E round .... Invitae is in the middle of a legal tussle with Myriad Genetics over its breast cancer test  [Ron Leuty, San Francisco Business Times, Dec 10, 13] 


Life Technologies up 8% as Thermo Fisher agreed to buy diagnostics equipment maker Life Technologies in a $13.6 billion deal that will significantly expand Thermo Fisher and establish it as a major force in the emerging personalized medicine market. [Robert Weisman, Boston Globe, Apr 15, 13]    formed in 2008 by the merger of Invitrogen ($4M SBIR) and Applied Biosystems (no SBIR); acquired AcroMetrix (one SBIR) in 2010; acquired Ion Torrent (no SBIR) in 2010; won a $45 million Army contract in 2012.

The California Institute for Regenerative Medicine, the state stem cell agency, has awarded $1B so far in research money.  SBIR companies got $10M of it.  Bio Time (Berkeley, CA; $300K SBIR)  $4.7M;   Vistagen Therapeutics (Burlingame, CA; $600K SBIR)  $970K; Gamma Medica Ideas  (Northridge, CA; $2.8M SBIR) $950K; Vala Sciences (San Diego, CA; $3M SBIR)  $900K; Invitrogen (Carlsbad, CA; $4M SBIR) $870K SBIR;  Fluidigm (South San Francisco, CA: $1.2M SBIR) [CIRM press release, Oct 28]

Invitrogen down 13% [Oct 27, 08]

Invitrogen up 15% [Oct 13, 08]

The Wall Street Journal's Patent Scorecard in Biotechnology ranks Invitrogen and Maxygen #2 and 3 in Science Strength (13-week rolling average). Sequenom was #6; Affymetrix #11 of 28 listed. Only Sequenom had an impressive stock price record, up 170% over 52 weeks.

Invitrogen, a provider of essential life science technologies for research, production and diagnostics, announced the launch of its Dynabeads® MAX Legionella, which enables a unique process for targeting and concentrating legionella from environmental water samples. The Dynabeads® MAX Legionella provides a rapid and highly reliable sample preparation process, improving the method used, and result achieved, for the detection and quantification of legionella.   [Water on-line, Aug 19, 08]

A test made by Invitrogen that can determine whether women with breast cancer could be helped by taking the powerful drug Herceptin was approved yesterday by the FDA [San Diego Union-Tribune, Jul 9, 08]

Invitrogen down 10% [Jun 12, 08]

Invitrogen, which makes kits that researchers use in gene cloning, will pay $6.4 B for Applied Biosystems (no SBIR) which makes systems that can analyze DNA, RNA, proteins and other molecules, which can be used in forensics, research, testing foods for contaminants, making and testing drugs, among other applications. [Boston Globe, Jun 12]

Invitrogen up 10% after the company said its second-quarter profit doubled. [Aug 2, 07]

Invitrogen up 10% [Feb 14, 07] after fourth-quarter results exceeded expectations and it agreed to dump its BioReliance unit.

Invitrogen lost 12% after bad news about profits and the next quarter.[Terri Somers, San Diego Tribune, Oct 28]  It had four Phase 2 SBIRs in the 1990s.

Invivosciences (Wauwatosa, WI)

Six start-ups will be recognized for making strides to commercialization at a biotech industry summit in October. ... part of a one-day Biotechnology Vision Summit 2009 that is being run by BioForward, an organization that represents Wisconsin's biotech industry. AquaMost LLC (Madison, WI; one SBIR) , Echometrix  (Madison, WI; no SBIR), Flex Biomedical Inc(Madison, WI; one SBIR), Semba Biosciences (Madison, WI; no SBIR),  Invivosciences LLC (Wauwatosa, WI; no SBIR), and Rapid Diagnostek Inc  (Hudson, WI; no SBIR).  [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 22, 09]

InVivo Therapeutics Holdings

InVivo Thera up 21% [Mar 1,16]

MassDevelopment, the Commonwealth’s finance and development agency, has granted a $2 million loan to InVivo Therapeutics Holdings (Cambridge, MA; no SBIR), ... looks to use polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury, plans to use part of proceeds to purchase equipment for the expansion of manufacturing and research capabilities at its new facility in Cambridge. [Chris Reidy, Boston Globe, Oct 9, 12]

InVivo Therapeutics Holdings priced a public offering to bring in gross proceeds of approximately $17.4 million .... developing technologies for the treatment of spinal cord injuries. [Rodney Brown, Mass High Tech, Feb 17, 12]

Invuity (San Francisco, CA)

Invuity up 28% [Sep 11, 18]

Invuity up 15% [Nov 10, 16]

Invuity down 45% [Nov 4, 16]  achieved 52% revenue growth in the third quarter, results were lower than our expectations   [company press release]

Invuity up 10% [Sep 29,15]

Invuity up 10% [Sep 21, 15]

Invuity up 10% [Aug 20, 15]

Surgical lighting developer Invuity (San Francisco, CA; no SBIR) was set to begin trading after an IPO that raised $48 million. [Cromwell Schubarth, Silicon Valley Business Journal, Jun 12, 15]

Invuity (San Francisco, CA; no SBIR), which makes lighting devices used in surgery, filed for a $69 million IPO.   ...  since December raised $20 million ... has raised around $96 million, including the most recent round in February.     [Cromwell Schubarth, Silicon Valley Business Journal, Apr 20, 15]  patented Intelligent Photonics™ devices provide direct visualization of the surgical cavity enabling enhanced precision, efficiency and safety. Our technology is integrated into sophisticated retractor systems, handheld devices and intracavity drop-in illuminators; each utilizing our proprietary waveguide technology that directs and shapes light into broad, uniform illumination to provide enhanced direct visualization inside dark surgical cavities. [company website]

Medical device company Invuity (San Francisco, CA; no SBIR) raised $36 million in a Series E round — including $15 million in debt ... to boost sales of its product line of minimally invasive devices that help surgeons peek into hard-to-see areas of the body during spine, breast, thyroid and plastic surgeries as well as other procedures.    [Ron Leuty, San Francisco Business Times, Mar 4, 14]

Inx Medical (Grover, MO)

Inx Medical (Grover, MO; no SBIR), a medical device startup, raised $700K capital, and today submitted its [FDA] application for a new device used to aid in the surgical removal of hemorrhoids.  [Amir Kurtovic, St Louis Business Journal, May 3, 13]

IoGyn (Cupertino, CA)

Boston Scientific, best known for its cardiovascular products, said it has agreed to buy IoGyn (Cupertino, CA; no SBIR, founded 2011) start-up that is working on technology to treat intrauterine fibroids and polyps that affect millions of women worldwide. ...  currently owns a 28 percent equity stake in IoGyn  .... IoGyn’s Symphion system, which has received regulatory approval, is designed for removing hysteroscopic intrauterine tissue such as fibroids and polyps. [Chris Reidy,, May 7, 14]


Iomai (Gaithersburg, MD; $5M+ SBIR) said that pharmaceutical firm Merck would test a patch Iomai is developing that is designed to stimulate a stronger immune system response to vaccines.  [Michael Rosenwald, Washington Post, Apr 4, 08]  The stock trades at about a third of its high after its 2006 debut.

Iomai up 11% on the beginning of testing of skin patch vaccines. [Nov 7, 06]

Iomed (Salt Lake City, UT)

Iomed jumped 31% to the value for which it agreed to be bought by ReAble Therapeutics Inc. in an all-cash merge. [May 18, 07]

Iomed (Salt Lake City, UT; one Phase 1 years ago) reported a 19% drop in revenue. [Salt Lake Tribuine, May 16,07]

IOmet Pharma

Merck agreed to purchase biotechnology company Afferent Pharmaceuticals (San Mateo, CA; no SBIR, founded 2009), whose lead drug candidate is being evaluated as a treatment for refractory, chronic cough and idiopathic pulmonary fibrosis with cough.  The deal will include an upfront payment of $500 million and milestones of up to $750 million.   Afferent focuses on targeting the P2X3 receptor for neurogenic conditions.  Last month, Afferent reported that its lead candidate, AF-219, significantly reduced cough frequency in the first cohort of a two-cohort, Phase 2b study of chronic cough patients.  In July, Afferent said it completed a $55 million Series C financing. Merck's resent acquisitions have included an $8.3 billion deal for antibiotic maker Cubist Pharmaceuticals ($5M SBIR) and the purchase of cancer-focused IOmet Pharma (no SBIR).  [Josh Beckerman, Wall Street Journal, Jun 9, 16]

Ion America

Ion America has developed a product, known as a solid oxide fuel cell, that strips the electrons from natural gas, generating electricity and leaving hydrogen as the only byproduct. In May and June, Ion was granted three patents in the U.S. to cover aspects of its technology. And last month, blue-chip venture capitalists including Kleiner Perkins Caufield & Byers and New Enterprise Associates invested more than $100 M. John Doerr sits on Ion's board  [Wall Street Journal, Sep 11]  Which leaves a residue of carbon. No SBA data on any SBIR, but why would a company take SBIR when it can have unlimited real money.

Ionic Materials (Woburn, MA)

Ionic Materials (Woburn, MA; no SBIR, founded 1986, 40 employees) announced it has secured $65 million in a Series C financing round from a leading group of financial and strategic investors [who] include companies from the battery manufacturing, consumer electronic and electric vehicle ecosystem who will be working with the company to speed the development of its solid polymer electrolyte battery material. ... has created a new composition of matter that will be fundamental to the transformation of the battery as we know it. [company press release, Feb 7, 18]

start-up Ionic Materials (Woburn, MA; no SBIR) is trying to turbocharge a type of battery that has been a mainstay for simple devices like flashlights and toys, but until now has been ignored as an energy source for computers and electric cars.   .....    said it had developed prototypes of a rechargeable alkaline battery that can be made using continuous manufacturing processes similar to the making of plastic wrap. So far, the company, which is backed by William Joy, a pioneering Silicon Valley computer designer, has demonstrated up to 400 recharge cycles for its prototypes. Ionic executives say they believe they will be able to triple that.  [JOHN MARKOFF, NY Times, AUG. 1, 2017]

Ionis Pharma(formerly ISIS Pharma)

Ionis Pharma (Carlsbad, CA; at least $4M SBIR) announced that GSK exercised its option to license Ionis' antisense medicines for people with chronic hepatitis B virus (CHB) infection following positive Phase 2 results. CHB is a chronic viral infection of the liver that can lead to significant and potentially fatal health conditions, including cirrhosis, liver failure and liver cancer. Current treatments for patients with CHB provide low levels of hepatitis B virus S antigen seroclearance, leaving many patients without a treatment to achieve sustained disease remission. There are more than 200 million patients worldwide living with CHB. [company press release, Aug 27, 19]

Ionis Pharma earns $84 million, reversing loss from a year ago [San Diego Union Tribune, May 9, 10]

The FDA approved two oral formulations of the Pfizer drug tafamidis, approved specifically to treat the potentially deadly heart problems faced by patients with both the hereditary and “wild-type” forms of ATTR, the latter of which develops over time. ... In 2018 the FDA approved two drugs Alnylam Pharmaceuticals and  Akcea Therapeutics (spinout of Ionis Pharmaceuticals, Boston, MA; no SBIR) for hereditary and wild-type ATTR. [Ben Fidler,, May 6 19]

Ionis Pharma up 15% [Feb 27, 19]

Akcea Thera up 17% [Feb 25, 19] Novartis [said it] will pay $150 million to license a heart disease medication discovered by Ionis Pharma co-developed by Ionis with its majority-owned subsidiary Akcea Therapeutics. Ionis will get half the money, paid for with Akcea stock.[Bradley Fikes, San Diego Union Tribune, Feb 25, 19]

ProQR (Netherlands) is licensing an RNA medicine from Ionis Pharmaceuticals for the treatment of retinitis pigmentosa, a form of rare, inherited blindness. The plan is to start a phase 1/2 trial of the drug in 2019.  ProQR is handing over an upfront payment of $2.5 million in ordinary shares in exchange for the worldwide rights to IONIS-RHO-2.5Rx, now called QR-1123. [Amirah Al Idrus, Fierce Biotech,| Oct 29, 18]

Breakthrough Prize In Life Sciences [for $3 million] awarded to C. Frank Bennett and Adrian R. Krainer – Ionis Pharmaceuticals and Cold Spring Harbor Laboratory, respectively for the development of an effective antisense oligonucleotide therapy for children with the neurodegenerative disease spinal muscular atrophy. .... The prize was founded in 2013 sponsored by Sergey Brin, Priscilla Chan and Mark Zuckerberg, Pony Ma, Yuri and Julia Milner, and Anne Wojcicki. [, Oct 17, 18]

Ionis Pharmaceuticals has signed on to a new collaboration with Roche worth up to $760 million, to help develop its RNA-based drug for advanced dry age-related macular degeneration and other diseases. [Conor Hale, Fierce Biotech, Oct 10, 18]

Ionis Pharma down 16% [Aug 28, 18]

Dynacure [French, founded 2016) raised $55M to take an antisense oligonucleotide therapy into the clinic. ... the centronuclear myopathy (CNM) prospect from its cofounder, Ionis Pharmaceuticals. [Nick Paul Taylor, Fierce Biotech, Jul 6, 18]

Roche has stopped development of the spinal muscular atrophy (SMA) drug [olesoxime] it acquired for €120 million ($140 million) upfront three years ago. ... When Roche acquired olesoxime, there were no approved drugs for SMA. Now, patients have access to Biogen and Ionis’ Spinraza and can look forward to experimental treatments including AveXis’ gene therapy. [Nick Paul Taylor, Fierce Biotech, Jun 1, 18]

Ionis Pharma down 11% [Apr 24, 18]

Biogen and Ionis Pharmaceuticals announced they have expanded their strategic collaboration through a new ten-year collaboration agreement to develop novel antisense drug candidates for a broad range of neurological diseases. ... Biogen will pay Ionis $1 billion in cash, which will include $625 million to purchase Ionis common stock at an approximately 25% cash premium, and a $375 million upfront payment. [joint companies press release, Apr 20, 18]

A year after GlaxoSmithKline bailed on a partnership with Ionis Pharmaceuticals for a transthyretin amyloidosis drug, Ionis sent the drug, inotersen, to spinout Akcea Therapeutics. Like a rival drug, patisiran, inotersen is under FDA review. [Frank Vinluan,, Mar 15, 18]

Ionis Pharmaceuticals has shared data from a phase 1/2 trial of its Roche-partnered treatment for Huntington’s disease. The small trial linked the two highest doses of antisense drug RG6042 to a 40% drop in levels of the mutant protein that drives the neurodegenerative disease. Ionis indicated it had solid data late last year when it revealed Roche had paid $45 million to license the drug after seeing dose-dependent reductions in mutant huntingtin protein. Now, Ionis has shared a glimpse at the size of the decline in protein levels.  Assay tests linked the two highest doses of RG6042 to a 40% mean reduction in mutant protein and a peak drop of 60%. [Nick Paul Taylor, Fierce Biotech, Mar 2, 18]

Ionis Pharmaceuticals announced it has licensed IONIS-AZ5-2.5Rx (AZD2373) to the global, science-led biopharmaceutical company AstraZeneca [for $30M license fee]  IONIS-AZ5-2.5Rx is a Generation 2.5 antisense drug, discovered by Ionis and designed to inhibit an undisclosed target to treat a genetically associated form of kidney disease. AstraZeneca will be responsible for developing and commercializing IONIS-AZ5-2.5Rx.  [company press release, Feb 21, 18]

AveXis (Bannockburn. IL; no SBIR, founded 2010, IPO Feb 2016, market cap $3.3B) is expanding trials of its gene therapy for children with spinal muscular atrophy (SMA) with a series of new trials as it plays catch-up with Biogen and Ionis, which claimed the first approval for an SMA drug.  .... already has pivotal trials of its AVXS-101 candidate underway in two variants of the severe neuromuscular disease—types 1 and 2—but says it will now start studies in patients with SMA type 3, older children with type 2, and very young children (less than six weeks old) who have yet to develop symptoms.  ....    Biogen and Ionis’ Spinraza (nusinersen) was approved by the FDA near the end of 2016 and is still the only drug approved to treat SMA, which can affect up to 10,000 children around the world and is one of the leading causes of early death and disability in young children. [Phil Taylor, Fierce Biotech, Jan 17, 18]

Ionis Pharmaceuticals signed the rights to another antisense drug over to [JNJ subsidiary] Janssen for a fee of $5 million. The candidate, IONIS-JBI2-2.5Rx, is orally delivered and acts on an undisclosed target to treat a gastrointestinal (GI) autoimmune disease.  [Amirah Al Idrus, Fierce Biotech, Nov 17, 17]

Alnylam has emerged victorious from its hereditary TTR amyloidosis (hATTR) data face-off against Ionis. Data presented by the RNAi pioneer suggest its patisiran has the edge over Ionis’ inotersen in terms of safety and efficacy, although it remains to be seen whether this translates into market share.  The safety and feasibility study took place at Royal Brisbane and Women’s Hospital in Australia. It evaluated the use of new, investigational robotic-assisted system in the lungs and appears in the journal CHEST.  [Nick Paul Taylor, Fierce Biotech, Nov 3, 17]

Ionis Pharma down 10% [Nov 2, 17]

Ionis Pharma down 12% [Oct 24, 17]

Ionis Pharmaceuticals has shared a closer look at phase 3 data on inotersen in patients with hereditary TTR amyloidosis (hATTR). The antisense drug triggered a 20-point improvement against a score of neuropathy impairment, laying a marker for the upcoming showdown with Alnylam [which] is yet to present a close look at data from its trial.   [Nick Paul Taylor, Fierce Biotech, Oct 16, 2017]

Akcea Therapeutics (Cambridge, MA; no SBIR) [spinout in July with a $125 million IPO] affiliate of Ionis Pharmaceuticals focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, announced the submission of a New Drug Application (NDA) to [FDA] for volanesorsen, an investigational medicine for the treatment of familial chylomicronemia syndrome (FCS).  [company press release, Sep 1, 17] .

Ionis Pharmaceuticals said that it has regained full rights, from GSK, to a drug called inotersen, which the company expects to submit to regulators in the U.S. and Europe for a review this year. If the FDA approves inotersen, it could become the first marketed treatment in the U.S. for FAP.  ...   Ionis partner GSK dumped the drug—as well as another experimental medicine Ionis plans to develop for an eye disease, and possibly other conditions—as part of an R&D shakeup engineered by new CEO Emma Walmsley   [Ben Fidler,, Aug 11, 17]

Ionis Pharmaceuticals touted Phase 3 results for its rare nerve disease drug, inotersen, and said it plans to file for FDA approval. But investors noted safety concerns and sent Ionis shares down while boosting rival Alnylam Pharmaceuticals  [Ben Fidler,, May 19, 17]

Ionis Pharmaceutical subsidiary Akcea Therapeutics (CAMBRIDGE, MA) announced that it has filed a registration statement for $100 million [IPO]    [PRNewswire, Mar 27, 17]  Akcea Therapeutics announced that the pivotal Phase 3 APPROACH study of volanesorsen met its primary endpoint of reducing triglyceride levels in patients with familial chylomicronemia syndrome (FCS). [Mar 1, 17]

Novartis has agreed with Ionis Pharmaceuticals and its affiliate Akcea Therapeutics to license two experimental cardiovascular treatments in a deal which Ionis said could eventually be worth more than $1 billion.   [Reuters, Jan 6, 2017]

A drug from Ionis Pharmaceuticals has officially become the first effective treatment for spinal muscular atrophy, a progressive muscle-wasting disease that can kill patients from their infant days.     The drug, Spinraza, received [FDA] approval for treating that condition. Generically named nusinersen, Spinraza was developed by Carlsbad’s Ionis and tested along with marketing partner Biogen of Cambridge, Mass. [Bradley Fikes, San Diego Union Tribune, Dec 23, 16]

drug from Ionis Pharmaceuticals shows signs of increasing survival and improving movement in infants with spinal muscular atrophy, according to a study published.   The Phase 2 (midstage) clinical study provides the latest evidence that the medication, nusinersen, alleviates symptoms of the rare genetic disease, which is sometimes fatal.    [Bradley Fikes, San Diego Union Tribune, Dec 5, 16]

Ionis Pharma up 12% [Nov 14, 16]

Ionis Pharma up 22% [Nov 9, 16]

Ionis Pharma up 18% [Nov 7, 16] company released the latest positive results for a drug designed to treat an incurable and sometimes fatal childhood muscle disease. The medication met the primary endpoint in an interim analysis of a Phase 3    [San Diego Union Tribune, Nov 7, 16]

Moving closer to what could be a landmark FDA approval, Ionis Pharmaceuticals and partner Biogen have announced the latest favorable results for nusinersen, their drug for spinal muscular atrophy. In a first, nusinersen showed signs of effectiveness in 13 infants genetically predisposed.  [Bradley Fikes, San Diego Union Tribune, Oct 10, 16]

San Diego County is noted as fertile ground for innovative start-ups[with] local biotech cluster that excels at bringing creative new ideas to market. It all began at UC San Diego and adjacent biomedical research institutions on the Torrey Pines Mesa. .... In the late 1970s, Hybritech (before SBIR) pioneered the use of monoclonal antibodies as diagnostics. Today, Illumina leads the world in developing advanced technology for sequencing DNA and Ionis Pharmaceuticals  leads the pack in using a broad method called antisense to create drugs that alter the effects of targeted genes. ... And this summer, the for-profit Synthetic Genomics (La Jolla, CA; no SBIR) unveiled a potential replacement for the workhorse bacterium E. coli, an engineered bacterium that replicates far faster, speeding up experiments and production of biotech products such as drugs.   [Bradley Fikes, San Diego Union Tribune, Sep 13, 16]

Ionis Pharma up 30% [Aug 1, 16]

Biogen said it would exercise an option to develop and commercialize an experimental genetic muscle-disorder drug after an interim analysis of late-stage data showed patients experienced statistically significant improvement in symptoms.     The drug, nusinersen, was being developed by Biogen in collaboration with Ionis Pharmaceuticals [$75 million license fee], to treat spinal muscular atrophy (SMA), a genetic disease affecting the part of the nervous system that controls voluntary muscle movement.   [Reuters, Aug 1, 16]

Ionis Pharma up 11% [Jul 15, 16]

Ionis Pharmaceuticals down 39% [May 26, 16] after the company said GlaxoSmithKline Plc had scrapped plans to test their heart drug in a late-stage trial two months after [FDA] put a clinical hold on the trial testing the drug, IONIS-TTR, citing safety concerns. [Reuters, May 26, 16]

Ionis Pharma down 11% [Apr 7, 16]

For Isis Pharma history see Isis Pharma

Ionis Pharmaceuticals (fornmerly Isis Pharma) has reclaimed rights to its cardiovascular drug Kynamro, which it had partnered to Genzyme in 2008.  ... The 2008 deal for Kynamro brought Ionis, then called Isis, $325 million and the promise of more once the drug reached the market. It was seen as a major vote of confidence by Genzyme in Isis.  [Bradley Fikes, San Diego Union Tribune, Jan 11, 16]

Ion Optics (Waltham, MA)

Ion Optics got a $4M VC infusion which make a total of nearly $8M toward economic success of its low-cost high-volume device packaging precise wavelength control of infrared. Started in the 90s by an escapee from Spire, Ion has had at least eight Phase 2 SBIRs from a variety of agencies. If the government cared about economic metrics, it would include Ion as a success for getting $8M into a government technology. 

Ion Optics (Waltham, MA) has an optical platform using photonic bandgap technology for controlling infrared emission and absorption wavelengths of a silicon surface. The company got another $2.5M as the opener of a $4M  funding. Infrared gas sensors operate using gases’ unique infrared signatures in the range of 2 to 14 microns. Because each has an individual signature, infrared sensors can conclusively identify and measure a target gas without interference from other gases. Ion Optics’ technology is called SensorChip, a chip that it says will offer the accuracy and reliability of large infrared sensors in the small, inexpensive format of chemical reaction sensors. In effect, it reduces the large, complex conventional infrared sensors to fit on a chip. [Jay Rizoli, Mass High Tech, Jun 9]  Ion Optics started life when Ed Johnson bailed out of Spire, soon thereafter getting seven Phase 2 SBIRs mostly from NSF and NASA. 

Ion optics gets $1.4m. (Jan 12) Ion Optics (Waltham, MA) closed a $1.4M investment for prototype development along its route to commercializing its optical technology platform, an optical-based gas sensor made on silicon wafers with MEMS The Red Herring ( says the funding round was way oversubscribed. The press release says the worldwide market for gas and chemical sensors is $560M, for the sensing elements alone. The worldwide market for emerging applications is estimated at more than 200 million additional units per year, representing an additional $1B in revenues.. Ion Optics started when Ed Johnson jumped out of Spire with high hopes of turning his SBIR-funded materials ideas into something commercial. He has had at least $2M of SBIR since 1996. (Government is slow in posting SBIR awards in public places.)

IonQ (College Park, MD)

Quantum computing firm IonQ (College Park, MD; no SBIR, founded 2016) announced the close of a $55M funding round .... brings its total raised to $77M. The move follows a major milestone for IonQ’s “trapped-ion” technology, which it says offers the most promise for reliable, scalable quantum computing. Recently, the startup built what it claims is the largest programmable quantum computer to date, demonstrating performance benchmarks that no others have yet matched. [DCInno, Oct 21, 19]

IonQ (College Park, MD; no SBIR, funded 2016) is a developer of quantum computing for commercial applications. .. total funding #20M [] recently reported that its prototype computer, using 11 qubits made of ionized atoms, performed more complex calculations with greater accuracy than any rival machine. [Jeanne Whalen, WashPo, Aug 18, 19]

Ion Torrent (Guilford, CT)

454 Life Sciences (no SBIR) was founded by Jonathan Rothberg originally as 454 Corporation, a subsidiary of CuraGen  (while a graduate student at Yale, Jonathan founded CuraGen). For their method for low-cost gene sequencing, 454 Life Sciences were awarded the Wall Street Journal's Gold Medal for Innovation in the Biotech-Medical category in 2005. ...  In late March 2007, Roche Diagnostics announced an agreement to purchase 454 Life Sciences for $155 million.[3]  Roche announced that it will shut down 454, and stop supporting the platform by mid-2016 ...   In 2007 founded Ion Torrent that also commercialized technologies for DNA sequencing that have significantly reduced the cost of sequencing a genome.[wikipedia]    sold Ion Torrent it for $500M which allowed him to ply the ocean on a 130-foot yacht and to indulge high-concept hobbies like sequencng the DNA of math geniuses ...  also founded an incubator 4Combinator to finance companies that combine medical sensors with a branch of AI called deep learning [Anthony Regalado, MIT Technology Review]

[post-merger internal reshuffling is] bad news for Life Technologies’ autonomous Ion Torrent Systems unit, the No. 2 player in the high-speed DNA sequencing industry. And bad news for Ion Torrent is good news for Illumina the unrivaled No. 1 in this fast-emerging and important market. [Luke Timmerman,, Apr 29, 13]

Life Technologies up 8% as Thermo Fisher agreed to buy diagnostics equipment maker Life Technologies in a $13.6 billion deal that will significantly expand Thermo Fisher and establish it as a major force in the emerging personalized medicine market. [Robert Weisman, Boston Globe, Apr 15, 13]    formed in 2008 by the merger of Invitrogen ($4M SBIR) and Applied Biosystems (no SBIR); acquired AcroMetrix (one SBIR) in 2010; acquired Ion Torrent (no SBIR) in 2010; won a $45 million Army contract in 2012.

Life Technologies took a step toward lowering the cost of genetic sequencing and expanding the availability of the revolutionary technology by launching its new Ion Torrent Personal Genome Machine. ... acquired the machine in August when it purchased the device’s creator, Ion Torrent (Guilford, CT, no SBIR), in a $725 million deal. .....  among several, including Illumina of San Diego, that are racing to introduce new ways of sequencing genes that expand the use of the technology  [, Dec 17, 10]

Life Technologies (San Diego, CA) said it will acquire Ion Torrent, (Guilford, CT; no SBIR, founded 2007) that has developed a new way of sequencing genes, in a deal worth as much as $725 million.  [Keith Darcé, San Diego Union Tribune, Aug 17, 10]

Iovance Biotherapeutics (San Carlos, CA)

Iovance BioThera (San Carlos, CA; no SBIR) up 36% [May 16, 19] reaction to new interim data from clinical trials evaluating its tumor-infiltrating lymphocyte (TIL) candidates. The data will be presented at ASCO in Chicago. [Douglas W. House,, May 16, 19]

Iovance Thera up 27% [Jan 25,18] priced its stock sale to raise $150M.

Iovance Biotherapeutics (formerly Lion Biotechnologies, San Carlos, CA; no SBIR, market cap $600M) up 11% [Dec 15, 17] announced that it has selected its Gen 2 manufacturing process for all three Phase 2 trials and for all future TIL clinical development. The protocols for the company’s three existing studies have all been amended to allow for enrollment of new patients with TIL manufactured with the Gen 2 process  [company press release, Dec 15, 17]

Iovation (Portland OR)

Iovation (Portland OR; no SBIR) startup wants to make the Internet a lot safer by making it a little less anonymous. ... $15M in new funding, including at least $10M from Intel Capital. ... The three-year-old company's technology tracks computers, cell phones or other gadgets that visit Web sites. ... uses that information to ensure that only authorized computers access a secure Web site -- even if someone types in a correct password. ...  forecasts $8.5 million in recurring revenue during 2007. The company says it currently tracks 16 million devices online  [Mike Rogoway,, Nov 8]

Iowa Thin Film Technologies (Boone, IA)

Meanwhile, Iowa Thin Film Technologies (Boone, IA)  has released solar-film radios and tents, and it’s now developing opaque BIPV products for roofs. [both company stories by Meredith Sadin, Business 2.0, Dec 05]  ITFT has had at least four Phase 2 SBIRs and a 2005 $3M Army contract for tents with flexible solar cells.   By contrast with XsunX, ITFT's web site talks only about the technology and nothing about the management squad.

iPierian (South San Francisco, CA)

After using its stem cell technology to discover drugs, iPierian (South San Francisco, CA; no SBIR) and its backers are hoping that splitting into two companies (spinout  company, True North Therapeutics) and infusing them with a collective $30 million will bring an Alzheimer’s disease therapy and autoimmune drug to market faster. [Ron Leuty, San Francisco Business Times, Sep 4, 13]

IPG Photonics

IPG Photonics said that its profit almost tripled in the second quarter as revenue surged on increased demand for its laser technology. [Boston Globe, Aug 2, 11]

IPG Photonics is advancing a new laser technology that may do for industrial lasers what the semiconductor chip did for computers, making them smaller, cheaper, and more powerful. .. Costs have plunged from $4,000 a watt to $75.  ... IPG's technology emerged from a Russian lab in 1990, when Valentin Gapontsev, IPG's chief executive, developed a high-power fiber laser by coupling light-emitting semiconductors, known as diodes, with optical fiber. He founded IPG a year later in a Moscow basement, later moving the company's headquarters to Germany and finally to Massachusetts. [Robert Gavin, Boston Globe, May 1]

IQuum ( Marlborough, MA)

IQuum ( Marlborough, MA; $14M SBIR) raised a $1 million debt financing ... has developed a rapid testing platform that can be used to quickly analyze a raw biological sample such as whole blood or plasma. The platform is based on technology developed by the company’s president and CEO, Shuqi Chen, who founded the company in 1999. [Lynette Cornell, Mass High Tech, Jan 3, 11]

iRhythm Technologies (San Francisco, CA)

IRhythm Technologies (San Francisco, CA; no SBIR) with an adhesive chest patch for detecting heart arrhythmias, scored a $17 million Series E round ....  for technology and development, studies that will boost clinical evidence of the patch's effectiveness and expanded sales of the ZIO patch, which has been used by nearly 250,000 patients at more than 800 institutions since its launch in 2011.    [Ron Leuty, San Francisco Business Times, May 22, 14]

start-up iRhythm Technologies (San Francisco, CA; no SBIR) raised $15.1 million in equity sale, the company said in [SEC] filing   ... The company's Zio patch is a cardiac rhythm monitor that can be used for up to two weeks, iRhythm said late last year.  [Chris Rauber, San Francisco Business Times, Apr 8, 13]


Trade wars easy to .... iRobot The maker of the popular Roomba line of robot vacuums launched its latest iteration called the s9 in late May with a starting price tag of $999. Unfortunately, that is also when tariffs on goods imported from China kicked in. iRobot thus had to raise the price of its already-pricey new vac by $100 to compensate, along with similar increases across several of its other models. [Dan Gallagher, Wall Street Journal, Jul 25, 19] ... easy to lower American profits

iRobot down 17% [Jul 24,19] reported lower earnings

iRobot down 23% [Apr 24, 19] after its report of disappointing sales growth in the March quarter .... company said margins would remain pinched until this year’s December quarter. [Bill Alpert, Barron's, Apr 24, 19]

iRobot said it paid $8 million in higher tariffs to bring its Chinese-made robots to U.S. markets as a result of the White House’s newly installed trade policies. The company announced it would be moving some production to a manufacturer outside of China for the first time since 2002. [Brian Dowling,, Feb 8, 19]

Google has formed a collaboration with iRobot, whose disc-like, self-driving Roomba vacuum cleaners have been trundling through rooms for years, sucking up dust while avoiding collisions. The Roomba i7+ model now has sensors and smart mapping software that allow it to construct floor plans for homes as it cleans—a feature that dovetails with Google’s plans to automate household tasks and populate living spaces with coordinated smart devices. [Bernadette Tansey,, Oct 31, 18]

iRobot said it absorbed $5 million in extra costs from U.S. tariffs slapped on its Chinese-made automated vacuum cleaners. President Donald Trump instituted the 10 percent import duties on $200 billion worth of imports from China and threatened to boost the tariffs to 25 percent on Jan. 1. The Roomba maker narrowed its focus to smart-home consumer robotics after shedding its defense and other commercial businesses in 2016. ... After next year, [CEO] Angle said the company could potentially move manufacturing operations out of China to avoid the higher tariffs. [Brian Dowling,, Oct 26, 18]

iRobot loses $250M in market value over Trump tariffs ... iRobot touted sales of its new i7 model, but said the Trump administration's tariffs on vacuums made in China would hurt the company's margins.[Kelly O'Brien, Boston Business Journal, Oct 24, 18]

iRobot up 17% [Jul 25, 18]]

The US Marine Corps just awarded $10 million for a ruggedized "throwable" robot useful in situational assessment in tactical situations. The platform is made by Endeavor Robotics, which was previously known as iRobot's Defense & Security Business Unit. [Greg Nichols., Jun 15, 18]

iRobot announced it reached a settlement with Black & Decker in a patent dispute. Black & Decker agreed to stop selling its home robotic vacuums “for a certain period of time” after it sells its existing inventory, while iRobot agreed to stop pursuing legal action against Black & Decker on this matter.  [Jeff Engel,, Dec 20, 17]

iRobot down 13% [Oct 25, 17]

iRobot down 16% [Sep 13,17]

iRobot up 21% [Jul 26, 17]

iRobot announced that it has signed a definitive agreement to acquire privately-held Robopolis SAS based in Lyon, France.  .... for $141 million   [company press release, Jul 25, 17]

iRobot down 10% [Jun 27,17]

iRobot announced new features intended to make its Roomba vacuums “smarter,” continuing the company’s sharper focus on consumer robotics and its goal of enabling the connected home.  .... is adding Wi-Fi connectivity to its cheaper Roomba 600 and Roomba 800 series of autonomous vacuums, a capability that was previously only available in its most expensive line of vacuums, the Roomba 900 Series   [Jeff Engel,, May 2, 17]

iRobot up 16% [Apr 26, 17]

IRobot down 13% [Feb 9, 17] said it predicted a weaker-than-expected earnings per share this year.  [David L. Harris, Boston Business Journal, Feb 9, 17]

iRobot up 11% [Oct 26, 16]

Executives from 11 New England robotics firms will travel to several cities in China later this month on a trade mission aimed at sparking business deals and more technology collaboration between the U.S. and China.  ...  large, well-established firms, such as iRobot and Vecna Technologies (Greenbelt, MD; $11M SBIR).  also small, young startups, including Soft Robotics (Cambridge, MA; no SBIR) and GreenSight Agronomics  (Boston, MA; no SBIR, over a decade of experience fielding these systems for customers including the Department of Defense and NASA).   [Jeff Engel,, Oct 14, 16]

At iRobot , the wars are overThe company first made a name for itself by building remote-controlled military machines that picked through the rubble of the World Trade Center after 9/11 and disarmed Taliban booby traps in Afghanistan.  But in 2002, iRobot began selling a robotic home vacuum cleaner called Roomba, and today those home robots generate nearly all the company’s revenues. Shareholders noticed, and so did management.   And so in February, peace broke out at iRobot. In a deal worth up to $45 million, the company sold its defense and security division to the private equity firm Arlington Capital Partners as a new company, Endeavor Robotics.  [Hiawatha Bray, Boston Globe, Aug 18, 16]

IRobot took one more step toward its overarching vision to become a leading "connected home" company when it became an Amazon Web Services customer this past quarter.  [Sara Castellanos, Boston Business Journal, Jul 27, 16]

New Vacuum CompetitionNext week, vacuum powerhouse Dyson brings its first bot to the U.S., the 360 Eye, which comes closer than any before to packing the suction of an upright into an adorable self-navigating sidekick. It’s raising the bar for iRobot’s iconic Roomba, whose 980 bot boasts 50% more cleaning performance than its previous model.  ... Robots are clearly the future of vacuum cleaners—they already account for 20% of the money spent globally on vacuums that cost more than $200.  [Geoffrey A. Fowler, Wall Street Journal, Jul 27, 16]

After a contentious proxy fight between robotics firm iRobot and investor Red Mountain, a majority of shareholders sided with iRobot  [Sara Castellanos, Boston Business Journal, May 26, 16]

IRobot has a new floor-washing robot called the Braava jet. Please don’t call it an upgraded Scooba—it’s very different, and it’s lightweight and relatively cheap ($199). This is the first new robot from the company since it divested its defense and security business to focus on connected-home robotics.  [Gregory Huang,, Mar 16, 16]

iRobot down 14% [Feb 11, 16]

iRobot announced that it has signed a definitive agreement to sell its Defense and Security business for up to $45 million in total consideration, including a contingent payment based on achieving certain milestones. [company press release, Feb 4, 16]  The business will operate as a newly created independent company, according to a release. The company, which will be renamed, will be the largest independent provider of ground-based robot to DOD.  [David Harris, Boston Business Journal, Feb 4, 16]

iRobot said it may purchase up to 1 million shares of iRobot common stock [in 2016] beginning Jan. 4. [Boston Business Journal, Dec 31, 15]  More cash than investment opporunity.

Red Mountain Capital Partners LLC raised the pressure on iRobot by disclosing plans to seek board representation at the maker of the Roomba robotic vacuum cleaners. ....  Red Mountain has been urging iRobot to shed its unprofitable peripheral businesses and focus on home-cleaning and maintenance robots, which accounted for 94% of sales in the nine months ended Sept 26.   Responding, iRobot [said] it was “focused on allocating capital” to the best opportunities for its shareholders. ....  wants iRobot to sell its unit making defense-related robots and stop investing in an emerging “remote presence” business that aims to use robots to help people participate in remote meetings with colleagues or doctors.   [James Hagerty, Wall Street Journal, Dec 1, 15]

iRobot's most expensive vacuum robot was unveiled in September, and the reaction, according to CEO Colin Angle, has been "tremendous." ...   that customers' enthusiasm for the Roomba 980, which retails for $899 [about $200 more expensive than its predecessor], has exceeded expectations. ... has "100 times more software in it" than any of iRobot's prior robots, Angle said    [Sara Castellanos, Boston Business Journal, Oct 21, 15]

CyPhy Works (Danvers, MA; $700K SBIR) announced a $22 million Series B round ...   [FAA] decision to green-light commercial drone use earlier this year appears to be spurring the deployment of even more capital into the fledgling sector. ...   founded by iRobot co-founder Helen Greiner.  ...   Other [VC recipients] in this sector include 3D Robotics (Berkeley, CA; no SBIR), which has raised more than $90 million, and Airware (San Francisco, CA; no SBIR), which has snagged more than $40 million. [Jeff Engel,, Oct 13, 15]

After spending more than $100 million in [R&D], iRobot has debuted its smartest vacuum robot.  The Roomba 980 can navigate through an entire level of a house while simultaneously mapping it. ...  The new Roomba is also one of the main reasons that iRobot acquired its rival, Evolution Robotics, (Pasadena, CA; no SBIR) for $74 million in 2012.  [Sara Castellanos, Boston Business Journal, Sep 16, 15]

The world’s most successful home robot, the Roomba [by iRobot], is getting some new skills. The robotic vacuum cleaner is gaining a camera and image-processing software that will let it find its way around an area as it cleans. [Will Knight,, Sep 16, 15]

U.S. regulators gave iRobot technical clearance to make and sell a robotic lawn mower. ...  Automated grass-mowers have spread across Europe in recent years. In the US, iRobot told the FCC its competitors only offer hands-free mowers that require underground fences or other elaborate setups. IRobot's stake design, however, required a waiver from the Federal Communications Commission to make sure that transmissions between its machines and the antennas wouldn't interfere with other devices using the same frequencies.   [Alina Selyukh, Reuters, Aug 12, 15]

An activist investor bought 5.1% of iRobot and wants to drive the company direction toward its high-growth home robots business by selling or shutting down its defense and security business and discontinuing its telepresence robot business. [David Harris, Boston Business Journal, Apr 21, 15]

iRobot typically spends roughly 12% of its annual revenue on research and development. ...[which means] over $67 million per year [Steve Symingtton, Motley Fool, Jan 26, 15]

Last week, iRobot released a new Android piloting system called uPoint Multi-Robot Control. Defense One tested it on site and found it fast, intuitive and not unlike an iPad-based first-person-shooter video game.  [Patrick Tucker, Defense One Tech Trends 2015,   Dec2014]

In Forbes 2014 list of 100 best small companies: iRobot, Neogen (Lansing, MI; $1M SBIR).

iRobot up 14% [Oct 22, 14] reported that sales for the third quarter, which ended Sept. 27, were $143.5 million, compared with $124.5 million for the same quarter one year ago. Analysts were expecting revenue of $134.3 million   [Mass High Tech, Oct 22, 14]

iRobot said that it received a $7.6 million order from the U.S. Navy for robot upgrades and spare parts. ... The same U.S. Navy division also awarded iRobot a three-year indefinite delivery/indefinite quantity (IDIQ) contract with a total ceiling of $13 million   [David Harris, Boston Business Journal, Oct 20, 14]

Machines who think.  iRobot introduced a new operating system that it says enhances the ability of robots aimed at the military to think for themselves when navigating terrain tougher than the living-room rug.  ...   replaces a joystick with an Android app that allows users to steer its robots on a tablet by pointing a finger. It includes technology that dovetails with the Pentagon’s push for robots that can steer and perform tasks themselves through tricky environments such as urban conflict zones or the sites of natural disasters.... [DARPA] has focused on developing wheeled or tracked robots that can pick their way through the debris of disaster sites and perform simple tasks such as moving rubble or closing a valve. The agency is sponsoring a robot challenge to test prototypes developed by private companies and universities in a simulated disaster area, replicating a contest it held for self-driving cars. But by the time it holds the final next June in California, Darpa said it only expects the robots to have the competence of a two-year old child.  Google which has been investing heavily in robotics, pulled Schaft Inc. from the Darpa contest in June after acquiring the Japan-based company.    [Doug Cameron, Wall Street Journal, Oct 8, 14]

Several military robots made by iRobot will be delivered to Canada by spring of next year as part of a $9.6 million contract with the Canadian Department of National Defense   ....  capable of bomb disposal, surveillance and reconnaissance, as well as real-time detection and identification of chemical, biological, radiological and nuclear materials   [Sara Castellanos, Boston Business Journal, Sep 8, 14]

Success breeds competition.  Dyson (UK) just announced its entry into the robot business, facing off against iRobot's Roomba early next year in Japan.  ...  the Dyson 360 Eye, a camera-equipped, tank-treaded robot with a lithium-ion battery and one of Dyson's signature digital vacuum motors. ....  iRobot CEO Colin Angle fired off a good-natured response: "Leading traditional vacuum companies are realizing what iRobot has known since our beginning 25 years ago—that many things are best left to a robot, and vacuum cleaning is one of them," reads his statement. "We've long anticipated that our success would inspire others to do the same and believe that good competition will help grow the industry as a whole."    [Wilson Rothman, Wall Street Journal, Sep 5, 14]

RE2 (Pittsburgh, PA; $4.6M SBIR) said it supplied the manipulator arm for a new product by iRobot for the defense and securities sectors.  .... includes a camera for the FirstLook robot from iRobot.  FirstLook is a compact, multi-mission lightweight robot that provides immediate situational awareness, performs persistent observation and investigates dangerous and hazardous materials  [Patty Tascarella, Pittsburgh Business Times, May 12, 14]

iRobot down 10% [Apr 23, 14]

iRobot announces $50M stock buyback starting May 1

iRobot up 11% [Feb 11, 14] 

iRobot up 12% [Feb 6, 14]

Two months after debuting a redesigned version of its popular Roomba home-cleaning robot, iRobot  announced that it has now "reinvented" its floor-scrubbing robot, Scooba, as well.  ....  [says] is three times more effective at cleaning floors than previous Scooba models, thanks to technology based on industrial-style cleaners. [Kyle Alspach, Boston Business Journal, Jan 6, 14]

iRobot up 17% [Dec 17, 13]

Picked in Forbes's top 100 small companies: Synaptics $340K SBIR ; Myriad Genetics one SBIR; iRobot  $7.5M SBIR; Landec  $1.6M SBIR.

Helen Greiner came up with the Roomba vacuum cleaner robot in 2002.  Born in London and the daughter of Hungarian refugees, she was a fan of Star Wars’ R2D2.  Her family moved to the U.S. and she went to MIT—naturally!—and formed a company, iRobot, with two other MIT graduates.  She initially focused on research and military robots, before turning to the consumer market.  She said her objective is “A robot in every office building.  A robot in every home that has a computer.  We will change the world with this technology.”   [Doug Bandow, Americans Are Living Better Then They Have At Any Point In Human History, Forbes. Nov 19]

From Boomba to Roomba.  iRobot debuted a redesigned version of its popular Roomba home-cleaning robot — and CEO Colin Angle says the new technology that's part of it represents the "most significant advancement in vacuuming since the robot." The company said the Roomba 880 eliminates a mainstay of vacuuming, bristle brushes. The new Roomba instead uses technologies that iRobot calls AeroForce Extractors, which break down debris and lifts dirt — ultimately providing 50 percent better pickup of dirt, debris and hair than the previous Roomba. [Kyle Alspach, Boston Business Journal, Nov 13, 13]  The IEDs of Iraq and Afghanistan supplied iRobot with a steady flow of breakneck development and sales revenue while commercial markets developed for robotic cleaning.

Neato Robotics  (Newark, CA; no SBIR), a startup that competes with Roomba (by iRobot) for automatic vacuum cleaners, disclosed that it raised $14 million in new funding ......  says that its cleaning robots are better than Roomba because they automatically map a room before starting and are laser-guided to sweep floors in overlapping lines.   [Cromwell Schubarth, Silicon Valley Business Journal, Aug 13, 13]  Commercial success induces competitors.

iRobotdown 13% [Jul 24, 13]

iRobot filed suit against five German companies to protect its intellectual property, the company said  [Patricia Resende, Boston Business Journal, Jul 1,13].

iRobot collected an indefinite-delivery/indefinite-quantity, firm-fixed-price contract worth up to $30 million for the supply of “robotic systems and spare parts” to the U.S. Army. .... after iRobot received contracts worth $7.2 million in May to provide unmanned ground vehicles to the government of Brazil    [Patricia Resende, Boston Business Journal, Jun 17, 13]

iRobot will soon launch a new robot to the market. ....  said it is working with Cisco to bring Ava 500, a video collaboration robot that enables users to remotely view and interact with others thousands of miles away, to market.  [Patricia Resende, Boston Business Journal, Jun 10, 13]

iRobot  won contracts worth $7.2 million to provide unmanned ground vehicles to the government of Brazil as the company prepares for a visit from the Pope this summer, the FIFA World Cup soccer tournament next year, and the 2016 Olympics Summer Games.  ... The 510 PackBot is a tactical mobile robot for missions including reconnaissance, route clearance, hazardous materials detection and bomb disposal. It is the same robot that was used to inspect the car allegedly hijacked by the Boston Marathon bombing suspects   [Don Seiffert and Pat Resende, Mass High Tech, May 15, 13]

iRobot up 14% [Apr 24, 13] after raising its full-year financial expectations for both revenue and profit based on the first three months.  [Boston Business Journal, Apr 24]

Martin Buehler, iRobot’s former director of research -  “Robot Guy” - touted the disruption that robotics companies in New England have made, such as Rethink Robotics (no SBIR),  iRobot  ($8M SBIR), Harvest Automation  (no SBIR), Kiva Systems (no SBIR; acquired by, Symbotic (no SBIR) and, of course, his company, Vecna Technologies (Greenbelt, MD; $8.5M SBIR). Buehler showed how iRobot’s devices are used in defenseapplications as well as cleaning floors, pools and gutters. He also showed how Harvest’s robots are used in labor-intensive agriculture applications. The audience was amazed by Kiva’s robots driving efficiency, and how the robots have replaced the “runners” who fill product orders.  [Patircia Resende, Boston Business Journal, Mar 7, 13]

iRobot down 13% [Feb 7, 13] reported full-year revenues that were down more than 6 percent from last year, and a net income less than half of what it saw last year, at the same time that it set a high bar for its home robots business over the coming year.... as expected, the decline in Defense & Security revenue resulted in lower total company revenue and profit [Don Seiffert, Boston Business Journal, Feb 7, 13]

iRobot is diving into the deep end, with a new machine that automatically cleans swimming pools. Among the new products being introduced by the robot-maker is a submersible named The Mirra 530, priced at $1,299, that automatically calculates the size and shape of a pool, then scour its floor and sides to remove algae and bacteria. [Boston Globe, Jan 4, 13]

iRobotis cleaning house at Gillette Stadium. Along with splashing its logos on scorecards throughout the stadium, and sending employees to demonstrate its FirstLook, PackBot and SUGV robots to fans, the company has teamed up with the New England Patriots to add a little comedy to the relationship. [Patricia Resende, Boston Business Journal, Dec 19, 12]

War's over, demand plummeting.  iRobot down 19%, which made a bundle on Iraq, after the company announced that it’s expecting lower-than-expected 2012 revenues, and said it’s closing its Durham, N.C.-plant and laying off 13 percent of its workforce. [Mass High Tech, Oct 24, 12]

iRobot will buy robot maker Evolution Robotics (Pasadena, CA; no SBIR)  for $74 million. ... adds a new line of floor-cleaning robots to iRobot’s suite of consumer and military robots. Evolution Robotics’ Mint, which is designed to Every new administration, not excluding ourselves, arrives with bright and benevolent ideas of using public money to do good.  The more frequent the changes of government, the more numerous are the bright ideas; and the the more frequent the elections, the more benevolent they become.  --- Winston Churchill, 1927   Can you think of any bright ideas for government that would benefit you, and by extension, the entire American economy? automatically clean wood floors, sell for about $200.  [Michael Farrell, Boston Globe, Sep 18, 12]

iRobot will buy robot maker Evolution Robotics (Pasadena, CA; no SBIR)  for $74 million. ... adds a new line of floor-cleaning robots to iRobot’s suite of consumer and military robots. Evolution Robotics’ Mint, which is designed to Every new administration, not excluding ourselves, arrives with bright and benevolent ideas of using public money to do good.  The more frequent the changes of government, the more numerous are the bright ideas; and the the more frequent the elections, the more benevolent they become.  --- Winston Churchill, 1927   Can you think of any bright ideas for government that would benefit you, and by extension, the entire American economy? automatically clean wood floors, sell for about $200.  [Michael Farrell, Boston Globe, Sep 18, 12]

iRobot up 18%  [Jul 25, 12]

RoboDoc< Military and consumer robot manufacturer iRobot will unveil a new product intended for the health care industry as it diversifies its product line in preparation for looming defense cuts. The 5-foot-4-inch, 140-pound “telemedicine” robot will be produced in partnership with InTouch Health of Santa Barbara, Calif., a maker of in-hospital robots, and is designed to help patients with health emergencies get more rapid treatment from specialists — especially at night, when hospital staff levels are lower, the company said.  [Dan Adams, Boston Globe, Jul 24, 12]

iRobot landed a $7.7 million contract with the U.S. Naval Sea Systems Command. ...upgrading its iRobot Aware 2 and delivering advanced sensors for nearly 250 fielded robots  [Mass High Tech, Jul 17, 12]

Despite predictions of a decline in military revenue this year, iRobot has announced its second order from the U.S. Army in the past week - this time a $12.6 million contract for 68 portable robots used to gather information in the field, as well as spare parts. [Don Seiffert, Mass High Tech, Jun 4, 12]

iRobot announced the receipt of two orders from the U.S. Army’s Robotic Systems Joint Program Office, totaling $6 million, for the delivery of spare parts for iRobot 510 PackBot robots  [Don Seiffert, Mass High Tech, May 29, 12]

iRobot is expanding its line of Scooba floor washing Robots. The compact Scooba 230 is being introduced to such markets as Europe, and it was developed to meet the need for a robot that cleans tight spaces, such as in bathrooms and kitchens. The company is also upgrading its iRobot Scooba 390, a floor washing robot designed for bigger jobs. The Scooba 390 has a 30 percent longer battery life than its predecessors.  [Chris Reidy, Boston Globe, Mar 15, 12]

Civil markets call.   [iRobot CEO] Angle said that a tap on Ava’s tablet screen could dispatch it to the right room and free doctors from the more mundane controls. Its mapping system, based partly on Microsoft’s 3-D motion sensor for the Xbox, could enable the robot to hustle to the patient’s bedside without slamming into obstacles. ... Such civil narkets call to fill a military spenddown gap.    As sales of its vacuums and military robots grew, iRobot’s earnings shot up to $40 million last year from $756,000 in 2008 ,.... But with pressure mounting for budget cuts at the Pentagon, Mr. Angle told analysts that the company’s military sales could drop by as much as 20 percent this year.  [Christophed Drew, New York Times, Mar 2, 11]

Goodbye, profits of war.   iRobot down 34%  announced its quarterly earnings, and the stock price plunged after the company gave a lower than expected guidance for 2012.  [, Feb 9, 12] War against IEMs is over as drones replace boots.  the company warned of possible losses as decreases in US defense spending reduce demand for its line of military robots.  [Hiawatha Bray, Boston Globe, Feb 9, 12]

iRobot will make a $6M investment in InTouch Health (San Diego, CA; no SBIR) , a telemedicine company. [Julie Donnelly, Boston Business Journal, Jan 31, 12]

iRobot up 17% [Oct 26, 11]

War was good business.  iRobot  laid off 8 percent of its work force, including 44 jobs in Massachusetts, because of anticipated cutbacks in government defense spending.  [Boston Globe, Oct 26, 11]

iRobot up 17% [Oct 4, 11]

iRobot received an $11 million order from the US Army for 70 of its battlefield robots and spares. [Chris Reidy, Mass High Tech, Oct 3, 11]

iRobot  down 10% [Oct 3, 11]

iRobot said it has received a five-year, $60 million contract from the US Army’s Robotic Systems Joint Program Office. [Chris Reidy, Boston Globe, Sep 29, 11]

iRobot is introducing a new version of the Seaglider, an unmanned underwater vehicle that can be described as a seafaring robot. The updated design of the Seaglider allows for increased payloads and additional sensors. The Seaglider has been used by both government agencies and oceanographers to collect such research data as water temperature and salinity. [Chris Reidy, Boston Globe, Sep 20, 11]

iRobothas received notice from The Boeing Co. that it is partially terminating its subcontract for the 320 SUGV robot, which was first awarded in 2004. ... the Army will terminate the contract “for convenience” of Sept. 30, ..... While the initial award in 2004 for the Small Unmanned Ground Vehicle for the U.S. Army’s Future Combat Systems (FCS) program was for $32 million, the total has exceeded at least $70 million since then. [Rodney Brown, Mass High Tech, Sep 6, 11]

iRobot said it is rolling out the latest version of its robotic Roomba vacuum cleaner in Europe. ... According to the company, its line-up of home robots account for about 60 per cent of its sales, and much of those sales come from outside the United States; iRobot also makes robots for military and law enforcement use. [Chris Reidy, Boston Globe, Sep 6, 11]

iRobotsaid it has received a $21 million order from the Naval Sea Systems Command for the delivery of more that 100 robots that can perform bomb-disposal operations and other dangerous missions. [Boston Globe, Aug 23, 11]

iRobot up 10% [Aug 11, 11] said it is exploring ways to develop robots that can be used in hospitals and that can also perform health care-related tasks. In a press release, iRobot said today that it has signed a joint development and licensing agreement with InTouch Health, a California company focused on telemedicine.[Chris Reidy, Boston Globe, Jul 20, 11]iRobot bumped up a credit line with Bank of America from $40 million to $75 million, and extended it for two years.[Mass High Tech, Jul 15, 11]

iRobot said it has received a $7.4 million order from the US military for some of its small unmanned ground vehicles [Boston Globe, Jun 16, 11]

iRobot said it has received a $14.1 million order from the Naval Systems Command. The order is part of a larger contract for battlefield robots.  [Boston Globe, Jun 3, 11]

iRobot said that it has teamed up with Google to create Android applications for its iRobot Ava mobile robotics platform. ... Autonomous navigation, mapping, and 3D picture taking are among the app possibilities for Ava, iRobot said.  [Boston Globe, May 12, 11]

iRobot, the only public company that focuses purely on robotics, is getting attention from investors indicates that this young industry is becoming more mainstream. ...  "No one has ever made money with robots before," said 43-year-old Chief Executive Colin Angle. "But ours create more value than they cost to build." ...  a company that teetered on the edge of survival for its first 15 years. Founded in 1990 by Angle, MIT Professor Rodney Brooks and graduate student Helen Greiner, the company's mission was initially vague: to make practical robots that could be useful in everyday lives.  [Alena Semuels, LA Times, Apr 23, 11]

home robots - dominated by vacuum cleaners - make up 55 percent of the company's revenue and are part of the reason iRobot is on a tear. Shares are up 43 percent since the start of the year, and the company earned a profit of $26 million on sales of $401 million last year,  ... IRobot is one of only two companies that provided robots to the military that have actually ended up on the ground, said Barbara Coffey, managing director at Brigantine Advisors, an investment research company. And the contracts keep coming in.  [Alana Semuels, LA Times, Apr 21, 11]

iRobot said it has received a $7.6 million order from the US Army for 50 of its tactical mobile robots and spare parts.  [Boston Globe, Apr 21, 11]

In [Japan] of break-dancing androids and artificially intelligent pets, nuclear cleanup crews on the tsunami-ravaged northern coast are depending on U.S.-made robots [by iRobot] to enter damaged reactor units where it is still too dangerous for humans to tread. ...  to measure radiation levels, temperatures and other conditions inside the reactors. ... The company was lending the two PackBots for free  [Jacob Adelma, AP, Apr 18, 11]

iRobot signed a four-year, $230 million contract to order bomb-disposal and reconnaissance robots and parts for the U.S. Navy [Mass High Tech, Apr 14, 11]

iRobot up 13% [Apr 13, 11]

A week after the massive earthquake and tsunami that devastated much of Japan, a truck left the headquarters of iRobot. Its cargo: four military robots, two of them prototypes. IRobot engineers had outfitted the robots with special modifications that could help the Japanese gain control of the Fukushima Daiichi nuclear reactors or conduct rescue operations in their shattered cities. Japanese government officials and relief agencies hadn’t asked for the robots, but the company saw no reason to wait for a request. ... “We’re standing by to see how the Japanese may seek to employ them,’’ Trainer said ...  Japan is a world leader in robotics. But Trainer said that the country’s top robotics firms mainly build stationary industrial machines for use on assembly lines rather than mobile rescue or surveillance robots.  [Hiawatha Bray, Boston Globe, Mar 26, 11]

iRobot said that it is sending four of its military robots to Japan to help first responders in the earthquake and tsunami relief effort  [Mass High Tech, Mar 21, 11]

iRobot said it has received international orders totaling $4.4 million in the first quarter of 2011 for the delivery of 27 iRobot 510 PackBot tactical mobile robots and spare parts. [Boston Globe, Feb 7, 11]

iRobot  up 12% [Jan 21, 11]

iRobot is introducing a tiny new robot designed to perform one of the more unpleasant household tasks: washing the bathroom floor.  ... claims the Scooba can neutralize up to 97 percent of common bacteria and -- unlike the old-fashioned mop and bucket -- never reuses dirty water. ...  available in the spring  [AP, Jan 3, 11]

iRobot said it has received a $14 million order to deliver software and spare parts for the PackBot robots that the Army uses for such missions as bomb disposal.  [Boston Globe, Oct 7, 10]

iRobot won a $20.3 million order for 125 PackBot Man Transportable Robotic System (MTRS) robots from the Naval Sea Systems Command  [Mass High Tech, Aug 5, 10]

Blobbot   DARPA giving $3.3m to iRobot  for the robot was that it had to fit through an opening half its full diameter. .... blob-like Chembot, which moves by deforming one side. To achieve this, iRobot’s engineers used a concept called “jamming”, which takes advantage of the fact that some particulate materials are quite stiff when compressed but, given space, flow like liquids  [The Economist, Jun 12, 10]

iRobot said its Seaglider Unmanned Underwater Vehicle, or UUV, is being used as a platform to collect ocean data in an effort to monitor the recent Gulf of Mexico oil spill.  [Boston Globe, May 25, 10]

iRobot up 10% [May 10, 10]

iRobot up 33% [Apr 29, 10] on a strong earnings report

Companies to Watch in personalized medicine. Affymetrix, Life Tech, Illumina, Helicos Biosciences, Metabolon.  Among the fifty most innovative:  A123 Systems, American Superconductor, Alnylam, Illumina, iRobot, Novomer, BIND Biosciences.  [MIT Tech Review, M/A10]

iRobot announced that it has delivered its 3,000th PackBot tactical mobile robot  [Boston Globe, Feb 17, 10]  War has been great for business.

Harvest Automation (Groton, MA; no SBIR) raised a $4 million tranche of a Series A round of funding, according to a company official. ... founded by ex-iRobot Corp. employees .. developing robots for materials handling, though it’s still stealthy about specific uses markets  [Mass High Tech, Jan 8, 10]

iRobot up 17% [Oct 22, 09]

iRobot reports it has landed $6.1 million from the U.S. Army for spare parts for robots. [Mass High Tech, Sep 8, 09]

iRobot  said that it has received an order for $35.3 million from the US Army TACOM Contracting Center for more of the company's PackBot battlefield robots.  [Chris Reidy, Boston Globe, Sep 2, 09]

iRobot  said today that it has received a $5.1 million order from the US Army for more of its battlefield PackBot robots and spare parts  [Boston Globe, Aug 12, 09]

iRobot said it has been awarded a $13.5 million contract from the Naval Sea Systems Command.  [Boston Globe, Aug 10, 09]

Robots are smart, tireless and effective--and over the last two years they've cut our spending on household help by 80%. My thanks to the Pentagon for helping fund development of the technology for bomb disposal and such. ... People pushing vacuums and mops aren't going to keep getting smarter, cheaper, faster and more reliable, but iRobots certainly are. Mass production is slashing the cost and boosting the capabilities of high-power semiconductors and motors that control the flow of power to the wheels of hybrid cars. ...  The prospect of new payroll taxes will certainly accelerate automation  [Peter Huber, Forbes, Aug 24, 09]

iRobot down 15% [Jul 23, 09]

iRobot down 10% [Jul 8, 09]

Roomba, made by iRobot, which has sold more than 3m of the frisbee-sized vacuuming robots. The latest model, the fifth incarnation of the Roomba, has more sensors and cleverer software than its predecessors. Press the “Clean” button and the robot glides out of its docking station and sets off across the floor. [The Economist, Jun 6, 09]

iRobot said it has received a $16.8 million order from the US Army for more of the company's battlefield robots.  [Boston Globe, May 7, 09]

iRobot  up 12% [Apr 29, 09]

iRobot   up 19% [Apr 23, 09]

iRobot up 11% [Mar 12, 09]

iRobot received a $7.8 million order from the US Army for 90 of its PackBot 510 military robots. The PackBots are used by soldiers in Iraq and Afghanistan for reconnaissance and bomb disposal. [Boston Globe, Feb 11, 09]

iRobot said that it has received a $5.5 million order from the US Army for its PackBot battlefield robots.that calls for the delivery of 72 iRobot PackBot 510 with FasTac Kit robots, spare parts, and repairs.  "This is the eighth order under the $286 million Indefinite Delivery/Indefinite Quantity (IDIQ) xBot contract," [Boston Globe, Jan 30, 09]

iRobot said it unveiled the second generation of its iRobot Looj Gutter Cleaning Robot at the International Consumer Electronics Show in Las Vegas [Boston Globe, Jan 8, 09]

iRobot down 11% [Dec 9, 08]

iRobot down 13% [Dec 1, 08]  On a stock bloodbath day

iRobot reports it has landed $4.4 million in [six SBIR] grants from the Army and Navy. [Mass High Tech, Nov 18, 08]

iRobot up 17% [Nov 21, 08]

Porkotic.   IRobot has been given $2 million worth of Congressional support to improve development and production of its Warrior 700 robot for combat areas. [Mass High Tech, Nov 12] As if all that military procurement for Iraq weren't enough to satisfy any hunger for small business success.

iRobot said it has opened its first retail kiosk. The kiosk, which will be open at Burlington (MA) Mall through mid January, will offer direct and online sales of such home robot products as the Roomba Vacuum Cleaning Robot, the Scooba Floor Washing Robot, the Looj Gutter Cleaning Robot, the Dirt Dog Shop Sweeping Robot, and the Verro Pool Cleaning Robot, the company said in a press release. [Boston Globe, Nov 8, 08]

War is Great for Business.  iRobot got a $3.7 million order to provide 17 customized PackBot Man Transportable Robotic System robots, due by the end of January next year.   ...part of an existing Indefinite-Delivery/Indefinite-Quantity contract that could result in up to $264 million in robots, parts, services and training. With this latest order, NAVSEA has placed about $102 million in orders. [Kevin Bullis, Mass High Tech, Oct 27, 08]

iRobot up 11% [Oct 23, 08] after it swung to a third-quarter profit on a 45% revenue increase  [Wall Street Journal, Oct 24]

iRobot down 10% [Oct 22, 08]

iRobot down 11% [Oct 21, 08]

iRobot said it got a $2.1 million order for spare parts and repairs from the Army [Boston Globe, Oct 17, 08]

iRobot up 20% [Oct 10, 08]

iRobot down 10% [Oct 9, 08]

The Army awarded iRobot a $3.8 million R&D contract for the delivery of two iRobot Warrior 700 platforms [Mass High Tech, Oct 2, 08]

The Army gave iRobot a combined $19.1 million dollars under its existing contract for the xBot systems  [Mass High Tech, Sep 25, 08]

iRobot down 12% [Sep 22, 08]

iRobot agreed to buy Nekton Research (Durham, NC; $4M SBIR, 24 employees), an unmanned underwater robot and technology company...  for $10M+.  [Boston Globe, Sep 9, 08]  Nekton has grown into an aquatic robotic power with customers that include defense agencies. ... iRobot already gets about 45 percent of its sales from the military and industrial segment. ...  traces its history to Duke University, where Wainwright was a biology professor. He wanted to understand how fish swim. [Jonathan Cox, Raleigh News & Observer, Sep 9, 08]

iRobot has been awarded a contract under which the US Army could order up to $200 million in military robots, spare parts, training, and repair services over the next five years.  [Boston Globe, Sep 2, 08]  And co-founder Rodney Brooks, who started iRobot in 1990 with two former MIT students, said he is giving up the part-time position to focus on his new venture, Heartland Robotics, a Cambridge company that will also develop robots, but not compete with iRobot.  [Boston Globe, Sep 2, 08] War has been really good to iRobot.

iRobot announced it has received an additional Army order totaling $17.5 million for robots that can scout battlefields and dispose of bombs. [Boston Globe, Jul 25, 08] The fortunes of war.

iRobot may dust off plans for an oil-industry robot as it considers adding a third division to diversify into industrial markets, two of its cofounders said. [Boston Globe, Jul 5]

iRobot up 13% [Jun 25, 08]

DARPA and the Army Research Office have given iRobot a $3.3 M, multi-year contract to create Chemical Robots for use in unmanned urban search and rescue and reconnaissance work [Mass High Tech, Jun 17,08] to "develop a soft, flexible, mobile robot that can identify and maneuver through openings smaller than its actual structural dimensions" to perform tasks "within complex and highly cluttered environments," iRobot said. [Boston Globe, Jun 18]

iRobot  said that it signed a licensing agreement with the University of Washington that "will help our robots conquer new underwater frontiers."  ... to commercialize Autonomous Underwater Vehicle, or AUV, Seaglider technology previously supported by [ONR and NSF].  [Chris Reidy, Boston Globe, Jun 10]  Because iRobot is now a public company, it cannot afford to play the pretend commercialization game to get SBIR money for endless R&D.

iRobot got another $22M in Army robot orders. [Mass High Tech, May 23, 08]

iRobot down 11% [May 1, 08]

War is good for business.  iRobot got a $6 million deal to supply the Army unmanned robots which ups iRobot's take to $63M.  BTW: what is a manned robot?

The editors of Baseline [magazine, Mar 31] identify the companies that have had the most disruptive impact in their industries by leveraging technology. Of the 25 most disruptive the only SBIR company was iRobot. If SBIR really cared about disruptive technology, how many would there have been? Remember that for all its hype, SBIR is miniscule on the scale of US R&D technology investment and completely out of touch with disruptive markets.

Just in time for spring, iRobot revealed an expanded lineup of home robots designed to clean pools of leaves, dirt, and other debris.  [Boston Globe, Mar 5]

iRobot reports it has invested in a California company from which it is also licensing 3-D camera technology. The robot-maker is licensing Advanced Scientific Concepts (Santa Barbara, CA; $12M SBIR)  3-D flash laser radar, dubbed "Ladar," technology. The Ladar camera emits a billionth-of-a-second long, eye-safe laser burst to create three-dimensional images of a landscape. The technology has mapping and navigation applications for robots, iRobot said. The deal grants iRobot exclusive rights to develop and market the Ladar technology for unmanned ground vehicles and robots in exchange for future commitments to purchase units. The company will demonstrate the technology for military customers this year, with product delivery next year, iRobot said. In a separate deal, iRobot also made a minority investment of $2.5 million for preferred stock  [Mass High Tech, Jan 23, 08]

iRobot said the Army has accelerated testing schedules for its program to develop a small unmanned ground vehicle, or SUVS.   The updated plan calls for iRobot to deliver 25 of these robots by April  [Boston Globe, Jan 17]

iRobot settled its lawsuits against Robotic FX accused of stealing intellectual property. Robotic conceded it infringed two iRobot patents. [Boston Globe, Dec 22] The Army had already switched the $268M procurement contract to iRobot.

iRobot says it got a $286M contract from the US Army [Dec 18, 07]

The Army has canceled a $280 million contract with a Chicago-area robot maker that is being sued by iRobot Corp. [Boston Globe, Dec 16].

iRobot announced upgrades to its PackBot battlefield robot. The company unveiled PackBot with Mapping Kit, a platform with a new payload designed to help warfighters deftly manage the dangerous tasks of search, surveillance, and reconnaissance missions [Boston Globe, Dec 12, 07]

A federal judge in Boston has issued an injunction against a Chicago-area robot maker accused of stealing trade secrets from iRobot [Boston Globe, Nov 3, 07]   Defendant Robotic FX was not reported as railing against "activist un-elected judges."

iRobot up 16% after a court victory. [Nov 5, 07]

iRobot up 16% [AP, Oct 25, 07] despite a loss in its third quarter due to a production slowdown at a new manufacturer

Bribing Companies. Local and state tax incentives have prevented a multimillion-dollar Massachusetts company and hundreds of jobs from crossing the border to New Hampshire. iRobot will be moving its headquarters across the town line from Burlington to Bedford [Melissa Beecher, Boston Globe, Oct 26]

Meanwhile, The Army has frozen a $280 M contract with a Chicago-area robot maker that is being sued by iRobot. ... iRobot was suing Robotic FX in federal courts in Massachusetts and Alabama, alleging theft of trade secrets and patent infringement [Hiawatha Bray, Boston Globe, Oct 26]

iRobot got an $8.8 M Army robot order [Oct 07]

A new device by iRobot resembles the company's disc-shaped Roomba vacuum cleaner but has a webcam bulging from the top for parents to watch home....  in beta, expect under $500... the company also announced the Looj, designed to clean roof gutters  - a messy job requiring repeated trips up and down a ladder. [Mark Jewell, AP, Sep 28, 07]

iRobot Retaliates. In a case complete with private detectives and accusations of downloaded documents and shredded evidence, iRobot alleged last month that Robotic FX's products were built with trade secrets stolen by the upstart company's founder, a former iRobot engineer. [Hiawatha Bray. Boston Globe, Sep 21]  Why didn't the government notice in the procurement competition? Because the judging is not set up to investigate patent cases as part of buying goods and services needed now. What the government should have been looking for is the company's capacity to support the hardware in the field. If the idea was simply copied, the winner is not likely to have the needed technical depth when the inevitable problems arise. Also, if the government buys knock-offs, it reduces the incentive for companies to invest their own capital in developing new technology fore the government. Instead, the government will be reduced to spending its own R&D money developing everything it will need, thus slowing the advance. But the government management of SBIR suggests such a situation is just what it wants anyway. Given a choice, government technocrats would rather have control than progress. It has to abandon that choice when an enemy (Russia or al-Qaeda or whoever) presents a new challenge.

iRobot got $19M Navy order for PackBots bomb-disposal robots. [Mass High Tech, Sep 19, 07]

iRobot fell 23% as the Army picked 8A firm Robotic FX (no SBIR) to supply 3,000 robots  for $280M "The loss of the contract to a startup suggests neither IP nor economies of scale are barriers to entry, and iRobot's sales and marketing execution may be flawed," wrote JPMorgan analyst Paul Coster [, Sep 17, 07]

iRobot reports it has filed two lawsuits against an Illinois robotics manufacturer and its president for alleged patent infringement and misuse of confidential information. ... one suit against Robotic FX , second against Jameel Ahed, Robotic FX president and former iRobot employee  [Mass High Tech, Aug 20]

iRobot up 12% on news of a new DOD order for 3000 anti-IED robots. [Aug 14,07]

iRobot up 18%  [Aug 8, 07]  Motley Fool notes that although iRobot is doing well selling robots, Foster-Miller is selling robots that have Army OK for shoot-to-kill.

More 'bots. DOD ordered another $17.5M of robots from iRobot. [Jul 07]

Slide Show: iRobot Takes Military Robots for a Test Drive  iRobot demonstrates its latest military robots, including the "Scooby Doo" PackBot EOD, which helps soldiers discover and disarm improvised explosive devices, and the PackBot 510, which features a video-game-style hand controller. [eWeek, Jun 11]

iRobot says it got $50M, a portion of which is earmarked for acquisitions. [Jun 20, 07]If little robots are good, ... iRobot got an Army sub-contract from Lockheed Martin to design a remote-controlled device to operate military unmanned vehicles. [Mass High-Tech, Jun 14]  BTW, a robot thinks for itself; a remotely controlled device gets its thinking directly from a human.

iRobot has forged a partnership with Boeing to produce unmanned vehicles. The companies are expected to develop 30-pound robotic vehicles, known as a Small Unmanned Ground Vehicle (SUGV) Early, by 2008 [Mass High Tech, Apr 25]

iRobot up 13% on news that it got a $14M Navy order [Apr 3, 07]

Down 46% and Still Overpriced, Says One Analyst. ROBOTIC VACUUMS THAT boast sophisticated artificial intelligence may represent the future of housekeeping, but hopefully they're smart enough not to pick up shares of iRobot.... Roomba demand looks to be cooling off. ... disappointing sales of the company's follow-up Scooba floor-washing robot, ... The consumer business has the real potential for the big upside over the next decade." The problem is, that's a pretty long time to wait and see upside on overpriced shares of a young company in an emerging market, especially when that company is still run by its founders. After all, it's almost an axiom of business that great entrepreneurs do not great managers make.   [Dan Burrows, Smart Money, Mar 14,07]

iRobot got a $2.8M German order for 22 bomb-disposal robots and spare parts.

iRobot tripped 15% on a loss and a bleaker outlook. [Feb 13, 07]

More robots. iRobot says it got a $16.6 M order for explosive-detection robots for use in Iraq. [Jan 31, 07]

iRobot got an attaboy from the Mass Technology Leadership Council as the annual winner for emerging technologies or clusters. [Mass High Tech, Oct 12]

iRobot got $6.9 M in new Navy orders for PackBot robots, spare parts and services as an installment of a contract that could go to $70M. Love those bots in Iraq as expendable soldiers. [Sep 06]

iRobot got a $3M Navy order for EOD robots to Iraq and Afghanistan.  [Aug 06]

iRobot jumped 17% after announcing a 33% quarterly revenue gain. Still no profit. [Jul 06]

iRobot got a $26M Navy contract for more bomb-disposal robots [Mar 05]. The insurgency war has been good for the EOD business.

Bad News - More R&D Spending.   When you're public, short term profit prospects drive your short term stock price.  IRobot took a 22% dive when it said it will spend more on R&D, selling, and marketing.

iRobot shot up 29% in its second day of trading. it also benefited from a friendly article by Bary Alyssa Johnson [PC Magazine, Nov 10]  on its newest home robot: the Scooba - a smart mop first unveiled in May 2005, as the "world's first floor-washing robot."

iRobot went public to raise $100M.  The maker of military robots and the Roomba automated vacuum had about $1M in SBIR from the Army which desperately needs and uses robots to clear Iraqi roadways of bombs. The future of Roomba is harder to gauge since it depends on consumer tastes and not merely on economic efficiency.

Iroko Pharmaceuticals (South Philadelphia, PA)

Iroko Pharmaceuticals  (Philadelphia, PA; no SBIR) biopharmaceutical company focused on pain medicines, withdrew a proposed $128.75 million IPO. [John George, Philadelphia Business Journal, Aug 9, 13]

Iroko Pharmaceuticals (South Philadelphia, PA; no SBIR) filed for IPO ... specializing in nano-formulations of existing pain therapies and other drugs [John George, Philadelphia Business Journal,  Jun 21, 13] 

Ironbridge Technologies

Self-heating food package maker HeatGenie (Austin, TX, founded 2007 as Ironbridge Technologies; one SBIR) has received $400,000 of a planned $450,000 round of funding. ... Its business model is to generate revenue by licensing the technology to container companies and heat manufacturers  [Austin Business Journal, Jul 6, 10] got $1M from TX Emerging Tech fund

Self-heating food package maker Ironbridge Technologies (Austin, TX; one SBIR) has received $250,000 in a third round of funding from the Texas Emerging Technology Fund. ...  for continued technology development and marketing. [Austin Business Journal, May 13, 10]  Government funding for marketing in a conservative, free-market, Republican state?? Ain't politics fun to watch?  More money than good new infant tech in central Texas?

The Texas Emerging Technology Fund is pumping more money into Central Texas technology startups.  Six more Austin companies have won grants totaling $5.3 million.  Among the six new grant winners is year-old NanoMedical Systems (no SBIR) which will use its $3.5 million to develop a tiny implantable capsule that delivers drugs a few molecules at a time, with the dosage controlled precisely for each patient. The company is completing a prototype using $4 million from a private investor, said co-founder and chief executive Randy Goodall. The grant will help fund it through the complex and time-consuming process of seeking Food and Drug Administration approval, Goodall said. ...... Farodox Energy Storage  (no SBIR), which has developed a new fabrication process for high-performance electrical capacitors, $250,000; ...  Ironbridge Technologies (no SBIR), which is developing self-heating food packaging technology, $250,000;  ... Merkatum (no SBIR), which is developing fingerprint and facial recognition identity technologies, $250,000;   .....  Stellarray (no SBIR), which is commercializing flat-panel radiation source technology, $750,000; ...  Sunrise Ridge Algae (no SBIR), which is commercializing technology to turn algae into a renewable energy source. [Lori Hawkins, Austin  American-Statesman, Nov 17, 08]

Ironwood Pharmaceuticals (Cambridge, MA)

Ironwood Pharmaceuticals (Cambridge, MA; no SBIR) is flush with funding after the maker of drugs to treat irritable bowel syndrome took in $25 million in its latest financing round, according to federal documents. The new financing pushes Ironwood over $315 million in total equity financing.  [Mass High Tech, Sep 4, 09]

Irvine Sensors Corp (Costa Mesa, CA)

After its second reverse split, Irvine Sensors re-qualified for NASDAQ listing. [Sep 16, 08]

Irvine Sensors down 19% [Nov 17, 06] after getting $16M in new orders after more than doubling the day before.

Irvine Sensors jumped 13% on news of a $7M classified contract. Irvine loves defense money. [Nov 3, 06] At least 82 SBIRs going back to the Stone Age (1983) with a total of something like $30M of which about $6M has my name on it.  It had many interesting technical ideas that just wouldn't convert into profitable ventures.

Irvine Sensors bought 70% of the stock of Optex Systems (Richardson, TX). Founded in 1987, Optex manufactures optical sighting systems and assemblies primarily for DOD. Its products are installed on the majority of U.S. military land vehicles, such as the Abrams and Bradley fighting vehicles, Light Armored and Advanced Security Vehicles and have been selected for installation on the Future Combat Systems (FCS) Stryker vehicle. Optex's revenues for calendar 2005 were approximately $19M. [PRNewswire, Jan 3] Irvine has had at least 45 SBIR Phase 2s, including 35 from DOD; Optex none.  

Irvine Sensors reported three more Phase 2 SBIRs for $2.2M. Profits? Change the subject, although it is nearly time for the quarterly fess-up. [Nov 04]

Irvine Sensors‘ retirement plan has spent $1M of President-Founder John Carson's poke to buy  Irvine stock at about a 5% premium over the market price. 

Irvine About Out of Juice.  After saying that it doubted one of the basic premises of a company - a going concern - Irvine Sensors says it raised $1M in equity financing to cover its rapidly failing cash balance after another big loss year of $6M. Irvine is a big user of SBIR but failed to make a commercial go of its imaginative technology breakthroughs. How about the government's saving it just for the technology? Sorry, that's not what the government does for small companies; Irvine is no Lockheed.with lots of employees and political donors.   

In sympathy with the battering that info-tech stocks have had this year, Irvine Sensors dropped back below the buck. And that is in the 1-20 reverse split stock that kept Irvine trading on NASDAQ. Market cap now below $7M.

Irvine Sensors stock zoomed 25% after news that it got yet another Phase 2 SBIR for $728K demonstrate a Miniature Night Vision Weapons Sight.

Four law firms are howling for blood over too much technical optimism at Irvine Sensors. A complaint alleges that IRSN violated federal securities laws, by, among other things, repeatedly maintaining throughout the Class Period, that Silicon Film Technologies, Inc., a majority-owned subsidiary of IRSN, was near completion of its Electronic Film System or "EFS-1," a device which would interface with a conventional camera to enable the camera to take digital pictures, all the while knowing that the EFS-1 was suffering from serious and insurmountable technical design flaws. On September 15, 2001, after nearly two years of touting the EFS-1 technology, IRSN abruptly announced that SFI had suspended operations and was considering bankruptcy, essentially ending the EFS-1 project. This news caused IRSN stock price to plummet from a Class Period high of $14 a share to a low of 12 cents. The stock price plummeted again well below the buck that was established after the recent 1-20 reverse split.

Irvine Sensors proudly announces government handout of $1.8M in SBIR - three Phase 1s and two Phase 2s. Said CEO Richards,The SBIR Program sponsors the development of technologies of interest to the government that also have commercial prospects. Because of this, these pending grants are significant not only to our current fiscal year, but potentially to our future,We will have more to say on the commercial demonstration objectives of the Phase 2 awards once the procurement activities are completed. That's nice! What about the commercial results from the gazillions of earlier SBIR in a company that recently had to do a 1-20 reverse split to keep its NASDAQ listing? The government would rightly argue that new technology was advanced which is the goal of R&D spending. But SBIR was supposed to have shorter range impact on commercial success.

Irvine Sensors did a 1-20 reverse split to avoid the bullet of NASDAQ de-listing.

Irvine Shutters Subsidiary
(Sep 17) Irvine Sensors is closing its Silicon Film Technologies subsidiary and preparing for its liquidation in bankruptcy, Irvine might like to continue to finance the development of a new Electronic Film System(TM) but Irvine itself needs money to fill its own yawning losses.

Irvine Faces Delisting
(Sep 10) Irvine Sensors has to scramble to avoid being de-listed from the NASDAQ which has now warned Irvine that it no longer meets market capitalization, net worth, or stockholder equity listing. NASDAQ had already told Irvine that the stock, surrently around 30 cents must trade above $1 per share for 10 consecutive trading days before October 10.

Although Irvine's situation has reached an extreme, most SBIR stocks have been hard hit in the past 18 months of info-tech swoon. APA Optics and American Superconductor have been halved this summer.

The Hurrieder They Go
(Sep 6) Irvine sinks deeper in the hole. After Irvine Sensors reported sales of both products and contract R&D up 50% in the recent quarter, the NASDAQ traders continue to abandon the stock to whoever will buy. From a mere 60 cents a share in early August, it has slipped to half even that meager number. Over the last two decades, the government has sunk a lot of R&D money for what promises to be interesting technology while private investors have sunk a lot more into losing year after losing year. The government will get its money's worth in knowledge but the private investors look they will get nothing back because the technology is too expensive to attract private vendors. Government, of course, especially big Irvine investor DOD, cares little for cost-based competitive advantage and doesn't really care whether Irvine lives or dies. The generals are still living in the world of only the best for DOD regardless of price and subsequent marekt availability. Which is why they regularly ask Congress for big appropriations to buy big expensive hardware.

Irvine Sensors got $55M for a high-speed router spinoff that will use superconducting technology -- a technique that involves freezing ceramics cooled at extremely low temperatures, eliminating their electrical resistance. The result is a conductor capable of shunting digital signals over telecom links an order of magnitude faster than today's high-end routers. Experimental labs have managed to get superconductors to transmit digital data at rates to 740 Gbit/s. ... Irvine isn't alone in its quest for a new router technology. Atlantic Technology Ventures has started its own superconducting router project. Chipmaker HYPRES is working. And superconductor vendors such as ISCO International say it's in their future plans. One question: Isn't it pointless to focus on such futuristic technology when existing firms are struggling? And where does superconducting leave optical networking -- out in the cold? ... Irvine's business plan calls for the development of a "SuperRouter," using funds obtained from U.S. government agencies under the auspices of the SBIR. One of the contributors: BMDO. In order to peddle the product commercially, Irvine has formed a spinoff called iNetWorks Corp. ... Irvine Sensor officials acknowledge that plans for an avant garde are fraught with risk. The company admits that at least two of its ventures aren't showing any products yet. [Mary Jander, Light Reading, Jul 31]. Heard that story before? Great business plan for a future products to induce the government to spend R&D with the visionary firm. BMDO also funded those other companies with money-losing technology. Irvine, in particular, has worked that scheme for nearly two decades. Some boo-birds came out: A Solution in search of a Problem. The previous "killer app" for superconductors was wireless. The space, power, and cost for the freezer unit made superconductors dead on arrival with respect to the cellular carriers and basestation equipment vendors. The networking world isn't going to be any better. And: it would be a good idea if these people would work on solving one problem with superconductors rather than several at the same time. They talk about switches and packet processors both implemented with superconducting materials. Both are independently enormous technical challenges. But together, it strains credibility that a vendor is just going to throw it all together at the same time. And: This makes no sense whatsoever. First, routing IP packets at this speed is not critical to national security (if it was, why isn't the network connection-oriented?). Secondly, a series of load balanced Juniper routers can achieve the same thing and a lot cheaper too.

Irvine Sensors says it won one of the four DARPA Jigsaw project team awards for combat detection that hands out $1 now and maybe up to $20M over three years. IRSN, of course, used stacked silicon chips, a technology that has been bringing in government money since the mid 80s. Other teams will also get $1M in a grand competition that will narow the field to two teams after a year. Somebody may get the $20M.

Irvine Sensors won another SBIR Phase 2 which makes about a billion. This time from BMDO for what sounds like a marriage of Irvine's fifteen year-old chip stack technology and the nearly as old low temperature superconductor dreams of HYPRES (Elmsford, NY). The stock traders don't seem impressed in that Irvine is still 90+% down from its high of early Y2K. Irvine and HYPRES have each had at least 30 Phase 2s (decent count good only through about 1998 because of long lag in SBA data).

Big up mover yesterday, Irvine Sensors up 34% to 6. It was below a dollar just before Christmas. But Irvine was up in this territory years ago and disappointed a lot of hopes when it just could not make a profitable go of its technically sweet government-supported 3D electronics which Irvine claims to be developer of proprietary technologies to produce extremely compact packages of solid state micro circuitry, which offers volume, power, weight and operational advantages. Irvine has averaged about $1M a year in SBIR funding since the mid 1980s which a much smaller number than the $60M of losses covered by private capital. Its investors have had $60M worth of faith for a decade.

the human brain has only a short time left as the smartest thing on earth. By 2102 the density of computer circuits will have jumped 1000-fold and the raw processing power of a human brain will fit in a shoe box. With luck, that milestone might coma a lot sooner - perhaps as early as 2005, says John Carson, chief technology officer at Irvine Sensors, a Silicon Valley chip company. [Business Week, Aug 30] Maybe, maybe. Carson has been predicting great compression for as long as he has been proposing SBIRs (since the mid 80s) for imaginative advances. He won a lot of SBIR but the biggest compression is in the value of his stock holding as Irvine wallows near $1. Note: Unless SV extends to Costa Mesa south of LA, Irvine is not in SV.

Irvine Sensors (Costa Mesa, CA) also raised cash by selling shares privately for $5.6M. But Irvine which has had a loooot of SBIR still languishes in disaster territory. Irvine Loses $1M+
(Feb 24) Irvine Sensors (Costa Mesa, CA) says it lost $1.36M for the quarter, about the same as last year's quarter. But optimism still reigns During the first quarter and for the first time in our history, we realized the majority of our consolidated revenues from sales of commercial products. As a result of its recently announced supplier relationships with large manufacturers, Novalog's revenues for the first quarter were greater than all of last year, making them the first of our three product subsidiaries to break into profitability. The other two, Imagek and MicroSensors, are still committing all of their available resources toward developing products with strong revenue potential which are intended for introduction later this year. Irvine has had about 22 Phase 2 SBIRs since 1986, the stock sells today for a tenth of its 1994 value, and it has lost a cumulative $37M in the last five years. Its specialty is extremely compact microcircuitry that is assembled in 3-D stacks instead of flat layouts in order to achieve lower weights and volumes and improved speeds that seems a perennial technology of the future.

Silicon Brain Again
(Sep 30) With the usual fanfare, Irvine Sensors (Costa Mesa, CA) announced another SBIR award for an ultra high density interconnect to enhance its 3D Artificial Neural Network (3DANN) technology. The new interconnect is part of Irvine's planned progression of technologies intended to eventually lead to a "Silicon Brain", a recognition system conceived to emulate performance of the human central nervous system. Irvine Sensors believes that human-level recognition technology could also have commercial applications in such fields as medical diagnostics, DNA sequencing, radiography, security systems, and speech recognition. Optical displays are also expected to benefit from the three-dimensional active transistor interconnect technology to be developed under the new contract. "Although it will take several years before the technology can be made available for products, we believe the Silicon Brain will ultimately be able to solve that problem . . . attaining petaflop performance, or quadrillions of operations per second, using less than ten watts of power, in one-third of a cubic foot, or about the size of a shoebox. This will be the same volumetric efficiency as the human brain."
That's the standard press release for what has become a continuous SBIR dating back to the 80s for an interesting idea that always seems to be the technology of the future. A substitute for or emulation of the brain has been a silicon dream for as long as there have been integrated circuits and neural networks. But whether SBIR should be the vehicle for long range development is a central SBIR issue. Recipients like Irvine can always create as much rhetoric as the government demands to keep the money flowing. As a business, ISC has been a good government servant, spending as much money as the government will press upon it plus $42M of losses in the past five years. ($13M+ from DOD alone.) BMDO likes the idea and finds a continuing rationale for more SBIR funding. Odds are that ISC will present BMDO with another golden opportunity in about 18 months when this SBIR money nears its end. What might ever end the government's dreaming? 

Irvine Makes A Profit  (Aug 13) Irvine Sensors (Costa Mesa, CA) proudly announced a profit for the quarter of $442,400 as compared to a $2,154,700 loss in the same 1997 period. That makes a cumulative profit through the third quarter of $639,800 versus a $6,408,400 loss in 1997. Irvine credits shutting its bleeding Burlington VT operation. Now if only it could graduate from SBIR.

Irvine Shoots Up (May 18) Irvine Sensors (Costa Mesa, CA) stock shot up Friday from under $2 to over $4 and settled at $3.3 without a news announcement. Irvine may (don't bet on it) make a profitable quarter after years of longing?

Irvine Makes Money (Apr 17) Irvine Sensors (Costa Mesa, CA) made $14K for the quarter after the Vermont money hog was finally lifted from its shoulders. During the first half of the year, the company said it has been able to achieve improvements in operating results while still making early-stage investments in several of its emerging market technologies, such as the Imagek EFS-1 Electronic Film System and MicroSensors' Silicon MicroRing Gyro. [Dow Jones, Apr 16] The market must have anticipated the improving news in the run-up of the stock in the past weeks to over $2. Uncle SBIR has poured millions into Irvine and is still waiting after more than a decade for any tax payment.

Irvine Rising Again  (Mar 6) Why on a day when all 13 of the most active NASDAQ stocks were down was Irvine Sensors making a new 12-month high of $2.3 (although far, far below its 1995 high of 10)? Another bull trap? A news item on Mar 3 said IRSN got a $1.3M first-phase order of an expected $2.1M subcontract from Boeing to develop a computer-in-a-cube with its chip-stacking technology and a possible follow-on contract for pilot for maybe $0.8M. Irvine said the computer-in-a-cube will be the core of a wearable computer system will use hands-free, voice-activated controls for a DARPA program. That's nice if you like notoriously profitless DARPA development programs. And, of course, the latest $750K Phase 2 SBIR adds to a long line of government contracts. Irvine is still losing money on ts continuing operations although in the past quarter it had a gain of $1M from settling a debt.

Year's Top Product  (Sep 12) Irvine Sensors got a 3 1/2-year, $2.1M subcontract to support and market processor chips being developed by a 12-member university consortium based at the University of California at San Diego, is to develop processor chips which will increase processing speeds with a parallel, optically switched processor core for computers under DARPA. At least the government money will help stave off the creditors for the overhead expenses.

And Two More Makes Twenty in Two YearsAnd Two More Makes Twenty in Two Years
(Aug 15) Irvine Sensors lost another $2M for the quarter which makes $20M in the past two years. Whatever they're brewing with that money better be profitable or a gaggle of investors will be grossly unhappier and it's not even Silicon Valley where bust is a way of life. Irvine gets 30% of its revenue from government contracts, especially SBIR and sales are up 50% from a year ago. If sales keep rising, it can go broke faster.

Direct to the Consumer  (Jul 1) Looking past the theory that government tech developers and tech sellers to the mass market must be different kind of people, Irvine Sensors (Costa Mesa, CA) announced a consumer product - the BayBeamer for IR transmission. With the PC market consolidating and competitors everywhere, Irvine will start by selling to OEM, as always, but says it is having "exploratory discussions" with "distribution channels". Lotsa luck, it's a jungle. Initial price $28.50 in lots of five. [Business Wire, Jul 1] 

Irvine Will Do A Yet Smaller Camera  (Jun 27) Irvine Sensors (Costa Mesa, CA) says it got another Phase 2 SBIR for yet a smaller credit card like camera, this time from DARPA piled onto the Navy development of a similar camera. If one is good, two is better. Let's guess, just guess, that the DARPA amount is whatever the standard amount is this year and that no consideration was given to combining the two awards into a single development program. Should DARPA and Navy even compare notes about a company with zillions in SBIR and a share price flirting with a buck? Would the generator company in Milwaukee or the anti-microbial company in Seattle agree that two is better than one if they can't even get a Phase 1 from DARPA?

Irvine Cuts the Loss  (May 22) Irvine Sensors (Costa Mesa, CA) swallowed hard and then swallowed the IBM deal by ending its Vermont lease and removing the capital equipment to some new unnamed place or destiny. Said Irvine, The market for the ultrahigh density products built on the IBM line has not matured fast enough to continue such a capital-intensive at this time. IBM's response was not reported. IBM is rid of an old manufacturing line and has the real estate available again as the company rides high in Wall Street's estimation. Did IBM dump a loser on an unsuspecting small company? Didn't most of Irvine's money come from government contracts anyway? If so, did IBM and Irvine find a way to sell IBM's line to the public? Whatever happens, the Irvine stacked electronics cube is cutting Irvine's throat while the government keeps pouring money into the technology. Would the government ever cut its losses and dump Irvine? Less likely. Government tends to stick with its decisions to pursue a technology, adding more money when success doesn't show up on plan.

Moving right along, Irvine won another government contract, for an inertial system in the Navy's cookie-cutter SBIR program. (Every contract gets $600K plus a possible option for $150K.) Bureaucrats like uniformity, fewer decisions to be criticized for. In a typical scenario, Irvine applauded the size of the MEMS market that the gizmo is related to, as if a government contract for a military version thereby conferred a commercial advantage. Probably not unless something drastic happens to the cost. No one in government, especially the Navy, will poo-poo Irvine's story (nor force Irvine to prove it by matching private investment in such a wonderful opportunity).

Irvine Red Ink  (Apr 30) Another loss for Irvine Sensors (Costa Mesa, CA). This quarter - $2.7M. Someday, the DOD wonderful new technology will either have to make lot of money, or Irvine and DOD will have to admit that it is merely an R&D arm of DOD.

Credit Card Camera   (Apr 7) The Navy will get a credit-card-size camera if the development at Irvine Sensors works out. Irvine says the camera will integrate a number of its proprietary technologies (stacked memory and IR transceiver) to cram 40 MB of solid state data storage into a cubic inch. In a typical statement of SBIR hope, Irvine said "While this goal is being driven by the needs of government customers, we believe an ultra-compact digital camera could also have applications in commercial markets such as law enforcement, security and traffic monitoring". Now where have I heard that before? And how long ago from Irvine? Oh, never mind; the government likes Irvine's technology and will spend as much SBIR on it as can be maneuvered. John Carson, VP for imagination, will keep the government guys smiling at the innovations. Even BMDO still falls for the rosy scenario line. 

Not even the raft of short coverers lifted the stock price. Irvine Sensors (Costa Mesa, CA) should have gotten some price lift from its short position declining 30% in the last month. To do so, someone had to buy a net of two whole days (170,000 shares) of average daily trading volume.

Enriching the Silicon Neuron (Mar 6) Irvine Sensors (Costa Mesa, CA) had an expensive dream - a 3-D chip that could recognize a face. The government, SDIO become BMDO, financed the dream over a few years for many chip stacking ideas, including $5.2M for a 3D Artificial Neural Network. Now BMDO is adding another $1.5M to keep the dream alive. [Classic question for government funded R&D: does Irvine have an incentive for the project to finally succeed?] Although only Irvine knows for sure how much the government has "invested" in its stacking technology, DOD SBIR is already in for over $10M. Whatever BMDO thinks it will get if and when the face is recognized - a core function of human individuality - the NASDAQ traders aren't convinced that Irvine's profits will flow any time soon as the stock languishes around a tenth of what it was not long ago even in the high-tech froth of the 1995-1997 market. Something doesn't seem to compute. Government technocrats usually rationalize the gap as the market's ignorance of a good thing. 

Some New Orders  (Feb 28) Two SBIR users got new orders. Irvine Sensors $3.2 M from Lockheed-Martin-Marietta-Whoever for a solid state data recorder program, and SI Diamond Technology (Austin, TX) $0.7M for something. SI Diamnond now bills itself as a holding company. Both firms' stocks are languishing around $1 on NASDAQ. 

Profit (Loss) (Feb 13) Irvine Sensors (Costa Mesa, CA) (lost another $1.5M) for the quarter. Conductus (Sunnyvale, CA) (also lost $1M). SBIR to the rescue??

From Consultant to CEO
(Feb 5) Irvine Sensors Corp (Costa Mesa, CA) hired itself a consultant to be CEO, having parted company with the previous CEO. James Evert will try to wrench Irvine out of SBIR/government-land and into profit-land before the stockholders get fed up with the 90% gyrations in stock price.

The Add-In Custom Trough. Irvine Sensors (Costa Mesa. CA) will absorb another SBIR to develop image enhancement processor, an add-in board for an AF lab's equipment with a custom version of Irvine's 3-D NN real-time processor. [Photonics Spectra, Dec 96] What's the trouble? An SBIR-junkie making one-of-a-kind equipment for an AF lab with SBIR. A great deal for Irvine and the AF lab: AF gets the equipment, Irvine stays afloat while its stock price plummets, AF mainline R&D doesn't have to use its budget to buy equipment. Who loses? The innovative SBs who won't be getting AF lab investment in future marketable products. Note also that such an award mocks the SBA's FAQ assertion that patented technology is ineligible for SBIR. 

More Irvine Loss.
Lost $11.5M on revenues of $12M for its fiscal year, did Irvine Sensors Corp (Costa Mesa, CA). And where would Irvine be today without the $11M of SBIR over a decade (which put it in 24th place for lifetime SBIR a year ago)? The market scowls at trend s it beat the price below $1. The DOD, though, likes the technology enough to keep pouring in SBIR and ignoring the market. After all, it would cost the DOD little for Irvine to fail because DOD is not an investor in companies; it is an investor in technology for its own purposes, and it owns all the Irvine technology that SBIR developed. Actually such a monolithic DOD does not even exist. DOD's sub-divided SBIR has no mechanism for seeing Irvine as a company or as an investment. 

Irvine Breaks the Buck
On a day when the blue chips stocks soared 2%, Irvine Sensors Corp (Costa Mesa, CA) slipped below a buck a share. About the same time Photonics Spectra reports another SBIR award to Irvine. Connected? Too much of a good thing?

Down Punters Quit the Irvine Game.
The shorts quit the game. Short interest in Irvine Sensors (Costa Mesa, CA) dropped 74% to one day's volume. (Shorts borrow stock to sell it and bet on buying it back later at a lower price; sell first, buy later.) The stock has taken a beating this year from nine-ish down to 1.6. The average NASDAQ short interest ration is 2.5 and small stocks 1.1, which brings Irvine back to average. The other SBIR company SI Diamond Technology that plunged this year has a ratio near 4.

Loss and Return
The quarter's revenues were double as prices and profits went south for Irvine Sensors (Costa Mesa, CA). Why? "declining margins and government procurement delays" (a convenient scapegoat who won't sue). And back to the operating helm came chairman Jim Alexiou who says he will "restructure our operations to stem our losses while exploitingthe near-term opportunities available to us from our technologies". About as definitive as Bob Dole's exposition of tax-cut arithmetic - trust me. Unfortunately for Irvine, the red ink river extends back as far as the eye can see. 

Irvine Sensors Under Two
The NASDAQ price for Irvine Sensors (Costa Mesa, CA) dropped below $2 after all that SBIR money and a deal with IBM. A long way from the occasional double digits. Now it's down in the low country with SI Diamond Technology (Austin, TX) for perhaps the same reason: eating capital in a long string of losses.

Irvine Sensors Posts Big Loss  Irvine Sensors Corp (Costa Mesa, CA), a big user of SDIO/BMDO SBIR, posted another substantial loss for the quarter - $3.1M lost on sales of $1.9M - which makes a loss of $6M for the half. While BMDO is probably neither surprised nor shocked (nor even interested) by the loss because BMDO wants the new technology, the investors will only stand so much getting ready before demanding a reckoning and a fix. BMDO would not, though. enjoy the company's collapse that would take the highly advanced 3-D chip technology down with it. Only in textbooks can the technology be just transferred to another lab or company. Too much of the technology is embedded in wetware. 

$7M for Irvine Sensors  Irvine Sensors Corp (Costa Mesa, CA) garnered $7M recently in new business: $6.3M from Lockheed-Martin-Loral-(whatever) and another Phase 2 SBIR award for its chip stacking. The SBIR is from DARPA (this year's name) to stack chips from British company, Aspex Microsystems sponsored in part by BMDO's Innovative Science and Technology parallel computing money. While it's all perfectly green money, it is more government work out of which ISC would like to graduate someday (or so it claims within the hearing of government SBIR managers). It does have a commercial subsidiary, NOVALOG which markets an IR transceiver module (says its July 2 PR).

Ischemia Care (Oxford,OH)

Ischemic Care (Cincinnati, OH; $7.93M in 9 Rounds from 1 Investor) lands $2.3M [VC] is preparing a major clinical trial as it sets up to hit the market this year. ...  commercializing a series of blood tests to stratify ischemic stroke and TIA patients by cause, leading to improved patient outcomes   [, May 13, 17]

Iscemia Care (Blue Ash, OH; no SBIR, founded 2009) is finishing out its latest round of clinical validation — putting it one clinical trial away from entering the market. ... is closing in on its goal of $6.4 million    [Tristan Navera, Dayton Business Journal, Jul 29, 16]    a total of $3.7M in funding to date .. Partners With Medtronic and Affymetrix on Stroke ...  technology is based upon proprietary biomarkers using RNA expression to stratify ischemic stroke patients by cause.  [company website]

Ischemia Care (Blue Ash, OH; no SBIR)  a clinical diagnostic laboratory developing a blood test for cause of stroke and other maladies ...  won $500K from Accelerant Fund I, a $9.1 million venture capital fund administered by the Dayton Development Coalition.   [Tristan Navera, Dayton Business Journal, Jul 16, 15]

Ischemia Care (Oxford, OH;  no SBIR, founded 2009) health care company is looking to raise $1.2 million through securities.  ....  produces the ISCDX, a blood test to help better diagnose and treat stroke patients in a less expensive manner. [Tristan Navera, Dayton Business Journal, Oct 22 13]


The Engine, a new VC fund in Cambridge, MA aims to bridge that [long lead time] gap by investing in breakthrough technologies that require extensive time and funding. Its [announced] first round of investments consists of seven startups (Analytical Space (Boston, MA, laser satellite data links w former Gen Pete Worden as advisor), Baseload Renewables (co-founded by Professor Yet-Ming Chiang who co-founded A123 Systems), C2Sense (Cambridge, MA; patented chemiresistive sensing C2Sense is able to selectively target gases unable to be sensed through other methods ), iSee (next generation of humanistic artificial intelligence technology for human and robotic collaborations), Kytopen (better genetically engineer cellsby developing technology that modifies microorganisms 10,000 times faster than current state-of-the-art methods ), Suono Bio (Cambridge, MA, ultrasonic therapeutics), and Via Separations (industrial separation processes, sonme SBIR) in sectors including aerospace, advanced materials, genetic engineering, and renewable energy. .... a for-profit, public-benefit corporation and a fund that’s separate from MIT ... MIT also contributed $25 million to your first investment fund of $200 million.    [Elizabeth Woyke,,  Sep 19, 17]

iSIGHT Partners (Dallas, TX)

iSIGHT Partners  (Dallas, TX; no SBIR) cyber threat intelligence company has raised $30 million [Series C round] to continue its fight against hacking and other online dangers. ... will bankroll iSIGHT's ThreatScape intelligence capabilities and help the company develop new partnerships   [Korri Kezar, Dallas Business Journal, Jan 6, 15] 

Isis Biopolymer (Providence, RI)

Isis Biopolymer (Providence, RI; no SBIR, founded 2007) has taken in $3 million in new funding, according to federal documents. ... developing a drug-delivery patch called the IsisIQ .. small, wireless patch that contains microprocessors, thin film batteries, biopolymers and proprietary adhesives. The patch can be loaded and pre-programmed to deliver a variety of drugs at specific intervals, officials said. ...  has raised approximately $4.5 million in funding to date.  [Mass High Tech, Mar 4, 10]

Isis Pharmaceuticals

Isis Pharmaceuticals, which shares a name with the Islamic State extremist group, has changed its name to Ionis Pharmaceuticals after resisting the change for some time  [AP, Dec 18, 15]

A drug from Isis Pharmaceuticals has shown early signs of effectiveness against treatment-resistant lymphoma and non-small cell lung cancer in a Phase 1 trial.  Tumors regressed in treated patients, providing up to two years more life, researchers said. [Bradley Fikes, San Diego Union Tribune, Nov 17, 15]

Isis Pharma up 12%  [Nov 9, 15] reported a smaller than expected quarterly loss and progress in developing a new cardiovascular drug.  [Bradley Fikes, San Diego Union Tribune, Nov 9]

Isis Pharma  up 11% [Oct 27, 15]

Isis Pharmaceuticals [market cap $6.5B] has signed another major drug development partnership. The partnership with AstraZeneca brings the biotech $65 million upfront. ... calls for Isis to find and develop drugs for cardiovascular, metabolic and kidney diseases, using Isis' antisense technology.  [Bradley Fikes,, Aug 2, 15]

Isis Pharma formed a subsidiary, Akcea Therapeutics, to commercialize its drugs for lipid diseases, which can increase the risk of cardiovascular problems. Established in Cambridge, Mass. in January, Akcea is Isis' answer to the problem of extracting the most value from its drugs while maintaining focus on its core technology, called antisense.  [Bradley J. Fikes,, July 1, 2015]

Infants with a fatal neurological disease have shown what appears to be unprecedented improvement, in a Phase 2 trial of an experimental drug from Isis Pharmaceuticals. [Bradley Fikes,, Jun 11, 15]

German drugmaker Bayer secured the rights to an experimental anti-blood-clotting drug in a deal with Isis Pharmaceuticals to bolster its cardiovascular business led by blockbuster pill Xarelto. ...  Under the agreement, Isis is eligible to an immediate $100 million payment and a $55 million payment depending on the success of a Phase II study in patients with compromised kidney function.   [Ludwig Burger, Reuters, May 4, 15]

Isis Pharmaceuticals said it earned [$15 million] milestone payment from GSK for advancing its drug for a form of familial amyloid polyneuropathy, or FAP. [Bradley Fikes,, Mar 2, 15]

Isis Pharmaceuticals experimental diabetes drug took a longer-than-expected 36 weeks to reduce blood sugar levels in patients with type 2 diabetes.  [Natalie Grover, Reuters, Feb 3, 15]

Isis Pharma and Alnylam Pharmaceuticals renewed their decade-old partnership to develop RNA-based drugs. ... In addition, Isis announced a collaboration with Janssen Biotech to develop drugs for autoimmune diseases of the gut, with an eye to making them orally available, something Isis hasn't done before.  [Bradley Fikes,, Jan 12, 15]

Isis Pharma up 11% [Jan 5, 15] will get $35 million upfront and potentially nearly $800 million more and royalties in a collaboration with Janssen Biotech to develop Isis' first orally active drugs.   [Bradley Fikes,, Jan 5, 14]

Isis Pharmaceuticals has started a second Phase 3 study of its drug for spinal muscular atrophy, a severe genetic disease that can be fatal.  In connection with the study, the biotech said it has earned a $27 million milestone payment from its partner, Biogen Idec ...  "To date, we're encountered no safety or tolerability issues; that of course makes things a lot easier," and the drug has "outperformed our expectations," [CEO Stanley] Crooke said.    [Bradley Fikes,, Nov 15, 14]

Isis Pharmaceuticals said it intends to offer $425 million in convertible debt. The deal will let Isis retire as much as $140 million of existing debt, then use the remainder to retain control over and potentially commercialize certain drugs in its pipeline.  [Alex Lash,, Nov 13, 14]

Infants with severe spinal muscular atrophy showed improvement in a Phase 2 clinical trial of a drug from Isis Pharmaceuticals, the company said  ... A Phase 3 trial of the drug is now under way in infants. A Phase 3 trial in older children is set to begin before the end of 2014, [CEO] Crooke said.    [Bradley Fikes,, Oct 10, 14]

Isis Pharma presented evidence that an already approved drug, Kynamro, dramatically reduces risk of heart attacks. And it announced another heart medication, ISIS-APOCIIIRx, has begun Phase 3 trials. Both drugs employ Isis' gene-blocking antisense technology, that stops diseases at the genetic level.  [Bradley Fikes,, Sep 2, 14]

Isis Pharma up 18% [Aug 26, 14]

Patient investors, lots of cash.  Isis Pharmaceuticals will become profitable in the fairly near future, [CEO] Crooke told investors   ... The company’s 2014 annual loss is projected to be $50 million, Crooke said. Given the scale of Isis’s large drug development programs and partnerships, it wouldn’t take much to nudge that figure into profitability, he said. The company had about $631 million in cash as of March 31.  [Bradley Fikes,, Jun 11, 14]

Isis Pharma up 10% [Jun 10, 14] 

Isis Pharma up 10% [Jun 5, 14]

Isis Pharma up 11% [May 23, 14] 

 Isis Pharmaceuticals said its experimental blood thinner was more effective than an approved drug in patients undergoing total knee replacement surgery.  [Reuters, May 22]

Isis Pharma down 10% [Feb 28, 14] 

Isis Pharma up 16% [Feb 21, 14] 

An experimental drug from Isis Pharmaceuticals for spinal muscular atrophy showed positive results in an ongoing trial, the Carlsbad-based company said Friday, and the company’s stock jumped on the news. Children given multiple doses of the drug showed improved muscle function, Isis said  [Bradley Fikes,, Feb 22, 14]

Isis Pharma  up 10% [Jan 9, 14]

Isis Pharma up 14% [Sep 19, 13] after spinal muscular atrophy trial data released.  [] 

Isis Pharma up 14% [Sep 9, 13] a $100-300M deal with fellow biotech Biogen Idec to develop drugs for neurological diseases using its gene-blocking antisense technology. []

An experimental drug from Isis Pharmaceuticals produced a sharp reduction in levels of triglycerides, a type of fat in the blood that increases the risk of heart disease, a small mid-stage trial showed. Codenamed ISIS-APOCIIIRx, the drug is attracting increased attention from investors who believe it could be a big money spinner for the U.S. biotech company. [Reuters, Sep 1, 13]

Isis Pharmaceuticals said patients with rheumatoid arthritis (RA) who were treated with its antisense drug ISIS-CRPRx reduced their levels of C-reactive protein (CRP) by as much as two-thirds. That was the good news, as CRP is associated with many diseases, including numerous inflammatory and cardiovascular diseases. The bad news, however, was that improvements in the RA patients’ symptoms were not statistically significant in comparison to RA patients who received a placebo. Isis said it would halt further development of ISIS-CRPRx for RA, but plans to continue to evaluate the drug for treating other diseases, including atrial fibrillation.   [Bruce Bigelow,, Aug 8, 13]

Isis Pharmaceuticals released more evidence Monday that its cardiovascular drug Isis APOIIIRx greatly reduces unhealthy levels of triglycerides and other blood fats. Results come a month after the biotech company released the first batch of Phase 2 results for the drug. [Bradley Fikes,, Jul 22, 13]

Isis Pharma up 25% [Jun 24, 13] on positive Phase 2 data on a triglyceride-lowering drug []

Isis Pharmaceuticals says it got a $10 million milestone payment from AstraZeneca for progress on ARRx, a drug for prostate cancer. The drug uses Isis' antisense technology to inhibit production of the androgen receptor. On Friday, Isis said underwriters of its recent secondary offering exercised an option to buy an additional 617,869 shares. That sale should conclude on Tuesday.  As a result of the option exercise, Isis said it should get gross proceeds of about $182.7 million. [Bradley Fikes,, Jun 3, 13]

Isis Pharma  down 10% [May 8, 13]

Isis Pharmaceuticals said it plans to sell up to 10.35 million shares of stock. bring about $225 million [Bradley Fikes,, May 7, 13]

Isis Pharma up 10% [Jan 30,13]

Isis Pharmaceuticals got approval  for its cholesterol-lowering drug, Kynamro.  ... to treat homozygous familial hypercholesterolemia, or HoFH. This is a rare form of inherited high cholesterol associated with a greatly increased risk of cardiovascular disease.   [Bradley Fikes, utsandiego, Jan 29, 13]

Isis Pharma up 10% [Jan 10, 13]

Isis Pharma up 12% [Jan 8, 13]

Isis Pharmaceuticals was hit with a shareholder lawsuit last week, accusing the biotech company of concealing bad news from investors about its flagship cholesterol-lowering drug, Kynamro. [Bradley Fikes,, Jan 4, 13]

A European committee has recommended against approving a drug for a rare form of high cholesterol from Isis Pharmaceuticals that would be marketed by Genzyme. The drug carries too high a risk of cardiovascular problems, the committee found. [AP, Dec 14, 12]

Isis Pharmaceuticals and British drug giant AstraZeneca announced they've partnered to find drugs for cancer. Isis will get $25 million upfront from AstraZeneca. [Bradley Fikes,, Dec 11, 12]

Isis Pharma  up 14% [Nov 9, 10]

Isis Pharma down 22% [Oct 16, 12] after U.S. regulators raised concerns about abnormal growths, some harmful, linked to the company’s drug for a rare genetic disease.[Bloomberg, Oct 16]

Isis Pharma   up 11%  [Sep 4, 12]

Altair Therapeutics, a spinoff from Isis Pharmaceuticals, has shut down operations after the startup’s only drug candidate failed in a mid-stage clinical trial against asthma  [, Feb 3, 11]

Isis Pharma was 278th on the new Deloitte Fast 500 list of fastest-growing technology companies  [Mike Freeman, signonsandiego, Oct 21, 10]

Isis Pharmaceuticals reported a $25.2 million loss for the second quarter, more than what analysts had expected, but the company predicted better results for the rest of the year as a new drug development partnership begins to pay off.  [Keith Darcé, San Diego Union Tribune, Aug 9, 10]

Genzyme said today that it is encouraged by test results for a potential cholesterol treatment it is collaborating on with Isis Pharmaceuticals. [Boston Globe, Aug 4, 10]

Alnylam Pharmaceuticals focused on using RNA interference technology to develop drugs, said it is in line to receive a $1.8 million payment from Regulus Therapeutics a California company it helped form with Isis Pharmaceuticals in 2007. [Boston Globe, Jun 22, 10]

Isis Pharmup 11% [Jun 2, 10]

Isis Pharmaceuticals announced a deal yesterday under which drug giant Glaxo-SmithKline will back Isis’ search for drugs in a number of new areas with the option for the larger company to license the drugs if the work goes well.   .... Isis will control the development programs up to midstage trials, with the potential to receive up to $20 million in milestone payments per program up to that point. Then GlaxoSmithKline would decide whether to license the drugs, with potential license fees, additional milestone payments and possible double-digit percentage royalties to follow. [Thomas Kupper,, Apr 1, 10]

Isis Pharma  down 19% [Feb 10, 10] said its cholesterol-lowering drug mipomersen was effective in a late-stage clinical trial, but safety concerns [on liver toxicity] pushed the company's shares down [Reuters]

OncoGenex Pharmaceuticals (Bothell, WA; no SBIR) has clinched $60 million in upfront payments from Israel-based Teva Pharmaceutical for the right to co-develop an experimental prostate cancer drug, as Luke reported. ... But OncoGenex’s stock took a dive as investors saw how much of the future royalties will end up going to Isis Pharmaceuticals.  [Gregory Huang, xconomy Seattle Times, Dec 22, 09]

Isis Pharma  down 17% [Nov 17, 09] An experimental drug from Isis and Genzyme  cut levels of "bad" LDL cholesterol by 25% in patients with a rare genetic disorder that causes extremely high and dangerous levels of cholesterol, according to data presented today at a medical meeting.  [theStreet,com, Nov 17]

Alnylam Pharma and Isis Pharma said they have formed a new collaboration focused on the development of single-stranded RNAi (ssRNAi) technology.  [Chris Reidy, Boston Globe, Apr 29, 09]

Alnylam Pharmaceuticals said it was one of two firms that invested a collective total of $20 million in Regulus Therapeutics (no SBIR) ... In 2007, Alnylam and Isis Pharmaceuticals established Regulus to "focus on the discovery, development, and commercialization of microRNA-based therapeutics," the two companies said in a press release.  [Boston Globe, Mar 5, 09].

Isis down 10% [Jan 20, 09]

Isis Pharmaceuticals said it will sell its subsidiary Ibis Biosciences, which developed germ detection technology, for $175 million to molecular diagnostics maker giant Abbott Labs.  [San Diego Union Tribune, Dec 18]

Isis Pharma up 10% [Dec 16, 08]

Isis Pharma  down 10% [Dec 1, 08] On a stock bloodbath day

Isis Pharma down 10% [Nov 12, 08]

Isis Pharmaceuticals third-quarter net income fell 84% on a revenue decline caused by year-earlier royalty payments. But the Carlsbad, Calif., drug-therapies developer closed up 4.8% as its third-quarter profit still topped Wall Street expectations.  [Wall Street Journal, Nov 11]

Isis up 12% [Oct 13, 08]

Isis Pharm up 10%  [Aug 8, 08]

Genzyme and Isis said FDA requirements will result in some delays for Mipomersen, the cholesterol-lowering antisense drug at the heart of their joint venture deal announced in January. The news sent Isis shares down 29% [, Apr 25, 08]

Isis Pharmaceuticals up 10% [Apr 1, 08]

Isis Pharmaceuticals up another 11% [Jan 9, 08]

Isis Pharmaceuticals(Carlsbad, CA; $5M SBIR) climbed 27%, after large-cap Genzyme said it would spend $325M upfront in a licensing and investment pact with the drug developer for the rights to a cholesterol-lowering drug that could be on the market within two years. [Wall Street Journal, Jan 9]

Island Data (San Diego, CA)

Island Data (no SBIR) is one of several companies in San Diego using sophisticated algorithms to analyze data to make better business decisions – a field known as analytics. The San Diego Software Industry Council says a cluster of analytics software companies is emerging locally. [Mike Freeman, San Diego Union Tribune, Nov 9]

Isogenis (Aurora, CO)

NIST TIP winners  $22 million in funding for nine research projects targeting innovative manufacturing technologies in fields ranging from biopharmaceuticals and electronics to renewable energy sources and energy storage:  Isogenis (Aurora, CO; $4.8M SBIR);  ActaCell,  (Austin, TX; no SBIR);  Engineered BioPharmaceuticals (Manchester, CT; no SBIR); Arsenal Medical  (Watertown, MA; no SBIR); Kent Displays (Kent, OH; $2.6M SBIR); Precision BioSciences (Research Triangle Park, NC; $340K SBIR); Ginkgo BioWorks (Boston, MA; one SBIR); Sinmat (Gainesville, FL; $4.4M SBIR); Polyera (Skokie, IL; no SBIR). 

Isomark (Madison, WI)

Isomark LLC said it has received a $1.7 million [NIH] grant to help bring to market a noninvasive device that detects infection using a breath sample....   The company's device, called the Isomark Canary, uses patented technology and methods to provide early warnings of potentially deadly infections by monitoring for changes in metabolism. ...   raised about $1.9 million, a good part of it from the founders and their friends.   [Kathleen Gallagher, Milwaukee Journal Sentinel, Oct 22, 14]

Isomark (Madison, WI; no SBIR) has recently raised $150,000 from the Wisconsin Alumni Research Foundation and another $130,000 from other investors as part of a $750,000 round. It’s following the de novo pathway to FDA approval and, if all goes well, will need to conduct at least one more clinical trial involving up to 600 patients before it can go to market.  ....  thinks it might be able to pick up on signs of an infection within hours of the body realizing it has one using a simple breath sample. ... it’s just wrapped up a proof-of-concept trial and is getting ready to launch a 110-patient study at University of Wisconsin Hospitals and Clinics.   [Deanna Pogorelc, Medcity News, Apr 30, 14]

General Dynamics, DRS Technologies and others will discuss their needs this week at the Resource Rendezvous, an event organized to help state companies increase their chances of winning federal grants and research agreements with defense contractors. Seventeen companies from the Upper Midwest also have been selected to pitch their science and technology-based products at the event  .... Presenting companies include Ingeneus (Milwaukee, WI) formed in August that is developing a tool for DNA analysis of hypertension; Isomark (Madison, WI; no SBIR)  with a technology for detecting infection as soon as two hours after onset; and Matrix Product Development  (Sun Prairie, WI;  SBIR) with a technology using battery-operated tags for hazardous waste material tracking. ....  To register or get more information, visit or call Joy Sawatzki at (608) 442-7557.   [Kathleen Gallagher, Milwaukee Journal Sentinel, Sep 16, 13]

Isomark (Madison, WI; no SBIR, founded 2005) has shown in a small study that its technology detected sepsis, a potentially deadly blood poisoning 48 hours before doctors were aware of it.  [Kathleen Gallagher, Milwaukee Journal Sentinel, Oct 25, 12]

IsoPlexis (Branford, CT)

Connecticut Innovations announced a $300,000 investment in IsoPlexis (Branford, CT; no SBIR) life science research company.  The money will be used for engineering and software updates and to finalize a beta version of its product.  ....  "The IsoPlexis micro-device and software helps drug developers identify cellular activity by providing 10 times more data per cell than the industry standard single-cell analysis tool."    [Matthew Sturdevant, Hartford Courant, Aug 11, 14]


biotech IsoRay (Richland, WA; no SBIR) will settle the lawsuit brought by shareholders who allege the company misrepresented results of lung cancer treatment study. ....  uses Cesium-131 seeds to treat various cancers.   [Ashley Stewart, Puget Sound Business Journal, Sep 28, 16]

IsoRay, a maker of radioactive "seeds" that are inserted into tumors to treat cancer, has raised $16.5 million in equity sales to institutional investors this week. ... IsoRay has raised $40 million in four rounds of financing in three years, [CEO] Girard said. [Amy Martinez, Seattle Times, Mar 24]

Isothermal Systems (KY and WA)

Efficient Ears. On average, companies generated roughly $28 in earmark revenue for every dollar they spent lobbying. By any standard, that's a hefty ratio: The companies in the Standard & Poor's 500-stock index brought in just $17.52 in revenues for every dollar of capital expenditure in 2006. ... Says Keith Ashdown, chief investigator for the watchdog group Taxpayers for Common Sense: "The lion's share of these projects is about politics and jobs, rather than real needs." [Business Week, Sep 17]  The earmark efficiency champ is an SBIR company, Scientific Research (Atlanta GA and others; about $15M SBIR), that got $344 in earmarked funds per dollar of political "investment".Other SBIR investors: Isothermal Systems (KY and WA; $2M SBIR) at $221 per lobbying dollar; Prologic (Fairmont WV; $2M SBIR) at $133 per dollar; Trex Enterprises (San Diego CA; $7M SBIR) at $116 per dollar. From an efficiency viewpoint, politicians make a good investment. You just have to learn how to kiss frogs.

Isthmus Biosciences (Madison, WI)

Seven [Wisconsin] companies each will receive a $75,000 grant under a new program aimed at helping them commercialize their products. The first-ever grants are being distributed by a program called SBIR Advance. ... with $1 million from the Wisconsin Economic Development Corp. and administered by the UW-Extension Center for Technology Commercialization.   All of the companies have already received [SBIR or STTR]. But they aren't able to use those funds for activities like patent work and customer development and validation. receiving the grants are: C-Motive Technologies (Madison, WI; one SBIR)  Isthmus Biosciences (Madison, WI; one SBIR); Nutrient Recovery and Upcycling LLC (Madison, WI; one SBIR);  Pan Genome Systems (Madison, WI; one SBIR);  V-Glass LLC  (Milwaukee, WI; one SBIR); Fiberstar Bio-Ingredient Technologies (Eau Claire,WI; one SBIR);  Medical Cyberworlds (Verona, WI; $600K SBIR).  [Kathleen Gallagher, Milwaukee Journal Sentinel. Sep 25, 14]

Isto Technologies (St Louis, MO)

ISTO Technologies (St Louis, MO; $900K SBIR, founded 1997) orthobiologic regenerative medicine company, announced it was recently awarded $1.2M [NIH SBIR] grant to fund pre-clinical research for the application of their novel biosynthetic scaffold, InQu®, to repair chondral defects. ... In 2001, [NIST]awarded the company a prestigious three-year Advanced Technology Program [$2M] award.   [company website, Jul 29, 15]

ISTO Technologies (Olivette, MO; $800K SBIR,  founded 1997)  orthobiologics company, has secured $8 million in a private debt financing  ... working to develop ways to repair and regenerate damaged or injured cartilage and bone.  [Brian Feldt, St Louis Business Journal, Mar 18, 14]

Isto Technologies  (St Louis, MO; $800K SBIR) raised just more than $2 million in June ... an orthobiologics company focused on producing technology that could regenerate function to damaged cartilage and bone. [Brian Feldt, St Louis Business Journal, Jul 19, 13]

Itaconix (Hampton Falls, NH)

Itaconix (Hampton Falls, NH, no SBIR) received $2 million to produce polyitaconic acid from Northeast hardwoods. The acid is a polymer that could be used to replace oil-based dispersants, detergents and super-absorbents. ... a $24 million joint USDA/DOE program to advance research in bio-based energy products. USDA funding comes through its National Institute of Food and Agriculture and requires a 20 percent funding match. [Mass High Tech, Nov 20, 09]

I-Therapeutix (Waltham, MA)

Hydrogel-based therapeutics company I-Therapeutix (Waltham, MA; no SBIR, founded 2006). reports it has raised $15 million in as Series C round of financing. [Mass High Tech, Jun 22, 09]

Itherx Pharmaceuticals (San Diego, CA)

Itherx Pharmaceuticals, (San Diego, CA; $3.5M SBIR mostly as Immusolhas raised almost $2.8 out of a planned debt offering of $3 million, according to a recent regulatory filing. ... says it is developing innovative treatments for Hepatitis C. [Bruce Bigelow,, May 22, 10]

Itseez (San Francisco, CA)

Intel signed a definitive agreement to acquire Itseez (San Francisco, CA; no SBIR, founded 2005 as Computer Vision Centeran expert in Computer Vision (CV) algorithms and implementations for embedded and specialized hardware. Itseez contributes software tuning and integration in many market-leading products shipping today from cars to security systems and more.   [Intel press release, May 26, 16]  terms not disclosed.  created a digital planetarium system installed in several locations in Russia and Eastern Europe. It has also rolled out vCount that is now one of the leading people counter systems in Russia. [Itseez website]

Itzbig (Texas)

When startup FireFly LED Lighting (Austin, TX; no SBIR) was accepted into the Austin Technology Incubator two years ago, its LED bulbs were still prototypes.  Since then, the company has launched its product line, signed customers including Kerbey Lane Cafe and the University of Texas and received $3.4 million from backers including the Central Texas Angel Network and the Texas Emerging Technology Fund.....  Since its founding in 1989 by legendary business leader George Kozmetsky, ATI has worked with more than 200 startups, helping them raise nearly $1 billion in investment capital.  [Lori Hawkins, Austin American Statesman, Jan 26, 12]  Graduates: Agile Planet,  Atomometrics, Axelo, Calxeda, Dorsan Biofuels, Famigo, GameSalad, Ideal Power Converters, Itzbig, Nitero, Notice Technologies, Open Algae, Qcue, RFMicron, RRE Solar,  Savara Pharmaceuticals, Spredfast, Terapio ($500K  SBIR), Unwired Nation,

Iveric bio (New York)

While pivoting to gene therapies, microcap Iveric bio (once Ophthotech, New York, no SBIR) posted positive data from its key eye drug Zimura (avacincaptad pegol). [Ben Adams, Fierce Biotech, Oct 28, 19]

iWalk (Cambridge, MA)

iWalk  (Bedford, MA; no SBIR) maker of a prosthetic ankle system received a  $17 million Series D financing round. .. led by a Dutch investor ...  to further develop and commercialize personal bionics products and expand its sales efforts, the company said  [Patricia Resende, Mass High Tech, Sep 13, 12]

iWalk (Cambridge, MA; no SBIR) received $20 million of a $21 million Series B round to fund development of a self-contained robotic prosthetic ankle, the company has confirmed.  [Mass High Tech, Aug 31, 09]

Jade Therapeutics (Salt Lake City, UT)

EyeGate Pharma (Waltham, MA; no SBIR) acquired Jade Therapeutics  (Salt Lake City, UT; $900K SBIR) with hydrogel-based technology that can be used to help deliver drugs to the eye. Eyegate will repay $300,000 in Jade debt and issue its backers 765,728 shares of stock. If a Jade product wins FDA approval, EyeGate would also shell out about $2.2 million in cash. [Ben Fidler,, Mar 10, 16]

J&YInternational (Menomonee Falls, WI)

J&Y International (Menomonee Falls, WI; no SBIR) water technology company, has been acquired by China-based Tri-Tech Holding Inc. for $1.5 million in cash and stock. ... designs and manufactures industrial chemical water recovery systems, desalination plants, domestic and industrial wastewater treatment systems and reverse osmosis filtration systems. Tri-Tech designs customized sewage treatment and odor control systems for China's municipalities and larger cities. J&Y is Tri-Tech's first overseas acquisition. (Milwaukee Journal Sentinel, Jun 14, 11]

Janssen Biotech (Cambridge, MA)

FDA granted marketing approval to Simponi Aria, a treatment for moderate-to-severe rheumatoid arthritis developed by Janssen Biotech [formerly Centocor (Malvern, PA; $300K SBIR in 1987), now a subsidiary of Johnson & Johnson [John George, Philadelphia Business Journal, Jul 19, 13]

Metamark Genetics(Cambridge, MA; no SBIR, founded 2007) and Janssen Biotech (Horsham, PA; no SBIR), a  therapeutics developer, have formed a research, collaboration and licensing deal that could bring [Metamark] molecular diagnostics company up to $365 million in milestone payments. [Michelle Lang, Mass High Tech, Dec 20, 11]

Janus Biotherapuetics (Cambridge, MA)

Janus Biotherapuetics (Wellesley, MA; no SBIR) biotech focused on autoimmune disease treatments, has raised $1.1 million of a planned $3 million equity financing ... The stealthy startup does not yet have a website and describes itself on LinkedIn as “a project-oriented, biopharmaceutical company focused on progressing a series of small molecule leads for the treatment of autoimmune diseases.”   [Mass High Tech, Apr 19, 11]

Stealthy Janus Biotherapuetics (Cambridge, MA; no SBIR) has landed $500,000 of a planned $3 million funding round, according to federal documents.  [Mass High Tech, Mar 17, 11]

Javelin Pharmaceuticals (Cambridge, MA)

Javelin Pharmaceuticals  surged 58% after large-cap Hospira, a maker of medical devices and injectable drugs, said it would complete its offer to buy out the Cambridge, Mass., company at the end of the month in a deal valuing the company at about $141 million. [Wall Street Journal, Jun 30, 10]

Javelin Pharmaceuticals down 30%  after its European commercial partner recalled all batches of its pain medication Dyloject from the U.K. market due to quality-control problems. The Cambridge, Mass., company and partner Therabel Pharma are cooperating with U.K. regulatory authorities to resolve the matter. [Wall Street Journal, May 25, 10]

Javelin Pharmaceuticals terminated its merger agreement with Myriad Pharmaceuticals Inc. and said it has entered into a definitive agreement to be acquired by Hospira Inc. [Boston Globe, Apr 19, 10]

Javelin Pharmaceuticals announced that it is terminating its existing merger agreement with Myriad Pharmaceuticals Inc. (MPI) in favor of a new acquisition deal from Hospira Inc. and its subsidiary Discus Acquisition Corp.  [Mass High Tech, Apr 12, 10]

Myriad Pharmaceuticals agreed to buy Javelin Pharmaceuticals (Cambridge, MA; no SBIR) in an all-stock deal worth about $96 million to acquire a postoperative pain drug, Dyloject.  [Reuters, Dec 18, 09]

Javelin Pharmaceuticals (Cambridge, MA; no SBIR) said that it has gotten approval to market its pain medication Dyloject in Scotland. [Boston Globe, Mar 11, 08]

Javelin Semiconductor (Austin,TX)

Javelin Semiconductor (Austin, TX; no SBIR, founded 2008, 29 employees)  has been sold to Avago Technologies Ltd. (San Jose, CA and Singapore) for an undisclosed price, according to an investor involved in the deal.  ... raised $21 million in less than five years of operations, has developed several innovative amplifier chips for cellphones made by Samsung Electronics. [Kirk Ladendorf, Austin American Statesman, Apr 23, 13]

Two chip-design startups from Austin will be sending marketing teams to Barcelona, Spain, next week to talk to the titans of the cell phone business ... [Black Sand Technologies and Javelin Semiconductor, neither had SBIR] are developing innovative chips that serve as signal amplifiers for advanced 3G cell phones. [Austin American Statesman, Feb 11, 10]

JDP Therapeutics (Blue Bell, PA)

JDP Therapeutics (Blue Bell, PA; no SBIR) specialty pharmaceutical company, secured up to $17m Series A equity financing to advance JDP-205 through its pivotal phase III clinical trial. [, Jun 28, 16]    focused on developing small molecule therapeutics to treat life threatening diseases with significant unmet medical needs, primarily for use of acute care in the hospital setting. [company website]


Jennerex (San Francisco, CA)

A South Korean contract research organization [SillaJen, a Jennerex shareholder since 2006, owns about 25 percent of Jennerex] will buy cancer immunotherapy developer Jennerex Biotherapeutics (San Francisco, CA; no SBIR) for up to $150 million, according to BioCentury.  [Ron Leuty, San Francisco Business Times, Nov 27, 13]

Jennerex(San Francisco, CA; no SBIR) raised $8.6 million in gross proceeds from a private placement. ... testing a treatment for liver cancer which is in mid-stage clinical development. It plans a Phase IIb test of that treatment “in the coming months.”   The company is also testing the same drug, JX-594, in a Phase Ib trial in patients with colorectal cancer.... has research operations in Ottawa and in Pusan, South Korea. [Stephen EF Brown, San Francisco Business Times, Aug 11, 11]

Jnana Therapeutics (Boston, MA)

Drug discovery startup Jnana Therapeutics (Boston, MA; no SBIR for stealth) announced its launch with a $50 million Series A financing. ...  building the first drug discovery platform dedicated to targeting the solute carrier (SLC) family of transporters, the cell’s metabolic gates. Jnana’s proprietary small molecule platform allows the company to address therapeutic targets rapidly and comprehensively across the SLC transporter family. [company press release, Dec 15, 17]

Joule Unlimited (formerly Joule Biotechnologies)  (Cambridge, MA)

Thermodynamics forbids a free lunch, even for bacteria.  The use of waste CO2 means that [Joule Unlimited  (no SBIR)]’s fuels won’t actually add more CO2 to the atmosphere than would’ve been there otherwise. [Kyle Alspach, betaboston,com, Sep 25, 14] Since waste CO2 got there by releasing a lot of energy, the C and O cannot be returned to their former useful fuel state without giving back (and more) the energy gained in their combining. Otherwise Joule would be making a perpetual motion machine. The news reports conveniently overlook the nastily complex and unforgiving world of thermodynamics. If the energy source is in the bacteria, it would take a lot of time and sunshine to make the bacteria. The company also states that its product could supply all of the transportation fuel for the United States from an area the size of the Texas panhandle. [Wikipedia].  For a technical discussion that states This approach, however, fundamentally suffers from thermodynamic limitations that make economic viability difficult, if not impossible, to achieve, see Berry, Bioengineered Bugs.   

Biofuels company Joule Unlimited (no SBIR) closed on $70 million in a third funding round from new, unnamed institutional and private investors  [Mass High Tech, Jan 17, 12]

Sunlight companies.  Joule Unlimited (formerly  Joule Biotechnologies,  Cambridge, MA; no SBIR) said it was the first company to patent an organism that secretes hydrocarbon fuel made continuously, directly from sunlight. Other companies, including Amyris Biotechnologies (Emeryville, CA; $700K SBIR), and LS9 (San Carlos, CA; no SBIR), are working on organisms that will make fuel if fed sugar from corn or cellulosic sources, but Joule’s bacterium does not require any sugar. Another company, Aurora Algae (Alameda, CA; no SBIR), said that it had developed an algae-based platform for production of fuel, pharmaceuticals and other valuable chemicals.  [Matthew Wald, New York Times, Sep 14, 10]

Joule Biotechnologies pulled in $30 million in a Series B round of financing. ...  founded in 2008 and came out of stealth mode last July, has developed a way to generate renewable fuels on a large scale by eliminating the need for feedstocks and instead using photosynthetic organisms to convert waste carbon dioxide into renewable diesel and ethanol. ..  plans to build its first pilot plant in Leander, TX  [Michelle Lang, Mass High Tech, Apr 27, 10]

Joule Biotechnologies (Boston, MA; no SBIR)'s secret ingredient - a designer organism - looks like green Jell-O before it’s refrigerated.  The stuff is kept behind several locked doors in an unmarked brick building on Rogers Street, where Joule researchers are still tinkering with how the organism, which no one here will name, consumes sunlight and carbon dioxide, then sweats ethanol. The 2-year-old company, which just made public news of its possibly revolutionary process, said that one day soon, its SolarFuel could be used to power vehicles. But until then, Joule officials said they intend to keep quiet about just what goes into their product.  [Boston Globe, Aug 24, 09]

[startup] Joule Biotechnologies (Cambridge, MA; no SBIR) revealed details of a process that it says can make 20,000 gallons of biofuel per acre per year. ... grows genetically engineered microorganisms in specially designed photobioreactors. The microorganisms use energy from the sun to convert carbon dioxide and water into ethanol or hydrocarbon fuels (such as diesel or components of gasoline). The organisms excrete the fuel, which can then be collected using conventional chemical-separation technologies. ....  the company claims that the process will be competitive with crude oil at $50 a barrel. [Kevin Bullis, MIT Tech Review, Jul 27]  At least the price of the sunlight would be correctly estimated.

Jounce Therapeutics

Jounce Thera down 33%  [Jun 4, 18]

Jounce Thera down 37%  [May 17, 18] upon the publication of an abstract for a phase 1/2 trial of its first-in-class ICOS inhibitor JTX-2011, although the company says the drug showed evidence of efficacy. [Phil Taylor, Fierce Biotech, May 17, 18]

Jounce Therapeutics (Cambridge, MA; no SBIR) has gone ahead of its projections and raised roughly $102 million in an IPO.   [Ben Fidler,, Jan 27, 17]

Presage Biosciences (Seattle, WA; no SBIR) has been named one of FierceBiotech ’s “Fierce 15” of 2013.  ... a spinoff company of the Fred Hutchinson Cancer Research Center  .... patented a novel method for simultaneously analyzing multiple cancer drug candidates and drug combinations within a single tumor while that tumor is still in a patient.  .... FierceBiotech evaluates hundreds of private companies from around the world each year before selecting the 15 it considers the most innovative, creative and promising.   The other Fierce 14 are:   Acetylon Pharmaceuticals;   AnaptysBioCytomX  (Santa Barbara, CA; $500K SBIR); FibroGen  (South San Francisco, CA; $1.3M SBIR);  Immunocore; Jounce TherapeuticsKala PharmaceuticalsMacroGenics  (Rockville, MD; $2.6M SBIR) ; Moderna Therapeutics; Nimbus Discovery; Scioderm; UltragenyxUniQure; and Visterra.  [Valerie Bauman,  Puget Sound Business Journal , Sep 24] 

Joyent (San Francisco, CA)

Intel Capital said it's investing more than $30 million in four technology startups...  Adaptive Computing   (Provo, UT) developer of software for data centers and cloud computing; Ciranova, (Santa Clara, CA) maker of chip design software; Joyent, (San Francisco, CA) provider of cloud-computing infrastructure; Nexant a (San Francisco, CA) developer of energy-efficiency software and clean-energy services.  [FM Russell, San Jose Mercury News, Sep 15, 10]  None had SBIR.

Joylux (Seattle,WA)

Joylux (Seattle, WA; no SBIR, founded 2014, six employees) developing an at-home medical device that uses LED light to treat pelvic floor disorders just closed a [ $3 million] seed funding round. ...  makes a product — called vSculpt — that it says uses light therapy to treat issues such as urinary incontinence, painful intercourse due to vaginal laxity and pelvic floor issues that might arise after childbirth.  [Annie Zak, Puget Sound Business Journal, Sep 22, 15]

Joyn Bio (Boston, MA and Woodland, CA)

Joyn Bio (Boston, MA and Woodland, CA;  SBIR), an agtech company entered a partnership with NewLeaf Symbiotics (St. Louis, MO;  no SBIR, founded 2012) valued at up to $75M to bring innovation and sustainability to modern agriculture with a new class of microbes that benefit crop health and protection. Joyn will gain access to NewLeaf's library of proprietary, strains of plant colonizing microbes and will engineer those microbes to bring novel disease and pest control options to farmers. [Rowan Walrath, BostInno, Jul 22, 19]

Juno Therapeutics (Seattle,WA)

A CAR-T biotech formed by Juno Thera ((now owned by Celgene) and WuXi got off a $90 million series A with Chinese backing, as it eyes clinical trials of its new cancer therapy.   [Ben Adams, Fierce Biotech, Mar 8, 18]

Juno Thera up 27% [Jan 22, 18]  Celgene will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. [Michael Erman and Tamara Mathias, Reuters,  Jan 22, 2018]

Juno Thera up 52% [Jan 17, 18]

Celgene [one of the biggest U.S. biotech companies] is in talks to buy Juno Therapeutics [market cap $5.5B, founded 2013]  just days after announcing another major deal to bolster its portfolio of blood-cancer drugs [by buying Impact Biomedicines for $1.1B].   [Jonathan D. Rockoff, Dana Cimilluca, and Dana Mattioli, Wall Street Journal, Jan 16, 18]

Juno Thera down 14% [Dec 11, 17]

Juno Therapeutics, which dumped its lead CAR-T program in March, has inked itself a potential lifeline: a trio of license agreements that will help it develop a combo treatment for multiple myeloma. The deals, signed with Eli Lilly, OncoTracker and Fred Hutchinson Cancer Research Center, aim to boost the development of a multiple myeloma therapy combining BCMA-directed CAR-T cells in combination with gamma secretase inhibitors (GSIs). [Amirah Al Idrus, Fierce Biotech, Dec 7, 17]

Juno Therapeutics up 24% [Nov 2, 17] "We are pleased with the potential best-in-class profile for JCAR017, and we look forward to presenting an updated dataset at the upcoming ASH conference," said [CEO] Hans Bishop [company press release, Nov 1, 17]

Juno Thera up 20% [Aug 29, 17]

Juno Thera up 19% [Aug 28, 17]

Juno Thera down 11% [Jun 5,17]

XBiotech down 10% [Jun 5,17]

Juno Thera down 11% [Mar 2, 17]

Juno Therapeutics is shutting down the clinical trial of one of its cancer drugs, three months after it was put on hold after patient deaths.  ...  will permanently stop the “Rocket” trial of JCAR015 to treat acute lymphoblastic leukemia (ALL) in adults. ... said it will start a different trial to treat adult ALL in 2018 that is more similar to its JCAR017 trial. That trial tests pediatric ALL and has been proceeding   [Rachel Lerman, Seattle Times, Mar 1, 17]

Doctors in London say they have cured two babies of leukemia in the world’s first attempt to treat cancer with genetically engineered immune cells from a donor.   ... The ready-made [off the shelf] approach could pose a challenge to companies including Juno Therapeutics and Novartis, each of which has spent tens of millions of dollars pioneering treatments that require collecting a patient’s own blood cells, engineering them, and then re-infusing them.  [Antonio Regalado. MIT,  Jan 25, 17]

Juno Thera down 24% [Nov 23, 16]

Juno Therapeutics said two more patients had died after suffering cerebral edema during a trial of its experimental leukemia drug, bringing the total to five.   The company's shares tumbled nearly 45 percent to $15.90 in premarket trading [Reuters, Nov 23, 16]

Juno Therapeutics is three years old, has not a single drug approval to its name but is nonetheless valued at $2.8 billion. [because] it is on the forefront of the most promising area of cancer treatments in decades: immuno-oncology.   .... It has a full line-up of experienced researchers, including from the nearby Fred Hutchinson Cancer Research Center, which helped Juno become one of the best funded biotech startups ever.   [The Economist, Oct 22, 16]

Juno Thera up 13% [Sep 27, 16]

Juno Therapeutics, a biopharmaceutical company focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced that it has acquired RedoxTherapies (Boston, MA; no SBIR) [for $10 cash upfront]. ... provides Juno with an exclusive license to vipadenant, a small molecule adenosine A2a (A2a) receptor antagonist that has the potential to disrupt important immunosuppressive pathways in the tumor microenvironment in certain cancers. [Juno press release, Jul 14, 16]

Juno Therapeutics said U.S. health regulators have removed a clinical hold on its cancer drug trial that was put in place last week following the death of three patients, sending its shares up about 28 percent in extended trading. [Reuters, Jul 12, 16]

Juno Therapeutics down 32% [Jul 8, 16]

Juno Therapeutics said a study of its closely watched anticancer treatment was placed on hold by [FDA] following two patient deaths from brain swelling last week. The company also disclosed that a previous patient death had occurred in May.  ...  shares fell 27% to $29.66 in after-hours trading  [Joseph Walker, Wall Street Journal, Jul 7, 16]

Juno Thera  up 10% [Jun 6, 16] announced that encouraging clinical data from JCAR015, a chimeric antigen receptor (CAR) T cell product candidate, support its strategic approach towards the commercialization of its first CAR T therapy. [company press release]

Over the past year, Juno Therapeutics went on a hiring spree, upping its full-time employment to 227 and providing a major boost to its ranking on the Top 25 Biotechnology Companies List.  [Melissa Crowe, Puget Sound Business Journal , May 13, 16]

Juno Therapeutics in partnership with WuXi AppTec, is forming a new Chinese company called JW Biotechnology Co.
WuXi is a leading pharmaceutical, biotech and medical device research and development company with global operations.[Coral Garnick, Puget Sound Business Journal, Apr 12, 16]

Ransom demand.  The decision to keep the fast-growing Juno Therapeutics biotech's headquarters in the city where it was founded will rest on whether policy makers in Washington state decide medical innovation is important, CEO Hans Bishop said. .... The state needs to look at its tax policy, Bishop said, and figure out how to incentivize new companies to grow in Washington and to attract mid-sized companies to the state. If it doesn't, his company and others may not be located here in 10 years.  Washington used to have a research and development tax credit that helped companies like Juno offset the business and occupation tax, but lawmakers allowed that credit to sunset last year.  ... While, Washington has a Life Sciences Discovery Fund to help support young biotech companies, its future funding was cut last year, as well.  [Coral Garnick, Puget Sound Business Journal, Mar 30, 16]   Everybody needs a handout, just ask them.

Juno Thera up 14% [Mar 1,16]

Juno Thera down 10% [Feb 2, 16]

 Juno Therapeutics focused on re-engaging the body's immune system to revolutionize the treatment of cancer, announced  that it has acquired AbVitro (Boston, MA; no SBIR). The acquisition provides Juno with a leading next-generation single cell sequencing platform that will augment Juno’s capabilities to create best-in-class engineered T cells against a broad array of cancer targets. Juno and Celgene Corporation have agreed in principle to enter into an agreement to license Celgene a subset of the acquired technology and to grant Celgene options to certain related potential product rights emanating from the acquired technology.  [company press release, Jan 11, 16]

Juno Therapeutics has agreed to acquire AbVitro (Boston, MA; no SBIR) biotechnology firm for more than $120 million in cash and stock, the company announced. Juno said the deal brings “a leading next-generation single cell sequencing platform that will augment Juno’s capabilities to create best-in-class engineered T cells against a broad array of cancer targets.”  [Seattle Times, Jan 11, 16]

A baby girl who was close to dying from cancer [acute lymphoblastic leukemia] has been rescued by a cell therapy [developed by Cellectis (France)] envisioned as a “one size fits all” treatment that had never been tested in people, doctors reported on Thursday. ... Other companies pursuing this approach, often called CAR-T, including Juno Therapeutics and Kite Pharma, have achieved large stock market valuations.  [ANDREW POLLACK, New York Times, NOV 5, 2015]

Juno Thera up 10% [Oct 15,15]

Juno Thera up 10% [Sep 24, 15]

Juno Thera down 11% [Sep 21, 15]

Juno Thera up 15% [Jun 30, 15]

Celgene, a leading biotech company, said it would pay about $1 billion to start a collaboration with Juno Therapeutics, a leader in the hot new area of cancer drugs that harness patients’ immune systems to attack tumors. Most of the $1 billion Celgene will pay will go toward acquiring about 9.1 million shares of Juno at $93 a share. That is about double the price at which Juno closed, before rising about 40 percent after hours.   [Andrew Plooack, New York Times, Jun 29, 15]

results in Philadelphia and New York had been close to miraculous. In 90 percent of patients with acute lymphoblastic leukemia that has returned and resists regular drugs, the cancer goes away. The chance of achieving remission in these circumstances is usually less than 10 percent. Those results explain why Juno Theraputics raised $304 million when it went public in December, 16 months after its founding  [Antonio Regalado,, June 18, 2015]  Got the goods? Get the cash.

Juno Thera down 12% [Jun 17, 15]

More biotech companies are teaming up together to produce better cancer drugs.  In the Seattle area, biotech Juno Therapeutics is leading the way in making new deals with other companies that also develop immunotherapy treatments for cancer.  [Annie Zak, Puget Sound Business Journal, Jun 9, 15]

Juno Thera up 12% [Jun 4, 15]

Juno Thera up 11% [May 19, 15]

Juno Therapeutics said it has acquired German biotechnology company Stage Cell Therapeutics, paying about $59 million and 486,000 shares of Juno stock, worth approximately $22 million.  ...  also reported a first-quarter net loss of $65 million, and said it ended the quarter with almost $448 million in cash and equivalents. [Seattle Times, May 11, 15]

Juno Thera down 10% [Apr 27,15]

Big success, big rewardsFounded just a year earlier, the [Juno Therapeutics (no time for SBIR)] now has four CD19-targeting CAR T-cell therapies in trials. The premise is simple: extract a patient’s T cells from blood and train them to recognize and kill cancer by modifying them with a viral vector to express an artificial, or chimeric, receptor specific for a particular cancer-associated antigen—in this case, CD19, an antigen expressed in  B-cell–related  blood cancers—then reinfuse the cells back into the patient. ....  Last December, scientists at Juno Therapeutics reported at the American Society of Hematology (ASH) meeting that, in an ongoing Phase 1 trial, its chimeric antigen receptor (CAR) T-cell therapy, JCAR015, put 24 of 27 adults with refractive acute lymphoblastic leukemia (ALL) into remission, with six patients remaining disease free for more than a year (ASH 2014, Abstract 382, 2014). ...  A few weeks after the ASH meeting, Juno went public for a whopping $264.6 million, the largest biotech initial public offering (IPO) of 2014. Within a month, the company’s valuation rose from $2 billion to $4.7 billion, the largest among biotechs in a decade.   [Vicki Brower,, April 1, 2015]

Hope feeds price swings.  Interim phase I clinical trial data presented by Novartis and the University of Pennsylvania on an experimental cancer therapy for solid tumors, known as CAR-T, fell short of expectations over the weekend.  The news left Novartis’s stock unscathed. But two companies developing similar therapies, Juno Therapeutics and , saw their shares plunge by about 9%. These are early days for CAR-T, so it’s premature to draw conclusions. Only six patients are enrolled in the Novartis study, and analysts at Morgan Stanley believe that treating solid tumors still represent a significant opportunity for developers. ...  But there are good reasons for share prices to fall. Juno and Kite both listed last year. In 2014, neither company made revenue and their aggregate net loss exceeded $285 million. Yet, even after Monday’s selloff, their combined market value is about $8 billion.    [Wall Street Journal, Apr 20, 15]

Juno Thera up 31% [Mar 19, 15]

Juno Therapeutics, which raised more than $300 million in its December initial public offering of stock, is getting $500,000 from the governor’s Strategic Reserve Fund to help with its planned Bothell manufacturing plant.  [Rami Grunbaum, Seattle Times, Mar 16, 15]

Hopes that fledgling companies will repeat and extend upon those advances [by Bristol-Myers-Squibb] are behind the recent share-price gains in Juno Therapeutics, Kite Pharma and bluebird bio. Their treatments, which take a different approach than Bristol-Myers’s, haven’t yet reached the market.  ....   Shares of Juno, which is developing therapies for leukemias and lymphomas, ended Friday’s trading at $45.52, following a December initial public offering at $24. Kite Pharma has soared to $62.80 from $28 since the beginning of October. Bluebird bio, driven more by advances by gene-therapy drugs than in immunotherapy, has climbed to $93.32 from $39 since early December.   [Gregory Zuckerman and Ron Winslow, Wall Street Journal, Feb 22, 15]

Juno Therapeutics said it is leasing a 68,000-square-foot building in Bothell [WA] for a biotech manufacturing facility to supply its clinical trials and potentially its first commercial products.  [Seattle Times, Feb 9, 15]

Juno Thera  up 10% [Jan 26, 15]  

Juno Thera  up 12% [Jan 16,15]

Juno Thera  down 14% [Jan 15,15]one insider bought $15M in December

Juno Thera up 12% [Jan 6, 15]

Juno Thera up 11% [Dec 29, 14]

Juno Thera up 22% [Dec 26, 14]

Juno Thera up 46% [Dec 19, 14] after IPO

Juno Therapeutics [priced its IPO] for gross proceeds of $264 million before costs. [Seattle Times, Dec 18, 14]

Just a week after setting the stock price for its initial public offering, Juno Therapeutics (Seattle, WA; no SBIR) upped those numbers from $15 to $18 dollars per share to between $21 and $23 per share, according to [SEC] documents  ...  focuses on creating immunotherapy treatments for cancer. These treatments work by extracting blood from a patient, re-engineering the patient's cells so the immune system is more equipped to battle the cancer, and then putting that blood back into the body. ....  has already raised $314 million in investments in a little more than a year   [Annie Zak, Puget Sound Business Journal, Dec 16, 14]   If a little bit is good, a whole lot is better, especially in a market in love with small biotechs.

Juno Therapeutics (Seattle, WA; no SBIR) has filed [IPO] plans to raise up to $150 million.  ... immunotherapy company said it intends to use the proceeds to advance one cancer drug into phase 2 clinical trials, move forward with other potential drugs under study, and establish its own manufacturing capabilities, among other things.  ...  Juno was unveiled last December with a bang, bringing together cancer-therapy research from the Fred Hutchinson Cancer Research Center, Seattle Children’s and New York’s Memorial Sloan-Kettering Cancer Center. It launched with $120 million, making it one of the country’s best-funded startups last year, and by August had accumulated $314 million in capital.    [Seattle Times, Nov 17, 14]

Juno Therapeutics  (Seattle, WA; no SBIR) biotechnology startup unveiled in December by leading cancer scientists here and in New York, has announced another $134 million in financing, bringing its total funding to $300 million in less than a year. The new

Just Biotherapeutics

The Bill & Melinda Gates Foundation has poured an additional $8 million into Just Biotherapeutics  (Seattle, WA; no SBIR, founded 2014, 50 employees) biotechnology venture working on a cheaper manufacturing process for medication it hopes will benefit the developing world.  ... announced a $14 million investment round ... [Gates]  previously awarded a $24 million grant to the company, to be distributed over four years ... raised an earlier $15 million Series A round   [Rachel Lerman, Seattle Times, Jul 26, 16]

Just Biotherapeutics (founded 2014 by esteemed former Amgen scientists) is focused on developing technologies that make the entire system of manufacturing biotherapeutic drugs more efficient and cheaper. That could mean making more cost effective therapeutic molecules, or designing smaller, more efficient manufacturing plants. ...  raised $15 million through a series A funding round last week to grow. It plans to add about 20 to 30 people — or more — to its current staff of 30 within the next year. Merck led that funding round  [Annie Zak, Puget Sound Business Journal, Sep 25, 15]